Data Management and Analyses in HIV-1 Therapeutic Studies by Mandalia, Sundhiya
  
1 
 
 
 
 
Data Management and Analyses in  
HIV-1 Therapeutic Studies 
 
 
 
 
 
 
Sundhiya Mandalia 
 
March 2014 
 
Imperial College London 
Department of Medicine 
 
Chelsea and Westminster Hospital 
369 Fulham Road 
London SW10 9NH 
 
 
A Thesis Presented For The 
Degree of Doctor of Philosophy  
 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
*  * 
* 
To the memory of my dear parents 
 
 
 3 
 
DECLARATION OF ORIGINALITY 
 
I confirm that the work presented in this thesis is my own. Where information has been derived 
from other sources, I confirm that this has been indicated in the thesis and referenced. 
 
 
Sundhiya Mandalia 
 
 
 4 
COPYRIGHT DECLARATION 
 
The copyright of this thesis rests with the author and is made available under a Creative Commons 
Attribution Non-Commercial No Derivatives licence. Researchers are free to copy, distribute or 
transmit the thesis on the condition that they attribute it, that they do not use it for commercial 
purposes and that they do not alter, transform or build upon it. For any reuse or redistribution, 
researchers must make clear to others the licence terms of this work. 
 
 
ABSTRACT 
5 
ABSTRACT 
 
The focus of this PhD is to demonstrate how routinely collected de-identified patient information 
can be used for basic science, clinical science and population science health research. Examples 
are provided on how routinely collected information from people living with HIV-1 (PLHIV) can 
provide strategic health information, enabling stakeholders to develop and implement strategies to 
improve the use, cost, outcome and impact of HIV-1 service provision. As more PLHIV are on 
combination anti-retroviral therapy (cART), the increasing number of PLHIV requiring long-term 
use of health services has long-term resource implications. De-identified personal information that 
are systematically collected and analysed can provide information to monitor and evaluate the use, 
cost, outcome and impact of HIV-1 service provision. 
 
The basic science study identified PLHIV who were long-term non-progressors and HIV controllers 
managed in a HIV referral centre and determined factors that contributed to their atypical 
prolonged asymptomatic infection. The clinical science study assessed the impact of HIV-1 
infection, cART and age on renal insufficiency in PLHIV managed at the referral centre. The 
population science study used information from an established national multicentre prospective 
monitoring system to report changing use and population cost of HIV-1 services in the UK, and 
estimated future population costs arising from projected increases in the number of PLHIV using 
NHS services.  
 
Despite recognised problems associated with observational data, the utility of de-identified 
personal information for such research was demonstrated. Personal health information needs to be 
collected longitudinally to ensure development of good electronic medical records nationally and 
globally requiring appropriate information technology aswell as analytic expertise. Main lesson from 
this PhD is that de-identified individual level information can be used at local, regional and national 
levels to monitor and evaluate the effectiveness, efficiency, equity and acceptability of HIV-1 and 
other health services provided. 
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CHAPTER 1: GENERAL INTRODUCTION 
This PhD demonstrates how routinely collected de-identified patient data can be used for research 
studies. Three examples of: basic science, clinical science, and population science studies are 
presented. Furthermore, this PhD provides examples on how routinely collected de-identified 
information from people living with HIV-1 (PLHIV) can deliver strategic health information. This 
would enable stakeholders to develop and implement strategies so that they can successfully cope 
with an increasing HIV-1+ population in order to improve the use, cost, outcome and impact of HIV-
1 service provision. 
 
Introduction and success of highly active antiretroviral therapy has increased the number of people 
requiring long-term use of health services. This has financial implications including ongoing 
development of new therapeutic agents. As more PLHIV are prescribed combination antiretroviral 
therapy (cART), the increasing number of PLHIV requiring long-term use of health services has 
resource implications. Systematically collected de-identified personal information, and analysed 
data, can shed further light on clinical issues by providing information to monitor and evaluate the 
use, cost, outcome and impact of HIV-1 service provision. An established research cycle was used 
as a framework for the three examples of research studies undertaken. 
 
The aim of the United Kingdom (UK) National Health Service (NHS) is to provide health care in 
order to improve treatment of chronic diseases such as heart disease, diabetes, HIV, and chronic 
kidney disease (CKD). People with chronic diseases are often in need of life-long treatment and 
care, which results in high costs for treatment and care, as these people need to be routinely 
monitored for disease severity and have their disease controlled by treatments that are efficacious. 
Health care systems have evolved and the two main areas of providing the healthcare are 
knowledge and process. Knowledge guides the care that should be delivered, and process aims to 
deliver it in a cost effective way.  
 
We live in the information age1 within which an increasing amount of data are generated and 
stored. Although there is no definition of information age, this is referred to the computer age 
where people have access to information from almost every part of the world. Organisations 
handle huge volumes of routinely stored data using terabytes2 and exabytes3. With these volumes 
of data stored and collected, there is a requirement for an efficient management and access to 
such data volume. Databases are used to store a large amount of historical data in order to allow 
users at different levels to make effective decisions. Database and data management from which 
                                               
Chapter 1:1
 Information age: a period which began in the last quarter of the 20th century when information became easily 
accessible through publications and through the manipulation of information by computers and computer networks. 
Description from http://www.thefreedictionary.com/Information+era 
Chapter 1:2
 A terabyte is 10
12
 bytes and is equal to 1,000 gigabytes (1 gigabyte =1 billion bytes) 
Chapter 1:3
 An exabyte is 10
18
 bytes (1 billion gigabyte) 
Information on bytes accessed from http://www.techterms.com/definition/ 
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trends in data are derived and explained and the inferences are based on generating a hypothesis 
by putting a number of facts together necessary for both research conduct and integrity are the 
essential aspect of this PhD thesis. 
 
The total global estimate of people living with HIV-1 infection continues to increase. By end of 2011 
the global estimate was reported as 34 million (UNAIDS World AIDS Day Report, 2012) while this 
had increased to 35.3 million one year later in 2012 (UNAIDS Report on the Global AIDS 
Epidemic, 2013). If HIV-1 is left untreated most patients eventually progress to AIDS with reduced 
quality of life. As a consequence, their reduced productivity in society will impact on the economic 
and psychological aspects of well-being. With potent anti-retroviral (ARV) drugs now available and 
in use to manage the condition, HIV-1 is now manageable and regarded as chronic disease 
(Williams et al., 2012). Data presented in this PhD thesis uses data collected from people living 
with HIV-1 who are managed at specialist centres in the NHS, and are here utilised as an example 
and a model to demonstrate the use of the NHS Hospital Information System (HIS) database that 
may help with decision making for health care professionals, business managers, policy makers, 
pharmaceutical companies and researchers so that social welfare and public services in addition to 
research conduct can be improved. 
 
1.1 DATA MANAGEMENT 
 DATA MANAGEMENT HISTORY (PRE-COMPUTERS) 
Herman Hollerith (29th February 1860 - 17th November 1929) was an American statistician who 
used Charles Babbage's4 original idea of punch cards and electromagnetic relays to develop a 
motor powered tabulator for the 1890 United States of America Census (Table 1.1.1). This 
tabulator was developed to process the data and tabulate statistics from more than 62 million 
Americans. Although this was developed and custom built for the census, its basic function was to 
count, add and produce results from punched cards. Hollerith developed a mechanism using 
electrical connections to trigger a counter for recording information. A key idea was that data could 
be coded numerically. The idea behind this was that if numbers could be punched in rows and 
columns on a card then these cards could be counted or sorted mechanically and the data 
recorded. A description of this system, ‟An Electric Tabulating System (1889)‟, was submitted by 
Hollerith to Columbia University as his doctoral thesis, and read before the Royal Statistical 
Society, 4th December 1894 (Hollerith, 1894).  
 
                                               
Chapter 1:4
 Charles Babbage (1791-1871), computer pioneer, designed the first automatic computing engines. Accessed 
from http://www.computerhistory.org/babbage/?gclid=CNTukdH7srUCFWbKtAodckQAOg 
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Having developed a new machine, Hollerith opened his own business under the name ‟Tabulating 
Machine Company‟. In 1924, the business merged and changed its name to ‟International 
Business Machines Corporation‟ (IBM). 
 
Table 1.1.1: Descendent of Herman Hollerith's 1890 Census Tabulator 
 
1890 Hollerith Census Tabulator Manual feed, wood cabinet, hardwired connections, counting 
only 
1896 Hollerith Integrating Tabulator Manual feed, true addition as well as counting 
1900 Hollerith Automatic Feed Tabulator First automatic-feed card reader, used in 1900 US Census 
1906 Hollerith Type I Tabulator (Type 090) Automatic feed; metal cabinet; first wiring panel 
1921 Hollerith Type III Tabulator (Type 091) First model with printer 
1925 Hollerith Type 3-S Tabulator First model with direct subtraction, removable plug board 
1928 Hollerith Type IV Tabulator  (Type 301) First 80-column-card model 
1931 Columbia Difference Tabulator Unique machine for CU Statistical Bureau 
1933 IBM Type 285 Tabulator Numeric only 
1933 IBM 401 Tabulator Alphanumeric 
1934 IBM 405 Accounting Machine Alphanumeric 
1948 IBM 402 Accounting Machine Alphanumeric, with 403, 412, 417, 419 variations 
1949 IBM 407 Accounting Machine High-speed alphanumeric. 421, 444, 447 variations 
IBM 405, 402 and 407 were electromechanical accounting machines 
Source: http://www.columbia.edu/cu/computinghistory/tabulator.html 
 
 DATA MANAGEMENT FROM 1950’S 
The next IBM computers (1959) were electronic digital computer for general purpose. Until the mid-
1970s, most computer access was via punched cards Figure 1.1.1. 
 
 
 
Figure 1.1.1: Punch Card Image 
Adapted from Programming with punched cards 2005 Dale Fisk: http://www.columbia.edu/cu/computinghistory/fisk.pdf 
 
In the 1980s data were processed using cards and computer programs with data punched on 
punch cards (Figure 1.1.1), using a key punch machine and read into a card reader. Next tapes 
were used for storage and retrieval of data. As technology advanced: using the punched cards, 
was followed by the use of tapes (sequential access media or fixed order of access), and 
subsequently followed by use of magnetic disks (random access media; Figure 1.1.2). 
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Figure 1.1.2: Tape (Sequential Access) and Disk (Random Access)  
Adapted from: https://commons.wikimedia.org/wiki/File:Random_vs_sequential_access.svg 
 
As technology began to advance it became possible to store single units of information in a single 
place and access that stored information or memory using random access memory (RAM). 
Examples of RAM are computer floppy disks and computer hard drives. As applications moved into 
real-time interactive applications, data management and data process management processes 
continued to evolve (Gray, 1996). Therefore, if the data were not defined well then there was a 
possibility of increased errors in data, while if the data management processes were not defined 
well then needs of the data users were not standardised. Research integrity in science requires 
good data management processes and it is important that the old data and applications continue to 
function as new data and applications are added (Gray, 1996). 
 
As reported in a paper by Gray (Gray, 1996), data management has evolved over time and there 
are six development phases of data management advancement ard these are summarised in 
Figure 1.1.3. The first computational tool was developed around 4000 BC and probably involved 
pebbles and twigs and lines in the sand for counting. The bead frame abacus was probably 
invented by the Chinese sometime around the second century AD. Although abacus was not 
technically a computer, the operator of the abacus manipulated data mentally and with skill came 
speed (Dilson, 1968). The six phases of data management depicted in Figure 1.1.3 are: 1) 
Manually processed data; 2) Use of punched-card equipment and electro-mechanical machines to 
sort and tabulate records; 3) Stored data on magnetic tape and used stored program computers to 
perform batch processing on sequential files; 4) Introduction of the database schema and online 
access to data. Automated access to relational databases and added distributed and client-server 
processing; 5) Storage of richer data types, notably documents, images, voice, and video data. 
The sixth generation systems are the storage engines for the Internet, Intranets. 
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Year 
 
Phase 1 
Phase 2 
Phase 3 
Phase 4 
Phase 5 
Phase 6 
 
Figure 1.1.3: The Six Phases of Data Management 
Source of figure (Gray, 1996). The six phases of data management advancement: from phase 1 manual methods 
through several phases of computerised data management. 
 
 DATA MANAGEMENT 
According to the definition provided by the Data Management Association (DAMA) international, 
data management is „the development, execution and supervision of plans, policies, programs and 
practices that control, protect, deliver and enhance the value of data and information assets‟ 
(Mosley, 2007). In information technology (IT) processes, data are generally represented as 
content in a data field which hold facts. Data become information when they are structured to 
provide context and meaning. Context for instance would mean: which data, how were the data 
collected, on whom, for what. Data management focuses on defining the data and how they are 
structured, stored and moved. Management of information is focused on the security, accuracy, 
completeness and timeliness of multiple data sources. 
 
Data analyses are conducted on quantitative data such as age, CD4 T-cell count, HIV-1 RNA 
plasma load, and categorical data such as severity of disease mild, moderate, severe. The 
population based statistical analysis of the data was performed using various techniques such as 
simple descriptive statistics, linear regression analyses, survival analysis and longitudinal data 
analyses (Armitage et al., 2001). Data analysis uses different statistical methods that help to 
describe data, detect patterns, provide clues and explanations, and test hypotheses (Machin & 
Campbell, 2005). 
 
 DATABASE 
A database stores information electronically which is held over a period of time in a computer 
readable form. Database technology has advanced since the 1950‟s (see section 1.1 Data 
Management from 1950‟s). Most databases store time-varying information. For example to collect 
CD4 T-cell count history of a patient, the design would need a unique identifier for a person such 
as the hospital identifier (HOSPID) and dates describing continuous periods of time together with 
results. 
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The purpose of a database5 is to help keep track of records, and the most commonly used type of 
database is the relational database. A relational database stores data in tables. Data are recorded 
facts and numbers. A table has rows and columns, such as those in a spreadsheet. Tables store 
information about a single subject and have columns that contain the different kinds of information 
about the subject and rows that describe all the features of the subject. A database usually has 
multiple tables, and each table contains data about a different type of records. A database shows 
the relationships among the rows of data which is an important characteristic and each row in a 
table is uniquely identified by a unique primary key where the values of these keys are used to 
create the relationships between the tables. 
 
 DATABASE MANAGEMENT SYSTEM 
Managing several hundred electronic spreadsheets using folders and subfolders becomes difficult 
and thus access to finding patient records become a challenge. Database management systems 
store and handle information using relational database management systems, which manage all 
data in tables. Databases have evolved over time and these advances allow users to access, 
update, and search information based on the relationship of data stored in a database, and also 
allows queries to be run in multiple databases. The databases now allow, in addition to text or 
numeric data, storage of other data types such as sound clips, pictures, and videos. The 
expanding data management include data independence, data integrity, data consistency, 
information retrieval, multimedia retrieval, and data visualisation. 
 
Broadly, data management involves: collection, storage, and retrieval of data. With IT advances, 
the volume of data collected continues to grow. The main data collected in the NHS that are used 
and discussed in this PhD thesis are based on patient care. Large collections of patient care data 
from different sources, such as laboratory, pharmacy data, activity data of outpatient and inpatient 
stay and many other sources of data may lead to errors such as data formats, data transfer errors, 
thus potentially jeopardising data integrity. To minimise these types of possible errors and thus 
increase confidence in predictions there is a need for appropriate processes for data collection, 
data storage, and data retrieval and data analysis (Figure 1.1.4). 
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Figure 1.1.4: Data Management Process 
Source: http://www.admin.ox.ac.uk/rdm/ 
 
The main ideas of database management are to ensure data independence, data integrity and 
data consistency where the principle aim is to ensure good quality data. 
 
 TWENTY FIRST CENTURY AND THE GROWING INFORMATION AGE 
In 2008, the analyst firm, International Data Corporation (IDC) released a report „The Diverse and 
Exploding Digital Universe‟ (Gantz et al., 2008). The report focused on the increasing size of 
electronic information around the world and noted that the amount of data in healthcare is large 
and growing. The IDC research showed that the information that is either created, captured, or 
replicated in computerised form was 281 exabytes in 2007. Whilst a 2010 IDC report predicted that 
by 2020, the information in the „Digital Universe‟6 will grow by a factor of 44 compared to 2009; the 
number of „files‟ to be managed in it will grow by a factor of 67, and storage capacity will grow by a 
factor of 30 (Figure 1.1.5) (Gantz & Reinsel, 2010).= 
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Figure 1.1.5: Worldwide Computerised Data Forecast to 2020 
Source of figure: http://www.economist.com/node/18226961 
 
As computer processor and storage capacities have grown exponentially, this has enabled the use 
of powerful, user-friendly software in medical practice. The UK Government has demanded an 
improved cost effective ways of working to produce better health outcomes for patients in order to 
provide an improved continuity of care. Information continuity, management continuity and 
relational continuity (Haggerty et al., 2003) are necessary in order to improve the quality of care 
provided.  
 
 MEDICAL RECORDS 
The two main methods of collecting patients medical data are paper based as well as electronic 
medical records. Data within the NHS or other health care setting in the UK are either collected in: 
patient‟s medical notes only and therefore only available in a paper format, in an electronic format 
captured into a specific database including local data warehouse, or are collected in a combination 
of both data collection methods.  
 
Medical records contain patient care documentation where care was received and include data 
such as lab results, visit notes, diagnostic test results, demographics, health histories, medication 
information, and more. Depending on the method of data collection these are either securely 
stored in paper files or in a securely held local server in an electronic format. Electronic medical 
records mostly contain same clinical data in an electronic format so for instance electronic 
documentation of care history of a patient attending for care at one treatment centre. Some of the 
advantages of these types of data collection include: allowing patients records to be tracked over 
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time, administrative ease of identifying patients who are due for appointments for instance, 
allowing checks regarding how patients are doing following clinic visit for instance. All these allow 
clinicians within one treatment centre to monitor and improve overall quality of patient care and 
hence improving patient outcomes. While same data held only in patient notes as paper based 
information are often held in large folders and filed in various locations such as the doctors‟ offices 
and hospitals, and not turned into electronic records, become difficult to locate and could 
potentially become a time consuming task to locate individual patient folders. 
 
Electronic patient medical records are used by health care professionals to access patient 
information and support decision making usually within one practice, through evidence-based 
health practice. Globally there is a need to ascertain the effectiveness, efficiency, equity and 
acceptability of health care services provided. As a result there is a commitment within the UK 
government for development of universal healthcare systems to be put in place (Figure 1.1.6).  
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Figure 1.1.6: Access to Health and Care Information 
Source: The power of information: Putting all of us in control of the health and care information we need (Department of 
Health, 2012) 
 
 HEALTH RECORDS 
Health care is part of the information age and electronic health records focus on the total health of 
the patient. This is in addition to the standard electronic patient medical records collected within 
one practice. Health records are medical records with the capacity for greater exchange; they are 
the health data held on a patient at different clinical practices and when in an electronic format 
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allow for data exchange between different health care team workers. The disadvantages of paper 
based collection of data are that these types of health record data exchange has limitations as 
papers need to be first retrieved and exchanged via normal post or fax which is time consuming 
and access to these data records are with some level of delay. The electronic health records in 
contrast include a larger view of data about the patient‟s care beyond one treatment centre that 
originally collected the information and share information with other health care providers, such as 
laboratories and specialists therefore these contain information from all clinicians involved in a 
patient‟s care. They are patient-oriented, aggregated, longitudinally collected data about the health 
of a patient over a wide area, potentially including many geographically dispersed data sources 
and the information collected moves with the patient to care providers such as: to hospitals, 
different specialists, to nursing homes, to different hospitals in other parts of the country. An 
electronic health record contains each individuals aggregate, secure and confidential lifetime 
record of health care history recorded within the health care system that is available electronically 
with authorised health care providers and the individual anywhere, anytime in support of high 
quality care (Garets & Davis, 2006).  
 
The databases that hold electronic health records are built so that routinely collected information 
can be shared with other health care providers such as laboratories, different specialist services, 
located locally as well as elsewhere in the country. The data from individual databases or local 
data warehouses are deposited into a national data repository or national data warehouses which 
therefore hold routine information about patients health care details from all clinicians involved with 
their care allowing information to be shared speedily across different care providers supporting 
healthcare team effort. Further, secondary uses of these routinely collected data into databases 
include: clinical research, service evaluation, clinical audits, surveillance and usual practice in 
public health (NRES, 2009) covering such areas as: public health, epidemiology, health trends, 
service developments, informing governments, monitoring quality of health care and informing 
patient choice, linkage to other data sources such as mortality data from the Office of National 
Statistics, national audits, cancer registries (Spencer, 2013). 
 
The UK government‟s commitment to develop universal healthcare systems will use IT to improve 
the NHS health care provision and such improved systems will help improve decision making for 
health care professionals, business managers, policy makers, pharmaceutical companies and 
researchers so that social welfare, public services and research conduct can be improved. The 
routinely collected data on HIV-1 infected people who are managed long-term with HIV-1 infection 
was used as an example and a model to demonstrate the use of the NHS health care system 
database. 
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 THE NATIONAL PROGRAMME FOR IT IN THE NHS: 2000-2011 
In June 2000, the UK government, responsible for NHS England, spent £11.4 billion for an update 
of NHS IT systems to help provide high quality services to patients through the National 
Programme for IT in the NHS (NPfIT). The NHS in England began deployment of electronic health 
records systems in 2005 together with other electronic health record initiatives in Wales, Scotland 
and Northern Ireland. The goal was to have the UK populations medical details on a centralised 
electronic health record by 2010. The UK governments aim was to replace local NHS computer 
systems with a modern integrated systems and make patient‟s health records available 
electronically throughout England and including other services, such as electronic prescriptions, an 
email and directory service for all NHS staff (NHSmail), computer accessible X-rays (Picture 
Archiving Communication Systems - PAC), and a facility for patients to book outpatient 
appointments electronically so that patient records can be shared (House Of Commons, 2007). 
 
The implementation of planned targeted work was delayed and subsequently stopped in 2011. The 
failures to meet IT implementation targets were highlighted in the 2007 House of Commons report 
regarding the shared electronic patient clinical records. The report highlighted NPfIT were running 
two years behind schedule with other examples of failures described in the report. Subsequent to 
this report and failures to meet the set targets, the UK government announced cancellation of work 
contracts with NPfIT. The critical area which led to the delays in the planned work were highlighted 
in a publication by Deutsch and colleagues (Deutsch et al., 2010) and a summarised opinion was 
published in computer weekly by a partner at Morrison & Forester (UK) LLP firm, with six points 
summary why the NHS NPfIT failed to meet the IT implementation targets (Maughan, 2010). The 
six points were summarised under the following broad headings: 1) Motives; 2) Buy-in; 3) More 
haste, less speed; 4) Poor contracting process; 5) Multi sourcing; 6) Accountability. 
 
The Department of Health (the Department) had hired British Telecom (BT) and Computer 
Sciences Corporation (CSC) as two main contractors to undertake IT systems upgrade in the NHS. 
Although payments were made in advance to CSC, however CSC delivered very few of the 
systems it was contracted to supply and instead implemented a large number of interim systems 
as a stopgap. BT also proved unable to deliver against its original contract. One factor which 
contributed to failings was the Department's weak programme management. This resulted in poor 
accountability for project performance. The shortcomings of the National Programme included poor 
negotiating capability, resulting in deals which were poor value for money and weak programme 
management and oversight. In addition there were failures regarding understanding of complexity 
of the tasks, the difficulties of persuading NHS trusts to take new systems that had been procured 
nationally, and to get people to operate the systems effectively when they were adopted. The 
Department was criticised as they could have avoided some of the pitfalls and waste if they had 
consulted with health professionals earlier. 
CHAPTER 1 
GENERAL INTRODUCTION 
38 
 
 THE CURRENT UK INFORMATION STRATEGY: FROM 2012 
In May 2012, the UK Department of Health published an information strategy policy document „The 
power of information: Putting all of us in control of the health and care information we need ‟ 
(Department of Health, 2012), which set a ten year framework to transform information for health 
and care which would allow people control of their health and care records and to give them 
access to these by 2014 (see section 1.1: Figure 1.1.6). The aims are to integrate information and 
new technologies in order to achieve higher quality care and improve outcomes for patients and 
service users under the Health and Social Care Act 2012, it covers public health, healthcare and 
social care in adult and children‟s services in England (Department of Health, 2012). 
 
The electronic capture, storage and transfer of information can provide different stakeholders with 
access to health care information with minimum delay (Department of Health, 2012). Improved IT 
will facilitate input, storage, access, analysis, and communication of data and information for 
clinicians and researchers thereby can help identify gaps in healthcare services. The knowledge 
generated from these electronic medical and health data is likely to improve resource allocations, 
reduce costs, and help define areas of further investigation in order to improve outcomes for 
patients and service users. 
 
The NHS in the UK underwent changes which became effective from 1st April 2013, NHS England 
took on the functions of the primary care trusts (PCTs) with regard to the commissioning of primary 
care health services, as well as some nationally based functions previously undertaken by the 
Department and the clinical commissioning groups will be overseen by the NHS England (Figure 
1.1.7). The main aim of NHS England is to improve the health outcomes for people in England.  
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Figure 1.1.7: The Health and Care System from April 2013 
Before in Figure 1.1.7 means prior to 1
st
 April 2013, while after refers to changes that took effect from 1
st
 April 2013 
Source: http://www.bbc.co.uk/news/health-19674838  
 
These changes are related to: which organisation will make decisions about the NHS services, 
how these services are commissioned, and the way money is spent. The changes that took effect 
are summarised in Figure 1.1.8. 
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Figure 1.1.8: The Changes to NHS Structure from April 2013 
Current in Figure 1.1.8 means prior to 1
st
 April 2013, while new refers to changes that took effect from 1
st
 April 2013 
Source: http://www.bbc.co.uk/news/health-12177084  
 
From April 2013, the clinical commissioning group (CCG) is led by GPs who are responsible for 
around 60% of the NHS budget. They have taken charge of overseeing the NHS from the 
Department. Since GPs are in a regular contact with patients, Ministers believe that CCG will be 
more responsive to the needs of patients and therefore will make the NHS more efficient and 
improve the quality of care. 
 
The NHS Englands recently published business plan for 2013-2014 through to 2015-16 „Putting 
Patients First‟ (NHS England, 2013) highlighted that the NHS England will publish a technology 
roadmap which will set a national vision for NHS IT for commissioners investing in IT and 
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informatics. With regards to IT, one of the target is to have 95% of trusts using the NHS number as 
a unique patient identifier in clinical correspondence by January 2015. The key deliverables 
highlighted in this report were 100% of practices will offer the facility to order repeat prescriptions 
and to book appointments by March 2015 (NHS England, 2013). In addition, e-referrals service 
would be operational by December 2013 and 100% of referrals will be made electronically by 
March 2017. The plan states that health and care data are one of England‟s greatest public assets 
and „putting it to work‟ is key to improving patient outcomes. In response to this the NHS England 
is developing the care.data, a programme designed to link patient data from different care sectors 
for the first time, which will provide linked data across the different components of the patient 
journey and the outcomes resulting from treatment. Once in practice, having access to such data 
quickly will allow early intervention which can help prevent adverse developments affecting 
patients' health, and therefore avoiding retrospective treatment. As a result this may have an 
impact on efficiency savings by reducing the cost of treatment and freeing time for hospital staff. In 
the current economic climate the NHS is balancing between providing high quality care and 
Government‟s intention of efficiency savings in the NHS, a saving of £20 billion a year by 20157.  
 
Often used term „big data‟ is not well defined but „big data‟ refers to datasets whose size is beyond 
the ability of typical database tools to capture, store, manage and analyse (Manyika et al., 2011) 
and is characterised by (Marr, 2013): Volume - the vast amounts of data generated every second; 
Velocity - the speed at which new data is generated and moves around; Variety - the increasingly 
different types of data (from treatment data to X-rays to voice recordings); and Veracity - the 
messiness of the data (e.g. text strings with hash tags, abbreviations, typos). 
 
„We live in the information age‟ is also synonymous to „we live in the data age‟ where large 
amounts of data: terabytes, exabytes are being collected. Data mining (knowledge mining from 
large amounts of data) turns a large collection of data into knowledge. The data mining is the 
process of discovering patterns in data after the required information has been extracted (Figure 
1.1.9). The data sources can include databases, data warehouses, the Web, other information 
repositories, or data that are streamed into the system dynamically, ordered/sequence data, graph 
or networked data, spatial data, text data, multimedia data, and the web. Data mining is currently 
evolving and other data sources will be included as these evolve over time.  
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Figure 1.1.9: Data Mining Process Diagram 
 
Definition of data mining (Oxford dictionary: http://oxforddictionaries.com) „the practice of 
examining large pre-existing databases in order to generate new information‟. The data mining 
process involves: Data cleaning: to remove noise and correct inconsistency in data, Data 
integration: merges data from multiple sources into a coherent data, Data selection: can reduce 
data size, for e.g., aggregating, eliminating redundant data fields, Data transformation: e.g. 
normalisation may be applied, where data are scaled to fall within a smaller range like log 
transformation, Data mining: Finding trends in data, Evaluate trends found in data, Knowledge 
presentation. 
 
There are however also many other terms with a similar meaning to data mining - for example, 
knowledge mining from data, knowledge extraction, data/pattern analysis, data archaeology, and 
data dredging. The ultimate goal of data mining is prediction and data mining is considered to be a 
blend of: statistics; database management; data base research; artificial intelligence; machine 
learning; pattern recognition; and data visualisation (Friedman, 1998).  
 
Big data analytics is the process of examining large amounts of data of a variety of types (big data) 
to uncover hidden patterns, unknown correlations and other useful information that may have been 
left untapped as technology is now advanced to bring all data of a variety of types together and 
analyse these. The economic value of „big data‟ was first termed as „data equity‟8. A report by The 
Centre for Economics and Business Research Ltd (CEBR) „Data Equity: Unlocking the value of Big 
                                               
Chapter 1:8
 The term „data equity‟ was first used in an article in The Economist in May 2011 by Adrian Wooldridge entitled 
„Building with big data‟ to mean the economic value of big data http://www.economist.com/node/18741392  
CHAPTER 1 
GENERAL INTRODUCTION 
43 
Data‟, the use of big data analytics across the healthcare sector could deliver additional revenues 
of £14bn from 2012 to 2017 (CEBR, 2012). 
 
1.2 HUMAN IMMUNODEFICIENCY VIRUS 
 HIV HISTORY 
The earliest case of Human Immunodeficiency Virus (HIV) infection was documented in a 1959 
blood sample taken from an adult male from the Democratic Republic of the Congo (Zhu et al., 
1998). Epidemiologists have speculated that the virus may have travelled from Africa to the United 
States during the 1970‟s where it was first transmitted via sexual intercourse among gay men in 
New York and San Francisco.  
 
In 1981 a number of gay men in New York and San Francisco developed rare cancers and 
opportunistic infections that were resistant to treatment. On 5th June 1981 a case of AIDS was 
reported (MMWR, 1981; Fee & Brown, 2006). The syndrome at the time was known as gay-related 
immune deficiency (GRID), which on 27th July 1982, at a meeting held in Washington, was 
renamed to Acquired Immunodeficiency Syndrome (AIDS) (Kher, 1982). In French, Portuguese, 
and Spanish, it is known as syndrome d‟immunodéficience acquise (SIDA). 
 
In 1983 the cause of AIDS was described as a retrovirus when lymphadenopathy associated virus 
(LAV) was isolated by the Institute Pasteur, France from a French homosexual patient with 
generalised hyperplastic lymphodenopathy (Barré-Sinoussi et al., 1983; Montagnier et al., 1984). 
In 1984 Robert Gallo and colleagues at The National Cancer Institute, USA characterised the 
AIDS-associated retrovirus as human T-lymphotrophic virus III (HTLV-III) (Popovic et al., 1984; 
Gallo & Montagnier, 2011), although both the French and US laboratories had identified the cause 
of AIDS, in 2008 the Nobel Prize for the discovery of HIV was awarded to Barre-Sinoussi and 
Montagnier. In 1987 the name human immunodeficiency virus (HIV) became internationally 
accepted during a World Health Organisation (WHO) Consultative Meeting and was confirmed by 
the International Committee on Taxonomy of Viruses (ICTV)9. 
 
In 1986, a second type of retrovirus (type 2; HIV-2) which belonged to the HIV group was isolated 
by Luc Montagnier and colleagues from West African patients with AIDS (Clavel et al., 1987). 
While HIV-1 is found worldwide, HIV-2 is largely confined to West African regions. Although HIV-1 
and HIV-2 are related, there are important differences between them which influence 
pathogenicity, natural history and therapy (Markovitz, 1993). Natural history studies indicate that 
HIV-2 is less pathogenic than HIV-1 and progression of disease among people infected with this 
strain alone is slower. HIV-2 infected people have shown a slower progression to AIDS with 86-
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95% of HIV-2 infected people fulfilling the definition of long-term non-progressors (LTNP) (Kanki, 
1999). The work presented in this PhD thesis will be focusing on HIV-1 infection.  
 
 HIV-1 
HIV-1 belongs to the lentivirus (or slow virus) family and causes slow progressive disease. Both 
HIV-1 and HIV-2 are ribonucleic acid (RNA) viruses and consist of two short strands of RNA along 
with the enzymes reverse transcriptase, protease, ribonuclease, and integrase (Tang et al., 1999). 
This genetic material is encased in a capsid within a membrane lined by a matrix protein, the viral 
envelope. Projecting from this viral envelope include 72 spikes formed from the viral proteins 
gp120 (surface) and gp41 (transmembrane). Figure 1.2.1 shows the different components of the 
virus structure. 
 
 
 
Figure 1.2.1: Structure of HIV Virus 
Source: http://www.niaid.nih.gov/topics/hivaids/understanding/biology/Pages/structure.aspx 
 
  Core Viral Enzymes 
Glycoproteins  Core capsid Reverse 
Transcriptase 
Integrase 
gp120/gp41 p24 p64 p32 
Mediate entry into host cell Within the capsid are two 
identical single strands of 
RNA (the viral genetic 
material) and viral 
enzymes 
Converts single stranded 
viral RNA into double 
stranded viral DNA 
Facilitates integration / 
incorporation of viral DNA 
into host DNA 
 
The main route of HIV-1 transmission is through sexual contact (semen, vaginal secretions), during 
pregnancy or vertical transmission from mother to child and through breast milk. Other possible 
routes of transmission include: infected blood and blood products; contaminated needle sharing 
among injecting drug users (IDU); contaminated blood transfusions. HIV-1 targets the host immune 
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system and renders it incapable of coping with opportunistic pathogens. HIV-1 infection initiates a 
process that leads to progressive destruction of CD4 T lymphocytes, a type of helper T white blood 
cell vital to the adaptive immune response. CD4 T lymphocytes are required for the normal function 
of the immune system, which defends the body against infection. When HIV-1 weakens the 
immune system due to the progressive decline in immune defence mechanisms, people with HIV-1 
infection develop a number of opportunistic infections during later stages of disease that is also 
characterised with onset of various tumours/malignancies and becoming infected with other 
viruses, bacteria and parasites. 
 
The course of the HIV-1 infection varies from person to person. A typical pattern of HIV-1 infection 
is divided into three stages: primary infection; asymptomatic infection; and eventually development 
of certain opportunistic infections, neoplasias or other conditions. The advanced stage of this is 
known as AIDS which may be accompanied by opportunistic infections and or decline of CD4 T-
cell counts below a nationally agreed defined threshold (Figure 1.2.2). A person who tests HIV-1 
positive is considered to have progressed to AIDS when the patient develops at least one of about 
25 different opportunistic infections (McCarthy & Mercey, 1994), diseases that may not necessarily 
affect a person with a normal immune system but that take advantage of weakened immune 
system. 
 
 
 
Figure 1.2.2: Typical Phases of HIV-1 Infection and the Dynamics of CD4+ T-Cell Counts and 
HIV-1 RNA Plasma Load 
Source of figure: http://upload.wikimedia.org/wikipedia/commons/a/a4/Hiv-timecourse.png 
cells/µL = cells/micro litre - this is sometimes written as cells per one cubic millimetre mm
3
 (cells/mm
3 
) 
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1. Primary infection 
The primary infection, which generally lasts for 2 to 8 weeks, is typically associated with high levels 
of virus in the patient‟s plasma and rapid CD4 T-cell decline in peripheral blood. During primary 
infection, the number of CD4 T-cell counts decrease but return to near normal levels within three to 
four months after infection. Similarly, there is rapid viral replication characterised by high HIV-1 
RNA plasma load during the acute phase that drops to a stable level (termed viral set-point) over a 
period of two to ten weeks (Figure 1.2.2).  
 
2. The asymptomatic phase 
The asymptomatic phase is characterised by a gradual decline in CD4 T-cell count, but this actual 
rate of decline varies substantially between individuals.  
 
3. The symptomatic phase 
The symptomatic stage occurs late in infection when opportunistic infections and malignancies 
occur due to poor immunity. During this stage, resurgence of HIV-1 RNA plasma load is seen and 
uncontrolled HIV-1 replication occurs. With the onset of AIDS, HIV-1 infected people may rapidly 
progress to death in the absence of appropriate treatment (Feinberg, 1996).  
 
At present there is no cure for HIV-1 infection (Eisele & Siliciano, 2012). HIV-1 infection that was 
once a fatal condition is now a chronic condition managed and controlled with ARV drugs (Palella 
et al., 1998; Deeks, 2011). These are prescribed life-long in order to sustain and control HIV-1 
replication. There are a large number of approved ARV drugs prescribed for controlling replication 
of HIV-1: occasionally alone as mono therapy; or mostly in combinations as 3 or more ARV drugs 
described as Highly Active Antiretroviral Therapy (HAART). Some of the ARV drugs prescribed 
and are approved for use in Europe are detailed in Table 1.2.1. 
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Table 1.2.1: ARV Drugs Approved for Use in Europe 
 
Cohort 
definition 
Class of ARV ARV drugs and year of approval for use in Europe 
and its availability in the UK 
ARV drugs are known with: their generic name, drug trade 
name (abbreviation) 
pre-HAART 
 (pre 1996) 
NRTI Zidovudine, Retrovir (AZT) 
Didanosine, Videx (DDI) 
Zalcitabine, Hivid (DDC) 
Stavudine, Zerit (D4T) 
Lamivudine, Epivir (3TC) 
Saquinavir Invirase
&
, Fortovase
&&
 (SQV) 
1987 
1991 
1992 
1995 
1994 
1995 
HAART era 1  
(1996-2000) 
NNRTI 
PI 
PI 
PI 
NRTI 
NNRTI 
NRTI 
PI 
Nevirapine, Viramune (NVP) 
Ritonavir, Norvir (RTV) 
Indinavir, Crixivan (IND) 
Nelfinavir, Viracept (NFV) 
Delaviradine, Rescriptor (DLV) 
Efavirenz, Sustiva (EFV) 
Abacavir, Ziagen (ABC) 
Amprenavir, Agenerase (APV) 
1996 
1996 
1996 
1997 
1997 
1998 
1998 
2000 
HAART era 2  
(2001-2004) 
 
 
 
 
Fusion Inhibitor 
Kaletra (LOP+RTV) 
Trizivir (AZT+3TC+ABC) 
Combivir (AZT+3TC) 
Enfuvirtide, Fuzeon (T-20) 
2001 
2001 
2003 
2003 
HAART era 3  
(2005-2008) 
 
 
 
 
 
Integrase Inhibitors 
CCR5 Entry inhibitor  
NNRTI 
Tipranavir, Aptivus (TPV) 
Truvada (TDF+FTC)  
Kivexa (ABC+3TC) 
Atripla (EFV+TDF+FTC) 
Raltegravir, Isentress (RAL) 
Maraviroc, Celsentri^ (MVC) 
Etravirine, Intelence (ETV) 
2005 
2005 
2005 
2006 
2007 
2007 
2008 
HAART era 4  
(2009-2011) 
NNRTI Rilpivirine, Edurant (RPV)  May 2011 
NRTI: Nucleoside reverse transcriptase inhibitor (NRTI), also called nucleoside analogues 
NtRTI: Nucleotide reverse transcriptase inhibitor (NtRTI), also called nucleotide analogues 
PI: Protease inhibitor 
NNRTI: Non-nucleoside reverse transcriptase inhibitors 
Fusion Inhibitor 
Integrase inhibitor 
CCR5 Entry inhibitor or CCR5 Fusion Inhibitor 
^Celsentri is known as Selzentry in the US 
&
 Hard gel capsule 
&&
 Soft gel capsule 
 
 GLOBAL HIV-1 
Worldwide, the total number of adults and children estimated to be living with HIV-1 continues to 
increase. At the end of 2011 it was 34.0 million (range: 31.4 to 35.9; Figure 1.2.3) (UNAIDS World 
AIDS Day Report, 2012) while by the end of 2012 it had increased to 35.3 million (range: 32.2 - 
38.8) (UNAIDS Report on the Global AIDS Epidemic, 2013). The HIV-1 pandemic continues to 
grow and majority of new infections occur in developing countries. Of the total world population that 
is reported to be infected with HIV-1, 69% are estimated to be living in Sub Saharan Africa. In 
Western and Central Europe, 2.6% of the world‟s adults and children are estimated to be living with 
HIV-1 (UNAIDS World AIDS Day Report, 2012). 
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Figure 1.2.3: Proportion of Total Global 2012 Estimate of People Living with HIV-1 by 
Continent 
Source of estimates of number of people living with HIV-1 by end of 2012: UNAIDS World AIDS Day Report, 2013 
Proportion of people living with HIV-1 for each continent derived relative to the total global 2012 estimate 
 
Many people diagnosed with HIV-1 early in the epidemic survived for a short duration. The 
advances in use of cART was announced in 1996 at the International AIDS Conference in 
Vancouver. Since entering the highly active (HA)ART era in 1996, mortality due to HIV-1 infection 
has declined, resulting in longer survival of HIV-1 infected people. Following the successful scale 
up of HIV-1 treatment access, worldwide the number of deaths attributed to AIDS related causes 
fell by 24% from 2.3 (2.1 to 2.6) million in 2005 to 1.7 (1.5 to 1.9) million by end of 2011 (UNAIDS 
World AIDS Day Report, 2012). Although there have been advances in treatment of HIV-1 
infection, the search for preventive strategies on the development of prophylactic and therapeutic 
interventions through effective vaccines and/or immune-based therapies continues to put an end to 
disease, to prevent infection or delay disease progression (Blankson, 2010; Imami et al., 2013; 
Walker & Yu, 2013).  
 
 PEOPLE LIVING WITH HIV-1 IN THE UK 
The number of people living with HIV-1 in the UK increased from 96,000 in 2011 (credible interval: 
90,800 to 102,500) to 98,400 in 2012 (credible interval: 93,500, 104,300), of whom an estimated 
Adults and children living with HIV (2012)
Source: UNAIDS report on the global AIDS epidemic 2013
Total Global Estimate
35.3illion
[32.2-38.8] million
6.1% 3.7%
4.2% 0.7% 70.8% 0.9%
13.7%
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22% (credible interval: 18% to 27%) were unaware that they were infected with HIV-1. By the end 
of 2012 76,500 people diagnosed as HIV-1+ had used the NHS services (credible interval: 75,000, 
78,000) of whom 19,123 (25%) were older adults (≥50 years). In comparison, in 2003 4,361 (12%) 
HIV-1+ people had used the NHS services in this ≥50 years age group (Aghaizu et al., 2013). 
 
 IMPACT OF HIV-1 INFECTION AND TREATMENT IN THE UK  
The rate of disease progression from asymptomatic HIV-1 infection to AIDS varies between 
patients (Pantaleo & Fauci, 1996). The basic science study presented in this PhD thesis 
determined factors associated with HIV-1 progression which may enable the development of 
prophylactic and therapeutic interventions through effective vaccines and/or immune-based 
therapies to put an end to disease, to prevent infection or delay disease progression (Chapter 3: 
long-term non-progressors - LTNP). 
 
Many HIV-1 infected patients in the UK need long-term medical care at specialist NHS hospitals 
and treatment centres, and with new and potent ARV drugs now available for treating HIV-1 
infection (see Table 1.2.1), people who have access to these drugs continue to live longer and 
therefore HIV-1 is now considered a chronic illness. Owing to the success of HIV-1 treatment and 
care, in combination with an increasing number of people who are older becoming infected with 
HIV-1, a greater number of people aged ≥50 years are living with HIV-1 (Deeks, 2011). In the UK 
and worldwide, the proportion of HIV-1+ people who are aged ≥50 years is increasing rapidly. 
Furthermore, these older treated HIV-1+ individuals are now facing a complex ‟ageing‟ process 
involving biological, social and psychological aspects. The clinical science study presented in this 
PhD thesis assessed the impact of HIV-1 infection, anti-retroviral therapy (ART) and age on renal 
insufficiency in PLHIV managed at the HIV referral centre (Chapter 4: HIV and Ageing). 
 
The ageing HIV-1 cohort together with increased number of people being diagnosed with HIV-1 
infection has resulted in an increased number of people accessing HIV-1 services in the NHS over 
time (Aghaizu et al., 2013). These increases in access of health care in the NHS implies that the 
costs associated with HIV-1 care will continue to also increase over time, if the current use of HIV-
1 services persist in the NHS hospitals. This therefore directly impacts on the NHS cost burden 
nationwide for treating HIV-1 infected people in the NHS specialist treatment and care centres. The 
population science study presented in this PhD used information from an established national 
multicentre prospective monitoring system to report changing use and population cost of HIV-1 
services in the UK, and estimated future population costs arising from projected increases in the 
number of PLHIV using NHS services (Chapter 5: Population Cost Study). 
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 IMPACT OF HIV-1 INFECTION AND TREATMENT ON THE HEALTH CARE 
Due to success of HAART in those people who are on ART, this has increased the life-
expectancy10 of HIV-1+ people. In a recent study, life-expectancy reported of an HIV-1+ aged 20 
years in North America and Europe ranged from 32 years for those who start ART with a CD4+ T-
cell count <100 cells/µL blood to 50 years for those who start ART with CD4+ T-cell >200 cells/µL 
blood (AntiretroviralTherapyCohortCollaboration, 2008). Similarly, HIV-1+ people on ART in 
resource limited countries can also attain near normal life-expectancy: A Ugandan study estimated 
that life-expectancy of an HIV-1+ aged 20 years was estimated to be 27 years, for an HIV-1+ aged 
35 years life-expectancy was estimated to be 28 years while an HIV-1+ aged ≥ 50 years life-
expectancy was estimated to be 24 years. Life expectancy was observed to increase substantially 
with increasing baseline CD4+ T-cell count with similar trends observed for older age groups (Mills 
et al., 2011).  
 
 RESEARCH DESIGN 
The design of any study from observational data is mostly implicit in the precise specification of the 
research question that needs to be answered. The research questions determine the general 
structure of the study design required together with the data requirements and the main analyses. 
The research design is required so that the research question can be answered systematically and 
scientifically. The aim is to control the variability in data as far as possible. A number of studies have 
examined factors associated with treatment failure and increased survival using a number of 
predictive analytical methods including time varying covariates. Three main areas of scientific 
research studies are presented in this PhD thesis and these are: Basic research: „is the 
investigation of a subject to increase knowledge and understanding about it. The information 
gathered from basic science research is essential for „translating‟ or applying new discoveries to 
patient care‟ (Stevens et al., 2002). Clinical research: „clinical research is that component of 
medical and health research intended to produce knowledge valuable for understanding human 
disease, preventing and treating illness, and promoting health‟. Clinical research involves 
interactions with patients, diagnostic clinical materials or data and include clinical knowledge, 
detection, diagnosis and natural history of disease; 
http://www.nap.edu/openbook.php?record_id=12983&page=67 Accessed 03rd Mar 2012. 
Population research: Although the term population research is not precise with a widely agreed 
meaning (Haaga, 2001), „A group of individuals of the same species occupying a particular 
geographic area. Populations may be relatively small and closed, as on an island or in a valley, or 
they may be more diffuse and without a clear boundary between them and a neighbouring 
population of the same species. For species that reproduce sexually, the members of a population 
interbreed either exclusively with members of their own population or, where populations intergrade, 
                                               
Chapter 1:10 Life expectancy is the statistical figure based on the average person‟s length of life and is usually quoted as the 
number of years of life remaining at a given age. http://stats.oecd.org/glossary/detail.asp?ID=1530  
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to a greater degree than with members of other populations.‟ (The American Heritage® Science 
Dictionary Copyright © 2010 by Houghton Mifflin Harcourt Publishing Company. Published by 
Houghton Mifflin Harcourt Publishing Company. All rights reserved) (Pearce, 1996; Pearce, 1999). 
 
 PHD FRAMEWORK 
Research methods that are used and presented in this PhD thesis are comparable for both 
developed and developing countries, but the methods to capture reliable and high quality data may 
differ. Many developing countries do not have the advanced databases and IT infrastructure 
required for data collection. To produce evidence that will be accepted by policy makers and be 
sustainable, a variety of research methods are used for this. A recently described research cycle 
(Figure 1.2.4) (Beck et al., 2008) is used as a framework for the three different studies that were 
undertaken during my PhD work and the aims of this work are to demonstrate how routinely 
collected de-identified HIV-1 patient information can be used for studying basic science (Chapters 
3: LTNP), clinical science (Chapter 4: HIV and Ageing) and population science research (Chapter 
5: Population Cost Study). Throughout the sections in this PhD I have used chapter labels: LTNP, 
HIV and Ageing and Population Cost Study as a reference to the three examples of research 
studies presented. 
 
Figure 1.2.4: Framework of Research Cycle 
Figure taken from (Beck et al., 2008) 
 
With reference to the research cycle (Figure 1.2.4), two analytic studies presented in this PhD are 
LTNP (Chapter 3) and HIV and Ageing (Chapter 4) while the Population Cost Study (Chapter 5) 
falls under operational research. Definition of analytic study: is concerned with identifying or 
measuring the effects of risk factors or with the health effects of specific exposure(s) or 
interventions. Contrast descriptive study, which usually does not test hypotheses. In an analytical 
study, individuals in the study population may be classified according to the absence or presence 
(or future development) of specific disease and according to “attributes” that may influence disease  
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occurrence. Attributes may include age; race; sex; other disease(s); genetic, biochemical, and 
physiological characteristics; social position, economic status; occupation; residence; and various 
aspects of the environment or personal behaviour. Definition of operational research: The 
systematic study, by observation and experiment, of the working of a system (e.g., health 
services), with a view to improvement. Definitions taken from Porta, 2008. 
 
The first analytic study presented identified the prevalence of LTNP among HIV-1+ people and then 
investigated which factors contributed to why disease progression did not occur as rapidly as does 
with most HIV-1+ people. Once these HIV-1+ people are identified as LTNP, they could potentially 
provide insights for HIV-1 preventive or therapeutic vaccine development, providing a useful model  
to study the mechanisms of viral control as a step towards development of prophylactic vaccines 
and immune therapeutic approaches. The second analytic study presented looked at the effect of 
HIV-1 infection on ageing HIV-1+ people on ART and deteriorating renal function. The findings from 
this study also informs the current debate on the time when HIV-1 infected individuals should be 
started on ART. The Strategic Timing of Antiretroviral Treatment (START) trial, which is an 
experimental study that randomised HIV-1+ people with CD4+ T-cell count ≥500 cells/µL blood to 
immediate or deferred ART treatment when CD4+ T-cell count dropped to below 350 cells/µL blood 
is due to report in 2014. The Population Costing study presented falls under operational research 
and estimated the population costs of HIV service provision in the UK 1997-2006 and predicted 
future population NHS costs 1997-2013 based on increasing numbers of HIV-1+ people as they 
move from first- to second-, to third- and to forth- line ART. 
 
1.3 THESIS AIMS AND STRUCTURE  
Society now lives in information age and the volume of data that are collected are a result of 
advancing computerisation with availability of ever increasing powerful data collection computer 
systems and availability of large storage capacity. In medicine this has led to vast amounts of data 
being collected daily. Analysis of routinely collected data is an important need, and data mining 
provides tools for building on existing knowledge as well as discovery of new knowledge and 
increased awareness. This is achieved through collection of good quality data from which new 
trends can be found which may provide missing information to advance existing knowledge (see 
section 1.1: Figure 1.1.9). 
 
There is an ongoing need for personal health information to be collected longitudinally to ensure 
development of good electronic medical and health records locally, nationally and globally requiring 
appropriate IT as well as analytic expertise.  
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With the development of universal healthcare systems, the need is to ascertain the effectiveness 
(the outcome or impact of programmes or services), efficiency (focuses on the resources required 
to achieve a certain outcome or impact), equity (who benefits from programmes or services) and 
acceptability (acceptability of programmes or services to users and providers and to the 
improvements in quality of life they achieve) of services provided. In the UK there is a requirement 
that good individual patient data are collected so these can be used: optimally for NHS use of 
services by individuals; to ascertain the effectiveness, efficiency, equity and acceptability of the 
services provided.  
 
In order to collect such data, databases need to be developed at local hospitals and also as part of 
the HIV response to HIV information systems. In 2005, UNAIDS published a report entitled ‟The 
Three Ones in Action: Where We Are and Where We Go from Here’ (UNAIDS, 2005) that was 
developed within the response to HIV information systems within the context of the short-term 
emergency response to the country‟s HIV epidemic. 
 
In response to this ‟three ones principle‟, a good database need to be put in place that collects 
good quality data at a specialist hospital as well as develop databases as part of the HIV response 
to collect HIV information. The three ones principle was offered to countries in order that they can 
optimise the roles and relationships in the fight against HIV.  
 
 THREE ONES PRINCIPLES 
1. One: Agreed HIV/AIDS action framework that provides the basis for co-ordinating the work  
                     of all partners. 
2. One: National AIDS Coordinating Authority, with a broad based multi-sector mandate. 
3. One: Agreed country level Monitoring and Evaluation System. 
(UNAIDS, 2004) 
 
Of the three ones principle, the ‟Third One‟ was developed within the context of the short-term, 
emergency response to the country‟s HIV-1 epidemic. With the ageing of HIV-1+ population 
requiring treatment and care from other specialists, further development of monitoring and 
evaluation systems are required and these are needed to be expanded to other clinical specialist 
areas. 
 
1.4 PRESENTED STUDIES 
Since HIV-1+ patients are seeking long-term medical care there are many specialist NHS hospitals 
in the UK with historical HIV databases. Analysing such data is important to discover knowledge 
from collected data. Therefore the availability of HIV-1 specific database with historical data both 
locally and nationally require data mining methods to be used to establish the patterns in data 
using statistical analyses. 
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Some HIV-1+ individuals are able to maintain stable CD4+ T-cell count within the normal healthy 
range between 450-1650 cells/μL blood; local laboratory reference range (Westrop et al., 2009) for 
a prolonged length of time and do not exhibit signs of HIV related opportunistic infections such as 
bacterial pneumonia, cytomegalovirus and other infections (Castro et al., 1992), despite not 
receiving ART (Chapter 3: LTNP). The patho-physiological changes observed in HIV-1+ patients 
are similar to those seen in older people not infected with HIV-1, and these changes are 
characterised by ongoing inflammation, immune activation and increased coagulability (Kuller et 
al., 2008; Tien et al., 2010; Eastburn et al., 2011), comparable to changes associated with 
‟immunosenescence‟ (Gress & Deeks, 2009). Furthermore, being treated long-term on ART, 
together with ageing, is a complex ‟ageing‟ process involving biological, social and psychological 
aspects. Identifying and investigating the interacting effects of age and HIV-1 infection and ART is 
likely to guide improved therapeutic intervention in HIV-1+ people with advancing age (Chapter 4: 
HIV and Ageing). 
 
HAART, which typically consists of at least 3 or more ARV drugs, is used to keep control of the 
HIV-1 RNA plasma load in the blood. Tests are used to establish how much virus is circulating in 
HIV-1+ person‟s plasma that allow monitoring effectiveness of the ARV drugs. Monitoring patients 
on treatment, both in terms of effectiveness and also efficiency, could help distribution of limited 
financial resources where money is needed for managing HIV-1+ people, and needs to be spent in 
the NHS (Chapter 5: Population Cost Study). 
 
The three results chapters presented in this PhD thesis together are themed in terms of the use of 
cohort databases, the data management and the use of the data stored and used both from a 
programming and statistical point of view. The three results chapters (Chapters 3, 4 and 5) use 
observational databases to evaluate how long-term follow-up of HIV-1 infected patients can be 
evaluated, giving further insights about their disease course, and the use and cost of HIV-1 
services and use three research areas of scientific research studies: basic science, clinical 
science, and population science.  
 
This chapter introduced data management, a statement of the problem using HIV-1 infection as an 
example. Objectives of the HIV-1 research, the analytical framework used to achieve these aims 
and the methods used to collect data. Chapter 2 describes the analytical methods used in the next 
three chapters. Work presented in: Chapter 3: LTNP; Chapter 5: Population Cost Study have 
appeared or will shortly appear (Chapter 4: HIV and Ageing) as papers in peer reviewed scientific 
journals and findings from these papers are included in this PhD thesis with slight modifications. 
References of these published papers can be found in the section ‟publications arising from this 
thesis‟. Because it was intended that each chapter could be read by itself, some overlap between 
chapters is unavoidable. The concluding Chapter 6 of this PhD thesis highlights novel results found 
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using statistical analysis applied in previous three chapters (Chapters 3, 4 and 5) and a general 
discussions about clinical database developments within the NHS and recommendations. 
 
Main lesson from this PhD is that de-identified individual level patient information can be used at 
local, regional and national levels to monitor and evaluate the effectiveness, efficiency, equity and 
acceptability of HIV-1 and other health services provided. 
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CHAPTER 2: MATERIALS AND METHODS 
 
2.1 OVERVIEW (for all three studies) 
 QUANTITATIVE DATA 
Quantitative data is any category of information or outcome/result that is expressed in a numerical 
form such as statistics, proportions, and/or percentages. Data collected can be used to answer 
specific questions raised using different types of research methods such as basic, clinical and 
population science research (see Chapter 1: section 1.2 for further details on these). The objective 
of quantitative research is to develop hypotheses that are related to some occurrence because it 
provides relationships between an observation and statistical summary of quantitative 
associations. The whole process of measuring this occurrence is central to quantitative research 
because it provides relationships between an observation and statistical summary of quantitative 
associations. Data are analysed using statistics and the ultimate aim is to derive an unbiased 
estimate that could be used to generalise into a defined population. In Medicine and Economics, 
quantitative research is used widely and quantitative methods can be used to verify or refute 
hypotheses. The quantitative research (hypothesising and generalising) methods are considered 
using data analyses where quantitative data are used to answer questions such as „how many?‟ or 
„how frequently‟, which are reported numerically and allow categorisation of set of amalgamated 
data, statistical analysis and mathematical modelling.  
 
 STRENGTH AND WEAKNESSES OF RESEARCH DESIGN 
There are a number of different methodologies used to conduct research data analyses and in 
particular observational study is described and categorised with strengths and weaknesses (Table 
2.1.1). The research questions determined the type of methodology that is used to carry out the 
research. In this PhD thesis the methods used within the studies presented in Chapters 3, 4 and 5 
are described. 
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Table 2.1.1: Methodology Strengths and Weakness 
Methodology Weakness Strengths 
Observational 
research (quantitative, 
epidemiological 
methods) 
Correlational studies 
as a means of 
looking for 
relationship between 
variables when 
experiments cannot 
be done 
Includes longitudinal 
data collection 
Cohorts can be difficult to identify due to 
confounding variables 
No randomisation therefore this could 
mean that imbalances in patient 
characteristics could exist 
Outcome could take time to occur 
Cannot draw conclusions about causality 
 
Costly and subjects may drop out or lost 
to follow up over time 
 
While it is possible to study how 
individuals change using longitudinal 
designs, it is more difficult to understand 
why they change as they do 
Cheaper than a randomised controlled trial 
 
Standardisation of outcome is possible 
Subjects in cohorts could be matched which 
minimises the effect of confounding 
variables 
Can be used to examine complex relations 
among variables  
 
Can examine changes in variables over time  
 
Longitudinal designs control for cohort 
differences 
 
 
 OBSERVATIONAL STUDY 
One of first observational longitudinal study was designed in the 1950‟s to identify risk factors for 
cardiovascular disease (Dawber et al., 1951). Observational longitudinal studies have since been 
undertaken to detect rare or late adverse effects of treatments, and provide an indication of what is 
achieved in daily medical practice. Evidence regarding adverse effects of therapy is undertaken 
after larger, post-market, observational studies have been performed (Papanikolaou et al., 2006). 
Observational studies are useful for demonstrating the benefits and harms of medical interventions 
(Black, 1996). Recommendations for the reporting of observational research was developed by a 
network of methodologists, researchers, and journal editors and is the Strengthening the Reporting 
of Observational Studies in Epidemiology (STROBE) Statement (VonElm et al., 2007) and more 
recently start of „the REporting of studies Conducted using Observational Routinely-collected Data‟ 
(RECORD11) initiative to develop an extension of the STROBE statement. 
 
 OBSERVATIONAL STUDY LIMITATION 
Observational study is conducted by: identifying a group of subjects who are at risk of  a condition 
being investigated; determining the exposure status of each individual; and assessing the 
individuals over time for the occurrence of a condition. Usually this involves a comparison of the 
outcomes for the two (or more) groups being investigated. However, observational studies are 
subject to bias. Bias is defined as “Systematic deviation of results or inferences from truth. 
Processes leading to such deviation. An error in the conception and design of a study - or in the 
                                               
Chapter 2:11
 http://www.equator-network.org/resource-centre/library-of-health-research-reporting/reporting-guidelines-under-
development/reporting-guidelines-under-development/#10 
www.record-statement.org 
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collection, analysis, interpretation, reporting, publication, or review of data - leading to results or 
conclusions that are systematically (as opposed to randomly) different from truth” (Porta, 2008). 
Different sources of bias have been classified into three broad and overlapping groups: the 
selection bias, information bias, and confounding between the risk factor and other possible factors 
(Miettinen & Cook, 1981; Delgado-Rodríguez & Llorca, 2004). Selection bias refers to systematic 
differences in the characteristics between those who are selected for study and those who are not. 
In any study, a selection process can lead to external bias if the selected study participants are 
unrepresentative. Information bias is related to the collection of data about the exposure or the 
outcome. Various forms of information bias derive from errors in measuring accurately. 
Confounding is an intertwining of the causal effect of the exposure with causal effects attributable 
to other factors. A potential confounding factor is a variable that is thought to affect the outcome 
independently of the treatment for instance. 
 
The main aim of research findings is to demonstrate the presence or lack of an association (eg, 
between an exposure and disease) or differences in parameter estimates (eg, means, standard 
deviations, proportions) between populations. Associations or differences may be real, may occur 
by chance (sampling error), or may be related to other factors such as bias. Bias when present 
introduce systematic errors that decrease the validity of estimates presented. Biases are present 
and are difficult to completely eliminate however, attempts are made to reduce this as far as 
possible so that the results presented have greater generalisability. Many types of bias have been 
described, with overlapping terminology (Miettinen & Cook, 1981; Delgado-Rodríguez & Llorca, 
2004). Some bias (eg, confounding) can be adjusted for in the statistical analysis. Uncorrected bias 
have an effect on validity and can lead to data misinterpretation and limit the applicability or 
generalisability of a study. The statistical methods described in this chapter have attempted to 
address sources of bias and in the analytical approach undertaken. The main limitation of an 
observational study is unadjusted confounding factors which may be due to unknown and therefore 
unidentified which may therefore distort the results. Observational data have been used in this PhD 
thesis to exploit rich single and multi-centre HIV-1 databases.  
 
2.2 STUDY POPULATION (for all three studies) 
The two main datasets used for data analyses in this PhD thesis are derived from routinely collected 
data from the NHS hospitals. These are on HIV-1+ people attending for care within the specialist 
centres within the NHS. The sources of data that were used were: 1) data from the Chelsea and 
Westminster HIV cohort which covers routinely collected data on all patients who ever attended for 
specialist care since 1988 up to February 2010 Chapter 3 (LTNP) and up to May 2011 used in 
Chapter 4 (HIV and Ageing). The routinely collected HIV-1 cohort data presented in Chapters 3 and 
4 are updated annually on average. Data presented in Chapter 3 were based on data extracted from 
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the local data warehouse in March 2010 while data presented in Chapter 4 are based on data 
extracted from the data warehouse in June 2011; 2) data from a multi-centre cohort of HIV-1 
infected patients attending for routine care within the participating sites and cover data between 1st 
January 1996-31st December 2006 and these have been presented in Chapter 5. Data collection 
and work on this data commenced from middle of 2007 and data collection completed March 2008. 
 
2.3 ETHICS STATEMENT (for all three studies) 
The Singapore Statement on Research Integrity (2010) for ethical consideration comprises four 
principles and 14 responsibilities. The four principles aim to balance the rights, interests, and 
duties of participating patients, volunteers, industry representatives, and medical scientists fairly12. 
There are four broad contexts to ethics principles that are required for research and these are: 1) 
autonomy (respect for individual rights) - informed consent, information, understanding, consent. 2) 
Beneficence (do good) - working with personal data, data documentation (the research protocol), 
storage of data, publication, exercise of judgement, scientific misconduct. 3) non-maleficence (do 
no harm). 4) Justice. 
 
Research work is required as people have the right to know about exposure of risk to their health 
and to make evidence-based informed choices regarding treatment and prevention. From an 
ethical point of view, it is essential that research must also be of good quality. Bad research may 
lead to wrong decisions that may have an impact on people‟s health and well-being.  
 
Data analyses in Chapter 3 (LTNP) had ethics approval. Data analyses were conducted on 
anonymised data and this study was approved by the Riverside Research Ethics Committee, now 
known as London Riverside National Research Ethics Service (NRES) Committee. This work was 
carried out under the ethical approval of the Riverside Research Ethics Committee (RREC1108). 
Chapter 4 (HIV and ageing) data analyses was conducted on routinely collected clinical 
management data and thus all treatments that the patients were prescribed were based on 
physician-client interaction and based on British HIV Association (BHIVA) guidelines and no 
random allocation of treatment was used. Based on these national BHIVA guidelines operative in 
the UK there is no requirement to seek approval from an ethics board or institutional review board 
(IRB) provided implementation of NHS confidentiality, security and privacy guidelines are upheld. 
The data presented in Chapter 4 (HIV and Ageing) were thus based on anonymised patient data. 
Data analyses resulting from the data collected by NPMS-HHC participating sites are described as 
                                               
Chapter 2:12
 Singapore Statement on Research Integrity 2nd World Conference on Research Integrity, July 21–24, 2010.  
Available from: http://www.singaporestatement.org/statement.html. Accessed Oct 23, 2012. 
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a service evaluation13 (Newton et al., 2000). The NPMS-HHC cohort therefore does not require 
informed consent and/or ethics approval as the project collected anonymised data and has had 
approval by National Information Governance Board for Health and Social Care (NIGB) formally 
known as Patient Information Advisory Group (PIAG). One of its functions was to allow the 
common law duty of confidentiality to be set aside in specific circumstances. However, with the 
changes that took effect within the NHS from 1st April 2013 (see Chapter 1: section 1.1 NHS 
England from April 2013), the NIGB's functions for monitoring and improving information 
governance practice was transferred to the Care Quality Commission, which is currently (May 
2013) establishing a National Information Governance Committee (NIGC) to oversee this work. 
The policy aims at maintaining the patient confidentiality and security and of HIV information which 
the international guidelines have reinforced the appropriateness of such procedures (UNAIDS, 
2007).  
 
2.4 STUDY SITE, SAMPLING AND COHORT DESIGN (for the two analytic studies) 
 CONFIDENTIALITY 
All data extracted from the local database were ensured that confidentiality14 and security of patient 
data were maintained. Data were kept in de-identified or pseudo-anonymised format. De-identified 
ensured that the data were totally anonymised, all personal identifiers (see Table 2.4.1) and other 
identifying information had been stripped and data could no longer be linked to the original source 
of the information. Pseudo-anonymised meant that data were stored in a form stripped from 
identifiers, but could be traced back to the original source through a key. The key for this was held 
at a centre where the data originated from. 
 
  
                                               
Chapter 2:13
 „a set of procedures to judge merit by providing a systematic assessment of its aims, objectives, activities, 
outputs, outcomes, and costs‟. Evaluation provides practical information to help decide whether a development or service 
should be continued or not. Evaluation also involves making judgments about the value of what is being evaluated. 
Chapter 2:14
 Confidentiality is the principle in medical ethics that the information a patient reveals to a health care provider is 
private and has limits on how and when it can be disclosed to a third party.   
http://medical-dictionary.thefreedictionary.com/confidentiality  
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Table 2.4.1: A List Through Which Persons Could be Identified in Their Own Right or in 
Combination 
Name: first, middle and last name 
Address 
Full postal code 
Telephone number 
Fax number 
Email address 
Date of birth 
Sex 
NHS Number 
Ethnicity 
Social security number 
National Insurance number 
Occupation 
Employer information 
Photographs 
 
 
 GEOGRAPHICAL LOCATION 
The Chelsea and Westminster HIV cohort comprises data based on three HIV clinics located in 
London within easy reach and these are: Kobler clinic (based at Chelsea and Westminster Hospital); 
West London Centre for Sexual Health (based at Charing Cross Hospital); 56 Dean Street (located 
in the Soho). 
 
 DATA COLLECTION INSTRUMENT 
Data from the local database were extracted by IT trained staff from the local data warehouse 
annually in either ASCII15 delimited text files or Microsoft Excel comma-separated values (CSV) 
files. Figure 2.4.1 demonstrates the flow of patient data to hospital data warehouse. The HIV 
cohort data are extracted periodically, usually annually from the Chelsea and Westminster Hospital 
Foundation Trust Oracle data warehouse and a broad list of data are listed in Table 2.4.2. 
  
                                               
Chapter 2:15
 ASCII stands for American Standard Code for Information Interchange codes and represent text in computers 
communications equipment, and other devices that use text. http://www.ascii-code.com/  
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Figure 2.4.1: Flow of Data Transfer to Trust Data Warehouse16 
                                               
Chapter 2:16
 A data warehouse is storage of information collected from multiple sources, stored under a unified schema, and usually residing at a single site. 
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 DATA TRANSFER 
Once authorised, the data are transferred for statistical analyses and this occurs, on average, 
annually (Figure 2.4.2) with appropriate level of security, in accordance with the local NHS Trust IT 
policy, in place. Security measures required include data encryption and data encryption software 
such as the AXCrypt, a web-based freeware software http://www.axantum.com is one such 
encryption software that is used locally to encrypt data before they are transferred for research and 
observational cohort data analyses (Figure 2.4.2). All data extracted are either de-identified or 
pseudo-anonymised.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4.2: Flow of Data Transfer to Research Database 
 
 STUDY DESIGN 
Chelsea and Westminster HIV cohort is based on routinely collected prospective data where HIV-1 
diagnosed patients are followed up routinely over time and a variety of variables related to 
demographic characteristic, results of tests performed, diagnoses, treatments prescribed over a 
period of time during which patients are under follow up are collected (Table 2.4.2). 
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Table 2.4.2: A List Showing the Type of Data Items Available From Local Database for 
Research and Cohort Data Analyses 
 
Research Database 
Demographic data: date of birth, date of death, gender, ethnicity 
HIV data: risk factors (sexual orientation, injecting drug use), year of HIV diagnosis, HIV diagnoses 
(eg opportunistic infections) 
Non-HIV diagnoses  
Use of hospital service data: outpatient visits (for HIV clinics), inpatient stay (including discharge 
dates) and day ward visits  
Treatment data: Drugs prescribed for HIV and for non-HIV related conditions and drug allergies 
(including the nature of the reaction) 
Test Results: results of all routine clinical investigations are stored including 
- Routine haematology 
- Biochemistry (liver, renal, bone profiles; lipids, glucose, CRP, urinalysis) 
- Hepatitis B/C serology 
- Toxoplasma, CMV and syphilis serology 
- Immunology including CD4 cell count & %, auto-antibodies 
- HIV-RNA levels 
- Genotypic and, if available, phenotypic HIV resistance testing 
- Co-receptor use (phenotypic and genotypic assays) 
- HLA typing 
- Other tests as required (eg haematinics, vitamin D, tumour markers) 
- Imaging (X-ray, CT, Ultrasound, MRI, DEXA) 
- Specialist investigations (PET, nerve conduction studies, endoscopy) 
- Microbiology (cultures, sensitivities, virus isolation) 
- Histology and cytology (including cervical screening) where appropriate 
 
 DATA COLLECTED 
Data were requested from the IT personnel to provide all historical HIV-1+ patient data since first 
attendance at clinic to the most recent time available as broadly listed in Table 2.4.2. Data collected 
reflected the remit of the local cohort data analyses work. The data are provided in an electronic 
format and transferred for data analyses in accordance with the local data protection policy where 
data are pseudo-anonymised. 
 
 DATA LINKING AT PATIENT LEVEL 
Over time the source database from which HIV cohort data were extracted changed from 
Genomics Unified Schema (GUS) to Oracle Data Warehouse (Figure 2.4.1). While data on GUS 
were managed by a unique patient identifier (pat_ref), historically due to attendances at three HIV 
clinics affiliated to Chelsea and Westminster Hospital (further details are under section 2.4.1), 
individual patients were assigned multiple hospital identifiers (HOSPIDs‟) and these were linked 
using pat_ref. The switch over from the GUS database system to Lastword database occurred in 
2008/2009 and multiple patient identifiers are no longer assigned to new HIV-1 diagnosed patients 
or a new attendance at the local institution, instead a unique patient identifier is assigned: the MRN 
number. 
 
The HIV cohort data extracted are for all HIV-1+ patients who ever attended for care: historical as 
well as newly diagnosed patients. The data linking of various extracted data files required 
CHAPTER 2 
MATERIALS AND METHODS  
66 
development of data linking process. All PAT_REF unique identifiers were extracted from the old 
GUS database system together with multiple hospital identifiers associated with the unique 
PAT_REF. In addition all HOSPIDS held under new unique identif ier MRN number on Lastword 
database were extracted for all patient records held. All new patients who attended the HIV centre 
since the switchover from GUS to Lastword database in 2008 were assigned a unique MRN number 
on Lastword database while cohort of patients who continued to be followed up continued to use 
their existing hospital identifier. The ID file from GUS was used as a base to derive a unique 
identifier data file that amalgamated identifiers extracted from both GUS and Lastword databases. 
 
For example: 
pat_ref hospid 
0000100023 99123456 
0000100023 99910111 
0000100023 99141516 
0000100023 99181920 
0000100023 99222324 
0000100023 99262728 
 
pat_ref hospid1 HospID2 HospID3 HospID4 HospID5 HospID6 
0000100023 99123456 99910111 99141516 99181920 99222324 99262728 
Note: the above identifiers are made up and do not identify a patient. 
 
All data received were linked using a unique identifier, PAT_REF. St Stephen‟s AIDS Trust (SSAT) 
is a registered data controller with the Information Commissioners Office17 and any personal 
information held and used are in accordance with the Data Protection Act 199818. There are eight 
broad principles to this act and these are:  
 Processing personal data fairly and lawfully (Principle 1); 
 Processing personal data for specified purposes (Principle 2); 
 Information standards 
 The amount of personal data you may hold (Principle 3); 
 Keeping personal data accurate and up to date (Principle 4); 
 Retaining personal data (Principle 5); 
 The rights of individuals (Principle 6); 
 Information security (Principle 7); 
 Sending personal data outside the European Economic Area (Principle 8) 
 
 DATA QUERIES AND RESOLUTION 
Once the data were linked these were reviewed by eye in table format in statistical package 
Statistical Analysis Softwwere (SAS; SAS Institute Inc., Cary, NC, USA) so that data errors such as 
incorrect input of decimal number, spelling and punctuations could be corrected in accordance with 
the International Conference on Harmonisation (ICH) of Technical Requirements for Registration of 
                                               
Chapter 2:17
 The Information Commissioner's Office is the Government organisation that enforces the Data Protection Act 
1998 and subordinate legislation. 
Chapter 2:18
 Data Protection Act 1998 principles taken from http://ico.org.uk/for_organisations/data_protection/the_guide  
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Pharmaceuticals for Human Use Guideline for Quality Assurance and Quality Control (Manghani, 
2011). Any anomalies found were reported to the team of personnel responsible for quality control of 
HIV cohort data. 
 
 QUALITY CONTROL PROCESS 
Once all data were linked queries were raised on any data that were not linked and these were 
resolved. In addition patient records were checked between files, for instance number of patients in 
the demographics data file needed to tally with other data files and vice versa. Where discrepancies 
were found these were raised and resolved. Some of the pre-planned queries included: 
 
 To test whether numbers of patients found in different files were in agreement. Where this 
was not the case queries will be raised and resolved at source clinic. 
 By checking consistencies in data codes found in each data variable provided.  
 Data captured on ARV were checked for consistencies in start and end date.  
 All laboratory data such as CD4+ T-cell counts and HIV-1 RNA plasma load data were 
checked for consistency regarding date of result and study time point as well as plausibility of 
data in terms of availability of data and also missingness. 
 
Once queries were generated and resolved these were then documented and data changes made 
using SAS program.  
 
 DUPLICATE PATIENT DATA 
All duplicate records were removed prior to commencing data analyses. This includes duplicate data 
checks within each individual file received before merging to form a large linked file. After all queries 
were resolved the data were then prepared using SAS programming to structure these for statistical 
analyses. At each stage of data restructuring consistency checks in data were performed.  
 
2.5 LONG-TERM NON-PROGRESSOR ANALYSES 
The rate of disease progression from asymptomatic HIV-1 (see Chapter 1: Figure 1.2.2) infection 
to AIDS varies between HIV-1+ individuals (Pantaleo & Fauci, 1996). Establishing factors that were 
associated with HIV-1 disease progression aims to enable development of therapeutic strategies to 
delay or reverse disease progression. The gradual decline in peripheral blood CD4+ T-cell count 
which occurs throughout the typical course of HIV-1 infection and is accompanied by excessive 
activation of the immune system and the sequential loss of immune responses, first to HIV-1, then 
to other pathogens, allogeneic and finally mitogenic stimuli (Clerici et al., 1989; Douek et al., 2009). 
 
AIDS defining opportunistic infections were originally used to indicate disease progression in the 
clinic, however in 1993 the definition of HIV disease progression was widened to also include a 
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drop in CD4+ T-cell count to <200 cells/μL blood or <14% of lymphocytes (Castro et al., 1992; 
MMWR, 1992). 
 
Historically some people living with HIV-1 remain healthy with CD4+ T-cell counts more than 500 
cells/μL blood for 10 years or more in the absence of ART (Klein & Miedema, 1995) and these 
were referred to as long-term survivors. In addition, in the absence of antiretroviral therapy they 
show no signs of opportunistic infection and remained asymptomatic. These groups of HIV-1+ 
patients have been referred to as LTNP. However these terms and definitions used to identify 
these patient groups were not uniform between studies and sites.  
 
Terms used to describe this unique and atypical group of HIV-1+ people were not uniform across 
published studies in the UK and internationally. Although studies to date, have identified only a 
small number of factors that were consistently associated with LTNP status (Vento et al., 2004). 
Establishment, definition and characterisation of HIV-1+ LTNP patient cohort could be used to 
identify factors that were associated with non progression status, and therefore aid in determining 
potentially successful prophylactic vaccines and novel therapeutic approaches. 
 
2.5.1 COHORT SELECTION CRITERIA 
 STUDY POPULATION 
Chelsea and Westminster HIV cohort is a large HIV cohort and is one of the largest single centre 
HIV cohorts in Europe. Routine data were prospectively collected at routine visits when HIV-1+ 
people were seen at emergency or regular intervals for assessment, follow-up and immunologic, 
virologic and clinical assessments. The study population used for data presented in Chapter 3 
(LTNP) of this PhD thesis included all patients who had attended for HIV care since start of HIV-1 
patient data collection commenced from January 1988. Data were extracted from the hospital Trust 
data warehouse on 28th February 2010 and therefore data presented in Chapter 3 were based on 
data collected until this date. Therefore last data collected were based on the data collected at the 
patients last recorded visit at the clinic for HIV-1 care. The entire HIV-1 cohort that was available 
was used to screen and identify LTNP, HIV controllers (HIC), patients with long-term stable low 
CD4+ T-cell counts, and amongst these a subset of patients who also controlled HIV-1 RNA 
plasma load to below the limit of detection (BLD) as detailed in the following sections. 
 
 LONG-TERM NON-PROGRESSORS 
The Chelsea and Westminster HIV Cohort LTNP selection criteria were applied to identify patients 
firstly with documented HIV-1 infection for greater than seven years (Pantaleo & Fauci, 1996). The 
duration of HIV-1 infection was derived from the date of first positive HIV-1 test result or, if this was 
unavailable prior to enrolment into the local HIV cohort, then the earliest clinic visit date was used. 
The second criterion for patient selection was never receiving ART (Imami et al., 2002; Westrop et 
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al., 2009). Thirdly, these patients were screened for history of opportunistic infection (OI). OI was 
defined as any symptomatic manifestation of HIV-1 illness recorded in the medical record. Entries of 
„acute infection‟, „persistent generalized lymphadenopathy (PGL)‟, and „asymptomatic infection‟ were 
not defined as OI. The fourth selection criterion used was „patients who had a stable CD4+ T-cell 
count‟. This was defined as a CD4+ T-cell count slope of ≥0 cells/μL blood from entry into cohort up 
to and until the most recent available CD4+ T-cell count (Mandalia et al., 2012). Analyses were 
performed by 3 monthly grouped time periods because, on average, clinically stable HIV-1+ patients 
were seen at quarterly intervals at the local institution where data originated from. 
 
 HIV CONTROLLERS 
Within the group of individuals classified as LTNP, a minority also control HIV-1 replication to BLD 
of the conventional HIV-1 RNA plasma load assay (50 copies/mL plasma or histocally, 500 
copies/mL was used at the time when sensitive RNA plasma load assays were not available). 
These individuals were selected and have been known as HIC (Westrop et al., 2009). 
 
 HIV NON-PROGRESSORS USING CONTROL OF VIRAL LOAD CRITERIA 
Recent review suggested that due to the low prevalence of HIV non-progressors patients need not 
be infected for a long period of time. Therefore two low level HIV-1 RNA plasma load 
measurements used to select these atypical patients would be sufficient (Gaardbo et al., 2012). 
The HIV cohort data were therefore further investigated using relaxed selection criteria to identify 
atypical patient group from the cohort. Measurements of low level HIV-1 RNA plasma load (<500 
copies/mL plasma in the absence of ART at the time of HIV-1 RNA plasma load assay) were 
initially used to identify and select patients. Further analyses were performed to identify individuals 
who fulfilled the atypical patient group selection criteria. Firstly, three consecutive HIV-1 RNA 
plasma load results of <500 copies/mL plasma within one year were chosen to allow for: potential 
HIV-1 RNA plasma load assay failure; individuals who missed attending their routine follow-up HIV-
1 care visit at the Chelsea and Westminster Hospital; subsequent HIV-1 RNA plasma load results 
which may occur at very close time points. The data were further refined to ensure that the three 
HIV-1 RNA plasma load results spanned for at least one year. This length of time was selected as 
on average, HIV-1+ patients who were stable were seen in clinic at quarterly intervals which would 
equate to 4 routine clinic visits per year. A conservative estimate of this (to enable 
rescheduling/missed appointment) is estimated at three visits per year. 
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2.5.2 STATISTICAL METHODS 
 NON-PARAMETRIC METHOD 
The Mann-Whitney U test was used for between group comparisons of non-parametric data while 
qualitative data are presented as numbers with percentages and compared using the chi-squared 
test statistic and where appropriate Yates‟ correction was applied. 
 
 TIME TO PROGRESSION: HIV-1+ LONGER THAN 7 YEARS AND NO ART N=1,204 
Survival analysis was used to estimate time from HIV-1+ diagnosis until disease progression in a 
group of patients who had been diagnosed HIV-1+ for longer than 7 years, and who had not been 
prescribed ART (n=1,204). HIV-1 progression in this group was defined as presentation with 
symptomatic or AIDS defining opportunistic illness or declining CD4+ T-cell count during follow-up 
(see Chapter 3: Figure 3.2.1). 
  
 TIME TO PROGRESSION: HIV-1+ LONGER THAN 7 YEARS, NO ART AND ASYMPTOMATIC 
N=312 
Time from HIV-1+ diagnosis until HIV-1 disease progression was estimated in 312 patients, a subset 
of the initial 1,204, who had been diagnosed HIV-1+ for longer than 7 years, had not been prescribed 
ART and who remained asymptomatic. Progression in this group was assessed through evidence of 
unstable CD4+ T-cell counts during follow up, or death.  
 
Joint probabilities of non-progression for more than 7 years, and remaining ART-naïve, in patients 
who fulfilled criteria of LTNP but eventually exhibited HIV-1 disease progression, was used to 
estimate progression time. This was estimated from the date of HIV-1+ diagnosis until each of the 
defined criteria indicative of HIV-1 disease progression. This was defined and included: 1) 
presentation with symptomatic or AIDS defining opportunistic illness or declining CD4+ T-cell count 
during follow-up; 2) evidence of unstable CD4+ T-cell counts during follow up, or death. All subjects 
whose CD4 count was stable since cohort entry were assumed to have either no change or an 
increase in CD4 count since entry to cohort indicated by a zero or positive slope whilst those 
patients whose CD4 count slope was negative since cohort entry were assumed to have an 
unstable CD4 count over time and were therefore removed from further analyses. Data were 
censored at the most recent visit to the clinic. The progression times were estimated and presented 
stratified by groups of patients whose CD4+ T-cell count either remained within, or was outside on at 
least one occasion, the normal range. 
 
 LONGITUDINAL METHOD 
Linear mixed models, using PROC MIXED in SAS are an extension of the general linear model. 
This method is an extension of techniques for estimating parameters (means, variances, 
regression coefficients, and standard errors), and are much more flexible. In repeated measures 
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data collection and longitudinal studies, the observations are clustered within a subject. This 
means the observations, and their residuals, are not independent but correlated. There are two 
approaches taken to deal with this correlation using either: the marginal model or the mixed model. 
 
 THE MARGINAL MODEL (POPULATION AVERAGED MODEL OR GENERALISED ESTIMATION 
EQUATION) 
This model alters the co-variance structure of the residuals, this means that instead of assuming 
that all observations are independent, as is the case when using a general linear model, the 
marginal model assumes the residuals from a single subject are related and their co-variances are 
non zero. This model therefore requires an estimate of the co-variances among all the residuals 
from a single subject. The difference between the marginal model and a linear model is that the 
residuals are not assumed to be independent with constant variance. So in cases where the 
assumptions of equal variances and equal correlations are not met, a much better fit of models are 
derived by using a marginal model. A covariance matrix (covariance structure) used in statistics is 
symmetric. This means all correlations on the diagonal of a matrix are 1, because they are the 
correlation of each variable with itself:  
 
Covariance matrix 
Covariance 1,1= 
Variance 1 
Covariance 1,2 Covariance 1,3 
Covariance 1,2 Covariance 2,2= 
Variance 2 
Covariance 2,3 
Covariance 1,3 Covariance 2,3 Covariance 3,3= 
Variance 3 
 
Covariance is a non standardised version of correlation. A correlation is derived by dividing 
covariance by the standard deviation of both variables to remove units of measurement. So a 
covariance is just a correlation measured in the units of the original variables. Unlike the correlation 
value which lies between -1 and 1, covariance is not constrained to lie between -1 and 1. However, 
the sign remains the same, and a covariance value of 0 has the same meaning as a correlation 
value of 0 i.e. no linear relationship. The diagonal variables are the variances of each variable: a 
covariance of a variable with itself is simply the variance. The covariance structure that is specified 
in SAS MIXED procedure includes the following: 
 Compound Symmetry: compound symmetry structure means that all the variances and all 
the covariances are equal. This is used when all variables in the model are measured on 
the same scale. 
 Variance Components: this assumes each variance is different, and all covariances are 0. 
Used when all variables in the model are measured on the different scale. 
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 Unstructured: This assumes that there is no pattern in covariance structure. Each variance 
and each covariance is completely different and has no relation to the others. 
 THE MIXED MODEL 
Another method used to deal with residuals that are not independent is by controlling for subject, 
by using it as a factor in the model. In this model the residuals are a distance between a data point 
and the mean of that subject and this is achieved by adding subject as a random factor in the 
model. In addition MIXED model also allows to control for time varying (such as CD4+ T-cell 
counts, renal function results measured over time on the same subject) as well as variables that 
are not time varying (such as baseline demographics e.g. gender) by including these as fixed 
variables in the model. The resultant estimates from the model gives mean of for instance CD4+ T-
cell counts over time adjusted for baseline variables such as gender. A mixed model contains both 
the fixed and the random factors.  
 
The main feature of longitudinal studies is that the patients are followed up over time and various 
immunological and clinical parameters together with age of a patient are measured repeatedly. 
Multiple measurements are obtained from each patient at different times and with changing 
conditions and therefore there may be a large amount of variation among patients in the number 
and timing of observations. One problem with data collected longitudinally is that the intended 
measurements are not taken for reasons such as patient lost to follow up when patients exit the 
cohort prematurely and unknown to the clinic or for reasons unknown, data are unavailable. The 
missing data process can be classified to three different categories (Rubin, 1976): 1) missing 
completely at random (MCAR) where the probability of the missingness does not depend on the 
measurements; 2) missing at random (MAR) if the probability of missingness does not depend on 
the unobserved measurements; and 3) when observations are neither MCAR nor MAR, they are 
classed as missing not at random where the probability of missingness depends on unobserved 
measurements and may be on the observed measurements. For example, it may happen that after 
a series of visits with good outcome, a patient drops out due to lack of efficacy. In this situation the 
analysis model based on the observed data, including relevant covariates, is likely to continue to 
predict a good outcome, but it is unreasonable to expect the patient to continue to derive benefit 
from treatment. 
 
As longitudinal data on CD4+ T-cell count were available, with multiple assessments of CD4+ T-cell 
count on the same patient at different time points, within patient assessments at different time points 
were expected to be correlated. This correlation needed to be accounted for when selecting 
analytical methods (Diggle et al., 1994). 
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The statistical analyses using longitudinal data needed to consider four main characteristics: i) time 
may be an explanatory variable; ii) repeat CD4+ T-cell count measurements for a patient are likely to 
be correlated; iii) the co-variables may be time-dependent, showing variation through time for a 
patient; and iv) missing data in the successive CD4+ T-cell count measurements may induce a bias. 
A repeated measures linear mixed model was used to derive time adjusted CD4+ T-cell count slope, 
or rate of change per quarter in CD4+ T-cell count since entry to cohort (Zeger et al., 1988). 
 
The MIXED procedure in SAS (Version 9.1.3; SAS Institute Inc., Cary, NC, USA) was used by fitting 
values of CD4+ T-cell counts from all available results at different time points as a dependent 
variable grouped into 3 monthly intervals. A random intercept model was fitted using MIXED 
procedure in SAS. The independent variables included the fixed effects of subjects and clinic visit 
time points grouped into 3-month intervals. This assumed that the intercept for each patient was 
random and the effects of CD4+ T-cell count changes (slopes) from baseline (at entry into the 
cohort) were also random and differed between subjects. A compound symmetry covariance matrix 
was used to model the within patient errors. This assumed that the variances were homogeneous. 
Correlation existed between two separate measurements, but it was assumed that the correlation 
was constant regardless of the time between successive CD4+ T-cell count measurements (Kincaid, 
2005). Estimates of CD4+ T-cell count slopes were obtained from patient by time interaction. All 
patients whose CD4+ T-cell counts were stable since cohort entry were assumed to show either no 
change or have an increase in CD4+ T-cell count since entry to cohort, indicated by a slope ≥0 
cells/μL blood (i.e. no decline in CD4+ T-cell count). Those patients whose CD4+ T-cell count slope 
was negative were assumed to have an unstable, declining CD4+ T-cell count over time, and were 
therefore excluded from selection. After excluding patients who had died, a further refined selection 
criterion was applied to patients who had stable CD4+ T-cell counts. Patients were defined as LTNP, 
who had a stable CD4+ T-cell count which continuously remained within the normal range (450-1650 
cells/μL blood) throughout clinical follow-up. These were compared with those patients whose CD4+ 
T-cell counts were stable but had at least one recorded CD4+ T-cell count below the normal range 
and referred to as patients with long-term stable low CD4+ T-cell counts. 
 
2.6 HIV AND AGEING ANALYSES: CO-EFFECTS OF HIV-1 INFECTION AND AGEING 
ON RESPONSE TO THERAPY, CO-MORBIDITY, PROGRESSION AND IMMUNE RE-
CONSTITUTION ANALYSES 
 
2.6.1 COHORT SELECTION CRITERIA 
 STUDY POPULATION 
The Chelsea and Westminster HIV cohort data were investigated from 1988 until May 2011, 
tracking the age of individuals and therefore the age profile of the HIV-1 positive people. Data for 
this study were extracted from the database on all adults ≥18 years including patients who were 
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ART naïve or treatment experienced and HAART was defined as therapy consisting of at least 
three antiretroviral drugs in accordance with published guidelines (BHIVA Writing Group, 2012). 
The work presented in Chapter 4 (HIV and Ageing) of this PhD thesis is based on a cohort of HIV-
1+ people, who, since 1st January 1988 attended and were followed up until 31st May 2011, the 
time when data were extracted from the local Trust data warehouse. 
 
Age was calculated to the most recent visit to HIV clinic. Whilst cohorts were grouped into pre 
HAART era (1988 to 31st December 1995), early HAART era (1st January 1996 to 31st December 
2000), post HAART era (1st January 2001 to 31st December 2004) and the late HAART era (1st 
January 2004 to date of data extraction). The choice of these cohort strata were selected as these 
coincided with the introduction, availability and prescription of new antiretroviral drugs during the 
cohort strata as part of HAART therapy (see Chapter 1: Table 1.2.1). Comparisons of immune 
changes were performed by assessing HIV-1+ patient groups following unbiased division according 
to age-defined quartiles for the entire Chelsea and Westminster HIV Cohort. Analyses were also 
performed by age grouped into decades due to large data size and large number of data points 
meant that using age as an ungrouped variable was computer intensive on modelling method used 
to derive estimates by age. Therefore using ungrouped age data did not allow estimates to be 
derived. Decade grouped age was practical from computing perspective as well as describing data 
by age groups commonly defined and used in literature with description of commonly used 
terminology (see Chapter 4: Table 4.1.1). These grouped age categories reflect „young adults‟ 18-
39 years, and „middle-aged‟ adults age ≥40 years when, on average, decline in thymic function 
commences and subsequently, on average start of immune senescence from age ≥50 years or 
„older‟ adults in this PhD thesis (Spits, 2002). 
 
As indicated above, comparisons of immunological parameters were performed by assessing 
HIV-1+ patient groups following immune considered age group strata for the entire HIV cohort 
relating to the estimated time of optimal thymic involution and decrease in thymic output/activity.  
For this, people in 3 age categorised groups were compared and described:  
1) Less than 40 years of age (prior to the time of maximal thymic involution). 
2) Between 40 and 49 years of age (encompassing the estimated time of maximal thymic  
involution, decreased thymic output and the current median age of the HIV-1 infected 
population). 
3) Age 50 years or above (immune senescence in the „older‟ HIV-1 infected population). 
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2.6.2 STATISTICAL METHODS 
 CROSS SECTIONAL DATA 
Quantitative data with hyper geometric distribution have been presented as median with inter-
quartile ranges, while qualitative data has been presented as numbers with proportions. Between 
group comparisons of quantitative data with hyper geometric distribution were assessed using 
Mann-Whitney U test, while qualitative data are compared by study arms using 2 test and where 
appropriate due to small sample in cells Yates‟ correction has been applied (Agresti, 2002). 
 
 LONGITUDINAL METHOD 
Longitudinal analytic technique were applied to longitudinally collected renal function variables 
described in Chapter 4 (HIV and Ageing). For further details see section 2.5.2. The renal function 
data were routinely collected on all patients since routine collection of these data commenced. As 
a result of availability of these longitudinal cohort data with repeat measurements longitudinal 
methods used for analyses was the same as those described in detail under section 2.5.2. 
 
eGFR and protein:creatinine ratio were analysed using longitudinal linear mixed models assuming 
that any data missing were missing at random. The linear mixed model was used to derive time 
adjusted eGFR and protein:creatinine ratio changes with age since exposure to either NRTI, PI or 
NNRTI drugs or the first-line regimens, 2NRTI+NNRTI or 2NRTI+boosted PI. MIXED procedure in 
SAS was used to generate random intercept models where all eGFR and protein:creatinine ratios 
from available 10 year age categories were fitted as dependent variable. Independent variables 
included the fixed effects of ARV drug class exposure or first-line regimen, cohort assessment of 
renal function results at each age group category where age-categories were based on age at the 
time of eGFR or protein:creatinine result and the interaction of ARV exposure with changing age. 
The eGFR and protein:creatinine ratio results were fitted into the model as time updated and 
described by age at the time of their respective results. An unstructured covariance matrix was 
used to model the within patient errors in order to account for dependence of observations across 
time within individuals. 
 
Estimates of change in eGFR and protein:creatinine ratio from baseline were obtained from 
treatment by time interaction. Trends have been described for ART naïve PLHIV and those 
exposed to different ARV drug classes and first-line HAART regimens. Trends over time are 
presented as point estimates derived using the maximum likelihood method while an unstructured 
covariance matrix was used to allow for association of eGFR and protein:creatinine ratio results 
over time within individuals. Factors considered in the model were age at time of eGFR and 
protein:creatinine ratio results and were entered as a covariate grouped into decades. Linear and 
quadratic equations were explored and the equations presented were those that best explained the 
greatest amount of variance of longitudinal eGFR trends based on exposure to ARV drug class or 
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first-line regimens, along with interaction terms involving age and treatment groups. The primary 
interest was to look at contribution from a number of factors on renal function over time and the 
importance of age, HIV-1+ infection and ARV class exposure combined or by themselves. While 
the majority of creatinine is excreted into the urine by glomerular filtration, the renal tubules also 
secrete creatinine. Creatinine clearance is thought to overestimate GFR by 10-20% (Breyer & Qi, 
2010), and therefore creatinine clearance values based on these „healthy‟ individuals were also 
used as comparators after they were reduced by 20%. An equation based on „the healthy‟ 
individuals creatinine clearance values were obtained from the Baltimore Longitudinal Study of 
Ageing (Rowe et al., 1976). 
 
 TIME TO EVENT OF RENAL FUNCTION MARKER 
Nadir estimated glomerular filtration rate (eGFR) values ≤30 ml/min per 1.7m2, indicative of CKD 
stages 4 and 5 or moderate to advanced renal failure was grouped into binary outcome. Cox‟s 
proportional hazards survival analysis was used to model time from first measurement of eGFR to 
either moderate to advanced renal failure and data were censored at most recent eGFR result. 
Univariate Cox‟s proportional hazards regression analysis was used to identify factors associated 
with the likelihood of moderate to advanced renal failure since cohort entry. Variables found to be 
significant in the univariate model (p<0.2) were used to build multivariable model which allowed the 
risk of a particular prognostic variable to be assessed while controlling for the others in the model. 
The final multivariable model presented was tested for its proportional hazards distributional 
assumptions using the complimentary log-log plot where data were plotted on the x-axis of the log 
of survival function and on the y-axis the log of the negative log of the estimated survivor function 
[(log(-logS(t)]. The final model presented was adjusted for age at nadir eGFR, gender, sexual 
orientation, injecting drug use, ethnicity, duration since HIV-1+ diagnosis, PI exposure, max viral 
load, recent renal function results, and nadir CD4+ T-cell count for possible confounding or residual 
effects. 
 
2.7 POPULATION COST ANALYSES 
The data from the NPMS-HHC study monitors prospectively the effectiveness, efficiency, equity and 
acceptability of treatment and care in participating HIV units since 1996. Using an agreed minimum 
dataset, standardised data are routinely collected in clinics and transferred to the NPMS-HHC 
Coordinating and Analytic Centre, ensuring both patient and clinic confidentiality. The data analyses 
are performed both at clinic and aggregate levels. The clinic specific analyses remain confidential, 
while aggregate analyses become public documents (Beck & Mandalia, 2000a, 2000b).  
 
With growing number of HIV-1+ people accessing care in the NHS as described in Chapter 1: 
section 1.2, one of the effects has been that number of people living with HIV-1 infection in the UK 
and elsewhere has increased. The implication of this is that increasing number of HIV-1+ people will 
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require long-term use of health services, which will have financial implications. In addition, on-going 
development of new therapeutic drugs will be needed. Such development should include novel ART 
or immune therapies particularly since it is likely that currently available ARV drugs will eventually 
fail, requiring the sequential use of different therapeutic regimens in order for HIV-1 infected subjects 
to remain alive and well.  
 
2.7.1 STUDY SITES, SAMPLING AND COHORT DESIGN 
 CONFIDENTIALITY 
At the Co-ordinating and Analytic Centre (CAC) each HIV-1+ individual is assigned an NPMS ID 
which is derived from and consists of soundex, gender and date of birth. Derivation of a unique 
identifier is based on these three fields. This therefore has a limitation that if a subject moves 
between clinics they will uphold their name and date of birth in particular. Soundex is generated from 
patients name and therefore ascribing a unique identifier assumes this is the same if a patient 
moves between clinics. Due to large scale of data checking, verification of this information on the 
very large numbers of patients included in the NPMS-HHC data cohort was considered to be 
unrealistic and not pragmatic and therefore for this work it is assumed otherwise. 
 
All data are linked using the NPMS ID and no names or other patient identifiers are requested by the 
NPMS-HHC CAC (see section 2.3 for further details on ethics statement). All clinic level analyses 
that are summarised are confidential and are only sent to the source clinic where the actual data 
originated from. 
 
 GEOGRAPHICAL LOCATION 
The geographical locations of the 14 sites who contributed to the data analyses from NPMS-HHC 
participating sites are from 7 London and 7 out of London centres with one centre located in 
Scotland. 
 
 DATA COLLECTION INSTRUMENT 
The NPMS-HHC data collection form containing comprehensively specified list of required fields 
document (see Appendix A5.I) were sent to each one of NPMS-HHC participating sites. Data were 
requested using this standard data collection document detailing a list of required fields. This 
document lists the demographics and risk factor data. In addition all hospital activity data since 1996 
together with the HIV-1 related diagnosis, HIV-1 RNA plasma load and CD4+ T-cell count history 
together with a history ARV drug prescription. 
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 DATA TRANSFER TO CO-ORDINATING AND ANALYTIC CENTRE (CAC) 
In order to answer the research questions data needed to be requested from the NPMS-HHC 
participating sites in a standardised format. These were requested and transferred to the CAC 
through secure methods and with security passwords in place (see Data Collection Instrument 
section for further details). Safety procedures, to ensure patient and clinic confidentiality discussed 
and agreed between the NPMS-HHC data manager and each of the clinic‟s information officers, 
were maintained and enforced.  
 
 STUDY DESIGN 
NPMS-HHC cohort include a group of HIV-1+ patients followed-up over time and a variety of 
variables are collected routinely by participating centres and relevant information as described in 
Appendix A5.1 are provided and that forms part of the study. 
 
 DATA COLLECTED 
Data were requested from the NPMS-HHC participating centres of all HIV-1+ people who had ever 
attended for care since 1996 which is the point when HAART was first introduced into routine HIV 
care in the UK. Data collected reflected the remit of NPMS-HHC that was to collect data on use of 
hospital activity. Each participating clinic extracted data as per the NPMS-HHC list of required fields 
from their local database. The data were provided in an electronic format and sent to the CAC in 
accordance with the local data protection policy ensuring no patient identifying data were sent such 
as patient names. Instead data were pseudo-anonymised where use of patient‟s soundex, date of 
birth and gender allowed a generation of a study identifier that was used to link different data sets 
across different files within a clinic.  
 
 DATA LINKING AT PATIENT LEVEL 
Each clinic provided different types of data in individual data files. For example, all demographics 
data were contained in one file, while all antiretroviral treatment history in another. This was the 
case for all data types and all follow-up data contained respective dates. All these files were linked 
using NPMS-HHC study derived identifier. Before each file was linked duplicate records were 
checked for and removed. There were variations in data received from each clinic, for instance 
some clinics data included use of service data whilst ARV history data were not available from some 
clinics. All available data were linked firstly by each patients derived unique identifier. 
 
 DATA QUERIES AND RESOLUTION 
Once the data were linked these were reviewed by eye in table format in SAS so that data errors 
such as incorrect input of decimal number, spelling and punctuations could be corrected in 
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accordance with sections 5.1, 5.4, and 5.5 of the ICH Guideline for Quality Assurance and Quality 
Control (ICH/GCP, 1996). 
 
 QUALITY CONTROL PROCESS 
Standard quality control processes were followed as described under section 2.4 Quality Control 
Process. Once all data were linked queries were raised on any data that were not linked and these 
were resolved. In addition patient records were checked between files, for instance number of 
patients in demographics file should tally with other files and vice versa. Where discrepancies were 
found these were raised and resolved. Some of the pre-planned queries include: to test whether 
numbers of patients found in different files were in agreement. Where this is not the case queries will 
be raised and resolved at source clinic; by checking consistencies in data codes found in each data 
variable provided. For instance gender may be coded as M and F and if any codes were found 
which do not match with what the clinics describe in their data extraction codes will be pointed out 
and resolved; to check whether all visit dates were consistent with patients clinic attendances; data 
captured on ARV were checked for consistencies in start and end date; all laboratory data such as 
CD4+ T-cell counts and HIV RNA load data were checked for consistency regarding date of result 
and study time point as well as plausibility of data in terms of availability of data and also 
missingness. In the event where more than 5% of the patients found in demographics data where 
lab results were found to be missing, clarifications for such an occurrence was sought as a form of a 
data query at clinic source.  
 
Once queries were generated and resolved these were then documented and data changes made 
using SAS program. In the event when updated data were provided these would be rechecked as 
detailed above.  
 
 DATA LINKING AT DIFFERENT HIV CLINIC LEVEL 
The data files received from each clinic were first read into the statistical package, SAS. 
Subsequently, individual files for each clinic were linked to form a large SAS database per clinic. 
As file structure differed between clinics, separate SAS programs were written for each of the 
clinics in order to manipulate the data and perform the statistical analyses. Specific issues that 
included data discrepancies and cleaning of the data files were dealt with by contacting the 
information officer from the respective clinic. Agreement between the HIV disease classificatory 
systems of stage of HIV infection at the clinics and CAC was investigated during previous analyses 
and a high correlation between the two was found. 
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 DUPLICATE PATIENT DATA 
All duplicate records were checked and removed at individual clinic level. However it is known that a 
proportion of HIV-1 infected patients attend more than one HIV clinic and this is identified by using 
the NPMS-HHC derived ID. This is based on patient‟s soundex, gender and DOB. While this NPMS-
HHC derived identifier allows identification of patients who move from one centre to another one of 
the limitation of this is that it assumes that when patients attend another centre they will provide 
identical name and date of birth. For a few this may not necessarily be the case as clinicians have 
reported (personal communication) some HIV-1+ patients attending different centres have used alias 
names. This however occurs in a minority of subjects. 
 
2.7.2 COHORT SELECTION CRITERIA 
 STUDY POPULATION 
At the time of data analyses for this work 24 clinics agreed to participate with the NPMS-HHC. 
However, not all clinics could contribute data for this work some due to problems with IT while others 
due to paper based medical data collection and therefore unavailability of these data in an electronic 
format. The prospectively collected data from the participating NPMS-HHC sites provided 
information on HIV-1 positive patients attending the NHS hospitals for routine HIV care. Information 
on the use of outpatient (OP), inpatient (IP) and day-ward (DW) services between 1st January 1997 
and 31st December 2006, were obtained from computerised information systems from the 
participating centres together with the demographic characteristics, risk factors, data on 
opportunistic HIV disease, history of ARV treatment combinations and data on CD4+ T-cell count 
and viral load results over time. These data were requested and transferred to the CAC through 
secure methods with security passwords in place. Data security procedures discussed and agreed 
between the NPMS-HHC Data Manager and each of the clinics‟ Information Managers to ensure 
patient and clinic confidentiality were maintained and enforced. Data were transferred from the 
participating NPMS-HHC centres to the CAC between November 2007 and April 2008. Once the 
data were received these were standardised at the CAC before commencing the data analyses. 
 
2.7.3 STATISTICAL METHODS 
 USE AND COST OF HOSPITAL SERVICES 
Information on the use of hospital IP, OP and DW services between 1st January 1997 and 31st 
December 2006, were obtained from 14 hospitals participating in this analysis. The mean number of 
IP days, OP and DW visits per patient-year (PPY) by stage of HIV-1 infection - asymptomatic (ASx), 
symptomatic non-AIDS (Sx non-AIDS) or AIDS - were calculated PPY from 1997 to 2006. The 
methods used for calculating the mean use of hospital services PPY were similar to those employed 
in previous studies (Beck et al., 2004; Badri et al., 2006). 
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The denominator consisted of the total duration of follow up for all patients during a calendar year, 
from when they were first seen during that year till the end of the year if still alive, or when they died, 
or if they were lost to follow up, which ever came first. If patients had attended prior to 1st January 
1996 (start of study period), data were left censored at 1st January 1996, whilst if patients were 
found to have used HIV services during the second half of 2006, then the data were right censored 
at 31st December 2006. Numerators were calculated by summing the use of IP, OP or DW services 
and mean use of services PPY were calculated using the following formula:  
 
 
M=                                                    x 365 
 
 
where   S ij = use of service of individual i at jth time point; 
 t ij = time since diagnosis of stage of HIV infection of individual i and remaining within the same stage  
 M = mean of services S per patient-year by stage of HIV-1 infection 
 
Annual cost PPY estimates for HIV service provision for individual HIV-1+ people by stage of HIV-1 
infection were produced by linking mean number of IP days, OP visits and DW visits with their 
respective unit costs. Costs were in UK pounds at 2006 prices. The unit cost estimates for an 
average IP day was £475, average OP visit was £94 and £384 for a DW (Beck et al., 2008).  
 
 USE AND COST OF ANTIRETROVIRAL THERAPY 
Average costs for treatment regimens were based on London Specialised Commissioning Group 
prices of each licensed ARV drug. Average annual cost, including 17.5% value added tax (VAT) at 
the time of data analysis (2009), were calculated for different ART regimens - mono-, dual-, triple- or 
quadruple-or-more therapy - and stratified by stages of HIV-1 infection: asymptomatic, symptomatic 
non-AIDS or AIDS.  
 
 OVERALL COST OF SERVICES BY STAGE OF HIV INFECTION AND TYPE OF ANTIRETROVIRAL 
THERAPY 
The costs for different ART by stage of HIV-1 infection were added to the cost for IP, OP and DW 
services for each of the clinical stages; costs of „other‟ drugs and tests and procedures performed, 
were added to obtain the total direct costs for treatment and care for HIV-1+ people by stage of HIV 
infection and type of ART (Table 2.7.1 and Table 2. 7.2). 
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Table 2.7.1: Table Showing Included Costs 
 
Cost of Treatment & Care Services  Cost of Support Services  
All relating to hospital services 
   
Direct costs  
Cost of tests  
Cost of procedures  
Cost of Drugs  
 
Staff costs  
Equipment  
Consumables  
Others  
   
Catering                           
Laundry                           
Medical Records             
Pottering                        
Storage and supplies     
Transport                         
Administration                  
Security                            
Building & Maintenance  
 
Table 2.7.2: Table Showing Costs 
 
Type of service  Unit cost used  
Inpatient visit £475 per day 
Outpatient visit £94 per visit 
Day ward visit £384 per attendance 
Tests/Procedures 
Asymptomatic 
Symptomatic non AIDS 
AIDS  
 
₤271 per year 
₤465 per year 
₤1,405 per year 
Other drugs 
Asymptomatic 
Symptomatic non AIDS 
AIDS 
 
₤274 per year 
₤1,582 per year 
₤6,814 per year 
Community care  
Asymptomatic 
Symptomatic non AIDS 
AIDS 
 
₤3,091 per year 
₤4,084 per year 
₤5,990 per year 
ARV drugs Individual ARV cost prices received from the 
London HIV consortium 
Unit costs are based on 2006 prices 
 
The direct cost-estimates were from a public service perspective (Beck & Miners, 2001), but some 
cost-estimates also included indirect or community care costs (Beck et al., 2008).  
 
 HIV DIAGNOSED PATIENTS USING NHS SERVICES BY TYPE OF ART 
The annual number of HIV-1 diagnosed people using NHS services by stage of HIV-1 infection and 
by type of ART prescribed using NHS services, were obtained from the Health Protection Agency 
(HPA). Not all of these data sets were complete; for some HIV-1+ people, the stage of HIV-1 
infection was known but the type of ART prescribed was unknown. These individuals with missing 
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ART data were proportionally distributed across the respective ART strata, ensuring that the 
proportion of subjects represented in each category remained unchanged. Secondly, HPA figures 
indicated that no subjects had been prescribed quadruple or more therapy in 1997 and 1998, which 
was unlikely and probably due to incorrect reporting during those calendar years. For these years 
linear least squares regression analysis (Aldrich, 2005) was used to estimate the number of HIV-1 
diagnosed patients using NHS services likely to have been prescribed quadruple or more therapy. 
 
 UK HIV POPULATIONS COST ESTIMATE 
To obtain the population cost estimates, the total annual treatment and care costs for a HIV-1+ 
people by stage of HIV-1 infection and type of ART were multiplied by the number of HIV-1 
diagnosed people using NHS services within those categories for each year. Costs were then added 
across stages of HIV-1 infection and types of ART regimens to obtain a total population cost by 
year, while community care costs were also included (Beck et al., 2008) .  
 
 UK HIV POPULATIONS AND COST PROJECTION 
NPMS-HHC currently holds cost data between 1996 and 2006, however HPA population data were 
available since 1997, the population cost figures derived therefore commence from the calendar 
year 1997 onwards and the ARV drug costs were calculated using the 2006 prices. Data were 
projected to estimate future costs for the years 2007 to 2013 using linear least squares regression 
analyses (Aldrich, 2005). These projections were based on the trends observed over 1997-2006.  
 
Three methods were investigated:  
1) First method extrapolated total annual population costs 1997-2006 to 2007-2013; 
2) Second method extrapolated the total number of PLHIV who used HIV services between 
1997-2006 and 2007-2013. The average annual cost of treating a PLHIV across all stages of 
HIV infection in 2006 was calculated and this was multiplied by the projected numbers of 
PLHIV using NHS services for the years 2007-2013; 
3) Third method extrapolated PLHIV for each of the three stages of HIV infection from 1997-
2006 to 2007-2013. Average 2006 annual cost of treatment and care for stage of HIV 
infection was used to extrapolate cost 2007-2013 by stage of HIV infection. Total projected 
annual treatment costs were obtained by adding annual population costs of individual stages 
of HIV-1 infection across all stages; 
 
o Method 1 
Population cost data for the years 2007 to 2013 were projected using these 2006 drug prices. 
Linear regression analysis in SAS was used to estimate costs since 2006 assuming the linear 
trends seen in previous years would continue. The total UK population costs were projected for 
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(regardless for the patients‟ stage of HIV-1 infection) and these were estimated excluding and 
including community care costs.  
 
The cost data were projected using 1997-2006 UK population cost figures for HIV-1 infected 
patients accessing HIV care in the UK NHS hospitals. The 1997-2006 cost data produced were 
used in linear regression models after combined costs for the three stages of HIV-1 infection 
(asymptomatic, symptomatic non-AIDS and AIDS). Two models were derived: excluding; and 
including; community care costs in order to estimate costs for years 2007-2013 using regression 
models described below.  
 
o Method 2 
Method 2 calculated the average direct population cost for 2006 for all HIV patients without 
accounting for patient‟s stage of HIV infection. The direct population cost was derived by dividing 
the NPMS-HHC calculated population cost for 2006 by the number of people living with HIV-1 in 
the UK in 2006 (HPA data). In order to obtain the direct population cost the average population 
cost that was calculated for 2006 was multiplied by the projected number of people living with HIV 
for that year. This process was applied to each subsequent years from 2007-2013. 
 
The figures were calculated from the average cost PPY regardless of the stage of HIV-1 infection. 
 
A) Project the total UK population figures obtained from HPA of HIV patients accessing  
     care in the UK.  
B) For the total UK HIV population from 1997-2013 for both including and excluding  
     community care (regardless of their stage of HIV infection) 
 
Once these number of HIV-1 population data had been projected for 2007 to 2013 from A and B 
these were added to the costs derived using the 2006 costs as a base cost figures to forecast the 
cost figures between 2007 to 2013. 
 
o Method 3 
For this method, the average population cost for 2006 were estimated. These were estimated by 
dividing the NPMS-HHC calculated population cost for 2006 by the number of people living with 
HIV-1 in the UK in 2006 (HPA data). In order to obtain the average population cost by stage of 
HIV-1 infection the average population cost that was calculated for 2006 was multiplied by the 
projected number of people living with HIV-1 for that year by the stage of HIV-1 infection. This 
process was applied to each of the subsequent years from 2007-2013. 
 
Linear least squares regression analyses was used for each stage of HIV-1 infection and the 
resulting linear regression models were used to estimate the population of patients living with HIV 
accessing care in the UK by stage of HIV infection. The UK HIV population costs for both including 
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and excluding community care from 1997 - 2013 were thus estimated for the three stages of HIV-1 
infection (asymptomatic, symptomatic non-AIDS and AIDS). 
 
2.8 GRAPHICAL REPRESENTATION OF DATA  
The data presented in this PhD thesis follow standard display of data depending on the type of 
data analysed19 (Armitage et al., 2001). Tables, graphs and charts have been used to display data 
or display selection of data sequence using flow charts. All data were analysed using SAS 
statistical software while GraphPAD and Microsoft Excel were used to prepare graphs and charts 
and further pictorial display of information were prepared using either Microsoft Powerpoint and 
Microsoft Word. 
 
 
 
 
 
  
                                               
Chapter 2:19
 http://www.bmj.com/about-bmj/resources-readers/publications/statistics-square-one/1-data-display-and-
summary 
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CHAPTER 3: LONG-TERM NON-PROGRESSOR COHORT ANALYSES: ESTIMATED 
TIME UNTIL DISEASE PROGRESSION 
 
Note: A modified version of this chapter has been published.  
Mandalia S, Westrop SJ, Beck EJ, Nelson M, Gazzard BG, Imami N.  
Are long-term non-progressors very slow progressors? Insights from the Chelsea and Westminster 
HIV cohort, 1988-2010. PLOS one. 2012;7(2):e29844. 
 
The total global estimate of people living with HIV-1 infection continues to increase. By end of 2011 
the global estimate was reported as 34 million (UNAIDS World AIDS Day Report, 2012) while this 
had increased 35.3 million one year later in 2012 (UNAIDS Report on the Global AIDS Epidemic, 
2013) (further details are in Chapter 1: section 1.2). If HIV-1 is left untreated most patients 
eventually progress to AIDS with reduced quality of life. Although there have been advances in 
treatment of HIV-1 and opportunistic infection, the search for preventive strategies on the 
development of prophylactic and therapeutic interventions through effective vaccines and/or 
immune-based therapies continues which would to put an end to: disease; prevent infection; or 
delay disease progression. The lessons learned from a unique and atypical patient group would be 
informative in designing novel strategies for the treatment of HIV-1 (Blankson, 2010; Imami et al., 
2013; Walker & Yu, 2013).  
 
Long-term non-progressors (LTNP) comprise a subgroup of HIV-1 infected people who naturally 
control HIV-1 replication without antiretroviral therapy (ART) and clinical progression of HIV-1 
disease is slow, with a few of these patients develop into AIDS even after prolonged infection. A 
group identified as LTNP could potentially provide a useful model in order to study the mechanisms 
of viral control as a step towards development of prophylactic vaccines and immune therapeutic 
approaches.  
 
3.1 INTRODUCTION 
The majority of HIV-1 infected patients display a gradual decline in peripheral blood CD4+ T-cell 
counts throughout the course of their illness. This is accompanied by excessive immune activation 
and the sequential loss of immune responses, first to HIV-1, then to other pathogens, allogeneic 
stimuli and finally mitogens (Clerici et al., 1989; Imami et al., 2001). The clinical course of HIV 
infection generally includes three stages: primary infection, clinical latency, and AIDS-defining 
illness (see Chapter 1: Figure 1.2.2).  
 
The rate of disease progression from asymptomatic HIV-1 infection to AIDS varies between 
patients and according to the rate of progression, HIV infection may be divided into four major 
types: (i) typical progressors (where the median time from first HIV-1 infection to progression to 
AIDS is eight to ten years); (ii) long-term survivors (those who progress to AIDS within a time frame 
similar to typical progressors, but in whom both clinical and laboratory parameters remain stable 
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for an unusually long period of time once disease progression has occurred); (iii) rapid progressors 
(where progression to AIDS occurs within two to three years of primary infection); (iv) LTNP (where 
individuals do not experience progressive HIV-1 disease for many years - eight to ten years 
following HIV-1 infection) (Pantaleo & Fauci, 1996).  
 
The rate of disease progression from asymptomatic HIV-1 infection to AIDS varies between 
patients and despite the varying disease progression rates, the majority of HIV-1 infected 
individuals eventually progress to AIDS. Determination of factors associated with HIV-1 
progression aims to enable the development of prophylactic vaccines and immune based 
approaches in order to delay HIV-1 progression or prevent infection. 
 
AIDS defining opportunistic infections were originally used to indicate disease progression in the 
clinic, however in 1993 the definition of HIV disease progression was widened to also include a 
drop in CD4+ T-cell count to <200 cells/μL blood or <14% of lymphocytes (Castro et al., 1992; 
MMWR, 1992). Some HIV-1+ individuals are able to maintain stable CD4+ T-cell count within the 
normal healthy range between 450-1650 cells/μL blood; local laboratory reference range (Westrop 
et al., 2009) for a prolonged length of time and do not exhibit signs of HIV related opportunistic 
infections such as bacterial pneumonia, cytomegalovirus and others (Castro et al., 1992), despite 
not receiving ART. The Chelsea and Westminster HIV-1 cohort of these atypical group of patients 
have been referred to as LTNP (Imami et al., 2002; Westrop et al., 2009). 
 
Within this group of atypical patients a few suppress HIV-1 replication to BLD of the HIV-1 RNA 
plasma load assay (<50 and including <500 when historically <50 copies/mL plasma load assays 
were unavailable) (Deeks & Walker, 2007; Westrop et al., 2009). These individuals are known as 
HIV Controllers (HIC) (Westrop et al., 2009). LTNP and HIC are terms that have been used to 
describe people known to have been living with HIV-1 for a „long time‟ without developing AIDS. 
While some studies claim that the prevalence of LTNP and HIC patients is low and is estimated at 
1 per 100 (Deeks & Walker, 2007; Walker, 2007) there is still no joined nomenclature for such 
atypical subjects. Despite the identification and study of LTNP and HIC in many international 
single- and multi-centre HIV-1 cohorts, no international consensus definitions of the LTNP or the 
HIC exist and consistent definitions have not been uniformly applied across all studies and sites. 
Confusion about definitions used exists in the published literature, resulting in difficulties when 
comparing results from patient groups from different cohorts. The unique immunological and 
virological profiles demonstrated by LTNP and HIC individuals may provide further clues towards 
development of prophylactic and therapeutic interventions through effective vaccines and/or 
immune-based therapies and highlight the importance of global unified definitions and 
classifications of patient groups of interest, especially the LTNP and HIC. LTNP have been 
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described to differ in genetics, virology and immunology compared to typical HIV-1 progressors as 
summarised in Table 3.1.1 (Gaardbo et al., 2012). 
 
Table 3.1.1: Table Summarised from Gaardbo et al., 2012 Describing Factors That Differ 
Between LTNP and Typical HIV-1 Progressors 
 
 Genetics Virology Immunology 
LTNP The presence of CCR5- 
delta32 polymorphism, and 
HLA B57 allele, are 
overrepresented in non- 
progressors. 
Infected with less virulent 
strains of HIV resulting in a 
more benign infection 
majority of non-progressors 
are infected with replicant-
competent virus. 
CD4
+
 T-cell from controllers 
are less susceptible to HIV-1 
compared to CD4
+
 T-cell from 
progressors; CD4
+
 T-cell from 
controllers are susceptible to 
HIV entry and productive 
infection. 
 
Differences in definition and criteria used to define atypical patient groups will impact on estimates 
of duration to HIV-1 progression before considering genetics, virology and immunology, further 
emphasising the need for agreed standardised use of terminology and definitions in order that 
these atypical patient groups are studied in-depth (Imami et al., 2013). In-depth study of such 
atypical patient group has the potential to provide insight into the control of HIV-1 infection in the 
absence of therapeutic intervention. Further, understanding the variables that are correlated with 
protective immunity to HIV-1 infection will guide in developing preventive HIV-1 vaccines as well as 
help determine treating HIV-1 infection by boosting immunity to HIV-1 (Imami et al., 2002; Migueles 
& Connors, 2010; Imami et al., 2013). 
 
3.1.1 SYNONYMS OF HIV NON-PROGRESSORS 
Many international single and multi centre HIV cohorts have identified LTNP and HIC however, 
terms used to describe these unique and atypical group of HIV-1+ people are not uniform across 
published studies in the UK and internationally and there are no unified and standardised 
nomenclature or definitions being used resulting in problems with respect to comparability of data 
(Imami et al., 2013). Although studies to date, have identified only a small number of factors that 
are consistently associated with LTNP status (Vento et al., 2004). Establishment, definition and 
characterisation of HIV-1+ LTNP patient cohort could be used to identify factors that are associated 
with non progression status, and therefore aid in determining potentially successful prophylactic 
vaccines and novel therapeutic approaches. The descriptions listed in Figure 3.1.1 portray some of 
the synonyms that have been used in published literature to define such atypical patient groups.  
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Figure 3.1.1: Synonyms of HIV Non-Progressors 
 
Figure taken with slight modifications from (Mandalia et al., 2012)  
 
 
Long term 
Survivor
HIV 
Controller
Viraemic
Controller
Elite 
Controller
Elite 
Suppressor
Elite
LTNP
LTNP True LTNP
Duration of 
HIV-1 infection
≥8 years ≥10 years Unspecified Unspecified Unspecified ≥8 years ≥8 years ≥10 years
CD4 T-cell 
count
≥500
cells/µL 
blood
Unspecified Unspecified Unspecified
Includes 
cells/µL blood
≥600 
cells/µL 
blood
>500 
cells/µL 
blood
>500 cells/µL 
blood
CD4 T-cell 
count slope
Decline <50 
cells/µL blood 
per year
Unspecified Unspecified Unspecified Unspecified
≥0 over prior 
5 years
Unspecified Non-declining
HIV-1 RNA 
plasma load Unspecified
90% <400 
copies/mL
plasma
<2000 
copies/mL
plasma
<50 
copies/mL
plasma
<50 
copies/mL
plasma
Unspecified Unspecified Undetectable
Opportunistic 
infection
None None None None None None None None
Anti-retroviral 
therapy
None None
None for ≥1 
year
None for ≥1 
year
None None None None
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 LONG-TERM SURVIVOR 
During the asymptomatic period, in some individuals with normal or lower than average CD4+ T-
cell counts, a lack of disease progression is observed, and these individuals have been described 
as „long-term survival‟ (Rutherford et al., 1990). Historically, individuals who were HIV-1+ remained 
healthy with CD4+ T-cell count >500 cells/μL blood for ≥10 years without ART (Klein & Miedema, 
1995) were referred to as long-term survivors. A number of synonyms were used to describe such 
patients and included: long-term asymptomatic; symptomless subjects; healthy long-term 
seropositives; long-term non-progressors; long-term survivors with high- or low- CD4+ T-cell count. 
 
These synonyms were then incorporated into a generic term, long-term survivors (Klein & 
Miedema, 1995) and these groups of individuals were defined as HIV-1+ subjects who had been 
followed up for ≥8 years in combination with one or more of the following end points: they were 
AIDS free; they had normal CD4+ T-cell count (≥500 cells/uL blood); minimal CD4+ T-cell count 
loss of <50 cells/uL per year; had normal CD4+ T-cell count to CD8 T-cell ratio (≥1.00); and they 
were not ARV exposed. 
 
 HIV CONTROLLERS 
HIV controllers were defined as HIV-1+ patients who had been followed up for ≥10 years, who had 
received no ARV treatment, and for whom >90% of the HIV-1 RNA plasma load measurements 
were <400 copies/mL plasma (Lambotte et al., 2005; Grabar et al., 2009). 
 
 VIREMIC CONTROLLERS 
In the paper by (Walker, 2007), viremic controllers were defined as people with asymptomatic HIV-
1 infection who maintain HIV-1 RNA load to below 2000 copies/mL plasma with no ARV therapy for 
1 year or longer. However episodes of viremia, the presence of virus in the blood, were defined as 
acceptable as long as they represented the minority of all available viral load determinations.  
 
 ELITE OR AVIREMIC CONTROLLERS 
Definition of elite controllers included people with asymptomatic HIV-1 infection who maintain HIV-
1 RNA plasma load to below 50 copies/mL plasma with no ARV therapy for the previous 12 
months or longer. Episodes of viremia were defined as being acceptable as long as there was no 
evidence of consecutive positive HIV-1 RNA plasma load tests (Deeks & Walker, 2007; Walker, 
2007). 
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 ELITE SUPPRESSORS 
In a publication by Han and colleagues (Han et al., 2008) an elite suppressor is referred to as „an 
HIV-1+ subject who is untreated and who maintains undetectable viral load‟‟. Although there is no 
clarity regarding repeat of CD4+ T-cell count measurements over time in these subjects, the 
publication displayed data on the most recent CD4+ T-cell count in this group of individuals. One 
individuals lowest CD4+ T-cell count value displayed was 399 cells/µL blood. 
 
 ELITE LONG-TERM NON-PROGRESSORS 
Grabar and colleagues (Grabar et al., 2009) described elite long-term non-progressors with the 
following criteria: asymptomatic HIV-1+ infected patients naïve to ART; documented CD4+ T-cell 
count and VL; known date of HIV-1+ diagnosis; age >13 years; and length of HIV-1 infection ≥8 
years; at least 3 measurements of HIV-1 RNA plasma load and CD4+ T-cell count in the 5 last 
years; a CD4+ T-cell count nadir ≥ 600 cells/μL blood; with CD4+ T-cell count slope ≥ 0 over the 
last 5 years. 
 
 LONG-TERM NON-PROGRESSORS 
Historically in a publication by Aiuti and colleague, long-term non-progressors (LTNP) were defined 
as HIV-1+ subjects who were asymptomatic for at least 8 years and had never received ARV 
treatment, with CD4+ T-cell count levels always above 500 cells/μL blood (Aiuti & D‟Offizi, 1995). 
 
HIV-1+ infected patients who immunologically did not progress to AIDS were termed LTNP and 
defined because of: documented HIV-1+ infection for more than 7 years; absence of symptoms; 
and the ability to maintain stable, high CD4+ T-cell count (>600 cells/μL blood) over many years; 
without receiving ART (Pantaleo et al., 1995). In this study the criteria used to define non-
progression included documented HIV-1+ infection for more than 7 years, stable CD4+ T-cell count 
greater than 600 cells/μL blood, the absence of symptoms, and no ARV therapy. 
 
A paper published in 1997 by Lefrere and colleagues described that despite being infected with 
HIV-1 for more than 10 years, a number of cohort studies had shown that a small percentage 
positive individuals remain symptomless and maintain a high CD4+ T-cell count without any 
therapeutic intervention of ART (Hardy, 1991; Learmont et al., 1992; Cao et al., 1995). These 
subjects who at the time maintained a CD4+ T-cell count >500 cells/µL blood over a 10-year period 
were described as LTNP.  
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 TRUE LONG-TERM NON-PROGRESSORS 
In a recent publication (Migueles & Connors, 2010) it was discussed that LTNP were historically 
defined as individuals who remained healthy: CD4+ T-cell count >500 cells/μL blood for ≥10 years; 
without ART (Klein & Miedema, 1995). With the availability of HIV-1 RNA plasma load tests, 
cohorts of LTNP classified using this „early‟ definitions were deemed heterogeneous with respect to 
HIV-1 RNA plasma load levels. The authors further conferred that a small subset of patients 
originally classified as LTNP maintained HIV-1 RNA plasma load BLD of the HIV-1 RNA plasma 
load assay (Lefrère et al., 1997; Migueles et al., 2000; Westrop et al., 2009). These LTNP with 
undetectable viral loads were exhibiting truly non-progressive HIV-1+ infection, with non-declining 
CD4+ T-cell count and were free from opportunistic infections during prolonged follow-up. These 
patients were therefore termed „true‟ LTNP. 
 
3.1.2 THE CHELSEA AND WESTMINSTER HIV COHORT AND DEFINITIONS OF 
ATYPICAL PATIENT GROUPS 
A small number of HIV-1+ patients who maintain a stable CD4+ T-cell count within the normal 
healthy range of 450-1650 cells/µL blood, who in addition have no history of symptomatic 
opportunistic infection or AIDS defining illness, despite never receiving ART. A subset of this group 
control HIV-RNA plasma load to BLD of HIV-1 RNA plasma load assay and are known as HIC. 
Within Chelsea and Westminster HIV-1 cohort, these patients have been referred to as „true‟ LTNP 
and/or LTNP. However as aforementioned these terms are not uniform between studies and sites 
as described in section 3.1.1, Figure 3.1.1 and there are no internationally agreed standardised 
synonyms or definitions of LTNP and HIC. The LTNP and HIC were identified from the entire HIV-1 
cohort: duration since HIV-1 infection was longer than 7 years, the median time until disease 
progression; no history of symptomatic HIV-1 disease; no history of ever prescribed ART; a stable 
CD4+ T-cell count which remained within the healthy normal range. Within the LTNP group, 
individuals who control HIV-1 replication to BLD of the conventional HIV-1 RNA plasma load assay 
(50 HIV-1 RNA copies/mL plasma) were also identified (Chapter 2: section 2.5.1). Based on a 
recent review (Gaardbo et al., 2012), data were further interrogated to establish whether any 
further individuals could be identified and subsequently classified into LTNP and/or HIC using only 
control of viral load criteria as described in detail in Chapter 2: section 2.5.1. The aims were: to 
estimate time until HIV-1 disease progression in different groups of patients identified during the 
study period by the application of different selection criteria; to establish the frequency of HIV-1+ 
patients who fulfilled the criteria of LTNP, long-term stable low CD4+ T-cell count, HIC and long-
term stable low CD4+ T-cell counts of whom controlled HIV-1 RNA plasma load to BLD; and to 
report immunological and virological profiles in the identified groups of individuals. 
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Figure 3.2.1: Flow Chart Showing Identification of LTNP and HIC from the Chelsea and 
Westminster HIV Cohort 
Figure taken with slight modification from (Mandalia et al., 2012) 
ART=Anti-retroviral therapy 
OI=Opportunistic infection 
Stable CD4
+
 T-cell count = rate of change in CD4
+
 T-cell count ≥0 cells/μL blood per quarter since cohort entry 
BLD=Below the limit of detection of the HIV-1 RNA plasma load assay (<500 or <50 HIV-1 copies/mL plasma since 
availability of this assay at our institution) 
HIC=HIV controller  
LTNP=Long-term non-progressor 
Entire Cohort
1988 – 2010*
HIV-1+ for 
>7 years
Yes No
History of 
ART
n=14,227
n=8,810
Yes No
n=4,213
History of 
OI
Yes No
n=892
Stable 
CD4+ T-cell 
count
Yes
n=258
History of 
CD4+ T-cell 
count <450 
/µl blood
Yes No
n=15
Died
Yes
No
n=2
n=13
Yes n=1
n=12
HIC
LTNP
n=1,204
n=5,417
n=312
n=54
n=39
History 
HIV-1 
Viraemia 
BLD No
n=2
No
Yes
n=3
HIV-1 RNA 
load BLD
Long-term 
stable low 
CD4+ T-cell 
counts
Yes
No
No
n=37
n=34
* Data to 28th Feb 2010
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3.2 RESULTS 
 HIV-1 COHORT CHARACTERISTICS 
From a total of 14,227 HIV-1+ patients in the study cohort, 5,417 subjects were identified to have 
been HIV-1+ for more than 7 years. Of whom, 1,204 had no history on the database of having been 
prescribed ART (Figure 3.2.1). Of 1,204 individuals, 312 in addition had no recorded history of 
opportunistic infection on the database. Time until HIV-1 progression in the two groups 1) 
individuals with duration of HIV-1+ greater than 7 years and no history of ART and 2) individuals 
with duration of HIV-1+ greater than 7 years, no history of ART and no history of opportunistic 
infection were estimated by those whose CD4+ T-cell count history did not remain within the normal 
range and those whose CD4+ T-cell count history remained within the normal range (Figure 3.2.2: 
a; Figure 3.2.2: b). 
 
a: Individuals with Duration of HIV-1+ > 7 
Years and No History of ART 
 
 
N=1,204 
b: Individuals with Duration of HIV-1+ > 7 
Years, No History of ART and  
No History of Opportunistic Infection 
 
N=312 
  
 
Figure 3.2.2: Survival Plots Showing Time to HIV-1 Progression 
 
 TIME UNTIL HIV-1 DISEASE PROGRESSION 
Of the 1,204 patients, 239 (19.9%) patients whose CD4+ T-cell counts remained within the normal 
range had an estimated median time until HIV-1 disease progression since HIV-1+ diagnosis of 6.2 
(IQR: 2.0 to 9.6) years, compared to 4.0 (IQR: 1.0 to 7.3) years for the 965 patients who had at 
least one CD4+ T-cell count below the normal range (Logrank 2 test: 21.26, p<0.001; Figure 3.2.2: 
a; Table 3.2.1). In addition, 312/1,204 (26%) patients had no recorded symptomatic opportunistic 
infection in the database and therefore were classified as remaining asymptomatic during the 
course of their routine HIV-1 follow up. Of whom 110 (35.3%) maintained CD4+ T-cell counts within 
the normal range and the estimated median (IQR) time to progression in this group, defined as 
CD4+ T-cell count decline or clinical progression showed some evidence of significantly longer 9.1 
(4.0 to 20.2) years compared to 7.3 (IQR: 2.3 to 13.3) years in 202 patients who had at least one 
CD4+ T-cell count fall below the normal range (Logrank 2 test: 3.72, p=0.054; Figure 3.2.2:b; 
Table 3.2.1).  
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Table 3.2.1: Time Since HIV-1+ Diagnosis Until Disease Progression in Patients Who Have Been Infected With HIV-1 for More Than 7 Years 
and Who Remain Symptomless in the Absence of ART 
 
Patients are stratified according to a history of at least one CD4+ T-cell count below the normal range (<450 cells/µL blood) 
 
 HIV-1+ >7 years, 
no ART† 
HIV-1+ >7 years, 
no ART†, 
no OI† 
HIV-1+ >7 years, 
no ART†, 
no OI†, 
unstable CD4+ T-cell count‡ 
 n=1,204 
Duration until 
disease 
progression# 
p- value n=312 
Duration until 
disease 
progression# 
p-
value 
n=258 
Duration until 
disease 
progression# 
p-
value 
CD4+ T-cell count 
ever below the 
normal range?  
  No  
  Yes 
  
  
 
 239  
965 
  
 
  
 6.2 (2.0 to 9.6)  
4.0 (1.0 to 7.3) 
  
  
 <0.001 
  
  
 
 110 
 202 
  
 
  
 9.1 (4.0 to 20.2) 
7.3 (2.3 to 13.3) 
  
  
 0.054 
  
  
 
 95  
163 
  
 
  
 5.8 (2.3 to 8.6) 
4.6 (1.8 to 8.4) 
  
  
 0.833 
†, ‡, 
See Figure 3.2.1 for definition of patient groups 
#
 median (IQR) years 
p-values using the Logrank 
2
 test 
 
Table taken from (Mandalia et al., 2012)
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 FREQUENCY OF UNSTABLE CD4+ T-CELL COUNT 
Of the 312 ART-naïve patients diagnosed as HIV-1+ for longer than 7 years who remained 
asymptomatic during the course of their routine HIV-1 follow up, 258 (82.7%) had unstable or 
declining CD4+ T-cell counts. Of these 95 (36.8%) had CD4+ T-cell counts consistently within the 
normal range and the estimated median time until HIV-1 disease progression in this group was 5.8 
(IQR: 2.3 to 8.6) years, this was similar to the 163 patients (63.2% of 258) who had a history of 
CD4+ T-cell counts below the normal range with an estimated time until HIV-1 disease progression 
of 4.6 (IQR: 1.8 to 8.4) years (Logrank 2 test: 0.045, p=0.833; Figure 3.2.1, Table 3.2.1). 
 
 DEMOGRAPHIC CHARACTERISTICS OF INDIVIDUALS WITH DURATION OF HIV-1+ GREATER 
THAN 7 YEARS AND NO HISTORY OF ART 
Of 1,204 (22.2%) who had no history of being prescribed ART (Figure 3.2.1) the demographic, 
immunology and virology data were compared between groups who had a history of CD4
+ 
T-cell 
count which remained ≥450 cells/μL blood and those whose CD4
+ 
T-cell count fell to <450 cells/μL 
blood (Table 3.2.2). There were no significant differences between patients whose CD4+ T-cell 
count had been documented below the normal range compared with patients whose CD4+ T-cell 
count remained within the normal range; in terms of gender (male 92.3% and 90.8% respectively; 
p=0.432) or median age (40.2 years and 39.9 years respectively; p=0.501). Significantly greater 
numbers of Caucasians were seen in the group whose CD4+ T-cell count had been recorded on at 
least one occasion as below the normal range compared to patients whose CD4+ T-cell count 
remained within normal range (68.5% and 58.2% respectively; p=0.003). 
 
Amongst those whose CD4
+ 
T-cell count fell to <450 cells/μL blood, significantly greater proportion 
deaths were observed (36.3%), significantly lower median (IQR): nadir CD4 T-cell count 123 (IQR: 
16 to 276) cells/μL blood; recent CD8 T-cell count 737 (IQR: 406 to 1,115) cells/μL blood; and 
nadir CD19 B-cell count 87 (IQR: 49 to 147) cells/μL blood; were observed compared to those who 
had a history of CD4
+ 
T-cell count which remained ≥450 cells/μL blood (Table 3.2.2). In those 
whose CD4
+ 
T-cell count fell to <450 cells/μL blood, a significantly higher median maximum HIV-1 
RNA plasma load was observed (47,148 copies/mL, IQR: 11,300 to 145,951) compared to those 
who had a history of CD4
+ 
T-cell count which remained ≥450 cells/μL blood. 
 
  
CHAPTER 3  
LONG-TERM NON-PROGRESSORS 
98 
Table 3.2.2: Demographic, Immunological and Virological Parameters of Patients With 
Duration of HIV-1+ >7 years and No History of ART 
 
  
Individuals with Duration of HIV-1
+
 > 7 Years and  
No History of ART
† 
 
 
 N(%) 
Total = 1204 
 
 
CD4
+
 T-cell count 
history  
<450 cells/μL blood 
 
Total=965 
CD4
+ 
T-cell count 
history  
≥450 cells/μL blood 
 
Total=239 
^p-
value 
Demographics    
Died  
No  
Yes 
 
615(63.7)  
350(36.3)  
 
225(94.1)  
14(5.9)  
 
<0.001  
Gender (%)  
 Female  
 Male 
 
74(7.7) 
891(92.3) 
 
22(9.2) 
217(90.8) 
 
0.432 
Ethnicity (%)  
 Caucasian  
 Black African  
 Other  
 
661(68.5)  
44(4.6)  
260(26.9)  
 
139(58.2)  
9(3.8)  
91(38.1)  
 
0.003  
Median age at last visit, years 
(IQR) [range] 
40.2(35.0 to 46.7) 
 
[25.8 to 77.6] 
39.9(34.4 to 45.9) 
 
[22.6 to 70.2] 
0.501 
HIV risk (%)  
 MSM  
 Heterosexual  
 Bisexual 
 
831(86.1)  
80(8.3)  
54(5.6)  
 
205(85.8)  
30(12.6)  
4(1.7)  
 
0.007  
&Median time since HIV-1
+
 
diagnosis, years (IQR) 
9.7 (8.2 to 12.6)  10.4 (8.2 to 13.7)  0.126  
Immunology    
Median nadir CD4
+
 T-cell count, 
cells/µL blood (IQR) 
123  
(16 to 276)  
551  
(491 to 670)  
<0.001  
Median most recent CD8
+
 T-cell 
count, cells/µL blood (IQR) 
737 (406 to 1115)  997 (764 to 1484)  <0.001  
Median nadir CD19
+
 B-cell 
count, cells/µL blood (IQR) 
N=448  
87 (49 to 147)  
N=94  
114 (88 to 212)  
<0.001  
Median nadir CD16/56 natural 
killer cell count, cells/µL blood 
(IQR) 
N=370  
40 (21 to 81)  
N=84  
54 (24 to 118)  
0.068  
Virology    
Median highest recorded HIV-1 
RNA plasma load, copies/mL 
plasma (IQR) 
 
N=265  
47148 (11300 to 145951)  
N=85  
11867 (1607 to 43898)  
<0.001  
† 
See Figure 3.2.1 for definition of patient groups
 
MSM: men who have sex with men 
^p-value using Mann-Whitney U test for quantitative data and 
2
 tests with Yates‟ correction for qualitative data 
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 DEMOGRAPHIC CHARACTERISTICS OF INDIVIDUALS WITH DURATION OF HIV-1+ GREATER 
THAN 7 YEARS, NO HISTORY OF ART AND NO HISTORY OF OPPORTUNISTIC INFECTION  
Of 1,204, 312 (25.9%) were found to have no recorded history of opportunistic infection (Figure 
3.2.1) and the demographic, immunology and virology data were compared between groups of 
individuals who had unstable CD4
+ 
T-cell count (n=258) and those who were classified as having 
long-term stable CD4
+ 
T-cell count (n=54), a group which included LTNP and HIC (Table 3.2.3). 
Among those with unstable CD4
+ 
T-cell count 15 (5.8%) had recorded death date while 4 (7.4%) in 
those with stable CD4
+ 
T-cell count had death date that was recorded. Between group 
comparisons of gender, ethnicity, duration since HIV-1+ diagnosis, nadir CD4+ T-cell count, recent 
CD8+ T-cell count, nadir CD19+ B-cell count and nadir CD16/56 natural killer (NK) cell count were 
significantly no different between the two groups. While significant between-group differences amid 
those with unstable and long-term stable CD4
+ 
T-cell count were found for age, HIV risk and 
highest recorded HIV-1 RNA plasma load (Table 3.2.3). 
 
Of the 50 patients alive with long-term stable CD4+ T-cell counts, 37 (74%) were identified and 
categorised into long-term stable low CD4+ T-cell count group while 13 (26%) fulfilled LTNP criteria 
who had CD4+ T-cell counts within the normal range and stable. Amongst whom 1 (7.7%) was 
identified as HIC where all but one HIV-1 RNA plasma load was 93 copies/mL plasma (Figure 
3.2.1). Those who exhibited long-term stable low CD4+ T-cell counts, all had at least one recorded 
CD4+ T-cell count below the normal range, 3 of whom controlled HIV-1 RNA plasma load to BLD. 
No significant differences were found between long-term stable low CD4+ T-cell count group and 
LTNP group for: gender, ethnicity, age, HIV risk, nadir CD19+ B-cell count, nadir CD16/56 NK cell 
count, and highest recorded HIV-1 load. While significant differences in: duration since HIV-1+ 
diagnosis, nadir CD4+ T-cell count, and recent CD8+ T-cell count were found between patients 
identified as long-term stable low CD4+ T-cell count and LTNP (Table 3.2.3). 
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Table 3.2.3: Demographic, Immunological and Virological Parameters of Patients With Duration of HIV-1+ >7 years, No History of ART and 
No History of Opportunistic Infection 
 
  
N=312 
 
 
N=54  
 Unstable CD4
+
  
T-cell count  
 
(Total=258) 
Stable CD4
+
  
T-cell count  
 
(Total=54) 
^p-
value 
Long-term stable low 
CD4
+
 T-cell count  
 
(Total=39) 
LTNP  
 
 
(Total=15) 
^p-value 
Alive at most recent 
time point 
n=243‡  
(Died n=15) 
N=50†  
(Died n=4) 
 
n=37†  
(Died n=2) 
n=13†  
(Died n=2) 
 
Demographics       
Gender (%)  
 Female  
 Male 
  
26(10.7)  
217(89.3) 
  
4(8.0) 
46(92.0) 
0.751 
  
3 (8.1)  
34 (91.9) 
  
1 (7.7)  
12 (92.3) 
 
0.584 
Ethnicity (%)  
 Caucasian  
 Black African  
 Other  
  
157(64.6)  
16(6.6)  
70(28.8) 
  
34(68.0)  
2(4.0)  
14(28.0) 
0.766 
  
22 (59.5)  
2 (5.4)  
13 (35.1) 
  
12 (92.3)  
0 (0.0)  
1 (7.7) 
 
0.090 
Median age at last visit, 
years (IQR) [range] 
39.9 (35.2 to 46.3) 
 
 [23.5 to 69.5] 
42.7 (36.8 to 49.9)  
 
[24.9 to 68.0] 
0.078 
41.7 (36.4 to 50.6) 
  
[24.9 to 67.1] 
40.2 (39.2 to 45.4)  
 
[29.6 to 68.0] 
0.782 
HIV risk (%)  
 MSM  
 Heterosexual  
 Bisexual 
 
 213 (87.7)  
28 (11.5)  
2 (0.8) 
 
 44 (88.0)  
3 (6.0)  
3 (6.0) 
0.021 
  
34 (91.9)  
2 (5.4)  
1 (2.7) 
  
10 (76.9)  
1 (7.7)  
2 (15.4) 
0.234 
Median time since HIV-
1
+
 diagnosis, years (IQR) 
[range] 
10.1 (8.3 to 13.7)  
 
[7.0 to 23.2] 
10.2 (8.1 to 14.2)  
 
[7.0 to 24.1] 
0.995 
9.3 (7.6 to 13.0) 
 
 [7.0 to 23.7] 
11.9 (9.4 to 19.4)  
 
[7.4 to 22.3] 
0.048 
Immunology       
Median nadir CD4
+
 T-cell 
count, cells/µL blood 
(IQR) [range] 
303 (226 to 415)  
 
[18 to 1055] 
337 (229 to 460)  
 
[17 to 1043] 
0.404 
296 (194 to 350)  
 
[17 to 400] 
583 (512 to 675)  
 
[460 to 1043] 
<0.001 
Median most recent 
CD8
+
 T-cell count, 
cells/µL blood (IQR) 
[range] 
978 (714 to 1302) 
 
 [168 to 3255] 
1067 (755 to 1293)  
 
[328 to 3168] 
0.613 
946 (712 to 1219) 
 
 [328 to 1803] 
1222 (1185 to 1624)  
 
[721 to 3168] 
0.015 
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N=312 
 
 
N=54  
 Unstable CD4
+
  
T-cell count  
 
(Total=258) 
Stable CD4
+
  
T-cell count  
 
(Total=54) 
^p-
value 
Long-term stable low 
CD4
+
 T-cell count  
 
(Total=39) 
LTNP  
 
 
(Total=15) 
^p-value 
Alive at most recent 
time point 
n=243‡  
(Died n=15) 
N=50†  
(Died n=4) 
 
n=37†  
(Died n=2) 
n=13†  
(Died n=2) 
 
Median nadir CD19
+
 B-
cell count, cells/µL blood 
(IQR) [range] 
90 (61 to 140)  
 
[4 to 584]  
n=147 
100 (59 to 176)  
 
[15 to 348]  
N=46 
0.354 
112 (53 to 187)  
 
[15 to 348]  
n=34 
94 (70 to 157)  
 
[41 to 269]  
n=12 
0.881 
Median nadir CD16/56 
NK cell count, cells/µL 
blood (IQR) [range] 
38 (18 to 80) 
 
 [2 to 362]  
n=129 
52 (24 to 89)  
 
[3 to 226]  
N=42 
0.218 
52 (25 to 90)  
 
[11 to 226]  
n=32 
52 (24 to 61) 
 
 [3 to 191]  
n=10 
0.701 
Virology       
Median highest recorded 
HIV-1 RNA plasma load, 
copies/mL plasma (IQR) 
[range] 
39,022  
(10,935 to 120,580)  
 
[<50 to 544,551]  
 n=130 
12,769  
(1,547 to 64,902)  
 
[<50 to 533,774]  
 N=44 
0.007 
13,022  
(3,424 to 66,433)  
 
[<50 to 533,774]  
 n=32 
3,113  
(11,00 to 42,238)  
 
[<50 to 481,775]  
 n=12 
0.377 
‡, † 
See Figure 3.2.1 for definition of patient groups 
^p-value using Mann-Whitney U test for quantitative data and 
2
 test with Yates‟ correction for qualitative data 
Where data is unavailable for patients within a group, the number of patients for whom data available is detailed 
 
Table taken from (Mandalia et al., 2012) 
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 FREQUENCY OF LONG-TERM NON-PROGRESSORS AND HIV CONTROLLERS 
From a total of 14,227 HIV-1+ patients, 13 were classified as LTNP and one of these was defined 
as HIC, whilst 37 were defined as long-term stable low CD4+ T-cell counts and of these 3 were 
also found to control their HIV RNA load BLD (Figure 3.2.1). Of 14,227 patients 8,810 had been 
HIV-1+ for <7 years. The 5,417 patients who had been HIV-1+ seropositive for ≥7 years were then 
investigated for history of ART. Seventy eight percent (4,213) of patients who had been HIV-1+ for 
≥7 years had a history of receiving ART, either past or current. 
 
Eight hundred and ninety two out of 1,204 individuals who had never received ART had a history of 
OI. The 312 patients who had no history of an OI, despite never receiving ART and being 
diagnosed as HIV-1+ for ≥7 years, were then investigated for maintaining their CD4+ T-cell count 
profiles. 
 
Eighty one percent (258/312) had declining, unstable CD4+ T-cell counts. Fifty four of 312 patients 
exhibited a stable CD4+ T-cell count indicated by a CD4+ T-cell count slope of ≥0 cells/μL blood per 
quarter, and so were investigated further. Four of the 54 patients with stable CD4+ T-cell counts 
were noted as having died during follow-up due to undocumented reasons (i.e. not related to HIV-
1+ infection and who were excluded from further investigation of CD4+ T-cell count profile (Figure 
3.2.1). 
 
Remaining 74% of the 50 patients in the analysis had a history of a CD4+ T-cell count below the 
normal healthy range (<450 cells/µL blood). These 37 patients were classified as long-term stable 
low CD4+ T-cell counts while 3 of these subjects were also found to have HIV-1 RNA plasma load 
consistently BLD (either <500 or <50 copies/mL plasma) and with reference to Figure 3.2.1. It is 
hypothesised that the CD4+ T-cell counts of these subjects, although below the normal range, are 
likely to be perched around the subject‟s own normal range. 
 
 FREQUENCY OF LONG-TERM STABLE LOW CD4+ T-CELL COUNT 
Twenty six percent of the 50 patients in the analysis had a history of a CD4+ T-cell count 
consistently above the normal healthy range (<450 cells/µL blood). These 13 patients fulfilled the 
criteria of CD4+ T-cell count within the normal healthy range, at all available time points. So these 
fulfilled the criteria of LTNP. Viral load data from these 13 patients were investigated and found to 
be consistently BLD in one individual. Such data were available for this patient from 7 visit dates 
over a 54 month period and on all but one HIV-1 RNA plasma load assay „blip‟ of 97 copies/mL 
plasma, the HIV-1 RNA plasma load was BLD of either 500 or 50 copies/mL plasma during the 
follow-up period. The variation in detection limit of the assay is due to the introduction of a new 
viral load assay with a lower detection limit. This patient was therefore considered an HIC. The 
CD4+ T-cell counts are depicted for the remaining 13 LTNP Figure 3.2.3 and for those with long-
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term stable low CD4+ T-cell count in Figure 3.2.4. In both figures (Figure 3.2.3 and Figure 3.2.4) 
HIV-1+ individuals with HIV-1 RNA plasma load BLD representing HIC are highlighted on the figure 
legend indicated by symbols used to plot the CD4+ T-cell count data for these small number of 
individuals who controlled their HIV-1 RNA plasma load to BLD.  
 
Figure 3.2.3: Distribution of CD4+ T-Cell Count Since Enrolment in the Cohort in 13 LTNP 
13 Long-term non-progressor including 1 HIC 
(normal healthy range 450-1650 CD4
+
 T-cell count cells/µL blood, marked with two dotted horizontal lines) 
Graph taken with slight modification from (Mandalia et al., 2012) 
 
The 37 individuals with long-term stable low CD4+ T-cell count profiles over time since HIV-1+ 
diagnosis, count are depicted in Figure 3.2.4. All these 50 individuals displayed in Figures 3.2.3 
and 3.2.4 displayed a stable slope of ≥0 cells/µL blood, per quarter. 
 
 
Figure 3.2.4: Distribution of CD4+ T-Cell Count Since Enrolment in the Cohort in 37 Long-
Term Stable Low CD4+ T-cell Count 
37 Long-term stable low CD4
+
 T-cell count including 3 who controlled HIV replication to BLD  
BLD = below the detection limit of the HIV-1 plasma viral load assay;  
(normal healthy range 450-1650 CD4
+
 T-cell count cells/µL blood, marked with two dotted horizontal lines) 
Graph taken with slight modification from (Mandalia et al., 2012) 
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 HIV NON-PROGRESSORS IDENTIFIED USING CONTROL OF VIRAL LOAD CRITERIA 
From a total HIV-1 cohort of 14,227 patients, 4,597 had 3 consecutive HIV-1 RNA plasma load 
<500 copies/mL plasma of whom 4,140 (90%) were on ART at the time when 3 consecutive HIV-1 
RNA plasma load were <500 copies/mL plasma. Of the 4,597 patients, 457 (9.9%) were not on 
ART at the time when 3 consecutive HIV-1 RNA plasma load were <500 copies/mL plasma and 
these were further investigated to identify patients for whom these 3 consecutive HIV-1 RNA 
plasma load results spanned at least one year as this would discount repeat tests at close 
proximity in time. One hundred and two (22%) patients had 3 consecutive VL results that spanned 
at least one year in the absence of ART. Of these a total of 102 patients were identified and 46 
(45%) of whom had no history on HIV-1 cohort database of ever receiving ART (Figure 3.2.5). 
Among the total of 102 patients who were identified, 7 of these were also part of a group of 
individuals who were identified as long-term stable low CD4+ T-cell counts and LTNP groups 
described in Figure 3.2.1. Of these 7 individuals, 5 were classified into long-term stable low CD4+ 
T-cell counts while the remaining 2 were classified as LTNP (Figure 3.2.5). 
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Figure 3.2.5: Flow Chart Showing Identification of HIV Non-Progressor Patient Groups 
Using Control of Plasma Viral Load Criteria from the Chelsea and Westminster HIV Cohort 
Entire Cohort
1988 – 2010 *
On ART 
when 
3xVl<500
n=14,227
Yes No
n=4,140 n=457
* Data up until, and including, 28th February 2010 
3 
consecutive 
VL <500
n=9,630 n=4,597
No Yes
3xVl<500 
>=12 
months
Yes
n=355 n=102
New criteria HIV-1 RNA 
plasma load <500 
copies/mL plasma
n=7
No 
ART
Hx
n=95
History of 
CD4+ T cell 
count <450 
cells /µl 
blood
Yes
n=5
No
n=2
Original 
n=37
Original 
n=13
Yes
n=46
In both 
data – n=50 
and n=102
LTFU LTNP
n=1 n=2
On 
ART
Rx
n=79
Yes
Case notes review 
Jan 2013
Duration 
<7 years
n=7
Unstable 
CD4 
count
n=9
No
On 
ART
n=3
Long-tem 
stable low 
CD4 count
N=1
Yes
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 HIV CASE NOTES REVIEW 
For the 102 patients identified to have 3 consecutive HIV-1 RNA plasma load results BLD, case 
notes of all 102 individuals were reviewed by an independent clinician in January 2013 to establish 
the current (January 2013) „atypical‟ status of the patients identified. Seven individuals were also 
part of a group of individuals who were identified as long-term stable low CD4+ T-cell counts and 
LTNP groups. Of whom, 5 (from previous selection criteria represented in Figure 3.2.1) were also 
classified as long-term stable low CD4+ T-cell counts while the remaining 2 were classified as 
LTNP using the HIV-1 RNA plasma load selection criteria (represented in Figure 3.2.5). The case 
note review showed that 3 of these 7 individuals had started ART by January 2013, 1 was lost to 
follow-up (LTFU) (using no evidence of clinic attendance within last 2 years as a definition of 
LTFU), while 2 of the remaining 7 continue to maintain LTNP status and the remaining 1 continues 
in the group of individuals with long-term stable low CD4+ T-cell count (Figure 3.2.5). 
 
Of the remaining 95 individuals, 79 (83%) were recorded on case notes to have received ART. Of 
the remaining 16 individuals who had no evidence of being prescribe ART, these 16 individuals 
were investigated further to establish reasons why these individuals were not part of the atypical 
individuals identified and represented in Figure 3.2.1. Of the 16 individuals who had not received 
ART (Figure 3.2.5): for 7 of these, duration of HIV-1+ was <7 years at the time of analysis; while for 
the remaining 9 individuals, CD4+ T-cell counts were defined as unstable as represented in Figure 
3.2.1.  
 
The distribution of HIV-1 plasma viral load, CD4+ and CD8+ T-cell counts data of these 9 
individuals‟ are depicted in Figure 3.2.6. The descriptions of these illustrate reasons why these 9 
patient were not identified in selection described in Figure 3.2.1 due to declining CD4+ T-cell count 
slope since entry to cohort were found „unstable‟ according to data represented in Figure 3.2.1 . 
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Figure 3.2.6: Distribution of HIV-1 Plasma Viral Load, CD4+ and CD8+ T-Cell Count Since Enrolment in the Cohort 
3 consecutive HIV-1 RNA plasma load <500 copies/mL plasma within 12 month period in the absence of ART (n=9). These 9 patients were not identified in the initial selection 
described in Figure 3.2.1 due to unstable CD4
+
 T-cell counts.
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3.3 DISCUSSION 
The caseload of HIV-1+ patients attending the HIV-1 unit for treatment and care during February 
2009 to February 2010 was 6,390, 13 (0.20%) were identified as LTNP, of whom one (0.02%) was 
an HIC. Thirty-seven (0.58%) were classified as exhibiting long-term stable low CD4+ T-cell counts, 
of whom 3 (0.05%) were able to control their HIV-1 RNA load replication BLD. This demonstrates 
that the number of patients fulfilling the criteria used to define LTNP, HIC or long-term stable low 
CD4+ T-cell counts within the Chelsea and Westminster HIV cohort is very small. 
 
 NOVEL SELECTION CRITERIA APPROACH 
Studies on HIV non-progressors to date have used varying definitions of rate of CD4+ T-cell count 
decline to identify the atypical patient groups but none have defined this with stringent criteria used 
as non declining since cohort entry that was used to identify LTNP and HIC. The Chelsea and 
Westminster HIV Cohort selection criteria included the stringent criterion of a non-declining CD4+ 
T-cell count slope since cohort entry, combined with additional clinical criteria as reported here. 
Despite having used one of the largest HIV-1+ cohorts in Europe to identify these atypical patients, 
only 50 (0.38%) exhibited maintenance of a long-term stable CD4+ T-cell count, of whom only 13 
could be confirmed as LTNP. 
 
Studies on HIV-1+ non-progressors to date have used varying definitions based on duration of HIV-
1 infection and CD4+ T-cell counts to identify atypical patient groups (Figure 3.1.1). In addition, 
most studies select these atypical patients who maintain their CD4+ T-cell count profile within the 
normal range. This study suggests that by using varying selection criteria, disease progression is 
very likely in the majority of patients living with HIV-1. The patients who had not progressed within 
the study period are likely to do so, as demonstrated in the analysis of patients found to have long-
term stable low CD4+ T-cell counts compared to patients with unstable CD4+ T-cell counts.  
 
 SUMMARY OF FINDINGS 
Marked differences were observed in some of the immunological markers of HIV-1 disease 
progression between groups of patients. Current CD4+ T-cell count, nadir CD4+ T-cell count and 
plasma HIV-1 RNA load were shown to be statistically different between groups of patients, 
however no differences were observed in CD8+ T-cell, CD19 B-cell or CD16/56 NK cell counts, 
indicating that the characteristics of HIV-1 disease, in the groups of i) LTNP, ii) patients with long-
term stable low CD4+ T-cell count and iii) individuals with unstable CD4+ T-cell counts, may be 
independent of the humoral acquired and NK cell-mediated innate immune responses. However, 
due to the small numbers of individuals in the LTNP and long-term stable low CD4+ T-cell count 
groups, power to detect a statistical significance was low. Small sample sizes decrease accuracy 
in point estimates used to describe quantitative data, including immunological and virological 
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markers, demonstrated by increased variability. A larger sample size would be required to reduce 
this variability, providing increased statistical power, sensitive hypothesis tests and decreased 
variability with narrower confidence intervals. In addition, studies that have investigated factors 
influencing CD4+ T-cell counts have indicated that sex (Maini et al., 1996), ethnicity (Tugume et al., 
1995), age (Hulstaert et al., 1994) and behavioural (i.e. smoking) (Maini et al., 1996) factors exert 
significant effects on CD4+ T-cell counts.  
 
Such potential effects on the observations reported above could not be performed due to small 
sample size, and relatively low numbers of women and ethnic diversity in our cohort. Furthermore, 
the infecting clade of HIV-1 and the geographic origin of infection are likely to impact the course of 
HIV-1 disease progression. However, clade data was only available for 19/50 patients with stable 
CD4+ T-cell count, 16 of whom were infected with clade B and 3 with clade C virus. Of the 13 
patients identified as LTNP, clade information was available for 5. Of these, 3 of whom were 
infected with clade B and 2 with clade C virus, while the clade for the remaining 8 LTNP have so 
far not been tested. However, the majority of HIV-1+ individuals in the UK are infected with clade B 
virus (Westrop et al., 2009). Infecting clade and viral fitness are important considerations for future 
work with the cases identified herein. 
 
Previously published data from our group and others further indicate that disease progression in 
LTNP is ultimately inevitable, and virological, immunological and genetic factors have all been 
consistently reported to be associated with rate of disease progression (Easterbrook, 1994; Lefrère 
et al., 1997; Westrop et al., 2009). HIV-1 control is thought to be attributable to immunological, 
virological and genetic components. 
 
The viral control exhibited by LTNP and HIC has been shown to be associated with HIV-1 specific 
CD4+ and CD8+ T-cell responses (Imami et al., 2002; Deeks & Walker, 2007; Westrop et al., 2009). 
Many LTNP are HLA-B57+, an MHC-class I allele that demonstrates enhanced peptide 
presentation to cytotoxic CD8+ T-cells on the surface of infected CD4+ cells (Migueles et al., 2000; 
Migueles et al., 2008; Pereyra et al., 2010). 
 
In our opinion, the rate of disease progression in HIV-1+ patients should be considered a 
continuous variable and not discrete. Studying patients at the extreme of this distribution may 
enable discovery of correlates of HIV-1+ disease progression, leading to identification of targets to 
be manipulated with novel therapeutic approaches, with the ultimate goal of inducing delayed 
disease progression, retarding ART initiation and alleviating pill burden and toxicity. The 
immunological mechanisms involved need to be studied as this may also provide clues towards the 
development of prophylactic and therapeutic vaccines against HIV-1. 
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 LIMITATIONS 
It is possible that many more HIV-1+ are LTNP or HIC, but due to the absence of clinical 
manifestations of disease these individuals have not yet attended an HIV-1 testing facility and 
consequently have not been diagnosed as HIV-1+. The criteria of time from HIV-1 seropositive 
diagnosis should also be considered as relatively arbitrary, as the date of first HIV-1+ test result, or 
date of first attendance at an HIV clinic, may not be an accurate representation of the date of 
infection. Instead, the date of first positive HIV-1 test should be considered a tool for healthcare 
professionals to identify patients exhibiting an unusual course of HIV-1 disease. 
 
Data used for this work are based on routinely collected observation data and like for other such 
databases data limitations are found such as HIV-1+ patients are lost to follow-up. Another 
limitation of observational data from a single centre is that HIV-1+ patients can also be managed in 
other centres and may receive ARV treatment from other clinical care providers, including private 
practice, which may not be captured in the database of the single centre. This was one of the 
findings when data were further investigated using a HIV-1 RNA plasma load criteria as 
summarised in Figure 3.2.5 where 83% or 79 individuals who were found to have 3 consecutive 
HIV-1 RNA plasma load <500 spanning at least one year were recorded on patient case notes to 
have received ART while ART history in these individuals were not recorded on computerised HIV-
1 database. Currently clinicians are reliant on patients‟ self reporting of ART treatment history 
including ART received elsewhere. The formation of a national centralised specialist observational 
database, highlighted by the UK governments Information Strategy (Department of Health, 2012) is 
a likely strategy to overcome such limitations in the future (for further details see Figure 1.1.6). 
 
 REPORTS FROM OTHER STUDIES 
To date many publications have used various definitions and synonyms essentially describing a 
unique HIV-1 positive population who, without exposure to ARV drugs, maintain a healthy immune 
system and low level viremia despite being HIV-1 positive for at least 7 years. Reports from other 
cohorts where atypical groups of patients have been identified, even though they used different 
criteria from those stated here, confirm the paucity of PLHIV who could be classified as LTNP. A 
recent investigation of a large HIV-1 cohort in France identified only 0.4% of their sample as LTNP 
(Grabar et al., 2009). 
 
The data presented in this PhD thesis and other studies emphasise a need for collaboration with 
other cohorts when studying such atypical patients, such as work performed within the international 
GISHEAL consortium (Imami et al., 2013), to increase the number of LTNP and HIC who can be 
identified and studied. In this study we demonstrate that using different criteria to define patient 
groups result in different estimates in time until disease progression, before even considering 
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functional immunology, genetic and virological factors, further emphasising the need for agreed 
standardised use of terminology and definitions before more in depth study of these individuals is 
performed. Figure 3.1.1 provides an indication of some of the different criteria used by different 
groups. Large cohorts of well-defined HIV-1+ infected patients will be essential for future 
investigation of genetic associations with HIV-1 control and delayed disease progression (Deeks & 
Walker, 2007), as the unique immunological and virological responses demonstrated by LTNP and 
HIC may provide clues towards both the change in disease status of these patients over time, and 
provide insights for HIV-1 preventive or therapeutic vaccine development, sentiments reiterated by 
Francoise Barre-Sinoussi as part of the preparations for the June 2011 United Nations High Level 
Meeting in New York (Barre-Sinoussi, 2011). 
 
 FUTURE WORK 
The individuals depicted in Figure 3.2.6 are currently being further investigated by a PhD student 
Nathali Grageda from the same department who is performing detailed immunological profiles and 
viral fitness in these individuals as these all show control of HIV-1 plasma viral load in the absence 
of ART. 
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CHAPTER 4: HIV AND AGEING ANALYSES: CO-EFFECTS OF HIV-1 INFECTION AND 
AGEING ON RESPONSE TO THERAPY, CO-MORBIDITY, PROGRESSION AND 
IMMUNE RE-CONSTITUTION ANALYSES 
 
Note: A modified version of renal function data from this chapter has been submitted for 
publication. 
Mandalia S, Herasimtschuk A, Farrington K, Westrop SJ, Nelson M, Gazzard BG, Imami N, Beck EJ 
Effect of HIV-1 infection, first-line ART and Ageing on renal function 
 
Everything that exists ages over time, and passes through three stages of development: embryo; 
growth and development; exhaustion and senescence, also known as the ageing process. The rate 
of ageing varies and there are theories of ageing that cover: genetic; biochemical; and 
physiological aspects. One of the problems associated with exploring senescence is distinguishing 
it between illnesses that are due to the ageing process or those that are caused by an underlying 
illness such as the HIV-1 infection.  
 
HIV-1 diagnosed people who have been treated long-term with ARV drugs and who have 
consequently aged are at an increased risk of non-HIV co-morbidities that are associated with 
ageing. Some of these are: cardiovascular disease (e.g. myocardial infarction); cancer; 
haematologic disease (e.g. anaemia); neurocognitive decline (e.g. dementia); bone disease (e.g. 
osteoporosis); lung (e.g. hypertension); liver disease (e.g. fibrosis); kidney disease (e.g. 
insufficiency). Ageing in this PhD thesis chapter will be investigated as a result of disease specific 
or HIV-1 processes together with effect of changes to the thymus as a result of normal ageing.  
 
4.0 EPIDEMIOLOGY OF AGEING 
Epidemiological study of older adults in the general population, have been described in census 
studies for many years. The estimated age distribution profile described in Figure 4.0.1 is of the UK 
general population by gender for the years 1995, 2000, 2010 together with the expected ageing 
population by 2020. 
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The estimated ageing of the UK‟s population based on data from US Census Bureau 17th July 
2003 illustrates the expected age distribution changes by 2020 
 
 
  
 
Figure 4.0.1: Population Pyramid Displaying Ageing of United Kingdom General Population 
by Gender 
Accessed 30
th
 March 2012: Figures taken from http://www.nationmaster.com/country/uk/Age_distribution  
 
Based on the projected population and the increased life expectancy of the general population this 
has meant that there is an expected increase in older population. Due to advances in medicine, 
public health policies and socioeconomic development (Dorshkind et al., 2009), these currently 
occurring and expected increased numbers of older people living in the general population has 
caused public heath directive for improved surveillance and control of diseases in the ageing 
population since susceptibility to infections and chronic diseases are often seen in advanced ages. 
In general there are differences in epidemiological study of „older‟ compared to „younger‟ and 
„middle-aged‟ adult population. These are: differences in clinical manifestations of disease and 
conditions among older persons; variations of the „natural history‟ trajectories and outcomes. 
Therefore this has led to exploration of disease occurrence, risk factors for morbidity and mortality 
and health outcomes. 
 
A typical course of HIV-1 is illustrated in Figure 4.0.2 which demonstrates how HIV-1 infected 
patients have to make adjustments to life regarding dependence/independence. The increased 
susceptibility to infections and chronic diseases with ageing has societal implications as costs 
incurred in caring for increasing number of older HIV-1+ people can have a significant impact on 
health-care system. The costs of health care services for acute and chronic conditions in general 
population are higher for the elderly, so the population growth in HIV-1+ people is likely to have an 
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effect on the NHS health care costs. While the health care costs of caring for the elderly HIV-1+ 
people is expected to rise, this is due to the patient‟s age as well as an increase in the complexity 
of the non-HIV co-morbidity in this group requiring tests and procedures. It is expected that as the 
proportion of older HIV-1+ people increase, greater financial and social care support will be 
required for their care.  
 
 
Figure 4.0.2: ‘Trajectory’ Illustrating the Course of a HIV-1 Infection in its Different Stages 
 
4.1 INTRODUCTION 
Globally the number of people estimated to be living with HIV-1 continues to increase. This was 
estimated at 34 million by end of 2011 (UNAIDS World AIDS Day Report, 2012) while at the end of 
2012 it had increased to 35.3 million (range: 32.2 - 38.8) (UNAIDS Report on the Global AIDS 
Epidemic, 2013). By the end of 2012 the number of adults living with HIV-1 in the UK (diagnosed 
and undiagnosed) was 98,400 and 76,500 people diagnosed with HIV-1 had used the NHS 
services (credible interval: 75,000 to 78,000) (Aghaizu et al., 2013). Further details of global and 
national HIV-1 infection are provided in Chapter 1: section 1.2. 
 
Since the HAART era the mortality due to HIV-1 infection has declined resulting in longer survival. 
With the new and potent ARV drugs available and the resulting success of these together with 
increasing number of older people becoming infected with the virus HIV-1+ patients have either 
survived to or become infected with the virus at age 50 years and beyond. The standard statistical 
reporting of HIV-1 cases in the UK by the HPA give data by 10-year intervals (<15 years, 15-24 
years, 25-34 years, 35-49 years) until 49 years after which ages are grouped to ≥50 years 
(Aghaizu et al., 2013). 
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 SEXUAL ACTIVITY IN OLDER PEOPLE 
Many „older‟ people are sexually active, although interest in sex and frequency of vaginal 
intercourse decline with age (Lindau et al., 2007). Since the first FDA approval of erectile 
dysfunction drug in 1998 this has extended sex life of many older individuals. Many studies have 
shown that „older‟ individuals are less likely than „younger‟ individuals to practice safer sex and the 
use of erectile dysfunction drugs has been associated with risky sexual practices in „older‟ 
individuals (Pantalone et al., 2008).  
 
 LIFE EXPECTANCY OF HIV-1+ PEOPLE 
In a recent study an increased life-expectancy20 of HIV-1+ people on ART was demonstrated. Life-
expectancy of HIV-1+ aged 20 years in North America and Europe ranged from 32 years for those 
who start ART with a CD4+ T-cell count less than 100 cells/µL blood to 50 years for those who start 
ART with CD4+ T-cell greater than 200 cells/µL blood (ART Cohort Collaboration, 2008). Similarly, 
HIV-1 diagnosed people on ART in resource-limited countries can also attain near normal life-
expectancy: Ugandan study estimated that life-expectancy of an HIV-1+ individual aged 20 years, 
35 years and 50 years or more was 27 years, 28 years and 24 years respectively. Life expectancy 
was observed to increase substantially with increasing baseline CD4+ T-cell count. Similar trends 
were observed for individuals who were in older age groups (Mills et al., 2011). The increased life-
expectancy of HIV-1+ people has given rise to the likelihood of developing non-HIV co-morbidities 
associated with ageing and the underlying process of immunosenescence (Spits, 2002). 
 
 INCREASES IN ‘OLDER’ HIV-1+ PEOPLE  
As life-expectancy increases, the number of „older‟ HIV-1+ people also increase, many of whom 
have been managed with long-term ART. Apart from increased life expectancy and increases in 
new HIV-1 diagnosis in people aged ≥50 years, number of people who are HIV-1+ and aged ≥50 
years are increasing. Some of the explanations for these increases are: with success of HAART 
people who are infected with HIV-1 in the „middle aged‟ group are likely to move into the „older‟ age 
category; the life expectancy in HIV-1 infected people continues to increase with „older‟ age group 
enjoying better health which will increase the likelihood to undertake risky behaviour; age related 
changes in the body‟s immune function and protective barriers, such as the drying of vaginal 
mucosa in women, make older people more susceptible to the HIV-1 infection when exposed; 
„older‟ adults may engage in risky sexual behaviours such as not using condoms, for reasons 
including lack of concern about birth control, lack of awareness about HIV risks, and difficulty 
manipulating protective devices due to conditions such as arthritis. 
 
                                               
Chapter 4:20
 Life expectancy is the statistical figure based on the average person‟s length of life and is usually quoted as the 
number of years of life remaining at a given age. http://stats.oecd.org/glossary/detail.asp?ID=1530  
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As people who are HIV-1+ grow older, they are at an increased risk of developing other non-HIV 
co-morbidities, in particular cardiovascular disease, non-AIDS related cancers, neurological 
complications, bone abnormalities and „frailty‟, liver and renal problems (Goetz, 2013; Deeks, 
2011). The number of HIV-1+ people ≥50 years is increasing rapidly in other high income countries 
such as the US as it is in the UK (Vance et al., 2011; Aghaizu et al., 2013). As a result of these, the 
number of people living with HIV-1 who are ≥50 years of age continues to increase in the UK 
where the infection rate in this age group increased by more than three-fold between 2000 and 
2007; from 299 new cases in 2000 to 710 in 2007 (Smith et al., 2010). 
 
The older HIV-1+ people are now facing a complex „ageing‟ process involving biological, social and 
psychological aspects. In addition to providing „older‟ HIV-1+ people with HIV-1 specific services, 
these need to be integrated with other specialist services: cardiovascular; renal; hepatic; 
neurological; endocrine; and other specialist services; as well as integrated with general geriatric 
services (Justice, 2010). 
 
 NON-HIV CO-MORBIDITIES 
Increasing numbers of studies are reporting that HIV-1+ infected people who are ageing while 
receiving ART treatment are at a risk of developing other chronic conditions that generally occur in 
„older‟ age such as cardiac and metabolic complications that are associated with ageing (Broder, 
2010). 
 
Ageing is a natural process that involves a gradual progressive decline in tissue and organ 
function. The increasing susceptibility to environmental challenges and an increasing risk of 
disease and death is the biological process of ageing. The increased numbers of HIV-1+ people 
≥50 years seen has led to an exploration of non-HIV co-morbidity and the risk factors associated 
with ageing so that there is an improved surveillance and control of conditions in the older HIV-1+ 
population. The characteristics of HIV-1 infection in different age groups will be described in this 
chapter. Data presented in this chapter explores one of the non-HIV co-morbidity, renal function. 
The co-effects of HIV-1 infection, ageing and effect of ART on renal function is explored and 
described. 
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4.1.1 BIOLOGY OF AGEING 
The oldest recorded human life span is held by Jeanne Calment of France, who died in 1997 at the 
age of 122 years, 164 days21. Natural ageing is a gradual reduction in the functional capacity of an 
individual without the onset of severe disabilities and these long surviving people remain active into 
their 90‟s and beyond. While Jeanne Calment followed an active and a „healthy‟ lifestyle many who 
also follow similar lifestyle do not survive to such an age. 
 
The rate of biological ageing (based on the quality of an individual‟s bodily systems) varies widely 
and is related to a gradual decline in functional reserve and is associated with the development of 
morbidity and mortality in the „elderly‟ and in patients with HIV-1+ (Deeks, 2011). There is however 
variability associated with the decline in functional reserve and lifestyle choices, environmental 
factors, genetics, and presence of co-morbidities. For example, loss of muscle strength, blood 
circulation, skin elasticity, joint flexibility and immune capacity occur faster in some people than in 
others. This is due to gene expression; the process by which information from a gene is used in the 
synthesis of a functional gene product (Anton et al., 2005). This means our genes do not change, 
but their expression changes. This may be formulated as: 
 
(life style, environment, diet) + (genotype22) = (phenotype23) 
(Anton et al., 2005) 
Ageing process involves accumulation of random molecular defects that build up within cells and 
tissues. These defects start to arise very early in life and over time the molecular defects increase, 
resulting eventually in age-related functional impairment of tissues and organs Figure 4.1.1 
(Kirkwood, 2008). 
 
 
Figure 4.1.1: The Ageing Process and Accumulation of Molecular Damage 
Figure taken from Kirkwood, 2008 
                                               
Chapter 4:21
 http://listverse.com/2010/02/07/top-10-oldest-people-ever/  
Chapter 4:22
 Entire set of genes in a cell in an individual 
Chapter 4:23
 The observable physical or biochemical characteristics of an organism, determined by genetic make-up and 
environmental influences 
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 VARIATIONS IN DEFINITIONS OF AGED 
Ageing is a continuous process and for example developing cataracts is considered as part of 
„normal ageing‟ since this develops with increased age. World Health Organization report most 
developed countries define age ≥65 years as „elderly‟ and United Nations age cut-off ≥60 years is 
referred to the „older‟ population (World Health Organisation, 2010b). However, the Centers for 
Disease Control and Prevention define older HIV-1+ people as those aged ≥50 years because 
originally 50 years was considered the upper age range for HIV-1 infection (Linsk, 2000). 
 
4.1.2 IMMUNOLOGICAL AGEING 
 AGE RELATED CHANGES TO THYMUS 
The development and maturation of T-cells occur in the thymus, which is a specialised organ of the 
immune system. In immunological terms, ageing is associated with a chronic inflammatory process 
and thymic changes that are expressed by changes in the total T-cells as well as T-cell subsets 
(Jamieson et al., 1999), Thymic function begins to decrease after birth, a process that accelerates 
at puberty (Buchholz et al., 2011). A steeper decline in naive CD4+ and CD8+ T-cells can be 
observed after the age of 40 years (Douek et al., 1998) and thymic involution is almost complete by 
age of 50 years (Brunner et al., 2011); after the age of 50 years, thymic epithelial space is reduced 
by 80% (Haynes et al., 2000). While thymic involution starts in early life, the thymopoietic potential 
per cell remains intact till around 50 years of age (Gruver et al., 2007). This immunological process 
is often referred to as „immunosenesence‟, and it is this immunological basis that people aged 50 
years or more are classified as being „older‟ in the work presented in this chapter. The age group 
used in this thesis are summarised in Table 4.1.1. 
 
Table 4.1.1: Defined Age Group Terms 
 
Term Age (years, 
inclusive) 
Used term in this PhD thesis  
Denarian 10 to 19   
 
Young adults: 
18-39 Vicenarian 20 to 29 
Tricenarian 30 to 39 
Quadragenarian 40 to 49 Middle-aged adults: 
40-49 
Decline in thymic function 
commences on average 
from ≥40 years 
+ 
Beginning of immune 
senescence on average 
commences ≥50 years 
Quinquagenarian 50 to 59  
Older adults: 
≥50 
Sexagenarian 60 to 69 
Septuagenarian 70 to 79 
Octogenarian 80 to 89 
Nonagenarian 90 to 99 
Centenarian 100 to 109 
Super centenarian 110 and older 
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 IMMUNOSENESENCE 
Immunosenecence is the deterioration of the immune system as a result of advancing age and is 
associated with a decline in naïve T-cell output which is thought to contribute to the reduction in T-
cells in older people which is likely to cause an increased susceptibility to infections in older people 
(Aw & Palmer, 2011). The patho-physiological24 changes observed in HIV-1+ people are similar to 
those seen in older people not infected with HIV-1 and these changes are characterised by 
ongoing inflammation, immune activation and increased coagulability (Kuller et al., 2008; Tien et 
al., 2010; Eastburn et al., 2011) which are similar to changes associated with „immunosenescence‟ 
(Gress & Deeks, 2009). 
 
4.1.3 WHITE BLOOD CELL COUNT 
The White Blood Cell (WBC) counts (leukocytes) are a component of the body's immune system. 
Indications for a WBC count include infectious and inflammatory diseases.  
 
Composition of WBC (leukocytes) 
 Lymphoid Myeloid 
Mono nuclear cells 
 
Lymphocytes 
Dendritic cells 
Monocytes  
 
Granulocytes  Neutrophils 
Eosinophils 
Basophils 
 
 T-LYMPHOCYTES 
The thymic derived lymphocytes originate in the bone marrow, develop and differentiate within the 
thymus and move through the lymphatic system and bloodstream to reside in the lymph nodes and 
spleen. T-cells comprise 70% to 80% of the peripheral blood lymphocyte population and have an 
average half-life of more than 2 years. The T-cell is important in providing protection against 
infections by fungi (e.g. Candida), viruses (e.g. HIV-1, Cytomegalovirus), and bacteria (e.g. 
Chlamydia, Tuberculosis).  
 
 T-HELPER AND T-SUPPRESSOR/CYTOTOXIC LYMPHOCYTES 
T-helper cells (these help the immune system by recognizing foreign substances on contact) 
account for approximately 40% to 60% of the peripheral blood T-lymphocyte population and they 
carry a protein on their surface called CD4. The T-helper cell‟s CD4 surface protein is the site on 
the cell to which the HIV-1 virus attaches. A second important subpopulation of T lymphocytes is 
the CD8+ T-cell known as the T-suppressor/cytotoxic or killer cells that expresses the surface 
protein called the CD8 molecule. 
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 The functional changes associated with or resulting from disease 
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 LYMPHOCYTE SUBSETS 
Immunoscenescence is the result of readjustment of immune cell functions and phenotypes (Effros 
et al., 2008). Ageing and atrophy of thymus is associated with dysfunction of stem cells and the 
decline in total number of T lymphocyte subsets (CD3 T-cell, CD4 T-cell, CD8 T-cell). The HIV-1 
cohort data routinely measure lymphocyte subsets (including B-cell and NK-cell) to monitor HIV-1 
infected patients morbidity (Burton et al., 2005), and the following results section describe results 
of routinely collected and available data on these.  
 
4.2 RESULTS  
 DEMOGRAPHIC CHARACTERISTICS BY IMMUNE CONSIDERED AGE GROUPS 
The HIV-1 cohort comprised of 15,241 HIV-1+ patients by May 2011 which was defined as the end 
of study period, 89% of whom were men, 70% Caucasian with a minority, 9% black African. Eighty-
one percent were MSM and only 3% were past or current IDU. 
 
The proportion of older HIV-1+ patient was less among black African while older patients were 
more likely to be bisexual, less likely to have an IDU history and more likely to have been living 
longer with HIV-1+ (Table 4.2.1). Relative to total women (n=1,673) and men (n=13,568) in the 
cohort, there were significantly fewer „older‟ ≥50 women 12% (95% CI: 11% to 14%) compared to 
„older‟ men 17% (95% CI: 16% to 18%), while significantly higher proportion of Caucasian were 
„older‟ 19% (95% CI: 18% to 19%) compared to „older‟ black Africans 13% (95% CI: 11% to 15%) 
and „older‟ other ethnic group 11% (95% CI: 10% to 12%). Significantly higher proportion of 
bisexuals were „older‟ 24% (95% CI: 20 to 28) compared to „older‟ MSM 16% (95% CI: 16% to 
17%) and „older‟ heterosexual 17% (95% CI: 15 % to 18%). 
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Table 4.2.1: Demographic Characteristics by Recent Age of the Chelsea and Westminster 
HIV Cohort (1988-2011)  
 
  Recent age (years) 
Grouped by immune considerations  
(Age known and ≥18 year olds) 
 
  
 
 
18-39 
 
40-49 
 
≥50 
 
  
Total cohort = 
15,241 
 
 
N=7769 
 
 
N=4961 
 
 
N=2511 
 
p-value 
 
Demographic characteristics:     
#Gender 
Female 
Male 
 
1673 
13568 
 
961 (12.4) 
6808 (87.6) 
 
504 (10.2) 
4457 (89.8) 
 
208 (8.3) 
2303 (91.7) 
 
<0.001 
#Ethnicity 
Caucasian 
Black African 
Other  
 
10731 
1329 
3181 
 
5176 (66.6) 
679 (8.7) 
1914 (24.6) 
 
3564 (71.8) 
481 (9.7) 
916 (18.5) 
 
1991 (79.3) 
169 (6.7) 
351(14.0) 
 
<0.001 
#Sexual orientation 
MSM 
Heterosexual 
Bisexual 
 
12385 
2355 
501 
 
6370 (82.0) 
1179 (15.2) 
220 (2.8) 
 
4017 (81.0) 
782 (15.8) 
162 (3.3) 
 
1998 (79.6) 
394 (15.7) 
119 (4.7) 
 
<0.001 
#IDU 
No 
Yes 
 
14773 
468 
 
7494 (96.5) 
275 (3.5) 
 
4819 (97.1) 
142 (2.9) 
 
2460 (98.0) 
51 (2.0) 
 
<0.001 
&Median (IQR) 
Duration since HIV-1
+
 
diagnosis, months 
66.5 
 
(23.6 to 131.2) 
41.0 
 
(13.1 to 81.1) 
97.0 
 
(40.3 to 158.3) 
126.7 
 
(57.6 to 188.9) 
<0.001 
MSM=Men who have sex with men 
#p-value using 
2 
test 
&Duration since HIV diagnosis is defined as HIV positive date to the most recent visit to clinic, p-value using Kruskal-
Wallis test 
See Table 4.1.1 for age group terms 
 
o Started First-line 2NRTIs+NNRTI or 2NRTIs+boosted PI 
There were 4,852 patients who started first-line 2NRTIs+NNRTI or 2NRTIs+boosted PI, 86% 
(n=4186) were men, 84% (n=3,506) were Caucasians and 85% (n=3,807) were MSM. Seventy-
nine percent started on first-line 2NRTI+NNRTI and 21% on 2NRTI+boosted PI. There was a 
significant increase in NNRTI containing regimens with increasing age ( 2 for trend, p=0.002; Table 
4.2.2). The demographic characteristics of patients who started these first-line regimens were 
comparable with the entire HIV-1 cohort. „Older‟ people (≥50 years) were less likely to be black 
Africans, more likely to be bisexual, less likely to be IDU and more likely to have been living with 
HIV-1+ for longer periods (Table 4.2.2). 
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Table 4.2.2: Demographic Characteristics by Recent Age of Patients Who Started First-line 
HAART Consisting of 2NRTI+NNRTI or 2NRTI+boosted PI 
 
  Recent age (years) 
Grouped by immune considerations  
(Age known and ≥18 year olds) 
Patients who started first-line HAART consisting 
of 2NRTI + NNRTI or 2NRTI + boosted PI 
 
  
 
N= 4,852 
18-39  
 
N=2,028 
40-49 
 
N=1,948 
≥50  
 
N=876 
 
p-value 
Demographic characteristics:     
#Gender 
Female 
Male 
 
666 
4186 
 
335 (16.5) 
1693 (83.5) 
 
238 (12.2) 
1710 (87.8) 
 
93 (10.6) 
783 (89.4) 
 
<0.001 
#Ethnicity 
Caucasian 
Black African 
Other  
 
3506 
625 
721 
 
1391 (68.6) 
281 (13.9) 
356 (17.6) 
 
1425 (73.2) 
253 (13.0) 
270 (13.9) 
 
690 (78.8) 
91 (10.4) 
95 (10.8) 
 
<0.001 
#Sexual orientation 
MSM 
Heterosexual 
Bisexual 
 
3807 
961 
84 
 
1614 (79.6) 
399 (19.7) 
15 (0.7) 
 
1526 (78.3) 
380 (19.5) 
42 (2.2) 
 
667 (76.1) 
182 (20.8) 
27 (3.1) 
 
<0.001 
#IDU 
No 
Yes 
 
4756 
96 
 
1992 (98.2) 
36 (1.8) 
 
1902 (97.6) 
46 (2.4) 
 
862 (98.4) 
14 (1.6) 
 
<0.001 
&Duration since HIV-
1
+
 diagnosis, months 
81.9 
 
(42.0 to 133.2) 
59.9 
 
(30.6 to 95.4) 
100.7 
 
(56.7 to 147.3) 
112.4 
 
(63.3 to 149.5) 
<0.001 
MSM=Men who have sex with men 
#p-value using 
2 
test 
&Duration since HIV diagnosis is defined as HIV positive date to the most recent visit to clinic, p-value using Kruskal-
Wallis test 
See Table 4.1.1 for age group terms 
 
o Exposure to Different Anti-retroviral Drug Classes  
Of the total cohort who had attended for HIV-1 treatment and care (n=15,241), 6,923 (45%) were 
ART naive. A progressive and significant gradual increase in ART exposure was observed with 
increasing age ( 2 for trend, p<0.001; Table 4.2.3) and over 70% of the „older‟ (≥50 year) patients 
in the cohort were ART experienced. The median duration of ARV class exposure increased 
significantly with increasing age, from 1.2 years in 18-20 year olds to 9.6 years for those older than 
70 years (Kruskal-Wallis test, p<0.001). Of the ART experienced patients (n=8,318), 4,314 (52%) 
had been exposed to PIs, whilst 5,982 (71%) had been exposed to NNRTIs (Table 4.2.3). 
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Table 4.2.3: Anti-retroviral Class Exposure by Recent Age of HIV-1 Cohort (1988-2011)  
 
  Recent age (years) 
Grouped by immune considerations  
(Age known and ≥18 year olds) 
N=15,241 
N(%) 
 
  
 
 
18-39 
 
40-49 
 
 
≥50 
 
 
Total cohort = 
15,241 
N=7,769 N=4,961 N=2,511 p-value 
Anti-retroviral treatment:     
#Duration of ARV 
exposure, years 
4.4(1.6 to 9.6) 
Range: 
0.01 to 23.5 
2.4 (0.8 to 4.7) 
Range: 
0.01 to 23.1 
5.9 (2.4 to 10.8) 
Range: 
0.01 to 23.3 
8.8 (3.7 to 13.7) 
Range: 
0.09 to 23.5 
<0.001 
&ART treatment ever 
Treatment naive 
Experienced 
 
6923 
8318 
 
4692 (60.4) 
3077 (39.6) 
 
1631 (32.9) 
3330 (67.1) 
 
600 (23.9) 
1911 (76.1) 
 
<0.001 
&NRTI experienced 
No 
Yes 
 
40 
8278 
 
21 (0.3) 
3056 (39.3) 
 
10 (0.2) 
3320 (66.9) 
 
9 (0.4) 
1902(75.8) 
 
<0.001 
&PI experienced 
No 
Yes 
 
4004 
4314 
 
1725 (22.2) 
1352 (17.4) 
 
1524 (30.7) 
1806 (36.4) 
 
755 (30.1) 
1156 (46.0) 
 
<0.001 
 
&NNRTI 
experienced 
No 
Yes 
 
2336 
5982 
 
1069 (13.8) 
2008 (25.9) 
 
828 (16.7) 
2502 (50.4) 
 
439 (17.5) 
1472 (58.6) 
 
 
<0.001 
&Other ARV drug 
class experienced 
No 
Yes 
(Includes Fusion 
Inhibitors, Integrase 
Inhibitors, CCR5 
antagonists) 
 
 
7611 
707 
 
 
2922 (37.6) 
155 (2.0) 
 
 
3035 (61.2) 
295 (6.0) 
 
 
1654(65.9) 
257(10.2) 
 
 
<0.001 
#Median (inter-quartile range: IQR), p-value using non parametric method test to test for differences in averages 
between the three age group strata using the Kruskal-Wallis method 
&p-value for qualitative data are based on 
2
 test  
No ART history where no ARV data available on the database for HIV-1
+
 patients in the cohort 
Total duration of ARV exposure defined as cumulative duration of all combinations prescribed over time 
See Table 4.1.1 for age group terms 
 
4.2.1 CROSS SECTIONAL DATA 
This cross-sectional method used included results of various parameters taken at a specific time. 
Below are results based on most recent results that were available in people with HIV-1 infection. 
Although the age changes are not measured directly, the average differences between the age 
groups is presented. Therefore, the effect of ageing was inferred from the between age group 
differences in averages. These differences are however confounded by the cohort effect using 
epidemiological definition as described in a paper by Keyes and colleagues (Keyes et al., 2010).  
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 CHARACTERISTICS OF IMMUNE MARKERS BY IMMUNE CONSIDERED AGE GROUPS 
o CD4 T-Cell Count 
From the total cohort who had attended for HIV-1 treatment and care the median (IQR) nadir CD4 
T-cell count by age showed a significant inverse trend with a low median nadir CD4 T-cell count 
among the „older‟ people (≥ 50 years) 125 (IQR: 39 to 232) cells/µL blood compared to those who 
were between 18-39 and 40-49 respectively: 227 (IQR: 64 to 378); and 158 (IQR: 47 to 281) 
cells/µL blood (Table 4.2.4). Similarly, median CD4 T-cell count at cohort entry was significantly 
lower among the „older‟ individuals 297 (IQR: 142 to 485) cells/µL blood compared to those who 
were 18-39 years (354, IQR: 195 to 524 cells/µL blood) or 40-49 years (333, IQR: 166 to 515 
cells/µL blood). In contrast recent median CD4 T-cell among „younger‟ people aged 18-39 years 
was lower (391, IQR: 144 to 582 cells/µL blood) compared to those who were 40-49 years or ≥50 
years and these were respectively: 450 (IQR: 227 to 652); and 458 (IQR: 249 to 662) cells/µL 
blood  
 
Table 4.2.4: Immunological and Virological Markers by Recent Age of HIV-1 Cohort (1988-
2011) 
  Recent age (years) 
Grouped by immune considerations  
(Age known and ≥18 year olds) 
N(%) 
 
  
 
 
18-39 
 
40-49 
 
≥50 
 
 
Total cohort = 
15,241 
N=7769 N=4961 N=2511 p-value 
Immunological information:     
#Nadir CD4 
T-cell count, cells/µL 
blood 
179 
(50 to 322) 
 
227 
(64 to 378) 
 
158 
(47 to 281) 
 
125 
(39 to 232) 
 
<0.001 
#First ever CD4 
T-cell count, cells/µL 
blood 
338 
(174 to 513) 
 
354 
(195 to 524) 
 
333  
(166 to 515) 
 
297  
(142 to 485) 
 
<0.001 
#Recent CD4 
T-cell count, cells/µL 
blood 
423 
(192 to 619) 
 
391 
(144 to 582) 
 
450  
(227 to 652) 
 
458  
(249 to 662) 
 
<0.001 
#First ever CD4 T-cell 
percent 
20.3 
(12.0 to 26.6) 
20.3 
(5.0 to 21.3) 
 
20.0 
(11.9 to 28.1) 
 
18.0 
(10.0 to 26.6) 
 
<0.001 
#Recent CD4 T-cell 
percent 
24.2 
(13.6 to 32.3) 
 
22.9 
(11.7 to 31.1) 
 
25.7 
(15.0 to 33.4) 
 
25.3 
(16.2 to 32.9) 
 
<0.001 
Cytotoxic T-cell counts:     
#Recent CD3 T-cell 
count, cells/µL blood 
1356 
(947 to 1776) 
 
1335 
(920 to 1748) 
 
1370  
(977 to 1804) 
 
1378 
(954 to 1800) 
 
<0.001 
#Recent CD3 T-cell 
percent 
78.6 
(71.6 to 84.2) 
 
79.9 
(73.0 to 85.2) 
 
77.9 
(71.0 to 83.6) 
 
76.8 
(69.9 to 82.7) 
 
<0.001 
#Recent CD8 T-cell 
count cells/µL blood 
792 
(530 to 1111) 
 
789 
(520 to 1102) 
 
790 
(537 to 1106) 
 
804 
(544 to 1141) 
 
0.174 
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#Recent CD8 T-cell 
percent 
50.3 
(40.7 to 61.0) 
 
52.0 
(42.6 to 62.8) 
 
48.7 
(39.4 to 59.8) 
 
48.2 
(38.6 to 58.8) 
 
<0.001 
B cell counts:     
#Recent CD19 B-cell 
count, cells/µL blood 
179 
(114 to 271) 
 
166 
(107 to 245) 
 
193 
(125 to 291) 
 
185 
(113 to 293) 
 
<0.001 
Natural killer cells:     
#Recent CD56 NK 
cells count cells/µL 
blood 
111 
(62 to 190) 
 
97 
(54 to 168) 
 
114 
(64 to 191) 
 
142 
(81 to 235) 
 
<0.001 
Virological information:     
#Highest recorded 
HIV-1 RNA plasma 
load, copies/mL 
plasma 
69,358 
(10,231 to 
251,204) 
 
55,429  
(10,067 to 
185,859) 
 
81,534  
(11,404 to 
291,856) 
 
93,666  
(9,588 to 
311,919) 
 
<0.001 
#Median (inter-quartile range: IQR), p-value using non parametric method test to test for differences in averages 
between the three age group strata using the Kruskal-Wallis method 
See Table 4.1.1 for age group terms 
 
o CD4 T-Cell Percentage 
First median CD4 percent for people aged: 18-39; 40-49; ≥50 years were 20.3 (IQR: 5.0 to 21.3), 
20.0 (IQR: 11.9 to 28.1), and 18.0 (IQR: 10.0 to 26.6) respectively. While recent CD4 percent were: 
22.9 (IQR: 11.7 to 31.1); 25.7 (IQR: 15.0 to 33.4); 25.3 (IQR: 16.2 to 32.9); for 18-39; 40-49; ≥50 
years respectively. 
 
o CD3 T-Cell Count 
The recent median CD3 T-cell count result of people who were 18-39 years was lower which was 
1,335 (IQR: 920 to 1748) cells/µL blood compared to those who were 40-49 years where this was 
1,370 (IQR: 977 to 1804) cells/µL blood and it was 1,378 (IQR: 954 to 1800) cells/µL blood for 
those who were ≥ 50 years. 
 
o CD3 T-Cell Percentage 
The most recent available median CD3 T-cell percentage by immune considered categorised age 
groups of 18-39, 40-49 and those who were ≥ 50 years were: 79.9 (IQR: 73.0 to 85.2); 77.9 (IQR: 
71.0 to 83.6); and 76.8 (IQR: 69.9 to 82.7) respectively. 
 
o CD8 T-Cell Count 
The recent CD8+ T-cell count respectively for 18-39, 40-49 and those who were ≥ 50 years were: 
789 (IQR: 520 to 1102); 790 (IQR: 537 to 1106); and 804 (IQR: 544 to 1141) cells/µL blood. 
 
o CD8 T-Cell Percentage 
The recent CD8+ T-cell percent for 18-39, 40-49 and those who were ≥ 50 years respectively were:  
52.0 (IQR: 42.6 to 62.8); 48.7 (IQR: 39.4 to 59.8); and 48.2 (IQR: 38.6 to 58.8). 
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o CD19 B-Cell Count 
The recent median CD19 B-cell count in individuals aged 18-39 years was significantly lower 166 
(IQR: 107 to 245) cells/µL blood compared to those who were 40-49 years this was 193 (IQR: 125 
to 291) cells/µL blood and it was 185 (IQR: 113 to 293) cells/µL blood for those who were ≥ 50 
years. 
 
o CD56: NK Cell Count 
Similarly, recent CD56 for 18-39, 40-49 and those aged ≥ 50 years were: 97 (IQR: 54 to 168) 
cells/µL blood; 114 (IQR: 64 to 191) cells/µL blood; and 142 (IQR: 81 to 235) cells/µL blood 
respectively. 
 
o HIV-1 RNA Plasma Load 
The highest recorded median HIV-1 RNA plasma load for 18-39, 40-49 and those aged ≥ 50 years 
respectively were: 55,429 (IQR: 10,067 to 185,859); 81,534 (IQR: 11,404 to 291,856); and 93,666 
(IQR: 9,588 to 311,919) copies/mL plasma 
 
 CHARACTERISTICS OF HEPATITIS B MARKERS BY IMMUNE CONSIDERED AGE GROUPS 
Significantly more „older‟ people (≥50 years) had tested hepatitis B positive, hepatitis B core 
antibody positive compared to „young‟ adults (18-39 years) and „middle-aged‟ (40-49 years) adults 
Table 4.2.5.  
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Table 4.2.5: Co-Infection Parameters by Immune Considered Age of HIV-1 Cohort (1988-
2011) 
 
  Recent age (years) 
Grouped by immune considerations  
(Age known and ≥18 year olds) 
N(%) 
 
  
 
 
18-39 
 
40-49 
 
≥50 
 
 Total cohort = 
15,241 
N=7769 N=4961 N=2511 p-value 
Co-infections ever:     
#Hepatitis B surface 
antibody 
Never tested 
Negative 
Ever Positive 
 
 
13779 
613 
849 
 
 
7425 (95.6) 
181 (2.3) 
163 (2.1) 
 
 
4301 (86.7) 
272 (5.5) 
388 (7.8) 
 
 
2053 (81.8) 
160 (6.4) 
298 (11.9) 
 
 
<0.001 
#Hepatitis B core 
antibody 
Never tested 
Negative 
Ever Positive 
 
 
8939 
3836 
2466 
 
 
5282 (68.0) 
1865 (24.0) 
622 (8.0) 
 
 
2524 (50.9) 
1401 (28.2) 
1036 (20.9) 
 
 
1133 (45.1) 
570 (22.7) 
808 (32.2) 
 
<0.001 
&Recent Hepatitis B 
DNA, copies/mL 
plasma 
N=357 
500 
(48 to 500) 
Range: 
1 to 2,837,604 
N=77 
500 
(48 to 721) 
Range: 
1 to 602,676 
N=172 
500 
(68 to 500) 
Range: 
34 to 400,000 
N=108 
500 
(34 to 500) 
Range: 
34 to 283,7604 
0.211 
&Median (inter-quartile range: IQR), p-value using non parametric method test to test for differences in averages 
between the three age group strata using the Kruskal-Wallis method 
#p-value for qualitative data are based on 
2
 test  
See Table 4.1.1 for age group terms 
 
 CHARACTERISTICS OF LIPID MARKERS BY IMMUNE CONSIDERED AGE GROUPS 
The recent lipid parameters appear to show statistically significant differences by age (Table 4.2.6), 
with patients who were middle-aged adults (40-49 years) and older adults (≥50 years) presenting 
with a significantly higher total cholesterol compared to younger HIV-1 infected adults (18-39 
years). 
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Table 4.2.6: Lipid Parameters by Immune Considered Age of HIV-1 Cohort (1988-2011) 
 
  Recent age (years) 
Grouped by immune considerations  
(Age known and ≥18 year olds) 
N=15,241 
N(%) 
 
  
 
 
18-39 
 
40-49 
 
≥50 
 
 Total cohort = 
15,241 
N=7769 N=4961 N=2511 p-value 
Recent lipids:     
&Total cholesterol, 
mmol/l 
4.7 
(4.1 to 5.4) 
 
4.5 
(3.9 to 5.1) 
 
4.9 
4.2 to 5.6) 
 
4.8 
(4.2 to 5.6) 
 
<0.001 
&High density 
lipoprotein, mmol/l 
1.13 
(0.93 to 1.36) 
 
1.12 
(0.92 to 1.33) 
 
1.13 
(0.92 to 1.36) 
 
1.15 
(0.94 to 1.39) 
 
0.004 
&Low density 
lipoprotein, mmol/l 
2.75 
(2.24 to 3.36) 
 
2.63 
(2.14 to 3.21) 
 
2.91 
(2.35 to 3.52) 
 
2.74 
(2.25 to 3.35) 
 
<0.001 
&Triglycerides, mmol/l 1.51 
(1.06 to 2.28) 
 
1.35 
(0.96 to 1.98) 
 
1.60 
(1.13 to 2.42) 
 
1.73 
(1.19 to 2.52) 
 
<0.001 
&Median (inter-quartile range: IQR), p-value using non parametric method test to test for differences in averages 
between the three age group strata using the Kruskal-Wallis method 
See Table 4.1.1 for age group terms 
 
 CHARACTERISTICS OF LIVER FUNCTION MARKERS BY IMMUNE CONSIDERED AGE GROUPS 
Similarly, significant differences were seen in liver function test results (Table 4.2.7) by age. 
 
Table 4.2.7: Liver Function Parameters by Immune Considered Age of HIV-1 Cohort (1988-
2011) 
 
  Recent age (years) 
Grouped by immune considerations  
(Age known and ≥18 year olds) 
N(%) 
 
  
 
 
18-39 
 
40-49 
 
≥50 
 
 Total cohort = 
15,241 
N=7769 N=4961 N=2511 p-value 
Recent liver function:     
&Alalnine 
transaminase, U/l 
30  
(20 to 45) 
 
28  
(19 to 45) 
 
31  
(21 to 47) 
 
30  
(22 to 44) 
 
<0.001 
&Alkaline 
phosphotase, U/l 
89  
(68 to 132) 
 
90  
(68 to 146) 
 
88  
(69 to 123) 
 
89  
(70 to 121) 
 
0.002 
&Aspartate 
transaminase, U/l 
33  
(25 to 50) 
 
34  
(25 to 56) 
 
32  
(24 to 48) 
 
31  
(24 to 46) 
 
<0.001 
&Gamma-
glutamyltransferase, 
U/l 
47  
(27 to 99) 
 
38  
(22 to 85) 
 
51  
(29 to 109) 
 
51  
(30 to 101) 
 
<0.001 
&Calcium, mmol/l 2.36  
(2.29 to 2.43) 
 
2.37  
(2.29 to 2.43) 
 
2.36  
(2.28 to 2.42) 
 
2.36  
(2.28 to 2.43) 
 
<0.001 
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&Phosphate, mmol/l 1.03  
(0.90 to 1.19) 
 
1.05  
(0.90 to 1.21) 
 
1.03  
(0.90 to 1.18) 
 
1.00  
(0.87 to 1.13) 
 
<0.001 
&Albumin, g/l 40  
(37 to 42) 
 
40  
(37 to 43)  
 
40 (37 to 42) 
 
39 (37 to 42) 
 
<0.001 
&Globulin, g/l 35  
(32 to 39) 
 
36  
(32 to 40) 
 
35  
(32 to 39) 
 
34  
(31 to 38) 
 
<0.001 
&Median (inter-quartile range: IQR), p-value using non parametric method test to test for differences in averages 
between the three age group strata using the Kruskal-Wallis method 
See Table 4.1.1 for age group terms 
 
 CHARACTERISTICS OF RENAL MARKERS BY IMMUNE CONSIDERED AGE GROUPS 
Table 4.2.8 describes the renal parameters by age and significant differences were observed in the 
renal markers by age. Patients who were ≥50 years had estimated glomerular filtration rate (eGFR) 
lower than those in the „younger‟ age groups. This table provides a cross-sectional description of 
the HIV-1 cohort population data by each age strata and presented are estimates of renal function 
markers available from the most recent clinic attendance. Although data presented in Table 4.2.8 
were available longitudinally, per each individual, these have not been fully explored in presented 
data in Table 4.2.8. 
 
Table 4.2.8: Renal Parameters by Immune Considered Age of HIV-1 Cohort (1988-2011) 
 
  Recent age (years) 
Grouped by immune considerations  
(Age known and ≥18 year olds) 
N(%) 
 
  
 
 
18-39 
 
40-49 
 
≥50 
 
 Total cohort 
= 15,241 
N=7769 N=4961 N=2511 p-value 
Recent renal:     
&Sodium, mmol/l 140 
(138 to 141) 
 
139 
(136 to 141) 
 
140 
(138 to 141) 
 
140 
(138 to 141) 
 
<0.001 
&Potassium, mmol/l 4.2 
(3.9 to 4.4) 
 
4.1 
(3.9 to 4.4) 
 
4.2 
(3.9 to 4.4) 
 
4.2 
(4.0 to 4.4) 
 
<0.001 
&Chloride, mmol/l 104 
(102 to 106) 
 
104 
(102 to 105) 
 
104 
(103 to 106) 
 
105 
(103 to 106) 
 
<0.001 
&Urea, mmol/l 5.2 
(4.2 to 6.3) 
 
4.9 
(4.0 to 6.0) 
 
5.2 
(4.3 to 6.3) 
 
5.7 
(4.6 to 6.9) 
 
<0.001 
&Estimated glomerular 
filtration rate (eGFR), 
ml/min per 1.73m
2
 
The modification of diet 
in renal disease 
(MDRD) formula was 
used to calculate eGFR. 
82 
(72 to 90) 
 
88 
(78 to 90) 
 
80 
(71 to 90) 
 
76 
(65 to 85) 
 
<0.001 
&Median (inter-quartile range: IQR), p-value using non parametric method test to test for differences in averages 
between the three age group strata using the Kruskal-Wallis method 
See Table 4.1.1 for age group terms 
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HIV-1 diagnosed people on long-term with ART are at an increased risk of non-HIV co-morbidities 
such as cardiovascular disease (e.g. myocardial infarction), cancer, haematologic disease (e.g. 
anaemia), neurocognitive decline (e.g. dementia), bone disease (e.g. osteoporosis), lung (e.g. 
hypertension), liver disease (e.g. fibrosis), and amongst others kidney disease (e.g. insufficiency) 
that are associated with ageing. While all non-HIV co-morbidities are of interest, due to space and 
time constraints one of the commodity is investigated further and presented in the following 
sections. The following section 4.2.2 explores in some detail the synergistic effect of HIV-1 
infection, long-term ART, ageing and risk of developing chronic kidney disease (CKD). 
 
In order to describe how the renal function parameters changed by age the longitudinal availability 
of renal function data are discussed further. Firstly, in order to describe renal function changes 
over time by age, ages were categorised into decades (Table 4.1.1) that encompass stages of age 
and ageing and secondly the renal parameter data are described using longitudinal availability of 
results so that the ages are described at the time of renal function result rather than cross-
sectionally as described in Table 4.2.1. For instance, the renal function data at successive points in 
time resemble each other to a greater degree than for example the renal function data of patients 
say from 10 years previously. Many factors change over time, making measurements close in time 
more similar than those across a long period of time. 
 
4.2.2 LONGITUDINAL DATA 
 NON-HIV CO-MORBIDITY: CHRONIC KIDNEY DISEASE 
One of the functions of kidneys is to remove all waste products of metabolism (such as urea, 
creatinine, and phosphorus), and to regulate the volume and composition (e.g. sodium and 
potassium) of body fluids. Glomerular filtration rate (GFR) measures the renal function and 
therefore effectiveness of the kidneys. Chronic Kidney Disease (CKD) is an indicator of level of 
damage to the kidneys and could occur as a result of physical injury to the kidneys or conditions 
such as diabetes, high blood pressure, or HIV-1 infection. Once the kidneys are damaged, they are 
unable to filter blood efficiently. 
 
There are 3 tests that could be used to determine the kidney disease. These are: 1) Blood 
pressure: High blood pressure is both a risk factor for kidney disease and a complication of kidney 
disease; 2) Protein in urine: Body require protein however proteinuria25 may be an indicator of 
kidney damage. Proteinuria does not increase with age; its appearance in the urine generally is 
due to some disease process. Proteinuria is evaluated using (Johnson et al., 2004b) (i) total 
protein:creatinine ratio, (ii) albumin:creatinine ratio; 3) Serum creatinine: Creatinine is muscle 
waste product and when the kidneys are insufficient, creatinine from blood filtration is impaired. In 
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addition since muscle mass decreases with age the creatinine in serum that is derived from muscle 
metabolism means the creatinine clearance may decrease substantially with age without increase 
in the serum creatinine concentration as muscle mass declines with age or with advancing HIV-1 
disease. Serum creatinine levels also increase with increased protein intake.  
 
Renal function deterioration is a common occurrence with advancing age. In a general population 
of „healthy‟ men kidney function described by creatinine clearance was shown to decline by 30% 
between ages 30 and 80 years in male cohort Table 4.2.9 (Rowe et al., 1976). 
 
Table 4.2.9: Longitudinal Changes in Creatinine Clearance by Age in ‘Healthy’ Men 
 
Table taken from (Rowe et al., 1976) 
 
In 2002 the Kidney Disease Outcome Quality Initiative (KDOQI) established a classification for 
CKD (National Kidney Foundation, 2002) defined as GFR below 60 ml/min per 1.73 m2 for 3 
months or more.  
 
 GLOMERULAR FILTRATION RATE 
GFR is the filtering of the blood also referred to as creatinine clearance which gives a measure of 
functional capacity of kidneys. GFR is estimated from serum creatinine concentration. Two 
commonly used formulas to calculate creatinine clearance (or GFR) are the Cockcroft-Gault 
formula and MDRD formula (Table 4.2.10).  
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The Cockroft-Gault formula for estimating creatinine clearance from serum creatinine concentration 
in older individuals has been improved upon using data from the MDRD study group (Levey et al., 
2009). 
 
Table 4.2.10: Formulae to Calculate Creatinine Clearance 
 
 
Formulae to calculate estimated creatinine clearance and eGFR) 
 
Cockcroft-Gault  
 
ml/min per 1.73m
2
 
 
 
Modification of 
diet in renal 
disease (MDRD) 
ml/min per 1.73m
2
 
 
Estimated GFR = 175 x SCr-
1.154
 x Age-
0.203
 x (1.212 if Black) x (0.742 if Female)  
(Levey et al., 2006) 
 
 
This formula gives normal range of eGFR: 90 to 120 ml/min per 1.73m
2
 
SCr: Serum creatinine concentration in ml/min per 1.73m
2
, age in years, weight in kilograms 
eGFR: Estimated glomerular filtration rate 
 
An eGFR is one of the pathways to assess kidney disease. Once the eGFR is impaired, 
progression to end-stage renal disease is likely to occur at high rates. There are 5 defined stages 
of CKD according to the eGFR measurement (Table 4.2.11). 
 
Table 4.2.11: National Kidney Foundation Classification of Stages of CKD 
 
Stage 
of CKD 
National Kidney Foundation  
 
Glomerular Filtration 
Rate  
(ml/min per 1.73m
2
) 
1 Kidney damage (eg. protein in urine) with normal GFR ≥90 
2 Kidney damage with mild decrease in GFR 60-89 
3 Moderate decrease in GFR 30-59 
4 Severe reduction in GFR 15-29 
5 Kidney failure <15 
CKD: Chronic Kidney Disease  
Table adapted from (Johnson et al., 2004a) 
 
The main aim is to understand the synergistic effects of HIV-1, ART and age on renal function. The 
symptoms of CKD are associated with complications on all organ systems. CKD related anemia, 
bone diseases, cardiovascular disease (Johnson et al., 2004a). The risk of complications like heart 
disease, anemia, or high blood pressure increases as the GFR falls below 60 ml/min per 1.73m2. 
The risk of co-morbidities increases when GFR declines to below 60 ml/min per 1.73m2. 
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Table 4.2.12: Risk Factors of CKD In ‘Normal’ HIV-1 Uninfected People 
 
Risk factor Description Example 
Susceptibility 
factors 
Increased risk of kidney 
damage 
 
Ageing, diabetes, hypertension, family history of CKD, 
Black ethnicity, 
Initiation factors Initiation of kidney 
damage 
 
Diabetes, high blood pressure, systemic infections, urinary 
tract infection, urinary stones, drug toxicity 
Progression factors Declining kidney 
function post initiation of 
kidney damage 
 
Higher levels of proteinuria, high blood pressure, high 
blood glucose, smoking, hyperlipidemia, anaemia, 
cardiovascular disease 
End stage Increased likelihood of 
morbidity and mortality 
due to kidney failure 
 
Anaemia, low serum albumin levels 
 
Adapted from (Parmar, 2002) 
 
CKD is associated with premature immunological ageing (Betjes et al., 2011) and renal impairment 
is also associated with a number of conditions including diabetes, hypertension, cardiovascular 
disease and others (Table 4.2.12). Among HIV-1+ people, having a low CD4+ T-cell count and high 
HIV-1 RNA plasma load (Mocroft et al., 2007; Fernando et al., 2008) are both associated with 
CKD. If left untreated, CKD can lead to moderate or advanced renal failure (Gilg et al., 2011) 
although the majority of patients with early CKD may not progress to these stages (Dalrymple et 
al., 2011). Since the advent of ART, studies have reported that people diagnosed with HIV-1 
receiving long-term ART are at risk of developing CKD (Mocroft et al., 2007; Levey et al., 2009; 
Mocroft et al., 2010; Young et al., 2012). However, HIV also directly infects renal cells, resulting in 
an inflammatory process or HIV-associated nephropathy (HIVAN) leading to CKD (Rao et al., 
1984; Ando et al., 2012). 
 
 DEMOGRAPHIC SHIFT SHOWING AGEING OF HIV-1 COHORT LOCALLY 
The success of HAART combined with older people being newly diagnosed as HIV-1+ has resulted 
in a demographic shift in age of HIV-1+ patients attending for care locally. A striking and 
progressive increase in the number of HIV-1+ individuals was observed over time with increasing 
age (Figure 4.2.1).  
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Figure 4.2.1: Age Distribution Shift by Cohort Strata Demonstrating an Increase in Older 
HIV-1+ People 
Figure taken, with slight modification, from oral presentation slides: Mandalia et al., 2011 
2nd International Workshop on HIV & Aging Baltimore, USA, 28
th
 October 2011, Session 7 Epidemiology and 
Pathogenesis. http://regist2.virology-education.com/2011/2Aging/docs/24_Mandalia.pdf 
 
Over time a progressive increase in the number of „older‟ (≥50 years) HIV-1+ patients was 
observed (Figure 4.2.1) comparing the period of HAART era 1 (1996-2000), HAART era 2 (2001-
2004), HAART era 3 (2005-2008) and HAART era 4 (2009-2011)26. The choice of these cohort 
strata were selected as these coincided with the introduction, availability and prescription of new 
ARV drugs during the year as part of HAART therapy (see Chapter 1: Table 1.2.1).  
 
HIV-1+ people who attended during 2009-2011 accounted for the largest numbers of patients aged 
≥40 years (n=4,399) compared to people who attended during 1996-2000 (n=1,609), 2001-2004 
(n=2,527), 2005-2008 (n=3,893). Compared to 1996-2000 (n=488) 11% were aged ≥50 years, the 
respective numbers aged ≥50 years who attended during 2001-2004 (n=783) were 15.5%, 2005-
2008 (n=1,241) 18.7%, 2009-2011 (n=1,621) 23.4%. These findings reflected increased numbers 
of HIV-1+ population aged ≥50 years attending for care within the cohort. 
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 DEMOGRAPHIC CHARACTERISTICS OF ART NAÏVE BY AGE 
Of the 6,923 patients who were ART naive, 91% (n=6304) were men, 66% (n=4,564) Caucasians 
and 84% (n=5,795) were MSM. The older PLHIV was more likely to have been living longer with 
HIV-1+ (Table 4.2.13). The percentage of women 50 years or older was 8% (95% CI: 6% to 11%), 
similar to the percentage of older men at 9% (95% CI: 8% to 10%). Similarly, 10% of Caucasian 
(95% CI: 9% to 10%) were 50 years or older compared with 8% of black Africans (95%CI: 5% to 
11%) and 7% of patients from other ethnic groups (95% CI: 6% to 8%). Sixteen percent of 
bisexuals (95% CI: 11% to 20%) were 50 years or older compared with 10% of heterosexuals 
(95% CI: 8% to 12%) and 8% of MSM (95%CI: 7% to 9%). 
 
 DEMOGRAPHIC CHARACTERISTICS OF PATIENTS WHO START FIRST-LINE HAART 
(2NRTI+NNRTI OR 2NRTI+BOOSTEDPI) BY AGE 
Of the 4,852 patients on first-line ART, 79% were on 2NRTIs+NNRTI and 21% 2NRTIs+boosted-PI 
(Table 4.2.13). Uptake of NNRTI containing regimens increased with age; of those who started 
first-line ART 86% (n=4,186) were men, 84% (n=3,506) Caucasians and 85% (n=3,807) were 
MSM. The percentage of older PLHIV was less among black Africans and higher among those 
persons who lived longer with HIV (Table 4.2.13). Significantly fewer women 50 years or older 
were in the ART cohort: 14% (95% CI: 11% to 17%) compared with 22% men (95% CI: 20% to 
23%). Similarly, 20% of Caucasians (95% CI: 18% to 21%) were older compared with 15% of black 
Africans (95%CI: 12% to 17%) and 13% of patients from other ethnic groups (95% CI: 11% to 
16%). Thirty-two percent of bisexuals (95% CI: 22% to 43%) were 50 years or older compared with 
19% of heterosexuals (95% CI: 17% to 21%) and 18% of MSM (95%CI: 16% to 19%). 
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Table 4.2.13: Demographic Characteristics by Age Group of ART Naïve and Patients on First-line 2NRTI+NNRTI or 2NRTI+boosted-PI 
ART naïve patients   18-19 years 20-29 years 30-39 years 40-49 years 50-59 years 60-69 years ≥70 years   
N=6,923 N=31 N=1,735 N=2,926 N=1,631 N=477 N=112 N=11 p-value 
Gender                         Female 619 6 (19) 218 (13) 250 (8) 94 (6) 40 (8) 10 (9) 1 (9) <0.001 
Male 6,304 25 (81) 1517 (87) 2676 (92) 1537 (94) 437 (92) 102 (91) 10 (91)  
Ethnicity                  Caucasian 4,564 23 (74) 1052 (61) 1956(67) 1096(67) 341 (71) 87 (78) 9 (82) <0.001 
Black African 420 2 (6) 111 (6) 187 (6) 87(5) 28 (6) 5 (5) 0 (0)  
Other  1939 6 (19) 572 (33) 783 (27) 448(28) 108 (23) 20 (17) 2 (18)  
Sexual orientation           MSM 5,795 24 (77) 1448 (84) 2447 (83) 1407 (86) 378(79) 83 (74) 8 (73) <0.001 
Heterosexual 838 7 (23) 228 (13) 367 (13) 150 (9) 67 (14) 17 (15) 2 (18)  
Bisexual 290 0 (0) 59 (3) 112 (4) 74 (5) 32 (7) 12 (11) 1 (9)  
IDU                                      No 6,685 31 (100) 1679 (97) 2798 (96) 1588 (97) 467 (98) 111 (99) 11 (100) 0.008 
Yes 238 0 (0) 56 (3) 128 (4) 43 (3) 10 (2) 1 (1) 0 (0)  
Median (IQR)  31 4 15 35 45 51 66 118 <0.001 
months since HIV diagnosis (8 - 71) (1 - 14) (3 - 42) (10 - 73) (12 - 95) (13 - 100) (18 - 110) (37 - 223) 
 
Patients on first-line ART  N=4,852 N=3 N=414 N=1,611 N=1,948 N=647 N=181 N=48 p-value 
2 NRTI+NNRTI 3,836 2 (67) 308 (74) 1253 (78) 1560 (80) 525 (81) 149 (82) 39 (81) 0.073 
2NRTI+boostedPI 1,016 1 (33) 106 (26) 358 (22) 388 (20) 122 (19) 32 (18) 9 (19)  
Gender                         Female 666 3 (100) 91 (22) 241 (15) 238 (12) 73 (11) 15 (8) 5 (10) <0.001 
Male 4,186 0 (0) 323 (78) 1370 (85) 1710 (88) 574 (89) 166 (92) 43 (90)  
Ethnicity                  Caucasian 3,506 0 (0) 274 (66) 1117 (69) 1425 (73) 495 (76) 159 (88) 36 (75) <0.001 
Black African 625 2 (67) 57 (14) 222 (14) 253 (13) 75 (12) 11 (6) 5 (10)  
Other  721 1 (33) 83 (20) 272 (17) 270 (14) 77 (12) 11 (6) 7 (15)  
Sexual orientation           MSM 3,807 2 (67) 323 (78) 1289 (80) 1526 (78) 497 (77) 134 (74) 36 (75) 0.002 
Heterosexual 961 1 (33) 91 (22) 307 (19) 380 (20) 130 (20) 40 (22) 12 (25)  
Bisexual 84 0 (0) 0 (0) 15 (1) 42 (2) 20 (3) 7 (4) 0 (0)  
IDU                                      No 4,756 3 (100) 411 (99) 1578 (98) 1902 (98) 633 (98) 181 (100) 48 (100) <0.001 
Yes 96 0 (0) 3 (1) 33 (2) 46 (2) 14 (2) 0 (0) 0 (0)  
Median (IQR)  81.9 24.1 38.3 67.6 100.7 116.2 102.7 127.4 <0.001 
months since HIV diagnosis  (42 - 133) (20 - 220) (20 - 64) (35 - 106) (57 - 147) (65 – 152) (49 – 147) (79 – 183) 
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The eGFR is a widely reported marker of renal function in HIV-1+ people and this is reported to 
detect progression of renal dysfunction. The following analyses will seek to describe longitudinal 
changes in renal function, as measured by eGFR (by MDRD method), by age in a cohort of HIV-1+ 
people and analyse the impact of HIV-1 infection and long-term ART in HIV-1+ people as they age. 
Age was grouped into decades and derived at time of renal function results in people who had 
been exposed to the three widely used ARV drug classes and assess whether the renal function is 
stable or progressive with changing age. This includes HIV-1+ people who were ART naïve and 
those who had been exposed to different classes of ARV drugs, including nucleoside reverse 
transcriptase inhibitors (NRTI), protease inhibitor (PI) or non-nucleoside reverse transcriptase 
inhibitors (NNRTI). As Highly Active ART (HAART) usually comprise the use of at least two classes 
of ARV drugs concurrently, longitudinal changes in renal function were also analysed for those 
starting the most commonly prescribed first-line HAART therapy comprising either 2NRTI+NNRTI 
or 2NRTI+boosted PI regimens by age. Finally variables that independently predicted the 
occurrence of CKD stage 4 or 5 (moderate or advanced renal failure) (see Table 4.2.11: eGFR <30 
ml/min per 1.73m2) were identified. 
 
 CHANGING EGFR FOR ART NAÏVE BY AGE 
In ART naïve individuals, eGFR remained relatively stable at 84 ml/min per 1.73m2 for the „young‟ 
adults aged 18-39 years. A progressive decline was subsequently observed at around 40 years, 
when thymic function declines, with a mean eGFR of 80 ml/min per 1.73m2 for the „middle-aged‟ 
adults 40-49 years and by the time HIV-1+ adults were 70 years or older the mean eGFR had 
decreased to 59 ml/min per 1.73m2.  
 
 CHANGING EGFR BY ARV CLASS EXPOSURE AND AGE 
eGFR results were available for 7,980 patients. Similar findings were observed by age in those 
patients who had been exposed to ART including NRTIs, PIs or NNRTIs (Figure 4.2.2; Table 
4.2.14). Polynomial models were generated that predicted mean eGFR by age for each of the four 
groups: ART naïve; NRTI; PI; or NNRTI exposed in addition a polynomial model based on 
creatinine clearance values from „normal‟ HIV-1 uninfected people by age (Rowe et al., 1976). For 
each of these five groups, the models with the „best fit‟ predicted a declining eGFR with increasing 
age for HIV-1+ and uninfected people (Table 4.2.15). The predicted eGFR for: ART naïve; NRTI; 
PI; or NNRTI exposed HIV-1+ people at age 20 years were respectively predicted as: 84; 84; 83; 
and 85 ml/min per 1.73m2. Similarly, the predicted eGFR for an HIV-1+ person aged 60 years for: 
ART naïve; NRTI; PI; or NNRTI exposed patients were 78, 76, 75 and 77 ml/min per 1.73m2 
respectively. Predicted creatinine clearance for „healthy‟ uninfected people was 103 ml/min per 
1.73m2 at age 20 years and 98 ml/min per 1.73m2 at age 60 years. 
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Figure 4.2.2: Longitudinal Changes in eGFR Age and ARV Class Exposure and Creatinine 
Clearance by Age in HIV Negative People and Reduced by 20% (Rowe et al., 1976; Breyer & 
Qi, 2010) 
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Table 4.2.14: Anti-retroviral Class Exposure and eGFR, by Age at the Time of Result of HIV-1 Cohort (1988-2011) and Patients Who Started 
First-line HAART Consisting of 2NRTI+NNRTI or 2NRTI+boosted PI 
 
 Recent Age of HIV-1 Cohort (1988-2011) 
N=15,241 
 18-19 
 
N=34 
20-29 
 
N=2,309 
30-39 
 
N=5,426 
40-49 
 
N=4,961 
50-59 
 
N=1,876 
60-69 
 
N=529 
>=70 
 
N=106 
ART naive 
N=6923 
85.0 
(80.5 to 89.4) 
85.1 
(84.2 to 86.0) 
82.5 
(81.8 to 83.3) 
80.3 
(79.4 to 81.2) 
77.6 
(76.1 to 79.1) 
77.3 
(74.1 to 80.5) 
58.9 
(53.7 to 63.2) 
 
Age at time of renal result (years) 
Mean eGFR (95% CI) ml/min per 1.73m
2
 
Total number of patients=7980 
 18-19 
 
N=33 
20-29 
 
N=1204 
30-39 
 
N=3293 
40-49 
 
N=3721 
50-59 
 
N=1482 
60-69 
 
N=435 
>=70 
 
N=85 
NRTI 
experienced 
84.1 
(79.1 to 89.1) 
84.8 
(83.7 to 85.8) 
83.0 
(82.2 to 83.8) 
79.9 
(79.0 to 80.9) 
76.2 
(74.7 to 77.8) 
71.8 
(68.5 to 75.0) 
64.8 
(59.8 to 69.8) 
PI  
experienced 
83.3 
(83.1 to 83.6) 
84.4 
(83.8 to 85.0) 
82.7 
(82.2 to 83.1) 
79.0 
(78.5 to 79.4) 
75.6 
(69.2 to 82.0) 
70.4 
(64.1 to 76.8) 
59.2 
(53.7 to 66.8) 
NNRTI 
experienced 
85.3 
(82.9 to 87.6) 
84.9 
(84.4 to 85.3) 
83.4 
(83.1 to 83.7) 
80.0 
(70.1 to 89.9) 
76.4 
(66.5 to 86.3) 
71.7 
(61.8 to 81.6) 
64.9 
(55.0 to 73.8) 
 Age at time of renal result of patients who started first-line HAART 
 
N=4,852 and ART naïve N=6923 
Mean eGFR (95% CI) ml/min per 1.73m
2
 
longitudinally estimated using MIXED model 
  
18-19 
 
N=3 
 
20-29 
 
N=414 
 
30-39 
 
N=1,611 
 
40-49 
 
N=1,948 
 
50-59 
 
N=647 
 
60-69 
 
N=181 
 
>=70 
 
N=48 
2 NRTI+NNRTI 
N=3,836 
87.0 
(81.8 to 92.3) 
85.1 
(84.3 to 85.8) 
83.4 
(83.0 to 83.9) 
81.3 
(80.8 to 81.8) 
77.9 
(77.1 to 78.7) 
75.4 
(73.7 to 77.0) 
70.8 
(67.2 to 74.4) 
2NRTI+boostedPI  
N=1,016 
85.1 
(76.8 to 93.4) 
84.2 
(82.7 to 85.7) 
81.9 
(81.0 to 82.9) 
78.9 
(77.9 to 79.9) 
78.1 
(76.1 to 80.2) 
69.6 
(65.6 to 73.7) 
67.0 
(57.7 to 76.3) 
See Table 4.1.1 for age group terms 
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Table 4.2.15: Relationship between Creatinine Clearance, eGFR, Age, ARV Class Exposure 
and First-line HAART 
 
 Trends over time in creatinine 
clearance or eGFR described by linear 
and polynomial relationship 
 
Proportion 
of variance 
explained 
Predicted 
values at 
20 years 
ml/min 
per 
1.73m2 
Predicted 
values at 
60 years 
ml/min 
per 
1.73m2 
     
Normal 
population 
(Rowe et al., 
1976) 
CrCl = -0.0157 Age
2
 + 1.115Age + 87.242 94.3%* 103* 98* 
     
Treatment 
naive 
 
eGFR = -0.0096 Age
2
 + 0.6131 Age + 75.535 
 
85.0% 84 78 
     
NRTI exposed  
eGFR = -0.0063 Age
2
 + 0.3054 Age + 80.781 
 
99.8% 84 76 
PI exposed  
eGFR = -0.0093 Age
2
 + 0.5442 Age + 76.078 
 
98.9% 83 75 
NNRTI 
exposed 
 
eGFR = -0.0057 Age
2
 + 0.2373 Age + 82.867 
 
99.9% 85 77 
     
 
2NRTI+NNRTI 
 
eGFR = -0.2569 Age + 93.038 
 
98.0% 88 78 
2NRTI+boosted 
PI 
 
eGFR = -0.0042 Age
2
 + 0.1081Age + 84.627 
 
96.9% 85 76 
 
*Includes a 20% reduction to compensate for creatinine clearance overestimation (Breyer & 
Qi, 2010) 
 
 CHANGING PROTEIN:CREATININE RATIO BY ARV CLASS EXPOSURE 
Protein:creatinine ratios were only available for 2,912 (36%) patients who also had eGFR results 
available. The protein:creatinine ratio in ART naïve people increased with increasing age from a 
mean of 15 mg/mmol for the „young‟ adults (18-19 years) to 105 mg/mmol for 60 years or above. 
Similar trends were observed among patients who had been exposed to NRTI with the mean 
protein:creatinine ratio increasing from 15 to 47 mg/mmol, while protein:creatinine ratios increased 
from 15 to 51 mg/mmol for HIV-1+ people who had been exposed to PIs and from 16 to 160 
mg/mmol for patients who had been exposed to NNRTIs (Table 4.2.16; Figure 4.2.2).  
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Table 4.2.16: Anti-retroviral Class Exposure and Protein:Creatinine Ratio, by Age at the Time of Result of HIV-1 Cohort (1988-2011) 
and Patients Who Started First-line HAART Consisting of 2NRTI+NNRTI or 2NRTI+boosted PI 
 
 Recent Age of Total cohort 
N=15,241 
 18-19 
 
N=34 
20-29 
 
N=2,309 
30-39 
 
N=5,426 
40-49 
 
N=4,961 
50-59 
 
N=1,876 
>=60 
 
N=529 
ART naive 
N=6923 
15.2 
(0 to 93.5) 
13.4 
(0 to 44.1) 
23.2 
(0.1 to 46.4) 
24.6 
(0 to 52.9) 
17.0 
(0 to 77.7) 
104.9 
(58.5 to 151.2) 
 Mean Protein:Creatinine ratio (95% CI) mg/mmol 
 
Total number of patients=2912 
  
N=6 
 
N=205 
 
N=855 
 
N=1259 
 
N=531 
 
N=635 
NRTI 
experienced 
15.2 
(0 to 93.5) 
54.9 
(22.2 to 87.6) 
26.9 
(3.2 to 50.5) 
40.2 
(11.7 to 68.8) 
43.2 
(0 to 104.1) 
46.9 
(0 to 111.5) 
PI  
experienced 
15.4 
(0 to 81.3) 
67.1 
(40.6 to 93.6) 
35.1 
(16.5 to 53.7) 
49.8 
(17.8 to 81.9) 
51.8 
(0 to 114.8) 
51.4 
(0 to 118.1) 
NNRTI 
experienced 
16 
(0 to 82.0) 
61.6 
(36.1 to 87.2) 
38.4 
(5.6 to 71.2) 
52.1 
(0 to 122.0) 
10.0 
(0 to 48.8) 
160.4 
(142.1 to 178.7) 
 Age at time of renal result of patients who started first-line HAART 
 
N=4,852  
Mean Protein:Creatinine ratio (95% CI) mg/mmol 
longitudinally estimated using MIXED model 
  
N=3 
 
N=414 
 
N=1,611 
 
N=1,948 
 
N=647 
 
N=181 
 
2 NRTI+NNRTI 
 
N=3,836 
14.0 
(0 to 102.2) 
44.4 
(36.7 to 52.2) 
20.3 
(16.0 to 24.5) 
20.1 
(15.4 to 24.7) 
39.8 
(31.9 to 47.7) 
36.2 
(22.3 to 50.1) 
2NRTI+boostedPI  
N=1,016 
17.0 
(0 to 101.4) 
20.5 
(5.4 to 35.6) 
21.0 
(11.8 to 30.2) 
25.6 
(17.1 to 34.2) 
43.2 
(26.0 to 60.4) 
56.1 
(30.3 to 81.8) 
See Table 4.1.1 for age group terms 
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Figure 4.2.3: Longitudinal Changes in Protein:Creatinine Ratio, Age and ARV Class 
Exposure  
Protein:creatinine ratio of ≥45 mg/mmol is indicative of proteinuria in the UK (Joint Specialty Committee on Renal 
Medicine, 2006; Lamb et al., 2009) 
 
 CHANGING EGFR FOR PATIENTS WHO START FIRST-LINE HAART (2NRTI+NNRTI OR 
2NRTI+BOOSTEDPI) BY AGE 
Figure 4.2.3 describes eGFR by age, the boxes above show immune considered age group strata. 
The eGFR level between 60 and 89 ml/min per 1.73m2 describe CKD stage 2 (Table 4.2.11). When 
comparing HIV-1+ people on first-line 2NRTI+NNRTI or 2NRTI+boosted PI regimens by age (Table 
4.2.14; Figure 4.2.3), people younger than 50 years did not show significant differences in mean 
eGFR between regimens with a mean difference in slope between the two treatment regimens of 
3.7 ml/min per 1.7m2 (95% CI: -1.2 to 8.7, p=0.136). However for people ≥50 years, a significant 
steeper decline in eGFR was observed between those on 2NRTI+boosted PI compared with 
patients on 2NRTI+NNRTI the mean difference in slope between the two treatment regimens was 
5.8 ml/min per 1.73m2 (95% CI: 3.9 to 7.7, p<0.001; using MIXED model). As can be noted the 
creatinine clearance values for HIV-1+ people remain lower with increasing age than „healthy‟ 
population (Rowe et al., 1976) and these are observed to be well above the normal values (eGFR 
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≥90 ml/min per 1.73m2 ) even when the healthy populations creatinine clearance were reduced by 
20% (Breyer & Qi, 2010). For each of the three groups - ART naïve, PLHIV on 2NRTI+NNRTI or 
2NRTI+boosted-PI - the ‟best fit„ models predicted a declining eGFR with increasing age for 
PLHIV. At age 20, the predicted mean eGFR for ART naïve individuals was 84 ml/min per 1.73m2 
compared with 88 and 85 ml/min per 1.73m2 for those who started first-line 2NRTI+NNRTI or 
2NRTI+boosted-PI respectively. The predicted eGFR for an ART naïve individual aged 60 years 
was 78 ml/min per 1.73m2, while for an individual aged 60 years who started 2NRTI+NNRTI or 
2NRTI+boosted-PI, the predicted eGFR was 78, and 76 ml/min per 1.73m2 respectively. 
 
 
 
Figure 4.2.4: Longitudinal Changes in eGFR Age and Patients on First-line 2NRTI+NNRTI or 
2NRTI+boosted-PI by Age HIV Negative People and Reduced by 20% (Rowe et al., 1976; 
Breyer & Qi, 2010) 
eGFR of >90 ml/min per 1.73m
2
 is considered normal  
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2
 indicates mildly reduced kidney function defined as stage 2 CKD 
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2
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2
 represent CKD stages 4 and 5 
 
Linear and polynomial „best fit‟ models were derived to describe the data observed for ART naïve 
people and those who started first-line 2NRTT+NNRTI or 2NRTI+boosted PI (Table 4.2.15). At age 
20, the predicted mean eGFR for treatment naïve people was 84 ml/min per 1.73m2 compared with 
88 and 85 ml/min per 1.73m2 for those who started first-line 2NRTI+NNRTI or 2NRTI+boosted PI 
respectively. The predicted eGFR for treatment naïve people aged 60 was 78 ml/min per 1.73m2, 
while for people who started 2NRTI+NNRTI or 2NRTI+boosted PI, the predicted eGFR was 78, and 
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76 ml/min per 1.73m2 respectively. Even when reduced by 20%, the creatinine clearance values by 
age were still well above the values for HIV-1+ people compared to people uninfected with HIV-1. 
At age 20 years, predicted „normal‟ creatinine clearance values was 103 ml/min per 1.73m2 and 98 
ml/min per 1.73m2 at age 60 (Table 4.2.15).  
 
 CHANGING PROTEIN:CREATININE RATIO FOR FIRST-LINE 2NRTI+NNRTI OR 
2NRTI+BOOSTED PI 
With increasing age the protein:creatinine ratio in ART naïve people increased from a mean of 15 
mg/mmol for the 18-19 year old patients to 105 mg/mmol for the 60-69 year olds. Of those on first-
line regimens, 836 (17%) had protein:creatinine results available on two or more occasion: 643 
(77%) had been on 2NRTI+NNRTI while 193 (23%) received 2NRTI+boosted PI. People who were 
less than 50 years showed no significant differences in protein:creatinine ratios by age between 
those on 2NRTI+NNRTI or 2NRTI+boosted PI (p=0.793, using MIXED model). „Older‟ adults 
demonstrated a significant steeper increase in the protein:creatinine ratio in patients on 
2NRTI+NNRTI compared with those on 2NRTI+boosted PI (using MIXED model, p<0.001; Figure 
4.2.4). However increases between ages of 60-69 years were based on a relatively small number 
of people and these results need to be interpreted cautiously. 
 
 
 
 
 
Figure 4.2.5: Longitudinal Changes in Protein:Creatinine Ratio, by Age in Patients Who 
Started First-line HAART 
Protein:creatinine ratio of ≥45 mg/mmol is indicative of proteinuria in the UK (Joint Specialty Committee on Renal 
Medicine, 2006; Lamb et al., 2009) 
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 UNIVARIATE AND MULTIVARIABLE COX’S PROPORTIONAL HAZARDS REGRESSION ANALYSIS 
Of the 7,980 people for whom nadir eGFR were available, 157 (2.0%) had eGFR classified as 
moderate to advanced renal failure. The univariate associations between demographic and other 
variables and a nadir eGFR<30 ml/min per 1.73m2 were estimated (Table 4.2.17). The 
multivariable model indicated that HIV-1+ people aged ≥50 years, IDUs and non-Caucasians and 
those who had PI exposure were more likely to have a nadir eGFR <30 ml/min per 1.73m2 (Table 
4.2.18: Figure 4.2.5). Similarly, those HIV-1+ people with a baseline eGFR <72 ml/min per 1.73m2 
and protein:creatinine ratio >22 mg/mmol were more likely to have a nadir eGFR< 30 ml/min per 
1.73m2 as did HIV-1+ people who had a nadir CD4≤ 100 cells/µL blood, while those HIV-1+ people 
diagnosed longest with HIV-1+ were less likely to develop end stage renal failure requiring dialysis 
or transplantation (Table 4.2.18: Figure 4.2.5). 
 
Table 4.2.17: Univariate Cox’s Proportional Hazards Regression Model showing Likelihood 
of Stage 4 or 5 CKD Defined Using Nadir eGFR 
 
  
Total  
=7,980 
Stage 4 or 5 CKD 
Nadir eGFR <30 ml/min per 
1.73m
2
 
n=157 
Hazard 
ratio 
(HR) 
95% CI p-
value 
#Age at nadir eGFR 
(years) 
40-49 
18-19 
20-29 
30-39 
50-59 
60-69 
>=70 
 
 
2,949 
30 
1,005 
2,568 
1,041 
320 
67 
 
 
53(1.8) 
0(0.0) 
6(0.6) 
33(1.3) 
34(3.3) 
24(7.5) 
7(10.5) 
 
 
1 
0.00 
0.68 
1.12 
1.88 
4.29 
5.73 
 
 
 
(unstable) 
(0.28 to 1.61) 
(0.72 to 1.73) 
(1.17 to 3.05) 
(2.53 to 7.28) 
(2.53 to 12.97) 
 
 
<0.001 
Gender 
Female 
Male 
 
975 
7,005 
 
33(3.4) 
124(1.8) 
 
1.84 
1 
 
(1.25 to 2.70) 
 
0.002 
Ethnicity 
Caucasian 
Black African 
Other  
 
5,876 
822 
1,182 
 
95(1.6) 
36(4.4) 
26(2.2) 
 
1 
1.47 
2.52 
 
 
 (0.95 to 2.26) 
(1.72 to 3.70) 
 
<0.001 
Sexual orientation 
MSM 
Heterosexual 
Bisexual 
 
6,527 
1,299 
154 
 
102(1.6) 
50(3.9) 
5(3.3) 
 
1 
2.13 
1.57 
 
 
(1.52 to 2.99) 
(0.64 to 3.85) 
 
 
<0.001 
IDU 
No 
Yes 
 
7,835 
145 
 
148(1.9) 
9(6.2) 
 
1 
3.05 
 
 
(1.56 to 5.99) 
 
0.001 
#Duration since 
HIV-1
+
 diagnosis, 
months 
<=35.48 
35.49-89.98 
89.99-152.98 
>152.98 
Missing 
 
 
 
1,908 
1,904 
1,905 
1,907 
356 
 
 
 
30(1.6) 
30(1.6) 
46(2.4) 
45(2.4) 
6(1.7) 
 
 
 
1 
0.37 
0.47 
0.41 
0.27 
 
 
 
 
(0.22 to 0.63) 
(0.29 to 0.77) 
(0.25 to 0.68) 
(0.11 to 0.69) 
 
 
 
 
0.002 
ART treatment 
Naive 
Experienced 
 
1,619 
6,361 
 
14(0.9) 
143(2.3) 
 
0.95 
1 
 
(0.54 to 1.66) 
 
0.857 
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#Median Duration of 
ARV exposure, 
years (IQR) 
<=2.48 
2.49-5.82 
5.83-11.09 
>11.09 
Treatment naive 
& missing 
 
 
 
1,584 
1,560 
1,577 
1,573 
1,686 
 
 
 
26(1.6) 
23(1.5) 
42(2.7) 
47(3.0) 
19(1.1) 
 
 
 
 
1 
0.55 
0.77 
0.82 
0.93 
 
 
 
 
(0.31 to 0.96) 
(0.47 to 1.28) 
(0.50 to 1.34) 
(0.51 to 1.68) 
 
 
 
0.249 
NRTI experienced 
Treatment naive 
No 
Yes 
 
1,619 
30 
6,331 
 
14(0.9) 
1(3.3) 
142(2.2) 
 
0.95 
2.16 
1 
 
(0.55 to 1.67) 
(0.30 to 15.40) 
 
0.782 
PI experienced 
Treatment naive 
No 
Yes 
 
1,619 
2,973 
3,388 
 
14(0.9) 
41(1.4) 
102(3.0) 
 
0.74 
0.52 
1 
 
(0.42 to 1.31) 
(0.36 to 0.74) 
 
0.001 
NNRTI experienced 
Treatment naive 
No 
Yes 
 
1,619 
1,253 
5,108 
 
14(0.9) 
28(2.2) 
115(2.3) 
 
0.99 
1.22 
1 
 
(0.56 to 1.74) 
(0.80 to 1.84) 
 
0.654 
#Recent Pr:Cr ratio, 
mg/mmol 
<=10 
11-14 
15-22 
>22 
Not tested 
 
 
878 
701 
608 
670 
876 
 
 
10(1.1) 
5(0.7) 
10(1.6) 
446.6) 
88(1.7) 
 
 
1 
0.59 
1.39 
5.31 
2.08 
 
 
 
(0.20 to 1.74) 
(0.58 to 3.33) 
(2.67 to 10.55) 
(1.08 to 4.00) 
 
 
<0.001 
#Recent eGFR, 
ml/min per 1.73m
2
 
<72 
72-82 
83-90 
>=91 
 
 
1,867 
1,991 
1,611 
2,511 
 
 
118(6.3) 
12(0.6) 
11(0.7) 
16(0.6) 
 
 
7.84 
0.77 
0.94 
1 
 
 
(4.65 to 13.23) 
(0.37 to 1.64) 
(0.44 to 2.02) 
 
<0.001 
#Nadir CD4, cells/µL 
blood 
<=108 
109-205 
206-331 
>331 
Unavailable 
 
 
1,989 
1,983 
1,996 
1,991 
21 
 
 
92(4.6) 
38(1.9) 
19(1.0) 
8(0.4) 
0(0.0) 
 
 
1 
0.43 
0.26 
0.17 
0.00 
 
 
 
(0.30 to 0.63) 
(0.16 to 0.42) 
(0.08 to 0.36) 
(unstable) 
 
 
<0.001 
 
#Highest HIV RNA 
plasma load, 
copies/mL plasma 
<=9,758 
9,759-7,0415 
70,416-254,845 
>254845 
Unavailable 
 
 
 
1,984 
1,983 
1,984 
1,983 
46 
 
 
 
36(1.8) 
33(1.7) 
29(1.5) 
58(2.9) 
1(2.2) 
 
 
 
1 
0.82 
0.62 
1.13 
5.05 
 
 
 
 
(0.51 to 1.31) 
(0.38 to 1.01) 
(0.75 to 1.72) 
(0.69 to 37.22) 
 
 
 
0.040 
AIDS 
No 
Yes 
 
7,893 
87 
 
156(2.0) 
1(1.2) 
 
1 
0.43 
 
 
(0.06 to 3.09) 
 
0.333 
#Categories are derived using median and IQR 
Pr:Cr is abbreviation used for protein:creatinine ratio 
Where HR is 1, this is indicated as the reference category 
Event time is defined as time since first measurement of eGFR to either moderate to advanced renal impairment or in 
subjects whose nadir eGFR was >=30 ml/min per 1.7m
2
, data are censored at most recent eGFR result 
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Table 4.2.18: Multivariable Cox’s Proportional Hazards Regression Model Showing 
Significant Independent Predictors of Likelihood of Stage 4 or 5 CKD Defined Using Nadir 
eGFR 
 
  
Total  
=7,980 
Moderate to advanced 
renal impairment  
n=157 
&Hazard 
ratio 
(HR) 
95% CI p-
value 
#Age at nadir eGFR 
(years) 
40-49 
18-19 
20-29 
30-39 
50-59 
60-69 
>=70 
 
 
2,949 
30 
1,005 
2,568 
1,041 
320 
67 
 
 
53(1.8) 
0(0.0) 
6(0.6) 
33(1.3) 
34(3.3) 
24(7.5) 
7(10.5) 
 
 
1 
0.00 
0.72 
0.85 
1.29 
2.07 
2.79 
 
 
 
(unstable) 
(0.30 to 1.75) 
(0.54 to 1.35) 
(0.76 to 2.17) 
(1.16 to 3.70) 
(1.15 to 6.78) 
 
 
 
0.978 
0.468 
0.499 
0.342 
0.014 
0.024 
IDU 
No 
Yes 
 
7,835 
145 
 
148(1.9) 
9(6.2) 
 
1 
3.70 
 
 
(1.79 to 7.67) 
 
 
<0.001 
Ethnicity 
Caucasian 
Black African 
Other  
 
5,876 
822 
1,182 
 
95(1.6) 
36(4.4) 
26(2.2) 
 
1 
1.18 
1.91 
 
 
(0.74 to 1.87) 
(1.12 to 3.27) 
 
 
0.484 
0.018 
#Duration since 
HIV-1
+
 diagnosis, 
months 
<=35.48 
35.49-89.98 
89.99-152.98 
>152.98 
Missing 
 
 
 
1,908 
1,904 
1,905 
1,907 
356 
 
 
 
30(1.6) 
30(1.6) 
46(2.4) 
45(2.4) 
6(1.7) 
 
 
 
1 
0.32 
0.28 
0.15 
0.08 
 
 
 
 
(0.18 to 0.56) 
(0.16 to 0.49) 
(0.08 to 0.27) 
(0.03 to 0.20) 
 
 
 
 
<0.001 
<0.001 
<0.001 
<0.001 
Recent Pr:Cr ratio, 
mg/mmol 
<=10 
11-14 
15-22 
>22 
Not tested 
 
 
878 
701 
608 
670 
876 
 
 
10(1.1) 
5(0.7) 
10(1.6) 
446.6) 
88(1.7) 
 
 
1 
0.70 
1.29 
2.86 
2.20 
 
 
 
(0.24 to 2.06) 
(0.53 to 3.13) 
(1.41 to 5.82) 
(1.13 to 4.28) 
 
 
 
0.517 
0.574 
0.004 
0.020 
PI experienced 
Treatment naive 
No 
Yes 
 
1,619 
2,973 
3,388 
 
14(0.9) 
41(1.4) 
102(3.0) 
 
1.62 
0.65 
1 
 
(0.80 to 3.27) 
(0.44 to 0.97) 
 
0.181 
0.033 
#Recent eGFR, 
ml/min per 1.73m
2
 
<72 
72-82 
83-90 
>=91 
 
 
1,867 
1,991 
1,611 
2,511 
 
 
118(6.3) 
12(0.6) 
11(0.7) 
16(0.6) 
 
 
6.39 
0.75 
0.96 
1 
 
 
(3.66 to 11.17) 
(0.35 to 1.61) 
(0.44 to 2.09) 
 
 
<0.001 
0.462 
0.924 
#Nadir CD4, cells/µL 
blood 
<=108 
109-205 
206-331 
>331 
Unavailable 
 
 
1,989 
1,983 
1,996 
1,991 
21 
 
 
92(4.6) 
38(1.9) 
19(1.0) 
8(0.4) 
0(0.0) 
 
 
1 
0.53 
0.29 
0.11 
0.00 
 
 
 
(0.36 to 0.78) 
(0.17 to 0.49) 
(0.05 to 0.26) 
unstable 
 
 
 
0.001 
<0.001 
<0.001 
0.995 
&Adjusted for gender, sexual orientation, PI exposure, maximum viral load and other factors in the model 
#Categories are derived using median and IQR 
Pr:Cr is abbreviation used for protein:creatinine ratio 
Where HR is 1, this is indicated as the reference category 
Event time is defined as time since first measurement of eGFR to either moderate to advanced renal impairment or in 
subjects whose nadir eGFR was >=30 ml/min per 1.73m
2
, data are censored at most recent eGFR result 
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Figure 4.2.6: Multivariable Cox’s Proportional Hazards Regression Model Figure Showing Significant Independent Predictors of Likelihood 
of Stage 4 or 5 CKD Defined Using Nadir eGFR  
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 UNIVARIATE AND MULTIVARIABLE COX’S PROPORTIONAL HAZARDS REGRESSION ANALYSIS 
IN PATIENTS ON FIRST-LINE ART 
 
Of the 4,346 PLHIV who started first-line HAART with available nadir eGFR, 87 (2.0%) had CKD 4-
5 with an eGFR <30 ml/min per 1.73m2 or moderate to advanced renal impairment. The univariate 
analysis investigated the association between a number of variables and nadir eGFR <30 ml/min 
per 1.73m2 (Table 4.2.19). The multivariable model derived from that indicated that the following 
factors were significantly associated with a nadir eGFR of < 30 ml/min per 1.73m2; PLHIV aged 
older than 60 years, being an injecting drug user (IDU) or non-Caucasian, having a recent 
protein:creatinine ratio greater than 20 mg/mmol, having had a recent eGFR below 73 ml/min per 
1.73m2 and having had nadir CD4 T-cell count below 113 cells/mm3 (Figure 4.2.7). 
 
Table 4.2.19: Univariate Cox’s Proportional Hazards Regression Model showing Likelihood 
of Stage 4 or 5 CKD Defined Using Nadir eGFR In Patients on First-line ART 
 
     Moderate        
    to advanced       
   Total  renal impairment        
   4,346 n=87 HR 95% CI p-value 
Age  40-49 1,645 30(1.8) 1   0.002 
at nadir 18-19 13 0(0.0) 0.00 (unstable)   
eGFR 20-29 483 6(1.2) 1.03 (0.42 to 2.53)   
(years) 30-39 1,579 23(1.5) 1.09 (0.63 to 1.88)   
 50-59 454 14(3.1) 1.71 (0.88 to 3.34)   
 60-69 142 12(8.5) 5.06 (2.52 to 10.19)   
 ≥70 30 2(6.7) 3.61 (0.85 to 15.33)   
Gender Female 575 24(4.2) 2.56 (1.60 to 4.09) <0.001 
 Male 3,771 63(1.7) 1     
Ethnicity Caucasian 3,167 47(1.5) 1   <0.001 
 Black African 522 26(5.0) 1.51  (0.83 to 2.75)    
 Other  657 14(2.1) 3.22 (1.99 to 5.20)   
Sexual  MSM 3,481 50(1.4) 1   <0.001 
orientation Heterosexual 797 36(4.5) 2.91 (1.89 to 4.46) 
  Bisexual 68 1(1.5) 0.78 (0.11 to 5.63)   
IDU No 4,282 82(1.9) 1   0.002 
 Yes 64 5(7.8) 4.16 (1.69 to 10.25)   
Duration  <=45.18 1,063 18(1.7) 1   0.241 
since 45.19-85.27 1,066 21(2.0) 0.58 (0.30 to 1.12)   
HIV-1
+
 85.28-134.85 1,063 26(2.5) 0.63 (0.34 to 1.19)   
diagnosis,  >134.85 1,064 21(2.0) 0.49 (0.25 to 0.96)   
months Missing 91 1(1.1) 0.25 (0.03 to 1.89)   
First-line  2NRTI+NNRTI 3,422 65(1.9) 1   0.133 
HAART 2NRTI+boosted-PI 924 22(2.4) 1.45 (0.89 to 2.35)   
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Duration  <=1.89 1,080 10(0.9) 1   0.790 
of ARV 1.90-4.08 1,084 21(1.9) 1.44 (0.67 to 3.06)   
exposure,  4.08-7.36 1,074 26(2.4) 1.26 (0.60 to 2.64)   
years >7.36 1,085 30(2.8) 1.30 (0.63 to 2.71)   
 missing 23 0(0.0) 0.00 (-)   
Recent  <=10 581 8(1.4) 1   <0.001 
Pr:Cr ratio, mg/mmol 11-13 384 3(0.8) 0.54 (0.14 to 2.03)   
 14-20 420 4(1.0) 0.68 (0.20 to 2.25)   
 >20 417 26(6.2) 4.30 (1.95 to 9.50)   
 Not tested 2,541 46(1.8) 1.56 (0.74 to 3.31)   
Recent eGFR, <=73 1,076 63(5.9) 6.83 (3.51 to 13.33) <0.001 
ml/min per 1.73m
2
 74-82 1,057 8(0.8) 0.90 (0.36 to 2.29)   
 83-90 892 6(0.7) 0.81 (0.29 to 2.23)   
 >90 1,321 10(0.8) 1     
Nadir CD4, Unavailable 1 0(0.0) 0 (unstable) <0.001  
cells/µL blood <=113 1,085 46(4.2) 3.50 (1.71 to 7.17) 
  114-193 1,086 20(1.8) 1.56 (0.71 to 3.44)   
 194-279 1,084 12(1.1) 1.02 (0.43 to 2.42)   
 >279 1,090 9(0.8) 1 
 
  
Highest HIV RNA 
plasma load, 
copies/mL 
plasma <=9254 1,086 22(2.0) 1   0.245 
 9255-82651 1,086 26(2.4) 0.93 (0.53 to 1.64)   
 82651-273786 1,086 15 (1.4) 0.50 (0.26 to 0.97)   
 >273786 1,086 24(2.2) 0.76 (0.42 to 1.36)   
 Unavailable 2 0(0.0) 0.00 (-)   
AIDS No 4,315 87(2.0) 1   - 
 Yes 31 0(0.0) 0.0 (-)   
Year of  1996 4 0(0.0) 0.0 - 0.725 
starting  1997 29 0(0.0) 0.0 -  
first  1998 81 2(2.5) 1.71 (0.15 to 19.00)  
line  1999 197 8(4.1) 3.01 (0.37 to 24.27)  
HAART 2000 160 2(1.3) 0.92 (0.08 to 10.24)  
 2001 189 4(2.1) 1.58 (0.18 to 14.21)  
 2002 195 5(2.6) 1.96 (0.23 to 16.89)  
 2003 242 5(2.1) 1.51 (0.18 to 13.00)  
 2004 332 10(3.0) 2.26 (0.29 to 17.75)  
 2005 306 6(2.0) 1.43 (0.17 to 12.00)  
 2006 322 12(3.7) 3.00 (0.39 to 23.26)  
 2007 424 9(2.1) 1.98 (0.25 to 15.71)  
 2008 555 8(1.4) 1.51 (0.19 to 12.14)  
 2009 523 11(2.1) 2.68 (0.35 to 20.79)  
 2010 574 4(0.7) 1.15 (0.13 to 10.28)  
 2011 213 1(0.5) 1   
Event time is defined as time since first measurement of eGFR to either moderate to advanced renal impairment or in 
subjects whose nadir eGFR was ≥30 ml/min per 1.7m
2
, data are censored at most recent eGFR result 
Pr:Cr is abbreviation used for protein:creatinine ratio 
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Figure 4.2.7: Multivariable Cox’s Proportional Hazards Regression Model Figure Showing Significant Independent Predictors of Likelihood 
of Stage 4 or 5 CKD Defined Using Nadir eGFR In Patients on First-line ART 
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4.3 DISCUSSION 
 
 NOVEL APPROACH 
Longitudinal changes in eGFR and protein:creatinine ratio associated with increasing age in adults 
living with HIV-1 infection have to date not been reported. The increased life-expectancy of HIV-1+ 
people has given rise to the likelihood of developing non-HIV co-morbidities associated with ageing 
and the underlying process of immunosenescence (Spits, 2002). CKD is one of the non-HIV co-
morbidities that is associated with increasing age. Using eGFR and protein:creatinine ratio as 
markers of renal function, longitudinal analysis indicated that renal function in HIV-1+ patients 
deteriorate more with increasing age than „healthy‟ older people. 
 
 SUMMARY OF FINDINGS 
Cross sectional data showed that HIV-1+ people who were „older‟ aged ≥ 50 years had lower nadir 
and first ever CD4 T-cell count compared to „younger adults‟. While recent values of CD4, CD3, 
and CD8 T cells, CD56 NK-cell counts, and maximum HIV RNA plasma load were higher in the 
„older‟ age group compared to the „younger adults‟ (18-39 years), CD19 B-cell counts were lower in 
„young adults‟ compared to „middle aged‟ and „older‟ adults. Patients who were „older‟ aged ≥ 50 
years were more likely to have ever tested hepatitis B antibody and hepatitis B core antibody 
positive. A number of further analyses were undertaken and summary of these results are under 
Appendix A4.1. 
 
Both ART naïve and HIV-1+ people exposed to different ARV classes and commonly prescribed 
ART regimens showed reductions in eGFR with increasing age well below the creatinine clearance 
levels observed in uninfected people. Similar but empirically weaker conclusions can be drawn 
from the protein:creatinine ratio analyses. ART naïve patients demonstrated increases in 
protein:creatinine ratio with increasing age as did patients exposed to different ARV classes and 
first-line regimens. However, due to the small number of patients who had their protein:creatinine 
ratio measured conclusions drawn from these analyses need to be viewed with caution. From the 
regression models, the degree of immuno-suppression, as indicated by nadir CD4 count, was 
predictive of likelihood of developing stage 4 or 5 CKD among HIV-1+ people. The relationship 
between immunosuppression and end-stage renal disease has been demonstrated (Betjes et al., 
2011) and a direct relationship between severity of immuno-suppression and occurrence of other 
non-HIV co-morbidities also seems to exist (Sighem et al., 2013). The increased probability of 
developing CKD is also related to the ageing process itself in PLHIV and other causes of CKD 
including cardiovascular disease, hypertension and diabetes mellitus. Increased duration of known 
HIV sero-status was associated with a reduced probability of stage 4 or 5 CKD and may be due to 
treatment and care received by PLHIV diagnosed earlier in their disease course (Sighem et al., 
2013). 
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 LIMITATIONS 
The eGFR according to the MDRD formula is standardised for body surface area, age, ethnicity 
and gender (Levey et al., 2006). However, some remaining residual effect of age may remain and 
some of the changes in renal function observed may be due to a persistent age effect. Although 
the data show a steeper decline in renal function markers in „middle-aged‟ adults 40-49 years and 
adults 50 years or older, the number of patients aged 70 years or older were relatively small 
resulting in greater variations in trends of the renal markers observed in these age groups. 
Furthermore, renal function measurements were taken from a diverse group of patients who 
contributed results at different ages. Ideally one would like to prospectively follow-up a defined 
group of „young‟ HIV-1+ adults as they age, and monitor changes over time, but such data would 
take a long time to collect. Furthermore, ART regimens are also likely to change over such long 
time periods, compounding longitudinal analyses. 
 
Creatinine clearance values from HIV uninfected people should strictly speaking not be compared 
with eGFR from HIV-1+ people as the creatinine clearance values were not adjusted for body 
surface area, age, ethnicity and gender (Rowe et al., 1976). In the absence of such standardised 
longitudinal data from a „healthy‟ populations, the current comparator including a 20% reduction to 
adjust for any over-estimation (Breyer & Qi, 2010) provides an insight into the degree of renal 
impairment associated with HIV-1 infection or ART. 
 
While eGFRs are less reliable for assessing stage 1 and 2 CKD when eGFR is 60 to 90 ml/min per 
1.73m2, it does becomes more reliable for picking up stage 3 CKD, with eGFR rates between 30 
and 59 ml/min per 1.73m2 (Stevens et al., 2007). A recent meta analyses demonstrated that the 
MDRD equation to calculate eGFR is not an optimal measure for all populations and eGFR ranges 
calculated using a single equation requires a tradeoff at higher or lower values of eGFR ranges 
(Earley et al., 2012). The eGFR is predicted based on the MDRD formula which employs serum 
creatinine measurements and patients body surface area, age, ethnicity and gender (Levey et al., 
2006). However, some residual effect of age or other contributing factors may remain and influence 
the changes in renal function observed. In addition, the MDRD formula excluded patients with renal 
failure, though it included patients aged 18-70 years, but it has not yet been validated in an „elderly‟ 
or „frail‟ population (Levey et al., 1999). Other formulae which has also appeared in the literature to 
estimate creatinine clearance from a single estimate of plasma creatinine without urine collection 
include the Cockcroft-Gault formula (Cockcroft & Gault, 1976). An alternative to the MDRD formula 
is the Cockcroft-Gault formula where the creatinine clearance is predicted from serum creatinine 
measurements and patients‟ age, gender and weight. While some prefer to use this formula 
(Cockcroft & Gault, 1976), as it is considered it to give better estimates of renal function in subjects 
with well preserved normal renal function (Robertshaw et al., 1989), others prefer to use the MDRD  
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formula (Barraclough et al., 2009). As routinely measured weights were unavailable for the cohort 
studied, the Cockcroft-Gault formula could not be used in this study. 
 
 REPORTS FROM OTHER STUDIES 
Other methods to improve early diagnosis of CKD have been suggested, including the use of 
improved equations to calculate eGFR by the Chronic Kidney Disease Epidemiology Collaboration 
(CKD-EPI) (Levey et al., 2009), however so far these have not yet been taken up by international 
guidelines (Levey et al., 2011) although some centres in the US are now starting to use this 
formula (Fine & Gallant, 2013). The CKD-EPI equation is thought to provide a more precise and 
accurate estimates of GFR, compared with the MDRD equation (Levey et al., 2009). This was the 
conclusion reported in a recent review that suggested that the CKD-EPI equation could provide a 
more precise and less biased estimate of kidney function in HIV-infected populations (Ando et al., 
2012). 
 
Clinical laboratories are routinely reporting eGFR, and computerised medical records highlight 
clinicians to the presence of CKD (Go et al., 2004) however existing formulae to calculate 
creatinine clearance have to date not been validated in HIV-1+ people (Barraclough et al., 2009). 
Blood urea levels increase with increased protein intake. Conversely muscle mass decreases 
with age or advancing disease as does serum creatinine levels and these changes may mask true 
renal function, while variations are also observed between different ethnic groups (Stevens et al., 
2006). Some studies indicated that low muscle mass is common in men living with HIV and that 
sarcopenia affecting muscle function could be present in a substantial number of people (Buehring 
et al., 2012).  
 
Serum cystatin C is an alternative marker of kidney function and some argue that this better predict 
morbidity and mortality in “older” adults as compared with creatinine, as cystatin C seems 
unaffected by gender, age, ethnicity, muscle mass, and co-existing malignancy (Shlipak et al., 
2005; Chew et al., 2008). However, some question the utility of routine cystatin C tests (Fine & 
Gallant, 2013) and these were not performed in our local setting and therefore this marker could 
not be used. Other clinics have reported a higher cost for using this assay and this may be one 
possible reason why it has not been introduced into routine testing in the NHS (Chew et al., 2008). 
 
ART naïve patients showed similar changes in renal function to the ART experienced patients. 
HIVAN is an important cause of CKD among the HIV-1+ people. While some statistically significant 
differences were observed in older patients on different first-line regimens, clinically these did not  
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seem large. While no differences were observed between ARV classes, at a population level, 
specific ARVs have been associated with impaired renal function (Mocroft et al., 2007; Mocroft et 
al., 2010; Ryom et al., 2013). Recently Tenofovir was shown to be associated with a greater 
decline in renal function than other NRTIs as indicated by a greater degree of inhibition of intra-
cellular telomerase compared with other NRTIs (Leeansyah et al., 2013). Renal function decline 
did not lead to greater rates of discontinuation of therapy and the renal function decline associated 
with Tenofovir and other NRTIs are considered to be a function of a longer duration of ARV 
treatment (Gallant et al., 2005). Increased renal impairment was also observed in patients with 
past exposure to Indinavir, Atazanavir or Lopinavir (Mocroft et al., 2007; Mocroft et al., 2010; 
Young et al., 2012; Fine & Gallant, 2013; Ryom et al., 2013). Another recent study demonstrated 
that Tenofovir with a boosted PI led to a greater decline in eGFR than Tenofovir with a NNRTI 
(Young et al., 2012) however the new formulations of Tenofovir may have less deleterious effect 
on renal function (Zolopa et al., 2013). 
 
 FUTURE WORK 
While specific ARV drugs are associated with impaired renal function, the findings presented in this 
study suggest that ART at a population level does not appear to be so nephrotoxic. This was also 
the conclusion of a recent Spanish study which suggested that ART may have a renal-protective 
effect (Masiá et al., 2012) although the follow-up period of their cohort was not as long as the study 
presented here. One of the consequences of declining renal function with age is reduced renal 
excretion of drugs and metabolites, potentially increasing the likelihood of nephrotoxicity. As HIV-1+ 
people age this poses a clinical challenge, in terms of the increasing number of patients requiring 
regular renal evaluation and, if progression to end-stage renal disease occurs, they may require 
renal dialysis. Renal function impairment may require the adjustment ARV drugs and other drug 
dosages in „older‟ HIV-1+ people.  
 
While the time to start ART in HIV-1+ people is still under discussion and awaiting the outcome of 
the START trial which randomised people with CD4 T-cell count ≥500 cells/mL to immediate ART 
versus deferred ART treatment to when CD4 T-cell count dropped to below 350 cells/mL (Babiker 
et al., 2013) a number of clinicians and guidelines recommend that some HIV-1+ people can start 
ART at diagnosis irrespective of CD4 T-cell count (Thompson et al., 2012). The finding that HIV-1 
infection and related immuno-suppression is a major driver of decreasing renal function, might add 
pressure to start treating HIV-1+ people with ART when HIV-1 infection is first diagnosed to reduce 
the inflammatory and other processes associated with HIVAN especially given that ART seems to 
retain its immune restorative capacity on a long-term basis (Wright et al., 2013).  
 
Finally, while we can celebrate the success of improved length and quality of life that ART provides 
for HIV-1 infected people, as they get older they are more likely to develop other conditions, 
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previously rarely seen. This not only pertains to deteriorating renal function but also cardiovascular 
diseases, cancers, neurological problems and other morbidity patterns associated with increasing 
age and frailty, all of which have to be monitored and managed in HIV-1+ people as they live 
longer. 
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CHAPTER 5: POPULATION COST FOR TREATING PEOPLE LIVING WITH HIV IN THE 
UK 
 
Note: A modified version of this chapter has been published.  
 
Mandalia S, Mandalia R, Lo G, Chadborn T, Sharott P, Youle M, Anderson J, Baily G, Brettle R, 
Fisher M, Gompels M, Kinghorn G, Johnson M, McCarron B, Pozniak A, Tang A, Walsh J, White 
D, Williams I, Gazzard B, Beck EJ; NPMS-HHC Steering Group.  
Rising population cost for treating people living with HIV in the UK, 1997-2013.  
PLOS one. 2010 Dec 30;5(12) 
 
Population cost paper cited here. 
http://www.publications.parliament.uk/pa/ld201012/ldselect/ldaids/188/18805.htm#a1 
 
„Life is priceless‟. However, decisions affecting lives are not only made by individuals but also by 
parliaments and public authorities on a regular basis. This implies lengthening of human life 
against finite resources are weighed up. The NHS lets political authorities decide on new 
pharmaceuticals, new therapies, and new medical devices are to be covered by the NHS. As a 
general rule, cost-increasing products that bring therapeutic advantages are preferred, by reducing 
the risk of pre-mature mortality in the at risk population. These types of new products may involve 
additional expenditure, for example, an installation of new dialysis equipment for patients with end-
stage renal failure. 
 
This chapter describes some of the analyses that were performed on data from the NPMS-HHC 
collaboration and these are based on data transferred to the NPMS-HHC Co-ordinating and 
Analytic Centre (CAC) in 2007/2008. At the time results presented in this chapter was carried out, 
data from the NPMS-HHC collaboration were available for the study period from 1st January 1996 
to 31st December 2006. The use and cost of hospital services presented in this chapter covers data 
for this period whilst population costs are from 1997 due to unavailability of UK HIV-1+ population 
figures for 1996. The analyses of data are based on a study that routinely collect data from multi 
HIV centres in the UK. The data are prospectively collected HIV-1 cohort data at the participating 
sites and are longitudinal (Chapter 2: Figure 2.1.1). The primary aim of this multi-centre cohort is to 
prospectively monitor the use, cost, and outcome of HIV service provision in the UK based on data 
from the NPMS-HHC participating centres. 
 
The aims of this chapter are: to estimate the use and cost of hospital services of HIV-1 diagnosed 
people in the UK; to estimate the population cost of treatment and care of HIV-1 population 
accessing HIV-1 care in the UK in the NHS by stage of HIV-1 infection based on the available 
population figures of number of people diagnosed and who had accessed the HIV services in the 
UK NHS between 1997-2006; to project population cost of treatment and care of HIV-1 for 2007-
2013.  
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5.0 HEALTH CARE EXPENDITURE IN THE UK 
Since the establishment of the Britain‟s National Health Service (NHS) on 5th July 1948, the UK 
Government spent £11.4 billion on heath during the first full year of its operation. The public 
spending of 2005 election briefing document showed £84.7 billion were spent on health 
(Emmerson & Frayne, 2005) . The figure since 1948 was over ten-fold higher £121 billion in 
2010/11 (Harker, 2012). The public health care expenditure (HCE) in the UK has increased since 
1948 in cost figures as well as a share of Gross Domestic Product (GDP) (Figure 5.0.1).  
 
  
 
Figure 5.0.1 UK Health Care Expenditure 1900-2011 
Source of graphs: http://www.ukpublicspending.co.uk/spending_brief.php 
FY=Financial year 
 
Since 1990, the UK Government increased HCE as a percentage of GDP from 5.1% in 1990, to 
over 8.1% in 2010 (Figure 5.0.1). To investigate whether the UK investments in health care and 
public health have been followed by the expected improvements in health using HIV-1 infection as 
one of the disease areas investigated. A recent study showed that the years of life lost (YLLs) due 
to premature mortality caused by HIV-1 infection in 20-54 year olds had declined between 1990 
and 2010 thereby demonstrating success of HIV-1 treatment and care in the UK (Murray et al., 
2013). 
 
5.1 INTRODUCTION 
Further details are described in Chapter 1 of this PhD thesis. HIV-1 pandemic continues to grow 
and by end of 2012, 2.4% (0.86 million, range: 0.80 to 0.93) of the world‟s adults and children were 
estimated to be living with HIV-1 infection in Western and Central Europe (UNAIDS Report on the 
Global AIDS Epidemic, 2013). As more drugs for treating HIV-1 become available people who 
have access to these drugs continue to live longer and therefore HIV-1 in these group of people 
has become a chronic illness. By the end of 2012 76,500 people diagnosed with HIV-1 had used 
the NHS services (credible interval: 75,000 to 78,000) (Aghaizu et al., 2013). The number of 
people living with HIV-1 infection continues to increase due to transmission of HIV-1 infection 
either in the UK or abroad (Health Protection Agency, 2009) as well as increased survival of people 
infected with the virus due to more effective ART regimens (Beck et al., 2008). 
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In 2010, 27,116 newly diagnosed cases of HIV-1 infection were reported by 28 countries of the 
European Union and European Economic Area (EU/EEA). Half of the HIV-1 cases reported with 
information on CD4 T-cell counts had low CD4 T-cell counts (<350 cells/µL blood) at time of HIV-1 
diagnosis indicating late diagnosis. The UK was one of the countries to have reported highest rates 
of HIV-1 diagnoses and in 2010, this was reported to be 10.7 cases per 100,000 population and 
61% of whom were heterosexually transmitted cases (World Health Organisation, 2011a). 
Therefore the increases in number of HIV-1 infected people accessing specialist care directly 
impacts on the NHS cost burden for treating HIV-1 infected people in UK NHS hospitals. 
 
In the UK, HIV-1 infected people seek long-term medical help at specialist as well as non-specialist 
NHS hospitals and treatment centres. The number of people accessing the NHS for HIV-1 services 
is increasing over time and these increases in access of care in the NHS implies that the costs 
associated with HIV-1 care also continue to increase. With increasing number of HIV-1 infected 
people requiring long-term medical care in the NHS the cost burden therefore continue to increase. 
At the time this work was undertaken, no publically available population cost estimates were 
available for treating HIV-1 infected people in the UK using the NHS services. In the current 
economic climate which is going through periods of cutting public expenditure, there was a need 
for estimates of population cost for treating HIV-1 infected people in the UK so that appropriate 
budgets within the NHS could be allocated for treatment and care of HIV-1 infected people. This 
study aimed to provide an estimate of direct population cost of treatment and care of HIV-1+ 
people. 
 
5.1.1 NPMS-HHC COHORT 
The National Prospective Monitoring System on the use, cost, outcome of HIV-1 service provision 
in UK hospitals - HIV Health-economics Collaboration (NPMS-HHC) was set up to prospectively 
monitor routinely collected data on HIV-1 infected people receiving care in the participating HIV 
centres during the study period which for this chapter ranged from 1st January 1996 to 31st 
December 2006. The objective was to describe, over time, how HIV-1+ patients who are in different 
stages of HIV-1 infection and are receiving HIV-1 care in the NHS HIV-1 specialist centres in the 
UK the use and cost of HIV services changed over time. The particular aim of this chapter is to 
estimate quantitatively changing use of HIV-1 services within the NHS setting and changing costs 
associated with this. The study to date has generated unique descriptive information on the 
changing use and cost of HIV-1 services in the UK, however the primary aim of this PhD chapter is 
to describe and provide direct population cost estimates of those who are accessing HIV-1 care in 
the NHS, and address the two relevant questions: what is direct population cost of treating HIV-1+ 
people in the UK? What are the expected future HIV-1 direct population costs? 
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5.2 RESULTS 
 DEMOGRAPHIC CHARACTERISTICS 
Of the 24 UK HIV centres between 1996 and 2006 participating with the NPMS-HHC data were 
available from 14 HIV centres 7 of these were London centres. 28,925 HIV-1+ people were 
managed in these 14 centres between 1996 and 2006. 76% were men while 51% were Caucasian. 
Not all clinics provided details of sexual orientation of the subjects. Of those whose sexual 
orientation was known, 62% were MSM. A small proportion of subjects were known IDU (4.5%) 
(Table 5.2.1) and significantly greater proportion of men (79%) were attending London HIV centres 
for care ( 2 test, p<0.001).  
 
Table 5.2.1: Demographic Characteristics of Patients Seen in the 14 Participating Centres 
  
N(%) 
 
 Total number of HIV-1
+
 
patients attending for 
treatment and care 
 
N=28,925 
Attendances at  
London clinics 
 
 
N=22,962 
Attendances at  
non-London clinics 
 
 
N=5,963 
Gender 
Male 
Female 
Unavailable 
 
22058(76.3) 
5876(20.3) 
986(3.4) 
 
18272(79.6) 
4429(19.3) 
261(1.1) 
 
3786(63.5) 
725(24.3) 
863(12.2) 
Ethnic origin 
Caucasian 
Black African 
Other 
Unavailable 
 
14607(50.5) 
4757(16.4) 
5232(18.1) 
4329(15.0) 
 
12352(53.8) 
3894(17.0) 
4921(21.4) 
1795(7.8) 
 
2255(37.8) 
863(14.5) 
311(5.2) 
2534(42.5) 
Sexual orientation 
MSM 
Heterosexual 
Bisexual 
Unknown 
 
9868(34.1) 
5537(19.1) 
596(2.1) 
12924(44.7) 
 
8006(34.9) 
3993(17.4) 
253(1.1) 
10710(46.6) 
 
1862(31.2) 
1544(24.9) 
343(5.8) 
2214(37.1) 
IDU 
 
 
1303(4.5) 
 
695(3.0) 
 
608(12.2) 
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The ART prescription pattern changed over time from predominantly mono and dual therapy in the mid 1990‟s to mostly triple and quadruple HAART 
whilst prescription of mono and dual therapy declined over time for all stages of HIV-1 infection. Over the same time period a sharp increase in 
prescription of HAART consisting of triple and quadruple or more therapy was observed and this is in line with the changes that occurred in 
prescription of HAART containing regimens over time (Table 5.2.2, Figure 5.2.1). 
 
Table 5.2.2: ARV Drug Prescription Trends Over Time by Stage of HIV-1 Infection 
 
 Study period 1st Jan 1996 - 31st Dec 1996 
 Number of recent prescription of ARV drugs 
 Total Number of patients prescribed 
Mono therapy  
(Number of ARV drugs=1) 
Number of patients prescribed 
Dual therapy  
(Number of ARV drugs=2) 
Number of patients prescribed 
Triple therapy  
(Number of ARV drugs=3) 
Number of patients prescribed 
Quadruple or more therapy 
(Number of ARV drugs=4 or 
more) 
Year  ASx Sx Non 
AIDS 
AIDS ASx Sx Non 
AIDS 
AIDS ASx Sx Non 
AIDS 
AIDS ASx Sx Non 
AIDS 
AIDS 
1996 3182 1041 21 349 503 43 449 174 18 495 16 7 66 
1997 4477 1219 25 417 590 45 334 567 67 879 49 16 269 
1998 5054 1286 23 477 473 37 213 841 99 1047 126 23 409 
1999 5437 1355 20 466 369 22 165 1015 133 1163 209 32 488 
2000 5627 1343 18 457 340 17 125 1088 149 1143 285 51 611 
2001 5863 1270 22 441 391 10 128 1181 182 1224 316 61 637 
2002 5793 1131 17 388 317 10 116 1196 199 1294 361 70 694 
2003 5338 875 16 354 217 10 124 1127 211 1319 300 71 714 
2004 5017 569 15 293 170 7 131 1136 222 1226 343 77 828 
2005 5064 368 10 212 198 8 155 1214 217 1239 475 100 868 
2006 5077 216 10 120 166 6 154 1325 223 1229 604 107 917 
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A small proportion (15%) were known to have attended more than one HIV treatment and care centre within the UK during the study period. 18% of 
the study sample had attended more than one London HIV centre compared to 3% who had attended more than one out of London HIV centre. A 
small proportion (3%) had attended both London and non-London centres during the study period (1996 to 2006) and over time this has declined 
(Table 5.2.3). 
 
Table 5.2.3: Proportion of HIV-1+ People Who Attended More Than One HIV-1 Centres 
 
Year 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 
Overall 
number 
Across all clinics 
 
19% 18% 17% 15% 14% 12% 15% 14% 15% 12% 10% 15% 
Attended more than one 
London clinic during the 
year 
23% 22% 20% 17% 17% 15% 17% 17% 17% 16% 15% 18% 
Attended more than one 
non-London clinic during 
the year 
3% 3% 3% 3% 3% 4% 4% 4% 4% 3% 3% 3% 
Attending a London and 
non-London clinic during 
the year 
6% 5% 5% 3% 3% 3% 3% 2% 2% 2% 2% 3% 
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Figure 5.2.1: Changing ARV Prescription Pattern Over Time by Stage of HIV-1 Infection 
 
CHAPTER 5 
POPULATION COST 
166 
5.2.1 USE OF HOSPITAL SERVICES BY STAGE OF HIV-1 INFECTION 
 AGGREGATE 
o Outpatient 
Asymptomatic: The mean number of outpatient visits per patient year (PPY) increased for 
asymptomatic patients from 4.45 in 1996 to 7.95 by 2002 and thereafter a steady decline was 
observed and by 2006 the mean number of outpatient visits PPY was estimated at 5.83 in this 
group Table 5.2.4.  
Symptomatic non-AIDS: Increases were observed in the mean number of outpatient visits PPY 
from 5.38 in 1996 to 8.98 by 2005 however a decline in outpatient visits PPY was observed since 
and by 2006 this was 7.62 Table 5.2.4.  
AIDS: The mean number of outpatient visits per patient year increased for HIV-1+ people with AIDS 
over time from 10.57 in 1996 to 11.63 by 1998 and a gradual decline was observed from 1998 
and by 2006 this was 7.00 Table 5.2.4. 
 
o In-patient 
Asymptomatic: The mean number of inpatient days PPY decreased for asymptomatic HIV-1+ 
people from 3.66 in 1996 to 2.38 by 2006 Table 5.2.4. 
Symptomatic non-AIDS: The mean number of inpatient days PPY increase was seen HIV-1+ 
people with symptomatic non-AIDS between 1996 to 1999 from 1.93 to 3.84 and a decline 
thereafter to 2.72 by 2006 Table 5.2.4. 
AIDS: The mean number of inpatient days PPY amongst HIV-1+ people AIDS stage of infection a 
decline was seen from 13.53 in 1996 to 7.55 by 1999 with a slight unsteady trend being observed 
thereafter to 2006 and by the end of the study period it was estimated to 9.26 Table 5.2.4. 
 
o Dayward 
Asymptomatic: The mean number of dayward visits PPY showed very little change in the 
asymptomatic HIV-1+ people between 1996 when this was 0.30 and steady increases were 
observed thereafter and by 2006 this was estimated at 1.29 Table 5.2.4. 
Symptomatic non-AIDS: The mean number of dayward visits PPY declined slightly then increased 
showing a slight U shaped change in HIV-1+ people in symptomatic non-AIDS stages of HIV-1 
infection between 1996 and 2006 from 0.37 to 0.84 respectively Table 5.2.4. 
AIDS: The mean number of dayward visits PPY showed very little change in HIV-1+ people with 
AIDS Table 5.2.4. 
  
CHAPTER 5 
POPULATION COST 
167 
Table 5.2.4: Mean Number of Outpatient Visits, Inpatient Days and Dayward Attendances by Stage of HIV-1 Infection During Semester 
 
 
Aggregate 
PPY 
  Asymptomatic Symptomatic Non-AIDS AIDS 
  OP visits IP days DW visits OP visits IP days DW visits OP visits IP days DW visits 
1996 4.45 3.66 0.30 5.38 1.93 0.37 10.57 13.53 1.28 
1997 5.28 2.93 0.28 8.19 1.76 0.79 11.77 7.68 1.53 
1998 6.40 2.60 0.35 8.51 2.48 0.73 11.63 7.09 1.16 
1999 6.12 2.53 0.27 7.51 3.84 0.51 10.28 7.55 0.97 
2000 5.99 2.22 0.20 7.60 2.17 0.48 9.10 7.78 0.64 
2001 6.41 1.61 0.17 8.47 1.63 0.44 9.16 9.53 0.68 
2002 7.95 1.52 0.41 9.24 1.94 0.54 9.90 6.73 0.78 
2003 7.18 1.58 0.57 8.72 3.23 0.71 9.12 8.99 1.28 
2004 7.11 2.05 0.78 8.53 3.21 0.87 8.61 7.10 1.31 
2005 7.08 1.89 0.97 8.98 4.95 0.92 8.99 9.71 1.52 
2006 5.83 2.38 1.29 7.62 2.72 0.84 7.00 10.90 2.04 
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Figure 5.2.2: Use of Hospital Services by Stage of HIV-1 Infection and Location of Clinics 
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 BY SITE OF CLINIC: LONDON 
o Outpatient 
Asymptomatic  
Similar trends between 1996 and 2002 were seen for asymptomatic PLHV in patients attending the 
London centres; from 5.12 to 10.32 and a decline was seen by 2006 to 7.18 Figure 5.2.2.  
Increasing trends in mean outpatient visits PPY between 1996 and 2002 were seen for PLHV in 
symptomatic non-AIDS stage of HIV-1 infection in patients attending the London centres from 5.68 
to 10.85 and a decline was observed thereafter to 6.99 by 2006 Figure 5.2.2. 
Symptomatic non-AIDS 
Since 1996 the mean inpatient days PPY gradually declined over time since 1996 to 2002 in 
patients attending London HIV centres in HIV-1+ people in symptomatic non-AIDS stages of HIV-1 
infection from 1.67 in 1996 to 0.88 and by 2006 this was slightly higher at 1.82 Figure 5.2.2. 
AIDS 
Similar increasing trends were seen between 1996 and 2002 for PLHV with AIDS from 9.57 to 
12.37 and thereafter a decline by 2006 to 8.03 Figure 5.2.2. 
 
o In-patient 
Asymptomatic  
Since 1996 the mean inpatient days PPY gradually declined over time since 1996 to 2006 in 
patients attending London HIV centres in HIV-1+ people in asymptomatic stages of HIV-1 infection 
from 1.16 in 1996 to 1.04 by 2002 and thereafter a slight increase was observed in 2006 to 2.09 
Figure 5.2.2. 
Symptomatic non-AIDS 
AIDS 
Since 1996 the mean inpatient days PPY declined substantially over time to 2006 in patients 
attending London HIV centres in PLHV with AIDS. The mean number of inpatient days declined 
from 11.8 in 1996 to 2.6 by 2006 Figure 5.2.2. 
 
o Dayward 
Asymptomatic  
Since 1996 the mean dayward visits PPY showed no change over time between 1996 and 2002 in 
patients attending the London HIV centres from 0.45 to 0.45 by 2002, however a steady increases 
were observed thereafter and by 2006 this was estimated to be 2.44. 
Symptomatic non-AIDS 
The mean dayward visits PPY showed very little change over time since 1996 and 2006 in patients 
attending the London HIV centres with symptomatic non-AIDS stage of HIV-1 infection from 0.43 in 
1996 to 0.74 by 2002 and thereafter an upward trend was observed and by 2006 this was 1.23.  
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AIDS 
For PLHV in AIDS stage of HIV-1 infection the mean dayward visits PPY declined from 3.35 in 
1996 to 1.12 by 2002 however increasing trends have been observed thereafter and by 2006 the 
mean dayward visits PPY were 2.6. 
 
 BY SITE OF CLINIC: NON-LONDON 
o Outpatient 
Asymptomatic  
HIV-1+ people in asymptomatic stage and who were attending non-London HIV centres, in 1996 
and 2002 mean OP visits PPY were 4.57 and 7.83 respectively and declined thereafter to 5.90 in 
2006 Figure 5.2.2. On average, in non-London clinics, the mean number of OP visits PPY were 
20% lower than those in London clinics. 
Symptomatic non-AIDS 
Similarly, in patients attending non-London HIV centres between 1996 and 2002 in HIV-1+ people 
in symptomatic non-AIDS stage of HIV-1 infection, mean OP PPY increased from 4.89 to 8.58. A 
decline was observed thereafter and by 2006 the mean OP visits PPY was 7.43 Figure 5.2.2. On 
average the non-London centres had OP visits PPY that were 15% lower compared to the London 
centres. 
AIDS 
Similarly in patients attending non-London HIV centres between 1996 and 2002, the mean OP 
PPY was 10.81 and 10.01 respectively and a decline was observed by 2006 to 5.72 OP visits PPY 
Figure 5.2.2. On average the non-London centres had OP visits PPY that were 20% lower 
compared to the London centres. 
 
o In-patient 
Asymptomatic  
For non-London centres the mean IP days PPY for patients who were classified into asymptomatic 
stage of HIV-1 infection showed a decline from 5.31 in 1996 to 1.84 by 2006 Figure 5.2.2. On 
average the non-London centres had mean inpatient days PPY that were two fold higher compared 
to the London centres. 
Symptomatic non-AIDS 
The trends over time showed in HIV-1+ people in symptomatic non-AIDS stage of HIV-1 infection 
an increase in mean IP days PPY between 1996 and 1999 from 2.35 to 5.01 respectively and an 
unsteady decline thereafter and by 2006 this was observed to be 2.67 Figure 5.2.2. On average 
the non-London centres had inpatient days PPY that was over three fold higher compared to the 
London centres. 
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AIDS 
The trends over time showed in HIV-1+ people in the AIDS the mean inpatient days PPY declined 
from 14.17 in 1996 to 5.67 by 2002 with an unstable variation between 2003 to 2006 and by the 
end of the study period this was observed to be 12.59 Figure 5.2.2. On average the non-London 
centres had IP days PPY that were over 2 fold higher compared to the London centres. 
 
o Dayward 
Asymptomatic  
Very little change was observed in the use of dayward visits PPY in non-London HIV centres in 
patients classified into asymptomatic between 1996 and 2006 and these were estimated to be 0.35 
and 0.17 respectively Figure 5.2.2. On average the mean number of DW visits PPY in non-London 
clinics were 50% lower than those in London clinics. 
Symptomatic non-AIDS 
There were very little variations in the use of dayward visits PPY in non-London HIV centres in 
patients classified into symptomatic non-AIDS stage of HIV-1 infection between 1996 when it was 
0.37 and 2006 when it was 0.28 Figure 5.2.2. On average the DW visits PPY were 40% lower in 
non-London centres compared to the London centres. 
AIDS 
The use of dayward visits PPY remained unchanged over time from 1996 when this was 0.17 and 
by 2006 the mean dayward visits PPY was 0.14 Figure 5.2.2. Overall the use of dayward services 
was observed to have been slightly higher for HIV-1+ people with AIDS compared to those who 
were classed as asymptomatic or symptomatic non-AIDS stages of HIV-1 infection. On average 
the non-London centres had DW visits PPY that were 70% lower compared to the London centres. 
 
5.2.2 COST OF HOSPITAL SERVICES BY STAGE OF HIV-1 INFECTION 
 AGGREGATE 
The mean total hospital services costs PPY showed a steady rise over time for all three stages of 
HIV-1 infection.  
Asymptomatic For HIV-1+ people with asymptomatic stage of HIV-1, the mean total cost of hospital 
service was estimated at £58K PPY in 1996 and by 2006 it had increased to £72K PPY Table 
5.2.5.  
Symptomatic non-AIDS For HIV-1+ people who were classified as symptomatic non-AIDS stage of 
HIV-1, this was £71K PPY in 1996 and £89K PPY by 2005 however a slight decline in cost was 
observed by 2006 at £84K PPY.  
AIDS For HIV-1+ people who were classified in AIDS stage of HIV-1 infection, the total direct costs 
of hospital service PPY remained relatively stable over time. In 1996 it was estimated to be £147K 
PPY and by 2005 a slight decline was seen £143K PPY followed by an increase of £147K PPY in 
2006 Table 5.2.5. 
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Table 5.2.5: Total Cost of HIV Service Use in HIV-1+ People by Time and Stage of HIV-1 Infection 
 
  
Total Cost  
PPY 
  
Excluding  
Community Care Cost 
 
 
Including  
Community Care Cost 
 
 
Year Asymptomatic 
Symptomatic non-
AIDS AIDS Asymptomatic 
Symptomatic non-
AIDS AIDS 
1996 £58,097 £70,827 £147,143 £89,007 £111,667 £199,419 
1997 £59,673 £77,827 £133,573 £90,583 £118,667 £185,849 
1998 £61,512 £83,361 £133,017 £92,422 £124,201 £185,293 
1999 £61,619 £87,097 £137,666 £92,529 £127,937 £189,942 
2000 £58,318 £75,571 £129,228 £89,228 £116,411 £181,504 
2001 £59,560 £76,980 £139,464 £90,470 £117,820 £191,740 
2002 £61,851 £80,945 £130,885 £92,761 £121,785 £183,161 
2003 £62,337 £86,506 £143,635 £93,247 £127,346 £195,911 
2004 £65,902 £84,768 £134,780 £96,812 £125,608 £187,056 
2005 £65,640 £89,210 £142,820 £96,550 £130,050 £195,096 
2006 £71,943 £83,665 £147,129 £102,853 £124,505 £199,405 
Costs include total use of services costs (OP,IP,DW) + Other drugs + Tests and procedure+ ART (Non London ART prices were estimated at 9.5% higher than London ART prices)  
  
CHAPTER 5 
POPULATION COST 
173 
 BY SITE OF CLINIC: LONDON AND NON-LONDON 
The overall trends of the mean total cost of hospital services PPY stratified by stage of HIV-1 
infection and clinic location showed shifts in changes in costs over time.  
Asymptomatic Compared to London HIV specialist centres, the HIV-1+ people treated in the non-
London centres with asymptomatic stage of HIV-1 infection, the total use of hospital service costs 
were 45% higher in 1996. However, over time the differences in hospital costs between London 
and non-London centres almost diminished and by 2006 the total hospital services costs for non-
London centres were 5% higher compared to London centres Table 5.2.6. 
Symptomatic non-AIDS For HIV-1+ people with symptomatic non-AIDS stage of HIV-1 infection, in 
1996 the non-London total hospital services costs PPY were 9% higher which rose to 45% higher 
by 1999 however decline in the differences in costs between clinic locations were observed and by 
2006 the total hospital services costs PPY for non-London centres were 10% higher compared to 
London centres by 2006.  
AIDS Variations in costs between the London and non-London centres were also found in patients 
with AIDS. In 1996 these costs were 10% higher in Non-London Centres and these differences in 
cost estimates continued to expand over time and by 2006 the total hospital service costs PPY in 
non-London centres were estimated to be 29% higher compared to the total cost of hospital 
services in the London centres Table 5.2.6. 
 
5.2.3 COST OF HOSPITAL SERVICES BY STAGE OF HIV-1 INFECTION INCLUDING 
COMMUNITY CARE COST 
The overall mean total cost of hospital services PPY by stage of HIV-1 infection and clinic location 
showed similar trends when community care costs were added to the total hospital services costs. 
The variations that were observed were the differences in costs between the London and the non-
London Centres. 
Asymptomatic After community care costs were added, in HIV-1+ people in asymptomatic stage of 
HIV-1 infection, the mean use of hospital services costs amongst those attending non London 
centres these were 27% higher in 1996 compared to the London centres whilst the differences in 
costs by clinic location had dropped to 4% by 2006 Table 5.2.6.  
Symptomatic non-AIDS Whilst for HIV-1+ people in symptomatic stage of HIV-1 infection the non-
London clinics‟ costs were 5% higher than the London clinic costs in 1996 and remained similar by 
2006 at 7% higher costs for Non-London centres compared to the London centres.  
AIDS Similarly, for HIV-1+ people with AIDS the non London centre total hospital services costs 
were 7% higher in 1996 however these differences increased over time and by 2006 total hospital 
services costs including the community care costs in non London centres were 21% higher than 
the London Centres Table 5.2.6. 
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Table 5.2.6: Total Cost of HIV-1 Service Use in HIV-1+ People by Year of Attendance, Stage of HIV-1 Infection and Clinic Location 
 
  
Total Cost  
 
 Excluding  
Community Care Cost 
Including 
Community Care Cost 
  
London 
 
Non-London 
 
London 
 
Non-London 
 
 
Year Asympto
matic 
Symptomati
c non-AIDS AIDS 
Asymptoma
tic 
Symptomati
c non-AIDS AIDS 
Asympto
matic 
Symptom
atic non-
AIDS AIDS 
Asympto
matic 
Symptom
atic non-
AIDS AIDS 
1996 £23,727 £33,937 £70,188 £34,370 £36,890 £76,955 £39,182 £54,357 £96,326 £49,825 £57,310 £103,093 
1997 £26,482 £36,489 £64,865 £33,192 £41,339 £68,708 £41,937 £56,909 £91,003 £48,647 £61,759 £94,846 
1998 £27,090 £38,764 £63,746 £34,421 £44,598 £69,271 £42,545 £59,184 £89,884 £49,876 £65,018 £95,409 
1999 £27,710 £36,197 £62,737 £33,909 £50,900 £74,929 £43,165 £56,617 £88,875 £49,364 £71,320 £101,067 
2000 £26,223 £35,188 £61,031 £32,095 £40,383 £68,197 £41,678 £55,608 £87,169 £47,550 £60,803 £94,335 
2001 £27,867 £36,504 £61,400 £31,693 £40,476 £78,065 £43,322 £56,924 £87,538 £47,148 £60,896 £104,203 
2002 £29,774 £38,857 £62,663 £32,077 £42,087 £68,222 £45,229 £59,277 £88,801 £47,532 £62,507 £94,360 
2003 £30,387 £38,825 £62,696 £31,950 £47,682 £80,939 £45,842 £59,245 £88,834 £47,405 £68,102 £107,077 
2004 £31,246 £37,341 £61,800 £34,656 £47,427 £72,981 £46,701 £57,761 £87,938 £50,111 £67,847 £99,119 
2005 £31,244 £38,477 £65,093 £34,395 £50,733 £77,727 £46,699 £58,897 £91,231 £49,850 £71,153 £103,865 
2006 £35,023 £39,844 £64,225 £36,920 £43,821 £82,904 £50,478 £60,264 £90,363 £52,375 £64,241 £109,042 
Costs include total use of services costs (OP,IP,DW) + Other drugs + Tests and procedure+ ART (Non London ART prices were estimated at 9.5% higher than London ART prices)  
  
CHAPTER 5 
POPULATION COST 
175 
5.2.4 COST OF DIFFERENT TYPES OF ANTI-RETROVIRAL THERAPY BY STAGE OF HIV-1 
INFECTION 
Although slight variations were observed between ARV costs in London and non London clinics 
(Table 5.2.7) the proportion spent on ART between London and non London clinics for any of three 
stages of HIV-1 infection nor for the four ART treatment categories were similar (Table 5.2.7). 
 
5.2.5 COST OF HOSPITAL SERVICES BY STAGE OF HIV-1 INFECTION AND TYPES OF ARV 
THERAPY 
Treatment and care costs PPY for PLHIV at different stage of HIV infection and different treatment 
regimens increased over time (Table 5.2.8) with similar trends being observed in London sites. 
 
 MONO THERAPY 
For asymptomatic individuals in 1996 the annual cost of care was £8,503, which increased to 
£10,020 in 2006. For those with symptomatic non-AIDS, the 1996 cost of £10,591 increased to 
£11,482, while for AIDS patients on mono-therapy, the annual costs decreased from £36,396 in 
1996 to £30,717 in 1997 which then increased to £32,760 by 2006 (Table 5.2.8). 
 
 DUAL THERAPY 
For asymptomatic PLHIV on dual therapy, the 1996 cost of £11,525 increased to £13,351 in 2006. 
For patients with symptomatic non-AIDS, the annual cost increased from £13,671 in 1996 to 
£15,692 in 2006, while for AIDS patients on dual therapy, a decreased from £39,409 in 1996 to 
£33,726 in 1997 was observed which increased to £36,580 in 2006 per patient-years in 2006 (Table 
5.2.8). 
 
 TRIPLETHERAPY 
For asymptomatic PLHIV on triple therapy, annual costs increased from £16,346 in 1996 to £18,280 
in 2006. For patients with symptomatic non-AIDS annual costs between 1996 and 2006 increased 
from £18,374 to £21,597, while for AIDS patients annual costs varied from £44,350 in 1996 to 
£41,747 in 2006 (Table 5.2.8). 
 
 QUADRUPLE OR MORE THERAPY 
Annual cost for those asymptomatic PLHIV on quadruple-or-more therapy ranged from £16,722 in 
1996 to £23,775 in 2006. Similarly annual costs increased between 1996 and 2006 from £21,139 to 
£25,135 respectively for PLHIV with symptomatic non-AIDS, while for AIDS patients annual costs 
first decreased from £46,041 in 1996 to £41,383 in 1997 and increased to £48,055 in 2006(Table 
5.2.8). 
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Table 5.2.7: Annual Cost Due to Different Types of Anti-Retroviral Therapy by Stage of HIV Infection, Aggregate and London Site, 2006 UK 
Prices 
  
ARV costs PPY 
 
 
Non London and London cost 
Mono therapy  Dual therapy Triple therapy Quadruple or more therapy 
Year ASx 
Sx Non 
AIDS 
AIDS ASx 
Sx Non 
AIDS 
AIDS ASx 
Sx Non 
AIDS 
AIDS ASx 
Sx Non 
AIDS 
AIDS 
1996 £3,504 £3,539 £3,735 £6,525 £6,619 £6,748 £11,347 £11,322 £11,689 £11,722 £14,087 £13,380 
1997 £3,839 £4,337 £3,976 £6,906 £6,946 £6,985 £11,877 £12,067 £12,146 £14,369 £14,985 £14,642 
1998 £4,163 £4,476 £4,339 £7,181 £7,375 £7,196 £12,062 £12,474 £12,355 £15,049 £15,438 £15,350 
1999 £4,243 £3,968 £4,212 £7,309 £7,040 £7,323 £12,196 £12,466 £12,263 £15,585 £15,626 £15,786 
2000 £4,144 £3,761 £4,085 £7,043 £6,814 £7,234 £12,003 £12,144 £12,052 £14,796 £14,937 £15,190 
2001 £4,091 £3,975 £4,107 £7,138 £6,796 £7,372 £12,060 £12,008 £11,860 £16,846 £16,195 £16,789 
2002 £4,018 £4,173 £4,077 £7,230 £6,586 £7,182 £12,130 £12,226 £11,996 £17,322 £18,686 £17,253 
2003 £4,047 £4,540 £4,158 £7,189 £6,715 £7,385 £12,292 £12,579 £12,152 £17,617 £17,194 £17,763 
2004 £4,233 £3,452 £4,209 £7,236 £6,663 £7,427 £12,713 £12,801 £12,532 £18,286 £17,839 £18,656 
2005 £4,357 £2,116 £4,139 £7,536 £6,971 £7,437 £12,601 £12,636 £12,618 £18,651 £18,526 £19,234 
2006 £4,346 £2,592 £3,660 £7,677 £6,803 £7,479 £12,607 £12,707 £12,647 £18,101 £18,061 £18,955 
  
 
London cost 
1996 £1,668 £1,685 £1,779 £3,107 £3,152 £3,213 £5,403 £5,391 £5,566 £5,582 £6,708 £6,371 
1997 £1,828 £2,065 £1,894 £3,289 £3,308 £3,326 £5,656 £5,746 £5,784 £6,842 £7,136 £6,972 
1998 £1,982 £2,132 £2,066 £3,419 £3,512 £3,427 £5,744 £5,940 £5,884 £7,166 £7,351 £7,310 
1999 £2,020 £1,889 £2,006 £3,481 £3,352 £3,487 £5,808 £5,936 £5,840 £7,421 £7,441 £7,517 
2000 £1,974 £1,791 £1,945 £3,354 £3,245 £3,445 £5,715 £5,783 £5,739 £7,046 £7,113 £7,233 
2001 £1,948 £1,893 £1,956 £3,399 £3,236 £3,510 £5,743 £5,718 £5,647 £8,022 £7,712 £7,995 
2002 £1,913 £1,987 £1,941 £3,443 £3,136 £3,420 £5,776 £5,822 £5,712 £8,249 £8,898 £8,216 
2003 £1,927 £2,162 £1,980 £3,424 £3,198 £3,517 £5,853 £5,990 £5,787 £8,389 £8,188 £8,458 
2004 £2,016 £1,644 £2,004 £3,446 £3,173 £3,537 £6,054 £6,096 £5,967 £8,707 £8,495 £8,884 
2005 £2,075 £1,007 £1,971 £3,589 £3,320 £3,541 £6,001 £6,017 £6,009 £8,881 £8,822 £9,159 
2006 £2,070 £1,235 £1,743 £3,656 £3,239 £3,562 £6,003 £6,051 £6,022 £8,620 £8,601 £9,026 
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Non London cost 
1996 £1,835 £1,854 £1,957 £3,418 £3,467 £3,535 £5,943 £5,931 £6,123 £6,140 £7,379 £7,008 
1997 £2,011 £2,272 £2,083 £3,618 £3,638 £3,659 £6,221 £6,321 £6,362 £7,527 £7,849 £7,669 
1998 £2,180 £2,345 £2,273 £3,761 £3,863 £3,769 £6,318 £6,534 £6,472 £7,883 £8,086 £8,041 
1999 £2,222 £2,078 £2,206 £3,829 £3,688 £3,836 £6,389 £6,530 £6,424 £8,163 £8,185 £8,269 
2000 £2,171 £1,970 £2,140 £3,689 £3,569 £3,789 £6,287 £6,361 £6,313 £7,750 £7,824 £7,957 
2001 £2,143 £2,082 £2,152 £3,739 £3,560 £3,861 £6,317 £6,290 £6,212 £8,824 £8,483 £8,794 
2002 £2,105 £2,186 £2,135 £3,787 £3,450 £3,762 £6,354 £6,404 £6,284 £9,073 £9,788 £9,037 
2003 £2,120 £2,378 £2,178 £3,766 £3,518 £3,868 £6,439 £6,589 £6,365 £9,228 £9,006 £9,304 
2004 £2,217 £1,808 £2,205 £3,790 £3,490 £3,890 £6,659 £6,705 £6,564 £9,578 £9,344 £9,772 
2005 £2,282 £1,108 £2,168 £3,947 £3,651 £3,896 £6,601 £6,619 £6,610 £9,770 £9,704 £10,075 
2006 £2,277 £1,358 £1,917 £4,021 £3,563 £3,918 £6,603 £6,656 £6,625 £9,482 £9,461 £9,929 
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Table 5.2.8: Annual Cost of Treatment and Care by Stage of HIV Infection and Different Types of Anti-Retroviral Therapy, 2006 UK prices 
 
Total Cost PPY: OP + IP + DW + other drugs + tests & procedures + ARV costs 
  
 
Non London and London 
Mono therapy  Dual therapy Triple therapy Quadruple or more therapy 
Year ASx 
Sx Non 
AIDS 
AIDS ASx 
Sx Non 
AIDS 
AIDS ASx 
Sx Non 
AIDS 
AIDS ASx 
Sx Non 
AIDS 
AIDS 
1996 £8,503 £10,591 £36,396 £11,525 £13,671 £39,409 £16,346 £18,374 £44,350 £16,722 £21,139 £46,041 
1997 £8,308 £12,076 £30,717 £11,376 £14,685 £33,726 £16,347 £19,806 £38,887 £18,839 £22,724 £41,383 
1998 £8,642 £13,008 £29,609 £11,660 £15,907 £32,467 £16,542 £21,006 £37,626 £19,528 £23,970 £40,621 
1999 £8,552 £13,481 £30,431 £11,619 £16,553 £33,542 £16,506 £21,980 £38,483 £19,894 £25,140 £42,005 
2000 £8,083 £11,299 £29,274 £10,981 £14,352 £32,423 £15,941 £19,683 £37,242 £18,734 £22,476 £40,380 
2001 £7,859 £11,489 £32,229 £10,906 £14,310 £35,493 £15,827 £19,521 £39,981 £20,613 £23,709 £44,911 
2002 £8,145 £11,901 £29,059 £11,358 £14,314 £32,164 £16,257 £19,954 £36,978 £21,449 £26,414 £42,235 
2003 £8,176 £13,435 £32,227 £11,319 £15,611 £35,454 £16,422 £21,474 £40,221 £21,747 £26,089 £45,831 
2004 £8,774 £12,272 £28,988 £11,777 £15,483 £32,206 £17,254 £21,621 £37,311 £22,827 £26,659 £43,436 
2005 £8,685 £12,192 £30,566 £11,864 £17,048 £33,864 £16,930 £22,713 £39,045 £22,979 £28,603 £45,661 
2006 £10,020 £11,482 £32,760 £13,351 £15,692 £36,580 £18,280 £21,597 £41,747 £23,775 £25,135 £48,055 
 London 
1996 £3,262 £5,085 £17,344 £4,700 £6,552 £18,778 £6,996 £8,792 £21,131 £7,175 £10,108 £21,936 
1997 £3,569 £5,636 £15,123 £5,030 £6,878 £16,556 £7,397 £9,317 £19,013 £8,584 £10,707 £20,202 
1998 £3,675 £6,008 £14,359 £5,112 £7,388 £15,719 £7,437 £9,816 £18,176 £8,859 £11,228 £19,602 
1999 £3,746 £5,364 £14,255 £5,206 £6,827 £15,737 £7,533 £9,411 £18,089 £9,147 £10,916 £19,766 
2000 £3,539 £5,221 £13,878 £4,920 £6,675 £15,377 £7,281 £9,213 £17,672 £8,612 £10,543 £19,166 
2001 £3,643 £5,440 £13,697 £5,094 £6,784 £15,251 £7,438 £9,265 £17,388 £9,717 £11,259 £19,736 
2002 £3,943 £5,729 £13,908 £5,473 £6,878 £15,387 £7,806 £9,564 £17,679 £10,278 £12,640 £20,182 
2003 £4,034 £5,924 £13,761 £5,531 £6,960 £15,298 £7,960 £9,752 £17,568 £10,496 £11,950 £20,240 
2004 £4,151 £5,239 £13,413 £5,581 £6,768 £14,946 £8,189 £9,691 £17,377 £10,843 £12,090 £20,293 
2005 £4,133 £5,005 £14,117 £5,647 £7,317 £15,687 £8,059 £10,015 £18,155 £10,940 £12,820 £21,305 
2006 £4,924 £5,468 £13,654 £6,511 £7,473 £15,473 £8,858 £10,285 £17,934 £11,474 £12,834 £20,938 
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5.2.6 NUMBER OF HIV-1+ PEOPLE USING THE NHS SERVICES 
 
 DURING STUDY PERIOD: 1997-2006 
The total number of HIV-1+ population who were reported to the HPA to have used the NHS 
services in the UK for treatment and care increased during the study period. In 1997, 16,075 HIV-
1+ people were reported to have accessed the NHS services, which increased to 52,083 patients 
by 2006. These increases in the numbers of HIV-1+ patients accessing the NHS for care were seen 
across all stages of HIV-1 infection in the UK population figures, however compared to 1997 in 
2006 the proportion of HIV-1+ people classified as asymptomatic increased from 38.1% to 48.7%, 
while the proportion of HIV-1+ people classified as symptomatic non-AIDS patients decreased from 
33.5% to 28.3% similarly the number of AIDS patients declined from 28.4% in 1997 to 22.9% in 
2006 ( Table 5.2.9). 
 
Table 5.2.9: Number of People Living With HIV-1 in the UK Using NHS Services by Stage of 
HIV-1 Infection and Year 1997-2006 
 
  
 
UK HIV-1 Population (%)  
   
Year Asymptomatic 
Symptomatic 
non-AIDS AIDS Total 
1997 6124(38.1) 5384(33.5) 4567(28.4) 16,075 
1998 5835(31.8) 6975(38.0) 5525(30.1) 18,335 
1999 6833(32.4) 7994(37.9) 6288(29.8) 21,114 
2000 8055(35.4) 8347(36.7) 6338(27.9) 22,740 
2001 10015(38.0) 9088(34.5) 7253(27.5) 26,356 
2002 12787(40.5) 10635(33.7) 8115(25.7) 31,537 
2003 15932(43.4) 11544(31.5) 9203(25.1) 36,679 
2004 18794(45.1) 12834(30.8) 10009(24.0) 41,637 
2005 21656(46.1) 14590(31.0) 10779(22.9) 47,025 
2006 25385(48.7) 14750(28.3) 11947(22.9) 52,083 
Source of data from HPA 
1996 UK HIV-1 population figures unavailable from HPA (from 1
st
 April HPA became part of NHS England) 
Table from (Mandalia et al., 2010) 
 
 DURING PROJECTED PERIOD: 2007-2013 
In 2006 the total number of HIV-1 infected people who accessed the NHS for care was 52,083. 
The extrapolation showed that by 2013, the expected total numbers of HIV-1 positive subjects who 
are likely to access the NHS for HIV-1 care is estimated to be 78,370. An estimated 38,951 are 
expected to be living with asymptomatic stage of HIV-1 infection in the UK by 2013 whilst 22,267 
are projected to be living with symptomatic non-AIDS stage HIV-1 infection and for AIDS patients 
its is estimated that by end of 2013, numbers accessing the NHS HIV services who are classified 
into AIDS stage of HIV-1 infection is expected to be 17,151 (Table 5.2.10, Figure 5.2.3). 
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Table 5.2.10: Projected and HPA Estimates of People Living with HIV-1 Using NHS Services 
by Stage of HIV-1 Infection and Year 2007-2013 
 Number of people living with HIV-1 in the UK using the NHS services 
Year 
Projected numbers 
 
n(%) 
HPA 
estimates 
n 
 
Asymptomatic 
Symptomatic 
non-AIDS 
AIDS Total  Total 
2007 25,485 (47%) 15,979 (30%) 12,378 (23%) 53,842 56,211 
2008 27,729 (48%) 17,027 (29%) 13,173 (23%) 57,930 61,019 
2009 29,974 (48%) 18,075 (29%) 13,969 (23%) 62,018 65,213 
2010 32,218 (49%) 19,123 (29%) 14,764 (22%) 66,106 69,298 
2011 34,462 (49%) 20,171 (29%) 15,560 (22%) 70,194 73,645 
2012 36,707 (49%) 21,219 (29%) 16,355 (22%) 74,282 76,500 
2013 38,951 (50%) 22,267 (28%) 17,151 (22%) 78,370 N/A 
Table adapted from (Mandalia et al., 2010) 
HPA estimates of people living with HIV-1 in the UK using the NHS services reported to the Public Health England 
(Aghaizu et al., 2013) (from 1
st
 April HPA became part of NHS England) 
N/A – Currently (November 2013) figure for this year was not available 
 
 
 
 
 
Figure 5.2.3: The Number HIV-1 Infected Population in the UK by Stage of HIV-1 Infection, 
Projected From 2007-2013 
 
The accuracy of the estimated projected figures were compared to the HPA estimates published by 
the Public Health England (from 1st April HPA became part of NHS England) and these estimated 
projected population to access the NHS for HIV services by end of 2012 was 74,282 whist the 
observed numbers were 76,500 (see Chapter 1 for further details) thereby 2012 projected 
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population presented in Table 5.2.10 were underestimated by 3% impacting the population cost 
estimate by this magnitude. 
 
5.2.7 ANNUAL POPULATION COST OF HIV-1+ PEOPLE 
 
 DURING STUDY PERIOD: 1997-2006 
The direct population cost increased over time for all stages of HIV-1 infection since 1997 to 2006 
reflecting in increasing numbers of subjects in the UK who are living with HIV-1 infection and 
accessing the NHS hospital services. 
 
In 1997 the direct population cost of treating HIV-1+ in patients classified in asymptomatic stage of 
HIV-1 infection was estimated at £22 million whilst for the same year this was estimated to be £39 
million for patients in symptomatic non-AIDS stage of HIV-1 infection and was £43 million for AIDS 
patients. In contrast these had increased by over 4.5 fold collectively to £483 million by 2006 and 
patients in asymptomatic, symptomatic non-AIDS and AIDS stage of HIV-1 infection the total 
population costs were £162, £146 and £176 million Figure 5.2.4. 
 
As expected, when community care costs were accounted for, the total cost increased from £164 
million in 1997 to £683 million in 2006 which was estimated to be 41% higher than £483 million, 
estimated when community care costs were not accounted for. 
 
  
 
Figure 5.2.4: Total UK Population Cost by Stage of HIV-1 Infection Excluding and Including 
Community Care Cost 
 
 DURING PROJECTED PERIOD: 2007-2013 
Three methods were investigated and the findings from these were: 
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o Method 1 
The first method projected the annual UK population costs per year from 1997-2006 and estimated 
population cost from 2007-2013 (including and excluding community care) (regardless of stage of 
HIV-1 infection) using the population cost figures derived for 1997-2006 using regression models. 
In Table 5.2.11, Figure 5.2.5 the original costs values were divided by 1,000,000. 
 
Method 1: Regression Models Used to Project Direct Total UK Population Cost 
 
 UK direct population cost regression models (TC) 
Per £1,000,000 
y= + x 
 Regression model 
Excluding Community Care 
 
Regression model 
Including Community Care 
 y= x y= x 
Total  TC =-4839+(42.52*year) TC=-116919+(58.61*year) 
Where y=UK direct population cost per £1,000,000 (TC) 
=intercept 
=slope or gradient of a line 
x=year 
 
 
 
 
 
 
Figure 5.2.5: Method 1 - Direct UK HIV-1 Population Cost Excluding and Including 
Community Care Cost From 2007-2013 
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Table 5.2.11: Method 1 - Total UK Population Cost From NPMS-HHC and Projected 
 
Calendar year Excluding community care costs 
combined for the three HIV-1 stages 
(asymptomatic, symptomatic non-AIDS and 
AIDS) 
Including community care costs 
combined for the three HIV-1 stages 
(asymptomatic, symptomatic non-AIDS and AIDS) 
1996 - - 
1997 £104 £164 
1998 £136 £206 
1999 £165 £244 
2000 £184 £276 
2001 £213 £318 
2002 £269 £395 
2003 £319 £462 
2004 £368 £531 
2005 £440 £625 
2006 £483 £683 
2007 £502 £713 
2008 £545 £772 
2009 £588 £830 
2010 £630 £889 
2011 £673 £947 
2012 £715 £1,006 
2013 £758 £1,065 
Figures in blue (from 2007-2013) are projected 
 
The figures in blue are projected cost figures and the figures in black are the original cost figures 
and both the figures in black and blue are costs per £1,000,000. The annual direct population costs 
were estimated to increase to £758 million by 2013 if community care cost were not accounted for 
while the cost were estimated to rise to £1,065 million by 2013 if community care costs were 
included (Table 5.2.11, Figure 5.2.5).  
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o Method 2 
The second method projected the population total of number of HIV-1+ people by 2013 (Table 
5.2.10) using the regression models.  
 
Method 2: Regression Models Used to Project Direct Total UK Population Cost 
 
 UK direct population cost regression models (TC) 
y= + x 
 Excluding community care 
costs 
Including community care 
costs 
Total Population cost from 
2006 
 
£483,362,397 
 
 
£682,824,388 
 
Total UK population based on 
HPA 2006 figures 
 
52,083 
 
 
52,083 
 
Average UK cost per patient 
year for 2006 (Mean) 
£483,362,397 
÷ 
52,083 
= 
£9,281 
 
£682,824,388 
÷ 
52,083 
= 
£13,110 
 
95% confidence Interval mean +/-1.96* 238.95 mean +/-1.96* 238.95 
Where y=UK direct population cost  
=intercept 
=slope or gradient of a line 
x=year 
 
Multiplied the average 2006 PPY costs to the projected number of HIV-1+ people using the NHS 
services by 2013, the annual population cost was estimated to increase to £727 million by 2013 
when community care cost were not accounted for and £1,027 million when including community 
care costs (Table 5.2.12). 
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Table 5.2.12: Method 2 - Total UK Population Cost From NPMS-HHC and Projected 
 
Calendar year Excluding community care costs 
combined for the three HIV-1 stages 
(asymptomatic, symptomatic non-AIDS and 
AIDS) 
Including community care costs 
combined for the three HIV-1 stages 
(asymptomatic, symptomatic non-AIDS and AIDS) 
1996 - - 
1997 £104 £164 
1998 £136 £206 
1999 £165 £244 
2000 £184 £276 
2001 £213 £318 
2002 £269 £395 
2003 £319 £462 
2004 £368 £531 
2005 £440 £625 
2006 £483 £683 
2007 £500 £706 
2008 £538 £759 
2009 £576 £813 
2010 £614 £867 
2011 £651 £920 
2012 £689 £974 
2013 £727 £1,027 
Figures in blue (from 2007-2013) are projected 
 
o Method 3 
The third method looked at the number of HIV-1+ people by stage of HIV-1 infection using the 
regression models. 
 
  
CHAPTER 5 
POPULATION COST 
186 
Method 3: Regression Models Used to Project Direct Total UK Population Cost 
 
 UK direct population cost regression models (TC) 
 
y= + x 
 Excluding community care costs Including community care costs 
  
ASx 
 
 
SNA 
 
AIDS 
 
ASx 
 
 
SNA 
 
AIDS 
Population 
cost from 
2006 
 
£161,558,459 
 
 
£145,622,691 
 
 
£176,181,247 
 
 
£240,024,772 
 
 
£205,862,874 
 
 
£236,936,742 
 
UK 
population 
based on 
HPA 2006 
figures  
 
 
25,385 
 
 
 
14,750 
 
 
 
11,947 
 
 
 
25,385 
 
 
 
14,750 
 
 
 
11,947 
 
Average 
UK cost 
per patient 
year for 
2006 
(Mean) 
£161,558,459 
÷ 
25,385 
= 
£6,364 
 
£145,622,691 
÷ 
14,750 
= 
£9,873 
 
£176,181,247 
÷ 
11,947 
= 
£14,747 
 
£240,024,772 
÷ 
25,385 
= 
9,455 
 
£205,862,874 
÷ 
14,750 
= 
13,957 
 
£236,936,742 
÷ 
11,947 
= 
19,832 
 
Confidence 
Interval 
calculated 
for each 
Mean +/-
1.96*193.88 
Mean +/-
1.96*46.21 
Mean +/-
1.96*33.73 
Mean +/-
1.96*22.94 
Mean +/- 
1.96*46.21 
Mean +/- 
1.96*33.73 
Formula for projecting ASx (asymptomatic), SNA (symptomatic non-AIDS) and AIDS and total population in the UK:  
y=  + x 
Where  =intercept 
  =slope or gradient of a line 
 x=year 
Formula for calculating the lower bound of the confidence interval for ASx, SNA and AIDS and total population in the 
UK: y= x , Where  =slope or gradient of a line, x=HIV population value for that year for that stage of HIV infection  
Formula for calculating the upper bound of the confidence interval for ASx, SNA and AIDS and total population in the 
UK: y=  x  Where  =slope or gradient of a line, x= HIV population value for that year for that stage of HIV infection 
 
These were projected and multiplied by the average annual 2006 cost for each stage of HIV-1 
estimated and respectively for people with asymptomatic, symptomatic non-AIDS and AIDS were: 
£248; £220; and £253 million which collectively gave a total population cost of £721 million for 
2013 when community care cost were not included. When community care costs were accounted 
for, the costs for asymptomatic, symptomatic non-AIDS and AIDS were: £368, £311, and £340 
million or a total of £1,019 million (Table 5.2.13). 
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Table 5.2.13: Method 3 - Total UK Population Cost From NPMS-HHC and Projected 
 
Calen
dar 
year 
Excluding community care costs Including community care costs 
 
ASx 
Sx Non-
AIDS AIDS 
Combined for 
the three HIV-
1 stages 
(asymptomatic, 
symptomatic 
non-AIDS and 
AIDS) ASx 
Sx Non-
AIDS AIDS 
Combined for 
the three HIV-
1 stages 
(asymptomatic, 
symptomatic 
non-AIDS and 
AIDS) 
1997 £22 £39 £43 £104 £41 £61 £63 £165 
1998 £24 £56 £56 £136 £42 £83 £80 £205 
1999 £32 £67 £67 £166 £53 £98 £93 £244 
2000 £37 £68 £79 £184 £62 £102 £112 £276 
2001 £45 £75 £93 £213 £76 £113 £129 £318 
2002 £63 £95 £111 £269 £103 £139 £154 £396 
2003 £79 £110 £130 £319 £128 £157 £177 £462 
2004 £101 £124 £143 £368 £159 £177 £195 £531 
2005 £118 £151 £171 £440 £185 £210 £229 £624 
2006 £162 £146 £176 £484 £240 £206 £237 £683 
2007 £162 £158 £183 £503 £241 £223 £245 £709 
2008 £176 £168 £194 £538 £262 £238 £261 £761 
2009 £191 £178 £206 £575 £283 £252 £277 £812 
2010 £205 £189 £218 £612 £305 £267 £293 £865 
2011 £219 £199 £229 £647 £326 £282 £309 £917 
2012 £234 £209 £241 £684 £347 £296 £324 £967 
2013 £248 £220 £253 £721 £368 £311 £340 £1,019 
Figures in blue (from 2007-2013) are projected 
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5.3 DISCUSSION 
 NOVEL APPROACH 
This study estimated that the direct population cost for treatment and care of HIV-1+ people in the 
UK rose by 4.6 fold between 1997 and 2006, from £104 million to £483 million respectively. The 
number of HIV-1+ people using NHS services during this period tripled from 16,075 to 52,083 HIV-
1+ people: the greatest increase was seen among asymptomatic HIV-1+ people and less so among 
HIV-1+ people with symptomatic non-AIDS or AIDS.  
 
When the annual population costs were projected using three different methods, the estimated 
population costs increased to between £721 million and £758 million by 2013, a 1.5 fold increase 
from the 2006 baseline. The three methods produced similar estimates, with only a 5% difference 
between the lowest and highest estimates. The accuracy of these estimated projected figures of 
HIV-1+ people using NHS services were compared with the actual figures published by HPA for 
2007. In 2007 the projected number of HIV-1+ people was 53,842 compared with 56,211 according 
to the HPA (Aghaizu et al., 2013), an under-estimate of 4%; these were up to maximum of 5% 
underestimated for each of the calendar years 2008, 2009, 2010, 2011 and 2012 reported by HPA 
when compared to the projected estimates for these years as described in Table 5.2.10. 
 
 SUMMARY OF FINDINGS 
An increase in mean annual IP days and DW visits among AIDS patients were observed, while 
number of OP visits declined. Increased use of IP services was also observed among HIV-1+ 
people with symptomatic non-AIDS while asymptomatic HIV-1+ people used more DW services 
over time. These increases in annual cost of treatment and care over time were most pronounced 
for AIDS patients on quadruple-or-more ART. This may be due to these ART-experienced patients 
having to use more IP and DW services, as well as their increased use of new and more expensive 
ARVs in the second half of the study period.  
 
 LIMITATIONS 
The majority of patients were seen in London clinics and increases in annual cost of treatment and 
care over time were most pronounced for AIDS patients on quadruple-or-more ART may have 
skewed our findings, though overall costs did not seem to differ substantially between London and 
non-London centres during the study period (Beck et al., 2008). This analysis is furthermore 
contingent on the fact that most if not all HIV-1+ people using NHS services during the study, were 
diagnosed and reported to the HPA. Examples were described in the methods section of how 
some of the HPA data had to be adjusted because of missing data. 
 
Another potential source of error for estimating the population cost was the extent that HIV- 
services also used generic, non-HIV services to operate. While the unit costs include facility-level 
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overheads, other general costs covered by the NHS, such as its drug procurement system, general 
staff training and other more general non-HIV indirect support, were not included in these 
estimates. However, these points suggest that the estimates produced in this study are likely to 
underestimate the true population cost of delivering HIV services in the NHS. Furthermore in the 
UK HIV-1+ people are entitled to standard care under the NHS and findings from this study are 
applicable to the UK only as the infrastructure of care of HIV-1 patients in the UK differs to those 
from other countries. 
 
 REPORTS FROM OTHER STUDIES 
At the end of 2012 the number of people living with HIV-1 infection in the UK was estimated to be 
98,400, of whom an estimated 22% (credible interval: 18% to 27%) were unaware of being infected 
with HIV-1 (Aghaizu et al., 2013); 6,364 people were newly diagnosed with HIV-1 in 2012, or 5% of 
the estimated 98,400 HIV-1+ people in the UK and 6% of the 76,500 HIV-1+ people reportedly 
using NHS services during 2012. A recent study in the UK, confirmed the benefit for starting ART 
early with CD4 T-cell count <350 cells/µL blood (Beck et al., 2010). The annual cost of treatment 
and care, for those who started ART with a CD4 T-cell count >200 cells/µL blood, is 30-35% less 
than for those who start ART with a CD4 T-cell count  200 cells/µL blood. However, between 
1996 and 2006, of 5,541 HIV-1+ people who started first-line therapy, 55% were diagnosed with a 
CD4 T-cell count  200 cells/µL blood, many of whom were Black Africans (Beck et al., 2010). It is 
likely that many of the HIV-1+ people, who are currently unaware of being infected, may well 
present late in their disease course with a CD4 T-cell count  200 cells/µL blood. Starting more 
HIV-1+ peoples with a CD4 T-cell count <350 cells/µL blood will increase the number of people 
receiving HAART, which will initially add to the financial burden of the NHS. However, starting HIV-
1+ people on cost-effective regimens earlier, will maintain them in better health, resulting in the use 
of fewer health or social services and thereby generating fewer treatment and care costs, while 
enabling them to remain socially and economically active members of society.  
 
 FUTURE WORK 
Increasing population costs for HIV treatment and care are raising serious concerns in high-income 
countries and the equally trivial answer as to where it will end is clearly the obvious limit of a finite 
GDP (Appleby, 2012), especially as many are going through periods of cutting public expenditure 
as a consequence of the global economic downturn. This issue is even more pertinent for middle- 
and lower-income countries. As part of universal access, many of these middle- and lower-income 
countries have been increasing treatment and care services and the number of HIV-1+ people on 
ART reported by WHO in June 2011 had reached 6.6 million HIV-1+ people (World Health 
Organisation, 2011b). While this constitutes a great success, if countries want to continue to 
increase their ART coverage the issue of providing sustainable quality services in the context of 
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limited country resources raises serious questions. Lessons from high-income countries teach us 
that increased coverage is going to result in increased population costs.  
 
The recent change in WHO criteria to start ART when CD4 T-cell count is <350 cells/µL blood 
(World Health Organisation, 2010a) increases the number of HIV-1+ people in need of starting on 
ART, and also raises the ethical issue whether HIV-1+ people with more severe HIV disease 
should receive ART first, or should HIV-1+ people with higher CD4 T-cell counts have preference 
because their treatment and care costs are less than those with higher CD4 T-cell counts? Starting 
ART early is effective in terms of decreasing rates of mortality observed (Severe et al., 2010) and 
cost-effectiveness (Badri et al., 2006) in resource limited settings and if ART is focused on these 
HIV-1+ people, one could argue that there will be more resources available that will enable more 
HIV-1+ people to be receiving ART, while allowing them to remain socially and economically active. 
These are some of the issues, which countries and resource-limited ones in particular, will have to 
face. Furthermore, many low-income countries will need to make these choices with the knowledge 
that many of them, at least for the foreseeable future, will continue to be reliant on donor agencies 
or countries to sustain their treatment and care services (Hecht et al., 2009). 
 
Trying to curtail the costs of service provision is one measure by which one could try and curtail the 
population cost. Measures which are being used range from sending laboratory test results by 
email, home delivery of the drugs to the patient, which is exempted from VAT in the UK, to using 
the most cost-effective regimens (Beck et al., 2010). Even if the costs could be brought down, 
without reducing the quality of services provided, the fact that the number of new people being 
infected with HIV continue to outpace those being put on ART, will continue to drive up population 
cost for HIV services.  
 
Only greater prevention efforts will reduce the number of people becoming infected with HIV. A 
study from the US suggests that even if incidence is reduced, HIV prevalence is likely increase 
creating additional demands for health care services (Hall et al., 2010). While putting HIV-1+ 
people on ART will reduce their infectivity and contribute to reducing the incidence of people newly 
infected with HIV-1 (Montaner et al., 2010), this in itself will not be sufficient to reduce incidence in 
a large number of settings. It is now recognized that in most instances a combination of prevention 
interventions are going to be required to achieve significant reductions in HIV-incidence (Hankins & 
de Zalduondo, 2010).  
 
While recent biomedical interventions are likely to be a cost-effective HIV prevention strategy, such as 
male-circumcision (Kahn et al., 2006), the development of a vaccine (Rerks-Ngarm et al., 2009) 
and microbicides (Baleta, 2010) - constitute important advances, they are most likely to be 
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successful when juxtaposed with relevant behavioural and structural changes (Hankins & de 
Zalduondo, 2010). One of the findings of the Second Independent Evaluation of the UN Joint 
Programme on HIV/AIDS highlighted the relative lack of success of global prevention programmes, 
including in high-income countries, and recommended a greater emphasis on making prevention 
more effective and efficient (Poate et al., 2009). Policy makers and other relevant stakeholders 
need to use evidence-informed HIV prevention, treatment and care strategies to ensure that HIV-1+ 
people have full access to the treatments that they need based on their clinical condition, which will 
prolong life, reduce morbidity, reduce transmission and ultimately deliver the best for both the 
individual and public health agendas. 
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CHAPTER 6: GENERAL DISCUSSION 
The thesis concludes with a general discussion of the novel results highlighted by the use of 
statistical analysis applied in Chapters 3, 4 and 5. 
 
6.1 DISCUSSION 
This chapter reviews some of the empirical findings and limitations from basic, clinical and 
population science research presented respectively in Chapter 3 (LTNP), Chapter 4 (HIV and 
Ageing) and Chapter 5 (Population Cost Study) concerning the effects of HIV-1 infected people 
using the NHS demonstrated by the use of patient level data in these chapters. This chapter 
summarises what has been presented in the preceding five chapters and draws lessons from the 
theoretical and empirical information derived using data management processes which have 
broader relevance for the HIV-1 research and policy implications. 
 
The aims of this PhD thesis were: to describe uses of data management to process data from HIV-
1 specific clinical databases that arise from single and multiple data sources; to identify groups of 
patients who exhibited atypical characteristics of HIV-1 infection described as long-term non-
progressors (LTNP) identified from a large cohort of HIV-1+ people and identify factors that were 
associated with LTNP so that these patients would provide a basis to study in detail 
immunologically in order to help determine the most appropriate prophylactic and therapeutic 
approaches such as immune based therapies; being treated long-term on ART, together with 
ageing, is a complex ‟ageing‟ process involving biological, social and psychological aspects. 
Identification of the interacting effects of age, HIV-1 infection and ART is likely to guide improved 
therapeutic intervention in HIV-1+ people with advancing age; and to provide an estimate of direct 
population cost of treatment and care of HIV-1+ in the UK to help determine budget allocation for 
treatment and care of HIV-1 infected people within the NHS. 
 
Chapter 1 described the rationale for having and setting up databases, the use of data 
management for collecting routine individual patient data, and provided a general introduction to 
HIV-1 infection with reference to its impact both globally and nationally. Chapter 2 described data 
management and statistical methods used to carry out the work in the three successive chapters. 
Chapter 3 (LTNP) looked at local experience of using a database and data management to identify 
HIV-1 patients with HIV-1 atypical characteristics. Chapter 4 (HIV and Ageing) looked the 
synergistic effects of HIV-1 infection, ART and age on one of the non-HIV co-morbidity examined 
(CKD) using local database in order to investigate the synergistic effect of HIV-1 infection, ART 
and ageing. Chapter 5 (Population Cost Study) used data from multi-centre HIV-1 cohort and used 
data management and data analyses to report changing use and cost of HIV services over time 
since the HAART era and estimate trends in direct population cost during the study period when 
data were available and use these trends to estimate direct population costs in the future when 
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data at the time were unavailable. Evaluation of HIV-1 patient data from the NPMS-HHC cohort 
was used to estimate direct HIV-1 population costs during the study period as well as project these 
for subsequent years. When compared to the HPA estimates of people living with HIV-1 using the 
NHS services used to estimate population cost the projected numbers of estimated HIV-1 
diagnosed people who would use the NHS services during 2007, 2008, 2009 and 2010 were 
underestimated by between four and five percent (see Chapter 5: Table 5.2.10). 
 
6.1.1 STATEMENT OF PRINCIPAL FINDINGS 
 BASIC SCIENCE RESEARCH: DATA ANALYSIS PRESENTED IN LONG-TERM NON-
PROGRESSORS CHAPTER 
Chapter 3 used data from the local database to identify HIV-1+ people with atypical characteristics 
of being infected with HIV-1 for long duration without developing symptoms of HIV-1 progression 
described as LTNP. The study presented demonstrated that the number of HIV-1+ people fulfilling 
the criteria used to define LTNP, HIC or long-term stable low CD4+ T-cell counts within the Chelsea 
and Westminster HIV cohort was very small. The caseload of HIV-1+ patients who had attended 
the centre for treatment and care during February 2009 to February 2010 was 6,390, only 13 
(0.20%) subjects fulfilled the criteria which defined them as LTNP. Further only 0.58% of the HIV-
1+ people in the cohort were classified as exhibiting long-term stable low CD4+ T-cell counts and 
0.05% were in addition also able to control their HIV-1 RNA load replication BLD. Further, the work 
from the LTNP study demonstrated that using different criteria to define atypical patient groups 
resulted in different estimates in time until disease progression, before considering functional 
immunology, genetic and virological factors, emphasising the need for standardised use of 
terminology and definitions before more in depth study of these individuals is performed. Detailed 
immunological work is currently under way on LTNP patients who were identified from the work 
carried out during this PhD including those with continued LTNP status and these identified 
patients are being used for detailed immunological study as part of another PhD work. 
 
 CLINICAL SCIENCE RESEARCH: DATA ANALYSIS PRESENTED IN HIV AND AGEING CHAPTER 
Recent studies demonstrated an increased life-expectancy of HIV-1+ people on ART. As life-
expectancy increased, the number of people aged ≥ 50 years with HIV-1 has also increased and 
many were managed with long-term ART. As HIV-1+ people grow older, they are at an increased 
risk of developing non-HIV co-morbidities, some of these are cardiovascular disease, non-AIDS 
related cancers, neurological complications, bone abnormalities, „frailty‟, liver and renal problems 
(Goetz, 2010; Deeks, 2011). Renal function, one of non-HIV co-morbidities, was investigated and 
was presented in Chapter 4. Studies have reported that people diagnosed with HIV-1 infection 
receiving long-term ART are at an increased risk of developing CKD (Levey et al., 2009). Data 
presented in Chapter 4 (HIV and Ageing) described the changing age distribution of an HIV-1+ 
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cohort of patients attending a single centre for HIV care since HAART era commenced. A 
description of renal function changes by age was investigated to establish the synergistic effect of 
HIV-1 infection, increasing age and exposure to most commonly prescribed ARV classes of drugs 
to HIV-1+ people: NRTI; PI; and NNRTI; aswell as those on first-line HAART comprising 
2NRTI+NNRTI; or 2NRTI+boosted PI. The longitudinal analyses presented in Chapter 4, 
comprised both ART naïve and ART experienced patients, and the findings demonstrated that 
renal function based on eGFR in HIV-1+ people deteriorated more with increasing age than 
„healthy‟ older people. ART naïve and HIV-1+ people on first-line ART showed similar reductions in 
eGFR with increasing age well below the creatinine clearance levels observed in uninfected 
people. In addition it reported that although eGFR are frequently reported in publications, 
equations to estimate eGFR have not yet been validated in HIV-1+ people. The similarity in eGFR 
reductions among ART naïve and those on first-line ART suggested that HIV-1 itself impairs renal 
function which may suggest that ART should be started soon after diagnosis to reduce end organ 
damage. As the HIV-1 infected population ages, these conditions may warrant novel therapeutic 
approaches, requiring improved linkage and integration of HIV services with renal services as well 
as services for other co-morbidities. 
 
 POPULATION SCIENCE RESEARCH: DATA ANALYSIS PRESENTED IN POPULATION COST 
ANALYSIS CHAPTER 
Findings described in Chapter 5 of this PhD thesis showed that the number of people accessing 
NHS HIV services increased substantially between 1996-2006 and more people who are HIV-1+ 
are now on triple or quadruple or more ART surviving longer and the relative lack of success of HIV 
preventing programmes, resulting in a rise of UK population costs during the study period for 
providing HIV services. The results presented in Chapter 5 estimated that by end of 2013 over 
78,000 people diagnosed with HIV-1 in the UK will be using the NHS services and the annual cost 
for treatment and care was shown to vary by stage of HIV infection and type of ARV therapy, which 
need to be taken into consideration when resources in the NHS are being allocated and spent. The 
estimated direct annual population cost to treat HIV-1+ people by end of 2013 was estimated to be 
£758 million. The HPA estimates of people living with HIV-1 using the NHS services used to 
estimate population cost during 2007, 2008, 2009, 2010, 2011 and 2012 the projected numbers 
were underestimated by up to maximum of five percent (see Chapter 5: Table 5.2.10) while the 
variations in population cost estimated using three different methods during 2007, 2008, 2009, 
2010, 2011 and 2012 was shown to differ by up to five percent. In the current economic downturn, 
containing and reducing the direct annual costs of HIV-1 treatment and care, without reducing the 
quality of services, remains a challenge for healthcare professionals and commissioners working in 
the field of HIV. Greater efforts are needed in order to reduce the number of people becoming 
newly infected with HIV-1. 
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 SUMMARY OF METHODS USED 
In order to either enhance current knowledge or to generate new knowledge, trends that emerged 
from the data were used to draw inferences. While databases and data warehouses are important 
as they are data repositories used to store large amount of data, data management ( „the 
development, execution and supervision of plans, policies, programs and practices that control, 
protect, deliver and enhance the value of data and information assets‟ (Mosley, 2007)) and 
analyses were used in all three studies presented in Chapters 3, 4 and 5 to help deliver knowledge 
in order to help make informed decisions based on data stored in large databases or data 
warehouse. So all three studies presented in this PhD thesis used data management (see Chapter 
1: Figure 1.1.4) and data mining processes (see Chapter 1: Figure 1.1.9). 
 
 GENERAL LIMITATIONS OF METHODS USED 
Epidemiological research in HIV-1 is complex as it is a multi-factorial and progressive disease 
influenced by biological, psychological, social, environmental, and genetic factors that can present 
significant challenges to patients. Successful management of the disease requires constant 
consultation with specialist HIV healthcare providers. In addition, with the increasing ageing HIV-1+ 
population, consultations with other healthcare specialists are also required for management of 
non-HIV co-morbidities such as the renal disease for instance. When data are linked together that 
come from different sources, corrupted bits of data have often crept into the datasets and after 
these were checked the rule was to treat these as problems and corrupted bits of data were 
removed. With relatively small data, reducing errors and ensuring high quality of data was essential 
since only a relatively small data are collected it was therefore important that these were recorded 
as accurately as possible. In addition, monitoring patients over a long period of follow-up meant 
there was a higher chance that patients being followed up in the cohort would leave the cohort 
either because of death or because they choose to leave the cohort for other reasons. Further, it 
was difficult to establish and measure causal relationships among several risk factors for HIV-1. In 
the UK the HIV-1 infected population is diverse and mobile, making individuals more difficult to 
track especially when they attend other health care centres for care. Caring physician often rely on 
the patient to accurately give details of their HIV-1 care history prior to receiving care at their 
institution. While successful treatment for HIV-1 requires a specialist HIV physician to guide the 
patient with their disease management referring patients to other specialists which may be in a 
specialist centre located elsewhere from their usual HIV-1 care centre. Clinical questions of 
relevance in HIV-1 are mostly always based on treatment strategies which often involve more than 
one treatment change and the development of ARV drug toxicity being the key issue. Patients on a 
long-term follow-up receive ARV therapy according to the protocols and national treatment 
guidelines in place at their HIV-1 care centre at the time of being treated for HIV-1. The cohort of 
patients are followed-up in their own treatment and care centre and the follow-up data are obtained 
from local clinic database or patient case notes therefore data such as renal function markers 
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(eGFR) for instance are measured frequently but may also be measured irregularly as information 
will be recorded as and when a patient attends the clinic. Although data collected on patients from 
one clinic are usually representative of the clinic population from which the data are drawn from. In 
addition, patients within a clinic have a level of adherance to treatment that is consistent within the 
indivudual care centre and therefore the information that is derived reflects what happens in 
practice therefore making it possible to make comparisons by treatments such as the renal function 
outcome by many ARV treatments. The comparisons between treatments is unbiased if the 
treatment groups have the same entry criteria at baseline and are treated similarly during follow-up 
apart from the differences of starting different ARV treatments which may not necessarily be the 
case in routinely collected observational cohort. Patient prognosis may well differ between the 
treatment groups and this may well be the reason why some HIV-1+ patients were treated with one 
ARV combination while others with another ARV combination. For example, patients receiving PI‟s 
as part of their ARV combinations may have been at an advanced stage of HIV as this group may 
well have received early PI drug formulations, were at an advanced stage of HIV with poor 
prognosis while those receiving newer NNRTI‟s as part of ARV combination could have been at a 
less advanced stage of HIV-1 infection and have therefore have improved prognosis. The 
statistical approach taken to minimise these types of biases was by using longitudinal MIXED 
model described in Chapter 2, adjusting for known factors at baseline, however, it is not possible to 
adjust for all residual factors due to unknown and/or unavailable factors. With some of the 
limitations highlighted herein routinely collected cohort data used in this PhD thesis are however 
valuable resource for monitoring the longitudinal changes in incidence of an outcome in a real life 
clinical setting as well as monitoring the use and cost of HIV service provision. 
 
6.1.2 LONGITUDINAL 
 USES OF INDIVIDUAL LEVEL LONGITUDINAL DATA 
In the same individual the longitudinal data collection were repeatedly measured at several 
different time points. The observations over time of each individual are not independent of each 
other, and therefore statistical techniques taking account of longitudinal nature of data described in 
Chapter 2 were applied that took account of correlation of the repeated measurements taken from 
each individual. One of the advantages of longitudinally collected data is that the development of 
an „outcome‟ over time can be studied and described. For instance, data presented in Chapter 4 on 
renal function by age describe how renal function changed with increasing age. 
 
o Why We Need Longitudinal Data 
One of the uses of collecting longitudinal individual health data is for the purpose of improving 
medical records. Managing individual medical needs such as managing chronic conditions like 
HIV-1 infection as described in Chapters 3, 4 and 5. Use of longitudinal data were described for 
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more detailed work such as that described in Chapter 4 (HIV and Ageing with reference to renal 
function changes over time) and Chapter 5 (Population Cost Study with reference to estimating the 
use of HIV services and costs per patient year). With this type of data collected lifestyle 
modification, medication management, patient education, lab results monitoring and adverse 
events can be co-ordinated across different clinical care teams. These type of longitudinally 
collected data provide access to evidence-based information at all points of care. Therefore this 
allows different clinical care teams to support a patient‟s care, encourage treatment adherence and 
allow different clinical team members from nurses, specialist physician to pharmacy to co-ordinate 
patient care. 
 
With the current economic climate with tightened financial resources, efforts within the NHS are to 
curtail costs. Data presented in Chapter 5 showed that the projected population cost of treating 
HIV-1+ individuals in the UK was estimated to increase by 1.5 fold since 2006 to £758 million by 
2013. The types of clinical databases used for such work such as NPMS-HHC cohort presented in 
Chapter 5 (Population Cost Study) are healthcare efforts which have shown that such use, cost 
and outcome data collected longitudinally can help drive clinical improvement to improve and save 
lives and help identify sources where costs can be saved. However, the data used for this work 
included data from HIV specialist individual participating centres who had data collected 
electronically. Those centres who were unable to provide data in an electronic format for various 
reasons, including not having an IT infrastructure to capture electronic medical data to difficulty 
with extracting data from existing databases which held electronic medical records, for these types 
of reasons not all clinics who agreed to participate with the NPMS-HHC could provide data and 
therefore not all clinics who were participating with the NPMS-HHC could be included in the work 
presented. This was one of the limitations of work presented in Chapter 5. Small clinics where 
electronic data capture was unavailable, database to collect specific fields for NPMS-HHC study 
participation was provided and this proved difficult even to a small clinic as capturing all required 
data retrospectively from patient notes was staff time and resource intensive. 
 
6.1.3 DATA MANAGEMENT 
Routinely collected health data of individuals captured electronically can eliminate rework by 
capturing data once at the source and presenting it for reuse as needed downstream. However, 
this approach assumes error free electronic medical record, which may not be achieved in an 
individual health care centre as described in a review by Hogan and Wagner, 1997. This review 
summarised studies evaluating both correctness and completeness and various sources at which 
errors could be introduced (Figure 6.1.1). Using an electronic medical record capture as an 
example, Figure 6.1.1 demonstrates some of the sources where data errors could be introduced. A 
review by Komaroff (Komaroff, 1979) provides a detailed review processes by which different types 
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of medical data are recorded and where different sources of errors may be introduced at each data 
collection stages. 
 
 
Figure 6.1.1: Electronic Medical Record – Some Of The Sources Where Errors Could Be 
Introduced 
Figure adapted from (Hogan & Wagner, 1997) 
 
The electronic health record can only be put in place if the electronic medical records of the various 
different health care stakeholders (both locally and nationally within a country), which include care 
centres such as the UK NHS hospitals, GP‟s, dentists, community based hospices, palliative care 
and others can create and support exchange of electronic information between different health 
care stakeholders.  
 
Problems could also occur in terms of computer hardware and software support. The increased 
resources required in terms of employee time and costs required to train on using the new software 
for routine data entry including how to avoid data loss. In some instances, newly established 
electronic medical records system may generate errors rather than prevent them, especially early 
in the adoption process where such errors could harm the care of a patient and create data gaps. 
Sources of errors include: fragmentation of data; failure to integrate all hospital systems; and 
human to computer interface difficulties in the machine rules. 
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 DATA PRIVACY, CONFIDENTIALITY AND SECURITY 
Privacy protections provide the overall framework within which both confidentiality and security are 
implemented (UNAIDS, 2007). While privacy is related to the way a patient could be identified and 
contacted, confidentiality deals with the identifiable data and who has access to the patient data. 
With increased access to data through electronic medical records at different locations via links to 
databases and data warehouses, there is a potential increased risks to the security of the 
information possibly violating patients confidentiality, security and privacy of health records (House 
Of Commons Health Committee, 2007). However, there needs to be a balance between protection 
of confidentiality and access to information to improve public health care. Connecting for Health is 
an organisation who has the responsibility for NHS operational security, including strong access 
controls and audit systems where data can be exchanged via the N327 network. While the NHS has 
guidance for encryption policy and provides guidance to safeguard confidential information (NHS 
Information Governance, 2013) and despite the fact that the IT specialists continue to work hard to 
prevent security risks, the internet is known to transmit malicious codes too. Malware authors are 
continuously able to learn how to manipulate the loopholes of ever advancing technologies and are 
then able to perform malicious attacks and intrusions. The losses from such intrusions may include 
loss of data confidentiality (unauthorised disclosure), loss of data integrity (unauthorised 
modification), or decreased system functionality. As a result costs incurred due to needing to repair 
the damage which may also include loss of individual productivity. For instance what happens if a 
doctor loses a server connection or is exposed to a computer virus while inputting notes into the 
computer for electronic record keeping? Currently it is unclear whether data held in an electronic 
format are any less safe than the paper based systems they replace. Electronic medical and health 
data confidentiality is important because some diseases such as HIV-1 are stigmatised. At different 
times in history, some people considered HIV-1+ status to be contagious just by touching an 
individual infected and that people who were HIV-1+ were to be avoided. Patients with HIV-1 
infection for instance have to provide information to their physician in order to receive treatment. To 
encourage open and honest exchanges, patients are assured that information about their medical 
records would be kept confidential. The assumption is that society benefits when patients are 
treated because the potential spread of the disease such as HIV-1 and cost of its treatment have 
been kept in check. When breaches in data security happen and become high profile with media 
coverage, this may affect patient-clinician relationship. 
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 N3 network has a variety of end user NHS organisations from GP practices to large hospitals with dedicated IT 
staff. It has gateways to the Internet. A number of approved NHS suppliers are connected to N3. All involved, including 
those who connect to it, have security responsibilities: Description taken from: 
http://n3.nhs.uk/technicalinformation/N3NetworkSecurity.cfm  
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6.1.4 DATBASES AND DATA WAREHOUSES IN THE UK 
 DATABASES 
With ever advancing technology, more and more medical data are now captured in databases. 
Clinical databases hold comprehensive clinical data with restricted access given to registered 
users and individual databases are held at care centre. Some of the types of data that may be held 
on clinical database are described in Chapter 2: Table 2.4.2. One of the main limitations of holding 
individual clinical database it is a standalone database with no link to other sources of patient care. 
For instance if a single database is created to collect specific patient information which excluded 
their inpatient stay, a physician looking at the database would not have electronic access to 
inpatient stay information from that stand alone database and would therefore need to acquire this 
information through other sources such as patient notes. 
 
 DATA WAREHOUSES 
In contrast data warehouses (see Chapter 2: Figure 2.4.1) are repository for data storage and 
extraction from different services. Once stored the data can be extracted using data warehousing 
software such as relational database. 
 
 SINGLE CENTRE DATABASES AND MULTIPLE CENTRE DATA WAREHOUSES - HIV-1 AND 
OTHER SPECIALTIES 
The Healthcare Quality Improvement Partnership (HQIP) was established in April 2008 to promote  
quality in health and social care services in the UK and is led by a consortium of the Academy of 
Medical Royal Colleges, the Royal College of Nursing and National Voices and is contracted by the 
Department of Health in England to deliver outcome focused quality improvement programmes 
structured around collection of clinical data, including clinical audits and registers. From 1st April 
HQIP is reporting to the NHS Commissioning Board rather than the DH. A list of HQIP Directory of 
Clinical Databases and Registers lists projects registered with HQIP in the UK (by February 2012) 
which collect systematic data on procedures, conditions and services in healthcare and contain a 
list of clinical registers, databases and surveillance registers (Table 6.1.1). These are listed under 
the following broad clinical areas and include audits, research and service evaluation databases 
which were mapped (HQIP, 2012). 
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Table 6.1.1: Register of Clinical Databases In The UK 
 
  
Total number of 
Clinical databases 
(local, regional and 
national) 
Number of local 
databases International 
Acute Care 14 3 0 
Blood Transfusion 4 0 0 
Cancer 20 2 0 
Cardiovascular 6 1 0 
Gastro-Intestinal 1 0 0 
Haematology 3 0 0 
Long-term 29
&
 2 1 
Ophthalmology 1 0 0 
Orthopaedic 3 0 0 
Peri-Neonatal & Children 20 0 0 
Trauma 3 0 0 
Other 9 0 1 
Current Audits 6 0 0 
Source of information in Table 6.1.1 is derived from HQIP, 2012 
&
 There are 6 registered HIV-1 infected patients clinical databases in the UK and these are: 
1. HIV and AIDS New Diagnoses Database (HPA) (from 1
st
 April HPA became part of NHS England) 
2. Survey of Prevalent HIV Infections Diagnosed (SOPHID) (HPA) (from 1
st
 April HPA became part of NHS England) 
3. UK Collaborative HIV Cohort Study  
4. UK HIV Drug Resistance Database 
5. UK Register of HIV Seroconverters 
6. National Haemophilia Database (surveillance for HCV, HIV and CJD in this group.)  
 
 HEALTH AND SOCIAL CARE BODIES DATABASES 
The Health and Social Care Information Centre (HSCIC) is a delivery organisation with statutory 
duties which was established on 1 April 2013 as an executive non-departmental public body 
(ENDPB) under the Health and Social Care Act 2012. As an ENDPB, the organisation is 
accountable to the Secretary of State for Health for discharging its functions, duties and powers 
effectively, efficiently and economically. The HSCIC is a data, information and technology resource 
for the health and care system and plays a role in driving better care, better services and better 
outcomes for patients. It is the source of data and information relating to health and care (Table 
6.1.2). It supports the delivery of IT infrastructure, information systems and standards to ensure 
information flows efficiently and securely across the health and social care system to improve 
patient outcomes. National data sets are generated from care records, from any organisation or 
system that captures the base data. They are structured lists of individual data items, which can be 
used to monitor and improve services (http://www.hscic.gov.uk/datasets). The data list is managed 
by the HSCIC (HSCIC, 2013). 
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Table 6.1.2: List of National Data From Health and Social Care Bodies in England 
 
Subject Data Collection and data 
sets 
Comment 
Community 
care 
Community Information Data Set There is currently no national data collection for community care, 
but the community information data set aims to address this by 
providing definitions for a national data set. In common with other 
secondary use data sets, this describes the data which NHS 
funded providers of community services will be required to submit 
to the centre for analysis and reporting. This is a subset of data 
needed for care delivery. 
Maternity and Childrens' Data Set 
Estates and 
facilities 
Hospital Estates and Facilities 
Statistics 
This is a data warehouse containing data on various different 
returns each NHS Trust has to complete, some dating back to 
1999/2000, and covers a great variety of information ranging from 
Estates Information Returns, Fires, Defects and Failures to the 
spend on such things as cleanliness and food in Hospitals. The 
system also allows the NHS to undertake benchmarking within the 
returns to assist in performance management. 
Hospital care KO41a - Hospital and Community 
Health Services Complaints 
There were fifteen million inpatient admissions to NHS hospitals in 
England in 2011. We have a variety of information covering all 
aspects of secondary care which can help you plan, monitor and 
improve services. 
KP90 - Admissions, Changes in 
Status and Detentions under the 
Mental Health Act 
Mental health Mental Health Minimum Data Set 
(MHMDS) 
In 2010/11 over 1.25 million adults accessed NHS services for 
severe or enduring mental health problems. 
Improving Access to 
Psychological Therapies (IAPT) 
Key Performance Indicators Data 
Collection 
Improving Access to 
Psychological Therapies (IAPT) 
Data Set 
Deprivation of Liberty Safeguards 
(DoLS) Data Collection 
Community Mental Health 
Activities Data Collection 
Child and Adolescent Mental 
Health Services Data Set 
Guardianship Collection 
Patient 
experience 
KA34 - Ambulance services Improving patient experience is a key aim for the NHS. By asking, 
monitoring, and acting upon patient feedback, organisations are 
able to make improvements in the areas that patients say matter 
most to them.The Health and Social Care Information Centre 
collects and publishes statistics related to many stages of the 
patient journey, including ambulance services, hospital facilities 
and follow-up services. 
KA41a - Hospital and Community 
Health Services Complaints 
Prescribing Primary Care Trust prescribing 
data (Opens in a new window)  
Prescribing is the most common patient-level intervention in the 
NHS, and covers all sectors of care: primary, hospital, public and 
community health. It is the second highest area of spending in the 
NHS, after staffing costs. 
GP Practice prescribing data 
Practice level prescribing data - 
released under the Transparency 
Agenda 
Primary care SBE515 General Ophthalmic 
Services (GOS): Activities 
As many people's first point of contact with the NHS, around 90 
per cent of patient interaction is with primary care services. In 
addition to GP practices, primary care covers dental practices, 
community pharmacies and high street optometrists. The 
information gives insight into how services are provided. 
KO41b - General Practice 
(including Dental) Complaints  
Public health NHS Stop Smoking Services The choices people make can have a lasting impact on their 
health. Improving patient care isn't just about treating people's 
individual diseases, it also means changing and preventing 
harmful behaviours which can improve and even save people's 
lives. 
KT31 Community Contraceptive 
Services 
KC50 Immunisation Programme 
Sexual and Reproductive Health 
Activity Data set (SRHAD) 
Smoking at Time of Delivery 
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Social care Social Care Collections  We collect and publish a wide range of information on adult social 
care, which you can use to plan, deliver and monitor services. 
Workforce KO41b - General Practice 
(including Dental) Complaints 
1.3 million people make up the NHS workforce, all contributing 
towards the effectiveness of the NHS. 
 KO41a - Hospital and Community 
Health Services Complaints 
National Workforce Data Set 
Health Visitors Minimum Data Set  
Workforce Minimum Data Set 
(wMDS) 
Source of information contained in table: http://www.hscic.gov.uk/datasets (Accessed 21st May 2013) 
 
 ADVANTAGES AND LIMITATIONS OF SINGLE CENTRE DATABASES AND MULTIPLE CENTRE 
DATA WAREHOUSES 
 
o How Are Data Collected 
Data in a data warehouse come from many different sources (Chapter 2: Figure 2.4.1). The 
relationships between different data added in the data warehouse may not necessarily be identified 
however the data field names and data types are usually reconciled. The data warehouses are 
now widely used as they provide a timely information for decision-making. However getting timely 
information in raw data format is not always beneficial as data from a large number of people 
usually in analysed form are beneficial and informative. Once data are integrated from multiple 
sources, this reduces costs to access historical data and therefore improves the turnaround time 
for analysis and reporting; allowing others to easily access and share data. Data held in data 
warehouse have the potential to withstand instances such as fire/flooding, where paper copies of 
patient notes could be ruined however copies of data stored in a data warehouse will remain intact. 
 
o Limitations of Data Collected 
Data represents the lowest raw format of information or knowledge. Large volumes of data 
available in varying complexity, (For example, in a graph, M and F can depict gender or can depict 
Monday and Friday) cannot be processed using standard data processing methods and algorithms 
such data include those that are machine generated data for instance from X-rays and scanning 
devices. One of the limitations of handling large volume of data from data warehouse is the speed 
of data processing. Speed of data processing requires a combination of: hardware, software, 
networking, and storage. Each of these has limitations and, in a combination, these limitations 
affect the speed of processing large data. Some of the limitations observed using routinely 
collected data in specialist HIV clinics are described using basic science, clinical science and 
population cost studies described in the previous three chapters. 
 
It is possible that many more HIV-1+ are LTNP or HIC, but due to the absence of clinical 
manifestations of disease these individuals have not yet attended an HIV-1 testing facility and 
consequently have not been diagnosed as HIV-1+. The criteria of time from HIV-1 seropositive 
diagnosis should also be considered as relatively arbitrary, as the date of first HIV-1+ test result, or 
date of first attendance at an HIV clinic, may not be an accurate representation of the date of 
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infection. Instead, the date of first positive HIV-1 test should be considered a tool for healthcare 
professionals to identify patients exhibiting an unusual course of HIV-1 disease. Data used for this 
work are based on routinely collected observation data and like for other such databases data 
limitations are found such as HIV-1+ patients are lost to follow-up. Another limitation of 
observational data from a single centre is that HIV-1+ patients can also be managed in other 
centres and may receive ARV treatment from other clinical care providers, including private 
practice, which may not be captured in the database of the single centre. This was one of  the 
findings when data were further investigated using a HIV-1 RNA plasma load criteria where 83% or 
79 individuals who were found to have 3 consecutive HIV-1 RNA plasma load <500 spanning at 
least one year were recorded on patient case notes to have received ART while ART history in 
these individuals were not recorded on computerised HIV-1 database. Currently clinicians are 
reliant on patients‟ self reporting of ART treatment history including ART received elsewhere. The 
formation of a national centralised specialist observational database, highlighted by the UK 
governments Information Strategy (Department of Health, 2012) is a likely strategy to overcome 
such limitations in the future. 
 
The eGFR according to the MDRD formula is which employs serum creatinine measurements and 
patients body surface area, age, ethnicity and gender (Levey et al., 2006). However, some 
remaining residual effect of age may remain and some of the changes in renal function observed 
may be due to a persistent age effect. Although the data show a steeper decline in renal function 
markers in „middle-aged‟ adults 40-49 years and adults 50 years or older, the number of patients 
aged 70 years or older were relatively small resulting in greater variations in trends of the renal 
markers observed in these age groups. Furthermore, renal function measurements were taken 
from a diverse group of patients who contributed results at different ages. Ideally one would like to 
prospectively follow-up a defined group of „young‟ HIV-1+ adults as they age, and monitor changes 
over time, but such data would take a long time to collect. Furthermore, ART regimens are also 
likely to change over such long time periods, compounding longitudinal analyses. Creatinine 
clearance values from HIV uninfected people should strictly speaking not be compared with eGFR 
from HIV-1+ people as the creatinine clearance values were not adjusted for body surface area, 
age, ethnicity and gender (Rowe et al., 1976). In the absence of such standardised longitudinal 
data from a „healthy‟ populations, the current comparator including a 20% reduction to adjust for 
any over-estimation (Breyer & Qi, 2010) and provides an insight into the degree of renal 
impairment associated with HIV-1 infection or ART. While eGFRs are less reliable for assessing 
stage 1 and 2 CKD when eGFR is 60 to 90 ml/min per 1.73m2, it does becomes more reliable for 
picking up stage 3 CKD, with eGFR rates between 30 and 59 ml/min per 1.73m2 (Stevens et al., 
2007). A recent meta analyses demonstrated that the MDRD equation to calculate eGFR is not an 
optimal measure for all populations and eGFR ranges calculated using a single equation requires a 
tradeoff at higher or lower values of eGFR ranges (Earley et al., 2012). The eGFR is predicted 
CHAPTER 6 
GENERAL DISCUSSION 
206 
based on the MDRD formula which employs serum creatinine measurements and patients body 
surface area, age, ethnicity and gender (Levey et al., 2006). However, some residual effect of age 
or other contributing factors may remain and influence the changes in renal function observed. In 
addition, the MDRD formula excluded patients with renal failure, though it included patients aged 
18-70 years, but it has not yet been validated in an „elderly‟ or „frail‟ population (Levey et al., 1999). 
Other formulae which has also appeared in the literature to estimate creatinine clearance from a 
single estimate of plasma creatinine without urine collection include the Cockcroft-Gault formula 
(Cockcroft & Gault, 1976). An alternative to the MDRD formula is the Cockcroft-Gault formula 
where the creatinine clearance is predicted from serum creatinine measurements and patients‟ 
age, gender and weight. While some prefer to use this formula (Cockcroft & Gault, 1976), as it is 
considered it to give better estimates of renal function in subjects with well preserved normal renal 
function (Robertshaw et al., 1989), others prefer to use the MDRD formula (Barraclough et al., 
2009). As routinely measured weights were unavailable for the cohort studied, the Cockcroft-Gault 
formula could not be used in this study. 
 
The majority of patients were seen in London clinics and increases in annual cost of treatment and 
care over time were most pronounced for AIDS patients on quadruple-or-more ART may have 
skewed our findings, though overall costs did not seem to differ substantially between London and 
non-London centres during the study period (Beck et al., 2008). This analysis is furthermore 
contingent on the fact that most if not all HIV-1+ people using NHS services during the study, were 
diagnosed and reported to the HPA. Examples were described in the methods section of how 
some of the HPA data had to be adjusted because of missing data. Another potential source of 
error for estimating the population cost was the extent that HIV- services also used generic, non-
HIV services to operate. While the unit costs include facility-level overheads, other general costs 
covered by the NHS, such as its drug procurement system, general staff training and other more 
general non-HIV indirect support, may not have been included in these estimates. However, these 
points suggest that the estimates produced in this study are likely to underestimate the true 
population cost of delivering HIV services in the NHS. Furthermore in the UK HIV-1+ people are 
entitled to standard care under the NHS and findings from this study are applicable to the UK only 
as the infrastructure of care of HIV-1 patients in the UK differs to those from other countries. 
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6.1.5 DEVELOPMENT OF DATABASES AND DATA WAREHOUSES 
 WORLDWIDE 
With the growing information age, many countries worldwide are in the process of implementing 
electronic medical records and electronic health records which is regarded as an opportunity for 
improvement in the public health sector to improve patient care, reduce health care costs and 
change the way medicine is practiced. Some of the countries, where electronic health record 
implementations underway are: Australia, Canada, France, Germany, Japan, The Nordics, Spain 
and the United Kingdom (UK). Internationally, the benefits of improvement in the public health 
sector are driving adoption of electronic health records worldwide despite variations in health care 
systems, market structures and regulatory requirements.  
 
 DENMARK 
Denmark is one of the first countries to have successfully implemented electronic health records 
and is using it for healthcare. eHealth28 is now commonly used in all areas of the Danish health 
service, and today IT supports many work processes (Kierkegaard, 2013).. The country comprises 
5.5 million citizens and by 2006 98% of the Danish 3,500 GPs, the majority of specialists, all 73 
hospitals, all 331 pharmacies and half of the 271 local authorities shared data over the network, 
about 80% of the totally exchanged healthcare information was sent electronically (Edwards, 2006; 
Deutsch et al., 2010). In addition to financial benefits, evidence suggests with the implementation 
of electronic health records, clinical benefits was seen such as improved adherence to care 
guidelines, faster exchange of test results, fewer duplicate procedures and more time for clinicians 
to spend with patients (Edwards, 2006). Some of the lessons learnt with the successful 
implementation are summarised in a monograph by Edwards, 2006 and include: start with basic 
needs then add other things; establish continual monitoring and evaluation process and this must 
include the measurement of improvements in the quality of care; align the incentives of providers; 
payer organisations and vendors; develop an approach to privacy and security that satisfies the 
demands of clinicians and patients, and then implement it consistently; keep an appropriate 
balance between central co-ordination and local leadership and devote plenty of resources to local 
implementation and training to ensure clinician adoption. 
 
 UNITED STATES OF AMERICA 
Unlike relatively small population in Denmark of 5.5 million, the US population is over 57 fold 
higher at 314 million. Like in the UK, in 2008 the US Congress embarked on a $30 billion program 
to encourage doctors throughout the country to adopt electronic health records by 2014. The 
purpose was to create an inter-connected system of electronic health records to improve safety 
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 eHealth means using digital tools and services for health. eHealth covers the interaction between patients and 
health-service providers, institution-to-institution transmission of data, or peer-to-peer communication between patients 
and/or health professionals. Description taken from http://europa.eu/rapid/press-release_MEMO-12-959_en.htm  
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and reduce medical costs. In the US dozens of IT companies competed for contracts most with 
commercial software products developed in secret competed for billions in funds. In the US, 
adaption of electronic health records caused problems. With so many different software products 
used, ensuring different software products were compatible became a challenge, therefore not 
allowing all clinicians to view the same patient's health information. Clinicians and hospitals 
reported many medical injuries and deaths and preventable heart attacks caused by problems 
related to computerised health records such as software errors and unreadable computer screens. 
Some errors resulted in drug doses that were 10 times higher than intended (Soumerai & Avery, 
2010). A recent report (May 2013) in a VentureBeat, which reports tech, money and innovation 
news in the US, reported that more than 50 percent of doctors and 80 percent of hospitals in the 
US have received funding for achieving „meaningful use‟ of digital records (Farr, 2013). The US 
healthcare therefore has a mammoth task and is currently in the process of computerising their 
populations medical records. 
 
6.1.6 LESSONS FOR THE UK 
 UK HEALTH DATA: TECHNICAL IMPLICATIONS FOR DEVELOPMENT OF LOCAL DATABASES 
AND REGIONAL AND NATIONAL DATA WAREHOUSES 
The three main results chapters presented used data stored in databases at individual HIV 
specialist centres both locally and nationally. The need for change requiring access to peoples 
health records is required. One of the reasons for this need is due to chronic nature of HIV-1 aswell 
as the growing ageing HIV-1+ population requiring other specialist service care both within the NHS 
and elsewhere such as use of social care. With more integrated services there is a requirement 
that different specialists have easy access to individual patient health care records quickly and 
efficiently with minimum time delay. As noted in previous sections, aswell as many countries 
worldwide, the UK government has committed to update the NHS IT systems by 2014/15. Once 
the identifiable electronic medical records are linked together into electronic health records these 
potentially could be held securely in an information centre in a national data warehouse repository. 
From there the UK governments commitment to publicly make available anonymised population 
health data from the national data warehouse repository to the individuals aswell as various 
professionals, commissioners, information specialists, researchers and others (see Chapter 1: 
Figure 1.1.5). 
 
 DATA CONFIDENTIALITY AND SECURITY RISK MANAGEMENT - INFORMATION GOVERNANCE 
With the move towards electronic health records, to cover issues of access to these records 
regarding patient confidentiality a number of legislation, standards and guidance has been 
produced in the UK, in order to cover Information Governance29. The Health and Social Care Act 
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 Information governance is the term used to describe he structures, policies and practice of the DH, the NHS 
and its suppliers to ensure the confidentiality and security of all records, and especially patient records, and to enable the 
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2008 established the National Information Governance Board for Health and Social Care (NIGB) 
as the body with statutory duty to oversee information governance. One of its functions was to 
allow the common law duty of confidentiality to be set aside in specific circumstances.  However, 
with the changes that took effect within the NHS from 1st April 2013 (see Chapter 1: section 1.1 
NHS England from April 2013), the NIGB's functions for monitoring and improving information 
governance practice was transferred to the Care Quality Commission30, which is currently (June 
2013) establishing a National Information Governance Committee to oversee this information 
governance work. 
 
 CHALLENGES OF ANALYSING ‘BIG DATA’ 
Research to date has been driven by hypotheses which are validated by collecting and analysing 
data on a „small‟ scale. In the future the availability of „big data‟ (for further details see Chapter 1: 
section 1.1) with large sample sizes will include structured as well as unstructured data. Some of 
the challenges of „big data‟ will include: (i) unstructured data will include accumulation or errors and 
spurious correlations; (ii) unstructured data plus large sample size will require heavy use of 
computing and will likely incur higher costs as a result. In addition, processing very large datasets 
may create instability of algorithms used to process the data; (iii) a very large sample size will be 
as a result of amalgamated data from multiple sources at different time points using different 
technologies. This will create issues of heterogeneity, experimental variations, and statistical 
biases, and thus will require developing statistical methods that are robust to complex data. Some 
of the problems that „big data‟ will introduce are: 1) by having so much unstructured and structured 
data spurious correlations will be found between outcomes and unrelated covariates, therefore 
caution will be required since as the number of data points and spurious variables increase, 
spurious correlations are also more likely to be observed which may lead to wrong statistical 
inference and false scientific conclusions (Fan et al., 2012). In particular, Fan and colleagues (Fan 
et al., 2012)) showed that when there are many spurious variables, 2 (variance) is 
underestimated, which leads further to wrong statistical inferences including model selection or 
significance tests, and false scientific conclusions; 2) unstructured data gives rise to endogeneity. 
The term „endogeneity‟ (Engle et al., 1983) means that some predictors in linear regression will be 
correlated with the residuals. Endogeneity happens as a result of selection biases, measurement 
errors, and omitted variables. In linear regression analysis, assumption is that the residuals are 
uncorrelated with all the predictors which is important for validity of the model. As the true model is 
unknown, many variables are collected that are potentially associated to the outcome, and include 
all variables that are collected in linear regression model in the data collection stage. Some of 
those collected variables may be correlated with the residuals which would violate one of the linear 
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regression model assumption. Greater the number of covariates that are collected, the validity of 
the linear regression assumption is violated (that the residuals are uncorrelated with all the 
predictors). The endogeneity therefore creates statistical biases and causes model selection 
inconsistency that lead to wrong scientific conclusions; 3) „big data‟ are created via aggregating 
many datasets from multiple and different sub-populations. Each sub-population may exhibit some 
features not shared by others. A very large sample size will allow hidden patterns associated with 
small sub-populations to be found. At the moment in the setting of „small data‟, data categorised as 
outliers are hard to model due to small number of observations where outliers are observed. In the 
„big data‟ era, the large sample size will allow to better understand these types of heterogeneous 
data, potentially shedding light such as exploring the association between certain covariates and 
rare outcomes (e.g., rare diseases or diseases in small populations) and will allow better 
understanding why certain treatments benefit a sub-population and harm another sub-population.  
 
6.2 SUMMARY 
The electronic data generated for each patient by doctors, nurses, lab technicians, emergency 
personnel, medical devices within a hospital, or care given at different institutions such as GP, 
social care, dentists through the use of data integration techniques and algorithms, will be collected 
and processed electronically to gain mathematical or statistical insights. These insights will provide 
useful information that will help improve quality of care for a given set of diseases. 
 
In the UK there are many clinical databases that exist and a handful of these are currently 
registered including multiple clinical database registries for one specialty (Table 6.1.1). With each 
cohort working independently, it is probable that there is repetition of similar work between cohorts. 
This is an area of likely waste of resources and clinical data base set up would be better if there 
were individual specialist databases in the UK that were co-ordinated by one organisation and 
regulated so that such repetition of work and wasted resources could be minimised. A single 
database of cancer patients is currently being set up by Public Health England which will deliver 
„real-time‟ cancer data containing detailed clinical information of 11 million historical cancer records 
going back 30 years (12th June 201331). These types of specialist databases are also required for 
other clinical specialties that manage chronic conditions. 
 
The availability of large volume of data from databases and data warehouses when linked with 
other data via data integration as „big data‟32 increases the value of data (Manyika et al., 2011). 
However, there is likely to be data management and data analysis challenges in terms of the size 
of the „big data‟. The volume, the velocity, the variety, and the veracity (Marr, 2013). The 
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information extracted from databases and data warehouses may not necessarily be in a format 
ready for analysis. For example, electronic health records, comprising data from different data 
sources, image data such as x-rays, multi-media data such as video. Data in these formats cannot 
be readily analysed and therefore these types of data will need data extraction processes 
developed that pull out the required information from the data sources and transform these in a 
format that could then be used for statistical analysis. 
 
Using all types of available data is becoming feasible as „big data‟. Allowing for imprecision in such 
data may be a positive feature and used as a trade-off although in many situations in medicine 
accuracy will continue to matter even with „big data‟. Where imprecision trade off with „big data‟ is 
used for instance, in return for relaxing the standards of allowable errors, it would be possible to 
get hold of much more data. By allowing for some imprecision with „big data‟, it is likely to open a 
window into previously untapped data which may provide greater insights and rigorous accuracy is 
likely to become less important than getting a grasp of what the data shows over time using 
previously unused data. 
 
 
Data analysis, data retrieval, and modeling are other challenges. With „big data‟ available future IT 
requirements will need to take this into consideration as powerful IT resources will be required for 
storage and processing of „big data‟ for data analysis and longitudinal statistical modeling which 
are often computer intensive. Furthermore, there are many possible sources of error: computer 
systems and programs to integrate data may have bugs, and the results derived could be based on 
erroneous data. Results derived will need to be verified by developing algorithms to check the 
validity of data which is likely to be a challenge due to volume and complexity of data and 
processes will need to be developed and worked on by data management team of personnel. 
 
In recent years, security has become important and the goal of database security is the protection 
of data from accidental or intentional threats to its integrity and access. Confidential and sensitive 
data (such as HIV-1 infected patient data) should be stored in a separate data warehouse where 
only authorised users are able to get access. The conventional method for securing computer 
systems is by use of firewalls, authentication mechanisms, and Virtual Private Networks (VPN) that 
create a protective „shield‟ around them. However, such security will have inevitable vulnerabilities 
and they do not always provide full security as new attacks are continually being adapted to exploit 
computer system weaknesses. So systems that hold clinical data as „big data‟ will need to be 
continuously monitored on an ongoing basis from such unauthorised attacks.  
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APPENDIX 
A 4.1 FIGURES SHOWING DISTRIBUTION OF IMMUNOLOGICAL PARAMETERS BY AGE AND COHORT STRATA 
 
Figure A4.1.1: Distribution CD3 T-Cell Count by Age at Time of Result by Cohort Strata 
Patients who attended for HIV care 
1988 – May 2011 
N=11,699 
Excluded subjects for whom no CD3 cell count available 
Patients who attended for HIV care 
1988 – 1995 only  
N=1,228 
Excluded subjects for whom no CD3 cell count available 
  
 
 Total=11,699 
n 
 
Median (IQR) 
 
p-value 
 Total=1,228 
 
n 
 
Median (IQR) 
 
p-value 
Age 
18-20 
21-30 
31-40 
41-50 
51-60 
61-70 
71-80 
81-90 
 
21 
1427 
4058 
4021 
1615 
457 
96 
4 
 
1586(1274 to 1880) 
1372(961 to 1791) 
1310(892 to 1721) 
1370(978 to 1798) 
1392(958 to 1818) 
1334(980 to 1742) 
1373(961 to 1743) 
1890(1135 to 2397) 
 
<0.001 
Age 
18-20 
21-30 
31-40 
41-50 
51-60 
61-70 
71-80 
81-90 
 
- 
169 
511 
318 
108 
21 
1 
- 
 
- 
426(216 to 728) 
385(181 to 729) 
393(215 to 737) 
444(229 to 869) 
750(181 to 1230) 
340 
- 
 
0.342 
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Patients who attended for HIV care 
pre HAART and post HAART 
N=3,092 
Excluded subjects for whom no CD3 cell count available 
Patients who attended for HIV care 
post HAART only 
N=7,479 
Excluded subjects for whom no CD3 cell count available 
  
 Total=3,092 
n 
 
Median (IQR) 
 
p-value 
 Total=7,479 
n 
 
Median (IQR) 
 
p-value 
Age 
18-20 
21-30 
31-40 
41-50 
51-60 
61-70 
71-80 
81-90 
 
2 
148 
734 
1231 
719 
210 
46 
2 
 
1120,1988 
1313(831 to 1820) 
1236(781 to 1666) 
1432(1036 to 1882) 
1460(1028 to 1932) 
1369(1030 to 1703) 
1273(852 to 1864) 
2240,2254 
 
<0.001 
Age 
18-20 
21-30 
31-40 
41-50 
51-60 
61-70 
71-80 
81-90 
 
19 
1110 
2813 
2472 
788 
226 
49 
2 
 
1586(1274 to 1880) 
1448(1124 to 1842) 
1426(1089 to 1804) 
1425(1082 to 1806) 
1405(1018 to 1765) 
1339(990 to 1776) 
1440(1216 to 1742) 
729,1540 
 
0.033 
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Figure A4.1.2: Distribution %CD3 T-Cell Count by Age at Time of Result by Cohort Strata 
 
Patients who attended for HIV care 
1988 – May 2011 
N=11,766 
 
Excluded subjects for whom no %CD3 cell count available 
Patients who attended for HIV care 
1988 – 1995 only 
N=1,156 
 
Excluded subjects for whom no %CD3 T-cell count available 
 
 
 
 Total=11,766 
n 
 
Median (IQR) 
 
p-value 
 Total=1,156 
n 
 
Median (IQR) 
 
p-value 
Age 
18-20 
21-30 
31-40 
41-50 
51-60 
61-70 
71-80 
81-90 
 
21 
1438 
4075 
4043 
1625 
463 
97 
4 
 
82(73 to 88) 
81(74 to 86) 
80(73 to 85) 
78(71 to 84) 
77(71 to 83) 
76(68 to 83) 
74(66 to 81) 
83(81 to 89) 
 
<0.001 
Age 
18-20 
21-30 
31-40 
41-50 
51-60 
61-70 
71-80 
81-90 
 
- 
178 
521 
321 
112 
23 
1 
- 
 
- 
73(60 to 82) 
72(58 to 83) 
72(57 to 82) 
73(59 to 84) 
67(54 to 84) 
85 
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0.855 
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Patients who attended for HIV care 
pre HAART and post HAART 
N=3,109 
Excluded subjects for whom no %CD3 cell count available 
Patients who attended for HIV care 
post HAART only 
N=7,501 
Excluded subjects for whom no %CD3 cell count available 
  
 Total=3,109 
n 
 
Median (IQR) 
 
p-value 
 Total=7,501 
n 
 
Median (IQR) 
 
p-value 
Age 
18-20 
21-30 
31-40 
41-50 
51-60 
61-70 
71-80 
81-90 
 
2 
148 
736 
1240 
723 
212 
46 
2 
 
72(71 to 73) 
83(77 to 88) 
80(73 to 86) 
79(73 to 84) 
77(71 to 83) 
76(67 to 82) 
74(70 to 83) 
82,93 
 
<0.001 
Age 
18-20 
21-30 
31-40 
41-50 
51-60 
61-70 
71-80 
81-90 
 
19 
1112 
2818 
2482 
790 
228 
50 
2 
 
82(75 to 88) 
81(76 to 86) 
80(74 to 85) 
78(71 to 83) 
77(72 to 83) 
77(69 to 83) 
74(66 to 79) 
79,84 
 
<0.001 
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Figure A4.1.3: Distribution Nadir CD4 T-Cell Count by Age at Time of Result by Cohort Strata 
 
Patients who attended for HIV care 
1988 – May 2011 
N=13,813 
 
Excluded subjects for whom no nadir CD4 T- cell count available 
Patients who attended for HIV care 
1988 – 1995 only 
N=2,750 
 
Excluded subjects for whom no nadir CD4 T-cell count available 
 
 
 
 Total=13,813 
n 
 
Median (IQR) 
 
p-value 
 Total=2,750 
n 
 
Median (IQR) 
 
p-value 
Age 
18-20 
21-30 
31-40 
41-50 
51-60 
61-70 
71-80 
81-90 
 
55 
2753 
6115 
3622 
992 
244 
31 
1 
 
266(120 to 467) 
251(104 to 406) 
175(47 to 311) 
155(40 to 291) 
155(40 to 291) 
154(49 to 277) 
192(60 to 267) 
137 
 
<0.001 
Age 
18-20 
21-30 
31-40 
41-50 
51-60 
61-70 
71-80 
81-90 
 
5 
682 
1170 
673 
183 
36 
1 
- 
 
79(9 to 190) 
150(13 to 378) 
25(6 to 154) 
18(6 to 88) 
20(8 to 60) 
15(6 to 54) 
4 
- 
 
<0.001 
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Patients who attended for HIV care 
pre HAART and post HAART 
N=3,445 
Excluded subjects for whom no nadir CD4 T- cell count available 
Patients who attended for HIV care 
post HAART only 
N=7,618 
Excluded subjects for whom no nadir CD4 T- cell count available 
  
 Total=3,445 
n 
 
Median (IQR) 
 
p-value 
 Total=7,618 
n 
 
Median (IQR) 
 
p-value 
Age 
18-20 
21-30 
31-40 
41-50 
51-60 
61-70 
71-80 
81-90 
 
3 
447 
1570 
1030 
322 
65 
8 
- 
 
281(272 to 532) 
186(48 to 330) 
126(32 to 238) 
120(35 to 206) 
111(35 to 198) 
107(58 to 175) 
208(161 to 261) 
- 
 
<0.001 
Age 
18-20 
21-30 
31-40 
41-50 
51-60 
61-70 
71-80 
81-90 
 
47 
1624 
3375 
1919 
487 
143 
22 
1 
 
266(123 to 467) 
287(176 to 433) 
235(128 to 370) 
220(120 to 369) 
204(92 to 340) 
194(97 to 325) 
188(60 to 280) 
137 
 
<0.001 
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Figure A4.1.4: Distribution CD4 T-Cell Count by Age at Time of Result by Cohort Strata 
 
Patients who attended for HIV care 
1988 – May 2011 
N=13,813 
 
Excluded subjects for whom no CD4 T- cell count available 
Patients who attended for HIV care 
1988 – 1995 only 
N=2,750 
 
Excluded subjects for whom no CD4 T-cell count available 
  
 
 Total=13,813 
n 
 
Median (IQR) 
 
p-value 
 Total=2,750 
n 
 
Median (IQR) 
 
p-value 
Age 
18-20 
21-30 
31-40 
41-50 
51-60 
61-70 
71-80 
81-90 
 
27 
1997 
4976 
4493 
1737 
480 
99 
4 
 
465(305 to 568) 
406(214 to 574) 
380(110 to 579) 
455(232 to 661) 
465(244 to 671) 
459(283 to 635) 
480(293 to 647) 
571(389 to 614) 
 
<0.001 
Age 
18-20 
21-30 
31-40 
41-50 
51-60 
61-70 
71-80 
81-90 
 
4 
636 
1197 
681 
194 
37 
1 
- 
 
128(13 to 395) 
186(17 to 433) 
30(8 to 198) 
24(8 to 120) 
24(9 to 75) 
32(8 to 72) 
4 
- 
 
<0.001 
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Patients who attended for HIV care 
pre HAART and since HAART 
N=3,445 
Excluded subjects for whom no CD4 T- cell count available 
Patients who attended for HIV care 
since HAART only 
N=7,618 
Excluded subjects for whom no CD4 T- cell count available 
  
 Total=3,445 
n 
 
Median (IQR) 
 
p-value 
 Total=7,618 
n 
 
Median (IQR) 
 
p-value 
Age 
18-20 
21-30 
31-40 
41-50 
51-60 
61-70 
71-80 
81-90 
 
2 
224 
912 
1299 
746 
213 
47 
2 
 
419(305 to 532) 
338(153 to 512) 
288(69 to 508) 
468(258 to 696) 
494(297 to 716) 
481(319 to 616) 
429(282 to 654) 
557,585 
 
<0.001 
Age 
18-20 
21-30 
31-40 
41-50 
51-60 
61-70 
71-80 
81-90 
 
21 
1137 
2867 
2513 
797 
230 
51 
2 
 
483(352 to 613) 
480(349 to 634) 
488(349 to 656) 
516(365 to 696) 
506(346 to 683) 
479(315 to 693) 
505(362 to 647) 
221,643 
 
<0.001 
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Figure A4.1.5: Distribution %CD4 T-Cell Count by Age at Time of Result by Cohort Strata 
 
Patients who attended for HIV care 
1988 – May 2011 
N=13,541 
 
Excluded subjects for whom no %CD4 cell count available 
Patients who attended for HIV care 
1988 – 1995 only 
N=2,559 
 
Excluded subjects for whom no %CD4 T-cell count available 
  
 
 Total=13,541 
n 
 
Median (IQR) 
 
p-value 
 Total=2,559 
n 
 
Median (IQR) 
 
p-value 
Age 
18-20 
21-30 
31-40 
41-50 
51-60 
61-70 
71-80 
81-90 
 
25 
1922 
4855 
4429 
1728 
479 
99 
4 
 
22(19 to 27) 
23(15 to 31) 
23(10 to 31) 
23(10 to 31) 
26(16 to 33) 
26(18 to 32) 
25(20 to 32) 
24(21 to 31) 
 
<0.001 
Age 
18-20 
21-30 
31-40 
41-50 
51-60 
61-70 
71-80 
81-90 
 
3 
576 
1118 
635 
190 
36 
1 
- 
 
16(2 to 22) 
13(3 to 23) 
4(2 to 13) 
4(1 to 10) 
4(2 to 8) 
4(2 to 6) 
1 
- 
 
<0.001 
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Patients who attended for HIV care 
pre HAART and since HAART 
N=3,393 
Excluded subjects for whom no %CD4 cell count available 
Patients who attended for HIV care 
since HAART only 
N=7,589 
Excluded subjects for whom no %CD4 cell count available 
  
 Total=3,393 
n 
 
Median (IQR) 
 
p-value 
 Total=7,589 
n 
 
Median (IQR) 
 
p-value 
Age 
18-20 
21-30 
31-40 
41-50 
51-60 
61-70 
71-80 
81-90 
 
2 
214 
882 
1290 
743 
213 
47 
2 
 
19,19 
21(13 to 27) 
18(8 to 27) 
26(17 to 34) 
27(18 to 34) 
25(19 to 32) 
25(20 to 36) 
19,23 
 
<0.001 
Age 
18-20 
21-30 
31-40 
41-50 
51-60 
61-70 
71-80 
81-90 
 
20 
1132 
2855 
2504 
795 
230 
51 
2 
 
24(21 to 28) 
27(21 to 33) 
28(21 to 34) 
29(22 to 35) 
28(21 to 35) 
28(20 to 34) 
25(19 to 30) 
25,37 
 
<0.001 
  
0
25
50
75
100
0 10 20 30 40 50 60 70 80 90M
o
s
t 
re
c
e
n
t 
%
C
D
4
 T
-c
e
ll
 c
o
u
n
t 
(c
e
ll
s
/µ
l 
b
lo
o
d
)
Age group (years) at the time of recent %CD4 T-cell count 
result
Cohort who attended pre and post HAART
Recent %CD4 T-cell count by age at time of 
result
0
25
50
75
100
0 10 20 30 40 50 60 70 80 90M
o
s
t 
re
c
e
n
t 
%
C
D
4
 T
-c
e
ll
 c
o
u
n
t 
(c
e
ll
s
/µ
l 
b
lo
o
d
)
Age group (years) at the time of recent %CD4 T-cell count 
result
1st Jan 1996-May 2011
Recent %CD4 T-cell count by age at time of 
result
APPENDIX 
239 
Figure A4.1.6: Distribution CD8 T-Cell Count by Age at Time of Result by Cohort Strata 
 
Patients who attended for HIV care 
1988 – May 2011 
N=13,278 
 
Excluded subjects for whom no CD8 T-cell count available 
Patients who attended for HIV care 
1988 – 1995 only 
N=2369 
 
Excluded subjects for whom no CD8 T-cell count available 
  
 Total=13,278 
 
n 
 
Median (IQR) 
 
p-value 
 Total=2,370 
 
n 
 
Median (IQR) 
 
p-value 
Age 
18-20 
21-30 
31-40 
41-50 
51-60 
61-70 
71-80 
81-90 
 
24 
1826 
4771 
4371 
1710 
476 
97 
4 
 
1043(820 to 1274) 
847(569 to 1149) 
772(502 to 1088) 
787(536 to 1104) 
801(544 to 1130) 
804(557 to 1164) 
859(522 to 1158) 
1201(662 to 1710) 
 
<0.001 
Age 
18-20 
21-30 
31-40 
41-50 
51-60 
61-70 
71-80 
81-90 
 
3 
502 
1057 
595 
178 
34 
1 
- 
 
1020(352 to 1575) 
713(360 to 1099) 
511(224 to 922) 
457(234 to 853) 
460(256 to 782) 
745(348 to 1156) 
268 
- 
 
<0.001 
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Patients who attended for HIV care 
pre HAART and since HAART 
N=3,404 
Patients who attended for HIV care 
since HAART only 
N=7,505 
  
 Total=3,404 
n 
 
Median (IQR) 
 
p-value 
 Total=7,505 
n 
 
Median (IQR) 
 
p-value 
Age 
18-20 
21-30 
31-40 
41-50 
51-60 
61-70 
71-80 
81-90 
 
2 
211 
895 
1293 
741 
214 
46 
2 
 
1077(866 to 1288) 
877(544 to 1178) 
780(474 to 1102) 
815(565 to 1186) 
852(587 to 1193) 
825(573 to 1167) 
723(477 to 1126) 
1555,1865 
 
0.002 
Age 
18-20 
21-30 
31-40 
41-50 
51-60 
61-70 
71-80 
81-90 
 
19 
1113 
2819 
2483 
791 
228 
50 
2 
 
1046(773 to 1260) 
878(640 to 1163) 
837(604 to 1124) 
824(587 to 1110) 
822(580 to 1109) 
802(557 to 1162) 
923(645 to 1192) 
478, 846 
 
0.001 
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Figure A4.1.7: Distribution %CD8 T-Cell Count by Age at Time of Result by Cohort Strata 
 
Patients who attended for HIV care 
1988 – May 2011 
N=13,316 
 
Excluded subjects for whom no %CD8 cell count available 
Patients who attended for HIV care 
1988 – 1995 only 
N=2,422 
 
Excluded subjects for whom no %CD8 T-cell count available 
  
 
 Total=13,316 
n 
 
Median (IQR) 
 
p-value 
 Total=2,422 
n 
 
Median (IQR) 
 
p-value 
Age 
18-20 
21-30 
31-40 
41-50 
51-60 
61-70 
71-80 
81-90 
 
24 
1846 
4778 
4379 
1710 
478 
97 
4 
 
52(46 to 60) 
53(45 to 63) 
52(42 to 63) 
48(39 to 59) 
48(39 to 59) 
47(39 to 58) 
47(36 to 55) 
57(51 to 62) 
 
<0.001 
Age 
18-20 
21-30 
31-40 
41-50 
51-60 
61-70 
71-80 
81-90 
 
3 
522 
1073 
606 
181 
36 
1 
- 
 
63(44 to 68) 
61(51 to 69) 
64(53 to 73) 
65(54 to 75) 
68(57 to 76) 
66(56 to 71) 
67 
- 
 
<0.001 
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Patients who attended for HIV care 
pre HAART and since HAART 
N=3,399 
Excluded subjects for whom no %CD8 cell count available 
Patients who attended for HIV care 
since HAART only 
N=7,495 
Excluded subjects for whom no %CD8 cell count available 
  
 Total=3,399 
n 
 
Median (IQR) 
 
p-value 
 Total=7,495 
n 
 
Median (IQR) 
 
p-value 
Age 
18-20 
21-30 
31-40 
41-50 
51-60 
61-70 
71-80 
81-90 
 
2 
212 
891 
1292 
740 
214 
46 
2 
 
46,54 
56(49 to 64) 
55(45 to 66) 
48(40 to 59) 
47(38 to 58) 
46(36 to 56) 
47(35 to 56) 
60,65 
 
<0.001 
Age 
18-20 
21-30 
31-40 
41-50 
51-60 
61-70 
71-80 
81-90 
 
19 
1112 
2814 
2481 
789 
228 
50 
2 
 
52(46 to 60) 
50(42 to 58) 
48(40 to 57) 
46(38 to 54) 
46(38 to 55) 
47(39 to 55) 
47(39 to 53) 
48,55 
 
<0.001 
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Figure A4.1.8: Distribution CD19 B-Cell Count by Age at Time of Result by Cohort Strata 
 
Patients who attended for HIV care 
1988 – May 2011 
N=10,557 
 
Excluded subjects for whom no CD19 T-cell count available 
Patients who attended for HIV care 
1988 – 1995 only 
N=0 
 
Excluded subjects for whom no CD19 T-cell count available 
 
 
 
CD19 not available pre HAART 
 Total=10,557 
n 
 
Median (IQR) 
 
p-value 
 Total=0 
 
n 
 
Median (IQR) 
 
p-value 
Age 
18-20 
21-30 
31-40 
41-50 
51-60 
61-70 
71-80 
81-90 
 
20 
1256 
3526 
3709 
1506 
440 
96 
4 
 
175(98 to 271) 
160(103 to 228) 
168(109 to 252) 
194(126 to 292) 
190(119 to 301) 
173(104 to 274) 
137(81 to 254) 
83(53 to 162) 
 
<0.001 
Age 
18-20 
21-30 
31-40 
41-50 
51-60 
61-70 
71-80 
81-90 
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Patients who attended for HIV care 
pre HAART and since HAART 
N=3,063 
Patients who attended for HIV care 
since HAART only 
N=7,494 
  
 Total=3,063 
n 
 
Median (IQR) 
 
p-value 
 Total=7,494 
n 
 
Median (IQR) 
 
p-value 
Age 
18-20 
21-30 
31-40 
41-50 
51-60 
61-70 
71-80 
81-90 
 
1 
144 
713 
1228 
717 
212 
46 
2 
 
756 
144(86 to 224) 
151(84 to 250) 
195(120 to 304) 
207(117 to 312) 
186(114 to 277) 
138(86 to 245) 
71,229 
 
<0.001 
Age 
18-20 
21-30 
31-40 
41-50 
51-60 
61-70 
71-80 
81-90 
 
19 
1112 
2813 
2481 
789 
228 
50 
2 
 
143(96 to 262) 
161(106 to 229) 
170(114 to 253) 
194(128 to 288) 
182(121 to 285) 
154(97 to 267) 
137(79 to 258) 
35,95 
 
<0.001 
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Figure A4.1.9: Distribution CD56 NK Cell Count by Age at Time of Result by Cohort Strata 
 
Patients who attended for HIV care 
1988 – May 2011 
N=9,524 
CD56 NK cell count results available since 1997 
Excluded subjects for whom no NK cell count available 
Patients who attended for HIV care 
1988 – 1995 only 
N=0 
 
Excluded subjects for whom no CD19 T-cell count available 
 
 
CD56 NK cell count not available pre HAART 
 Total=9,524 
n 
 
Median (IQR) 
 
p-value 
 Total=0 
 
n 
 
Median (IQR) 
 
p-value 
Age 
18-20 
21-30 
31-40 
41-50 
51-60 
61-70 
71-80 
81-90 
 
22 
1048 
3177 
3456 
1335 
393 
89 
4 
 
73(44 to 122) 
97(55 to 165) 
97(54 to 170) 
116(65 to 193) 
138(77 to 222) 
157(91 to 266) 
197(113 to 319) 
107(61 to 171) 
 
<0.001 
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Patients who attended for HIV care 
pre HAART and since HAART 
n=2,808 
CD56 NK cell count results available since 1997 
Patients who attended for HIV care 
since HAART only 
N=6,716 
CD56 NK cell count results available since 1997 
  
 Total=2,808 
n 
 
Median (IQR) 
 
p-value 
 Total=6,716 
n 
 
Median (IQR) 
 
p-value 
Age 
18-20 
21-30 
31-40 
41-50 
51-60 
61-70 
71-80 
81-90 
 
- 
99 
621 
1201 
647 
195 
43 
2 
 
- 
92(56 to 144) 
91(47 to 160) 
114(60 to 188) 
144(80 to 230) 
175(104 to 299) 
193(106 to 305) 
49,141 
 
<0.001 
Age 
18-20 
21-30 
31-40 
41-50 
51-60 
61-70 
71-80 
81-90 
 
22 
949 
2556 
2255 
688 
198 
46 
2 
 
73(44 to 122) 
98(55 to 166) 
98(56 to 171) 
117(67 to 195) 
133(74 to 213) 
146(81 to 233) 
216(123 to 426) 
73,201 
 
<0.001 
 
 
 
 
0
500
1000
1500
2000
2500
0 10 20 30 40 50 60 70 80 90
R
e
c
e
n
t 
C
D
5
6
 N
K
 c
e
ll
 c
o
u
n
t 
(c
e
ll
s
/µ
l 
b
lo
o
d
)
Age group (years) at the time of recent  CD56 NK cell count 
result
Cohort who attended pre and post HAART
Recent CD56 NK cell count by age at time of 
result
0
250
500
750
1000
1250
0 10 20 30 40 50 60 70 80 90M
o
s
t 
re
c
e
n
t 
C
D
5
6
 N
K
 c
e
ll
 c
o
u
n
t 
(c
e
ll
s
/µ
l 
b
lo
o
d
)
Age group (years) at the time of recent CD56 NK cell count 
result
1st Jan 1996-May 2011
Recent CD56 NK cell count by age at time of 
result
APPENDIX 
247 
A 5.1 NPMS-HHC: LIST OF REQUIRED FIELDS 
 
 
 
 
 
 
 
 
 
 
 
NPMS-HHC 
 
 
 
 
List of Variables  
to be collected for NPMS-HHC 
 on the use, cost and outcome  
of HIV service provision in U.K hospitals 
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NOTES 
 
If any of our variables have a different format or use different codes from the ones that you use, we 
will write a program to convert them to the format we require. We ask that you include with your 
data a list of formats or codes that you have used. 
 
Please include in each file: 
 
 SOUNDEX 
 
 DATE OF BIRTH 
 
 GENDER 
 
 A UNIQUE IDENTIFIER YOU USE OR ONE THAT IS CONSISTENT THROUGH ALL FILES. 
This should not be patient identifiable that is used in the clinic/hospital. For example do 
not provide hospital ID number. 
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Demographic File 
 
REQUIRED FIELD  
NOTES 
 
SOUNDEX SOUNDEX coding program, J Nash 11/07/87 
version 2 based on Surname 
DATE OF BIRTH DD/MM/YY e.g. 12/03/97 – same for all dates 
GENDER Male/Female 
ETHNIC GROUP We will map your codes to the following: 
1 = White 
2 = Black – Caribbean 
3 = Black – African 
4 = Black – Other 
5 = Black – Unspecified 
6 = Indian Sub-Continent 
7 = Chinese 
8 = Asian – Other 
9 = Other 
10 = Unknown 
NATIONALITY AT FIRST ATTENDANCE We will map your codes to the following: 
1 = British 
2 = EU Other than British 
3 = North American 
4 = South American 
5 = Caribbean 
6 = Sub-Saharan African 
7 = North African – Middle East 
8 = African – Unspecified 
9 = Asian 
10 = Australasian 
11 = Other 
12 = Unknown 
SOURCE OF REFERRAL AT FIRST 
ATTENDANCE 
We will map your codes to the following: 
1 = On your own accord (self-referral) 
2 = Referral by GP 
3 = Referral by Family Planning Clinic 
4 = Referral by consultant within hospital 
5 = Referral by consultant elsewhere 
6 = Other 
7 = Unknown 
DHA OF PATIENT AT FIRST ATTENDANCE We will map your codes to the CDSC codes 
LOCAL AUTHORITY OF PATIENT AT FIRST 
ATTENDANCE 
We will map your codes to the CDSC codes 
IS PATIENT REGISTERED WITH GP AT 
FIRST ATTENDANCE 
Y/N 
(IF YES) GP ID NUMBER GP name if ID unknown 
DATE FIRST HIV POSITIVE TEST - 
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LOCATION WHERE FIRST POSITIVE TEST 
WAS MADE 
We will map your codes to the following: 
1 = At this clinic 
2 = Other local service 
3 = Other UK clinic – London 
4 = Other UK clinic – Non-London 
5 = Other UK clinic – Unspecified 
6 = Clinic outside UK 
7 = Unknown 
 
 
demographic file contd..  
DATE FIRST AIDS DIAGNOSIS - 
LOCATION WHERE FIRST AIDS DIAGNOSIS 
WAS MADE 
We will map your codes to the following: 
1 = At this clinic 
2 = Other local service 
3 = Other UK clinic – London 
4 = Other UK clinic – Non-London 
5 = Clinic outside 
6 = Unknown 
DATE OF DEATH - 
STAGE IF HIV ON 1ST JAN 1996  
(IF PROVIDING DATA FROM 1996 
ONWARDS) 
We will map your codes to the following: 
1 = Asymptomatic 
2 = Symptomatic Non AIDS 
3 = AIDS 
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Self Reported Risk Factors File 
 
 
REQUIRED FIELD 
 
 
NOTES 
RISK  
 
(for each patient any number of the following can be 
selected – but only one of the first three) 
We will map your codes to the following: 
1 = Homosexual 
2 = Heterosexual 
3 = Bisexual 
4 = IDU 
5 = Haemophiliac 
6 = Blood transfusion recipient before October 
1985 (UK) or abroad 
7 = Prostitute 
8 = Child of Seropositive mother 
9 = Sexual intercourse with partner from high 
endemic area 
10 = Sexual intercourse with partner from Africa 
11 = Sexual intercourse with partner from SE 
Asia 
12 = Sexual intercourse with partner from W 
Indies 
13 = Sexual intercourse with partner from USA 
14 = Sexual intercourse with partner from S 
America 
15 = Sexual intercourse with partner from 
Europe 
16 = Sexual intercourse with partner from other 
high endemic area 
17 = Sexual intercourse in a high endemic area 
18 = Sexual intercourse in Africa 
19 = Sexual intercourse in SE Asia 
20 = Sexual intercourse in W Indies 
21 = Sexual intercourse in USA 
22 = Sexual intercourse in S America 
23 = Sexual intercourse in Europe 
24 = Sexual intercourse in another high 
endemic area 
25 = Other risk factor apart from the above  
26 = Unknown 
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Visit File 
 
 
REQUIRED FIELD 
 
 
NOTES 
For each patient we would like the following information for every visit i.e. inpatient, outpatient or 
day case. 
VISIT TYPE We will map your codes to the following: 
O = Outpatient 
I = Inpatient 
D = Dayward 
DATE OF VISIT 
(or admission date if inpatient) 
- 
LATEST DHA OF PATIENT We will map your codes to the CDSC codes 
LATEST LOCAL AUTHORITY OF PATIENT We will map your codes to the CDSC codes 
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Inpatient File 
(a patient who has been admitted to hospital and has spent at least one night in hospital) 
 
REQUIRED FIELDS 
 
 
NOTES 
DATE OF VISIT (or admission date) - 
NATURE OF VISIT We will map your codes to the following: 
1 = Planned: planned test/procedure duration of 
stay which includes at least one night in hospital 
2 = Emergency: where the patient is admitted to 
hospital when admission is unpredictable and at 
short notice because of clinical need 
3 = Unknown 
DATE OF DISCHARGE Date of admission already recorded in Visit File 
DISCHARGE VENUE We will map your codes to the following: 
1 = Home alone 
2 = Home with support  
3 = Staying at friends or relatives 
4 = Hospice 
5 = Other hospital 
6 = Unknown 
OUTCOME OF EPISODE We will map your codes to the following: 
1 = Improved 
2 = Stable 
3 = Deteriorate 
4 = Death 
5 = Unknown 
ITU ADMISSION DATE - 
ITU DISCHARGE DATE - 
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Outpatient File 
(a patient attending the outpatient clinic for consultation) 
 
REQUIRED FIELDS 
 
 
NOTES 
DATE OF VISIT - 
NATURE OF VISIT We will map your codes to the following: 
1 = Planned: planned or booked in advance 
2 = Emergency: to deal with acute problems, 
not booked 
3 = Unknown 
HAS PATIENT RECEIVED CARE FOR HIV 
FROM GP? 
Y/N 
HAS PATIENT RECEIVED CARE FOR HIV 
FROM INPATIENT AT ANOTHER CLINIC? 
Y/N 
HAS PATIENT RECEIVED CARE FOR HIV 
FROM OUTPATIENT AT ANOTHER CLINIC? 
Y/N 
 
  
APPENDIX 
256 
 
Professionals File 
(for both Outpatient and Day Ward files) 
 
REQUIRED FIELDS 
 
 
NOTES 
DATE OF VISIT - 
WHICH PROFESSIONAL DID PATIENT SEE 
DURING OUTPATIENT/DAY WARD VISIT? 
We will map your codes to the following: 
1 = HIV Consultant team 
2 = Clinic Nurse 
3 = Surgeon 
4 = Neurologist  
5 = Respiratory Physician 
6 = Gastroenterologist 
7 = Haematologist 
8 = Psychiatrist 
9 = Oncologist 
10 = Psychologist 
11 = Social Worker 
12 = Dietician 
13 = Home Support Team Nurse 
14 = Physiotherapist 
15 = Occupational Therapist 
16 = Health Advisor 
17 = Dermatologist 
18 = ENT 
19 = Cardiologist 
20 = Opthamologist 
21 = Dentist 
22 = Other 
23 = Unknown 
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Day Ward 
 
 
REQUIRED FIELD 
 
 
NOTES 
DATE OF VISIT - 
NATURE OF VISIT We will map your codes to the following: 
1 = Day case: a patient who is pre-booked for a 
procedure and not expected to stay overnight in 
hospital and who returns home the same day as 
expected 
2 = Day attendance: a patient admitted regularly 
and electively for treatment over a planned 
sequence of days, being discharged each 
evening 
3 = Unknown 
LOCATION OF DAY 
TREATMENT/PROCEDURE 
We will map your codes to the following: 
1 = Outpatients 
2 = Inpatients 
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Tests 
(for inpatient, outpatient and day ward files) 
 
REQUIRED FIELDS 
 
NOTES 
 
 At least collected when first seen, at first AIDS 
diagnosis and subsequent AIDS diagnosis 
DATE OF TEST - 
TYPE OF TEST 1 = Haemoglobin (mg/dl) 
2 = Lymphocytes (x 109 /1) 
3 = CD4 count (x 106/1) 
4 = Viral Load (RNA copies/ml) 
RESULT (in units stated) - 
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Drugs 
(for inpatient, outpatient and day ward files) 
 
REQUIRED FIELDS 
 
NOTES 
 
DATE PRESCRIBED - 
DRUG NAME Use free text – codes to be finalised 
DOSE - 
ROUTE OF ADMISSION Oral 
Intravenous (IV) 
Intramuscular (IM) 
Other; including rectal, topical, inhaled, 
nebulised, subcutaneous 
 
 
If possible we would prefer to receive the ARV drug history in the following format instead: 
 
ARV combination 
(for inpatient, outpatient and day ward files) 
 
Sounde
x 
Gender 
DOB 
Date 
started 
therap
y 
Date 
stopped 
therapy 
ARV
1  
ARV
2 
ARV
3 
ARV
4 
ARV
5 
ARV
6 
Arv
7 
ARV
8 
ARV
9 
e.g. 
Patient 
1 
12/3/97 13/01/98 AZT DDI NFV       
e.g.. 
Patient 
1 
14/01/9
8 
Ongoing 
at 
current 
data 
downloa
d 
AZT 3TC EFV       
 
Refer to page 16 for ARV drug codes if necessary  
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Diagnoses File 
(For inpatient, outpatient and day ward files) 
 
REQUIRED FIELDS 
 
NOTES 
 
DATE OF VISIT (or diagnosis) - 
HIV DIAGNOSES Provide details of all opportunistic infections 
NON-HIV DIAGNOSES READ/ICD10 
 
Please note when you do extract the Diagnosis file from your clinics database, please could you 
download this particular file from when the patient was first seen even if this means that the data is 
prior to 1996. The reason for this is we will be calculating the patients stage of HIV from their first 
attendance at your clinic and then see when they change clinical stage status. 
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Procedures File 
(for Day Ward file) 
 
REQUIRED FIELD 
 
 
NOTES 
DATE OF PROCEDURE - 
PROCEDURES OPCS Coding – Tabular list of the Classifications of 
Surgical Operations and Procedures – 4th Revision 
 
 
 
 
  
 
 
  
 
